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Haemoglobinopathies are a group of diseases caused by abnormal structure, function 
or quantity of the globin chain subunits that form haemoglobin. They are a global health 
problem with 7% of the population being asymptomatic carriers. The UK has 
implemented new-born screening and antenatal screening to identify affected 
individuals. A wide variety of variants causing haemoglobinopathies have been 
documented, from single base substitutions to large insertions, deletions and complex 
rearrangements. Next Generation Sequencing (NGS) could streamline laboratory 
diagnosis as it has the potential to identify both single nucleotide changes and large 
rearrangements in a single assay. With this objective in mind, we evaluated NGS and 
its ability to detect all varieties of causative variants in thalassaemia. DNA samples 
from persons with known thalassaemia-causing mutations and unknown novel variants 
were selected for NGS. DNA samples were fragmented and prepared for sequencing. 
The two genomic regions that are affected by variants causing thalassaemia, were 
enriched for using in-solution bait capture and sequenced on an Illumina platform. 
Sequence ‘reads’ of the DNA fragments were aligned to a reference sequence of the 
human genome using NextGene software (SoftGenetics) and sequence indels and 
small variants were reported. Dosage changing events were identified by changes in 
coverage between test and negative control samples. The breakpoints of structural 
variants could be identified by the presence of sequences that spanned the breakpoint 
region. The method was honed by analysis of samples with known, previously 
characterised variants and tested in samples with unknown novel variants. The findings 
were confirmed by Gap-PCR and sanger sequencing. We conclude that NGS is a 
technique that represents an improvement on the current diagnostic standard. An 
examination of the features of the structural rearrangements identified in this study 
revealed that multiple mutagenic mechanisms contribute to the range of variants that 
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Haemoglobinopathies are a group of disorders caused by genetic variants that prevent 
the adequate production or function of haemoglobin, the molecule responsible for 
oxygen transport around the body. These diseases can be extremely heterogeneous in 
both their underlying genetic cause and clinical severity. New DNA sequencing 
technologies have the potential to streamline the process of identifying genetic variants 
that cause haemoglobinopathies in a diagnostic setting. These new technologies must 
be evaluated for their utility in diagnosing these disorders, as their implementation 
could improve patient care.  
Haemoglobin 
The Haemoglobin Molecule 
Red blood cells are responsible for transporting gasses around the body: they supply 
oxygen from the lungs to other tissues and also from a pregnant woman to her foetus. 
They also remove the waste gasses cells produce, ferrying them back to the lungs for 
expulsion. The molecule within red blood cells that permits gas transport is 
haemoglobin. Haemoglobin is a metalloprotein made up for four subunits: two alpha (or 
alpha-like) subunits and two beta (or beta-like) subunits (see Figure 1). Each of the four 
units contains a heme group with an iron core to which oxygen can bind. One molecule 
of haemoglobin can therefore transport four oxygen molecules simultaneously. A single 





Figure 1: Haemoglobin. A molecule of haemoglobin is made up of four subunits; two alpha like 
subunits and two beta like subunits. Each subunit contains a heme group with a ferrous core to 
which an oxygen molecule can reversibly bind (Image adapted from (Wheeler 2007)). 
Haemoglobin takes advantage of ‘cooperative binding’ to deliver oxygen from areas 
where its partial pressure is very high (the lungs) to areas where it is low. ‘Cooperative 
Binding’ means that as oxygen binds to haemoglobin, the shape of the molecule 
changes in a way that increases its affinity for additional oxygen atoms. Therefore, in 
an oxygenous environment a lot of oxygen binds to haemoglobin, while in an oxygen 
poor environment it is released readily. Haemoglobin’s oxygen affinity is reduced by 
hydrogen ions and carbon dioxide, both of which are found in respiring tissues. The 
higher the respiration rate of a tissue, the greater the release of oxygen it triggers in 
nearby red blood cells. This is known as the Bohr Effect (Benesch and Benesch 1961, 
Berg JM, Berg et al. 2002). 
 Every cell in the body requires oxygen in order to respire and creates carbon dioxide 
as a waste product of respiration. It is therefore critical to the operation of all tissues 
and organs in the body that haemoglobin performs its function correctly. The structure 
and production of haemoglobin are both determined by DNA. Iron deficiency can have 
similar effects but for the individuals in this study iron deficiency had been excluded. 
Heme synthesis disorders also occur, but are rarer and individuals that have problems 
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with heme synthesis suffer from porphyria and present with a different phenotype. This 
is beyond the remit of this investigation and will not be discussed further.  
The Globin Genes 
The structure of the globin subunit proteins (or globin chains) are encoded by genes. 
The sequence of nucleotide bases within the gene dictates the sequence of amino 
acids that must be joined together to construct these proteins. Humans have eight 
genes which code for haemoglobin subunits, as well as five globin-like pseudogenes 
which are organised into two clusters on chromosomes 11 and 16 (See Figure 2). The 
globin genes are highly similar in their structure, sequence and function. The subtle 
differences in their sequence and expression confer different physical properties and 
functions (Czelusniak J 1982, Steinberg and Adams 1991)  
The Globin Gene Loci 
 
Figure 2: The Globin Gene Loci. Upper panel: The alpha globin gene cluster on chromosome 16, 
Lower panel: The beta globin gene cluster on chromosome 11. Chromosome schematic pictures 
obtained from the UCSC Genome Browser 
36 
 
The alpha globin gene cluster is situated on the short arm of chromosome 16 p13.1p 
(Waye and Chui 2001). The cluster consists of four alpha pseudogenes, the zeta globin 
gene (HBZ) the mu globin gene (HBM) and two alpha globin genes – alpha 1 (HBA1) 
and alpha 2 (HBA2) and theta globin (HBQ1) (Steinberg and Adams 1991). Forty 
kilobases upstream of the gene cluster is an erythroid-specific DNAse1 hypersensitive 
region which is essential for the expression of the genes (Sharpe, Summerhill et al. 
1993). The HBA1 and HBA2 genes are identical except for their promoter regions. Both 
genes are used to synthesise alpha globin subunits throughout life, but the alpha globin 
2 (HBA2) subunit is more highly expressed than alpha globin 1 (HBA1). This is 
believed to be due to the subtle differences between their promoter regions (Liebhaber 
1986).  
Although low levels of mRNA from the theta globin pseudogene have been detected in 
vivo, no transcribed product of the gene has been identified and mutations removing 
the gene do not appear to have any clinical consequences (Albitar, Peschle et al. 
1989). The other pseudogenes are thought to have been inactivated over time by 
mutations and deletions in their promoter regions (Fischel-Ghodsian, Nicholls et al. 
1987).  
The beta globin gene cluster is located on chromosome 11 p15.5q. The cluster 
contains the beta and beta-like globin genes; beta globin (HBB), pseudobeta globin 
(HBBP1), delta globin (HBD), gamma globin 1 (HBG1), gamma globin 2 (HBG2) and 
epsilon globin (HBE) which bind to alpha or alpha-like subunits to form a haemoglobin 
molecule. The expression of these genes is controlled by the locus control region 
(LCR) centromeric of the globin gene cluster (Hardies, Edgell et al. 1984). HBB is the 
primary beta-like globin gene expressed during adulthood. Expression of the other 
globin genes change over the course of development. HBD is postulated to have arisen 
from gene conversion of HBB, given their extremely high homology. Despite this, delta 
haemoglobin protein (HBD) only makes up around 2-3% of total adult haemoglobin 
compared to the beta globin gene due to transcriptional deficiencies and low half-life 
mRNA. A change in the promoter region sequence is believed to confer the decreased 
transcriptional output (Humphries RK 1982, Hardies, Edgell et al. 1984, Kosche K 
1984). Like HBA2 and HBA1, the HBG1 and HBG2 genes are highly homologous. 
They differ by one amino acid residue, where codon 136 denotes glycine in HBG2 and 
alanine in HBG1. Like the alpha globin genes, they are not produced at equal rates: 
gamma globin 2 (HBG2) is the dominant beta-like globin subunit produced up until 




The reason that multiple globin genes exist is that their different chemical properties 
are necessary at different stages during development (see Figure 3) (Weatherall 2001). 
The alpha and beta globin gene loci are activated approximately three weeks after 
conception. In early embryos, four of the globin genes are active, producing four 
different forms of haemoglobin. Three of these are considered embryonic 
haemoglobins: Hb Portland (combining Zeta and Gamma globin chains), Hb Gower I 
(zeta and epsilon globin chains), and Hb Gower II (alpha 1 and epsilon globin chain). 
Foetal haemoglobin (HbF: alpha and gamma globin chains) is also produced early in 
pregnancy and becomes the most abundantly produced form of haemoglobin from 
approximately eight weeks post-conception until six weeks after birth. At this stage it is 
gradually replaced by adult haemoglobin (HbA: alpha and beta globin chains) (Figure 
4). HbF continues to be produced at low levels (<5%) throughout adult life and a small 
amount of HbA2 (HbA2: alpha and delta globin) is also produced (Choi and Engel 1988, 
Weatherall 2001).  
Haemoglobin Switching 
 
Figure 3:Haemoglobin Switching. Graph shows changes in globin gene expression during prenatal 




Haemoglobin Proteins Produced By The Combination Of Different Globin 
Subunits
 
Figure 4: Haemoglobin Proteins Produced By The Combination Of Different Globin Subunits. 
Haemoglobin types expressed during adulthood are coloured in red.  
Haemoglobinopathies 
Haemoglobinopathies are a group of diseases which affect either the structure or 
production of one or more of the haemoglobin subunits. These diseases are caused by 
genetic mutations that affect the globin genes or the regions that control them (Trent 
2006). Haemoglobinopathies are the most common group of genetic disorders 
worldwide, and affect approximately 7% of the global population (Weatherall 2008). 
They are more common in individuals of Middle Eastern, African, Mediterranean and 
South East Asian ancestry, and the incidence of different forms of haemoglobinopathy 
varies regionally (Huehns and Shooter 1965). Genetic variants that alter the amino acid 
sequence of the globin chains results in haemoglobin variants that can have altered 
properties and function. The most common and best studied is the sickle cell variant 
which causes sickle cell disease. Genetic variants that result in a reduced quantity of 
globin chain being produced give rise to the thalassaemia’s and these are subdivided 
by the globin chain affected, the most common forms are alpha thalassaemia and beta 
thalassaemia (Weatherall and Clegg 2001). 
Sickle Cell Disease 
Sickle cell disease is the most common form of haemoglobinopathy. It is estimated 
2.8% of the global population are carriers of the sickle cell variant, which has clinical 
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consequences in a homozygous or compound heterozygous state (Modell 2008). The 
causative mutation is a single base substitution (A>T) within the coding region of the 
beta globin gene. Clinical symptoms of the disease begin to appear around six weeks 
after birth when adult haemoglobin (HbA) production (incorporating the affected gene) 
overtakes foetal haemoglobin (HbF) production. The mutation (also designated rs334) 
changes the amino acid sequence of the gene, replacing glutamic acid with valine at 
codon 6, after the N terminal methionine is cleaved from the processed chain (Ingram 
1957). This produces a variant form of the beta globin molecule which can combine 
with alpha globin to form sickle haemoglobin (HbS). The valine residue in HbS is 
hydrophobic, and reduces the solubility of the molecule in its deoxygenated state and 
allows it to bind to other HbS molecules. This results in the formation of irreversible 
intracellular polymers of deoxygenated haemoglobin molecules which alter the 
structure of the red blood cell and affect membrane function. The accumulation of 
polymers contorts the red blood cells, and they eventually become irreversibly sickled 
(Bunn 1997).  
The structure of HbS is similar enough to HbA that it does not have significantly 
different oxygen affinity. The HbS globin subunit interacts slightly less efficiently with 
alpha globin subunits than the beta globin subunit. For this reason, most heterozygous 
carriers of the sickle cell variant will produce HbS globin at a rate of 40:60 HbA globin.   
Normal haemoglobin is extremely hydrophilic but HbS is hydrophobic and under low 
oxygen conditions, the deoxygenated HbS molecules interact and polymerise. In this 
conformation the cells are ‘sticky’ and less flexible than normal red blood cells. Their 
inflexibility and their stickiness trigger vaso-occlusion of capillaries and small blood 
vessels, which reduces blood flow and extends the time spent in a hypoxic 
environment. If the vaso-occlusions are not cleared the number of red cells undergoing 
polymerisation increases and the blood flow is reduced further, creating a cycle which 
is difficult for the body to resolve. These acute episodes are thought to induce what 
used to be known as a sickle cell crisis and in some cases requires hospitalisation with 
opiate medication for pain relief. The acute attacks overlay a chronic condition of 
anaemia and a hypercoagulable state. The balance between acute and chronic is 
different between individuals and influenced by both genetic and environmental factors. 
Sickled cells are extremely fragile with a lifespan of 16-20 days (compared to a normal 
red cell span of 120 days), resulting in haemolytic anaemia.  
The clinical consequences of sickle cell disease can be wide ranging: The most 
common symptoms arise from the anaemic element of the condition and include 
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fatigue, dizziness, headaches, pallor and jaundice. The onset of sickle cell crisis can be 
accompanied by episodes of serious pain. Downstream consequences of sickle cell 
crisis include hand and foot syndrome in children (pain and swelling in the hands and 
feet), splenic crisis (in which the spleen attempts to hold more red blood cells than it 
should, exacerbating anaemia), increased vulnerability to infection (as a consequence 
of spleen damage), acute chest syndrome (due to infected or sickled cells becoming 
trapped in the lungs), ulcers, pulmonary hypertension, stroke, eye problems, priapism 
and other issues linked to the occlusion of small blood vessels. In severe cases, if 
sickle cell crisis affects several organs simultaneously, multiple organ failure may 
develop (Stuart and Nagel).  
For a disease that stems from one single, precise genetic change, sickle cell disease 
has an incredibly heterogeneous phenotype. Many other genetic or environmental 
factors can influence disease severity and progression. A major factor that influences 
the severity of sickle cell disease is the amount of HbF produced by the individual (Ali 
1970). All people produce small amounts of HbF throughout adulthood, but in some 
individuals the level is slightly elevated. People who have this trait and also have sickle 
cell disease experience a less severe disease state. Knowledge of these modifying 
factors is important for accurate diagnosis, counselling and patient care.  
Alpha Thalassaemia 
Normal individuals have four copies of the alpha globin genes; two on each copy of 
chromosome16 (αα/αα). Alpha thalassaemia is caused by variants that inactivate these 
genes. Inactivation of a single alpha globin gene (αα/α-) has no clinical consequences. 
Inactivation or loss of two alpha globin genes (αα/-- or α-/α-) has no clinical 
consequence to the affected individual but they have a microcytic hypochromic red cell 
morphology. Inactivation or loss of three alpha globin genes (α-/--) causes HbH 
disease. This is often a mild condition and the reduced availability of alpha globin 
chains forces excess beta chains to combine to form β4 tetramers, otherwise known as 
HbH. Individuals with a α-/-- genotype (three alpha globin genes deleted) have excess 
gamma chains early in gestation and this permits ᵧ4 tetramers to form, known as Hb 
Bart’s. Hb Bart’s disappears 3 to 6 months after birth as gamma globin production is 
replaced by beta globin production (Harteveld and Higgs 2010). Both HbH and Hb 
Bart’s are unstable globin variants, and have a higher affinity for oxygen than normal 
haemoglobin. This results in poor oxygen delivery to tissues and microcytic 
hypochromic anaemia (Clegg and Weatherall 1967). Inactivation or loss of all four 
alpha globin genes (--/--) means that no normal haemoglobin can be produced after the 
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first embryonic switch. This condition is called Bart’s Hydrops Fetalis and is lethal, 
usually in utero, or occasionally shortly after birth. Death in utero often results in late-
term miscarriage of the affected foetus with potentially serious physical and 
psychological consequences for the mother (Lehmann 1970). Hb Bart’s Hydrops 
Fetalis is common where alpha thalassaemia deletions which remove both the alpha 
globin genes on the same chromosome are common; most notably Southeast Asia and 
the Mediterranean. In Africa, alpha plus thalassaemia is very common with the single 
alpha globin gene deletion –α being carried by 0.33 of the population. As the alpha (--
/αα) deletion of both genes on the same chromosome is rare in Africa and the Middle 
East, HbH disease and severe alpha thalassaemia is not a clinical concern (Chui and 
Waye 1998).  
Alpha globin gene loss is most commonly caused by deletions. Duplications of the 
alpha globin genes possible, with some individuals documented as having eight copies 
of the alpha gene, when a duplication is inherited on both chromosomes. These 
duplications have not been shown to have any thalassaemic consequences in isolation 
even though there is evidence that they are expressed (Harteveld, Refaldi et al. 2008). 
This may reflect that alpha globin chains are chaperoned by alpha globin chaperone 
protein prior to tetramer formation with a beta globin like chain (Kihm, Kong et al. 
2002). Common deletions that cause alpha plus thalassaemia (single gene deletions) 
include the 3.7 Kb deletion and the 4.2 Kb deletion. Common deletions that cause 
alpha zero thalassaemia (two genes deleted from the same chromosome) are the SEA 
(Southeast Asian) deletion, MED (Mediterranean), alpha 20.5 deletion and FIL 
(Filipino) deletion. Single base changes causing alpha thalassaemia include Hb 
Constant Spring (Alpha 2 codon 142 TAA > CAA) which causes a premature stop 
codon and Hb Quong Sze (Alpha 2 codon 125 CTG > CCG) which creates an unstable 
alpha-like globin chain variant (Chui and Waye 1998). These non-deletional mutations 
can have more severe consequences compared to single gene deletions as cellular 
energy is spent creating a non-productive transcript, while in the presence of a deletion 
all transcriptional energy is focused on the remaining transcriptionally active genes 
(Chui, Fucharoen et al. 2003). In the UK, antenatal screening tries to identify instances 
where two alpha globin genes deleted from the same chromosome, as these mothers 
are at increased risk of having a child without any alpha globin genes resulting in Bart’s 
Hydrops Fetalis. As alpha zero thalassaemia is rare in African populations but the -α/-α 
two gene deletion is relatively common, antenatal cases with African ethnicity are not 
considered at risk for alpha thalassaemia. Their greatest risk is HbH disease (-α/--) and 
this is usually a mild condition.    
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Large deletions removing upstream genes in addition to the alpha globin genes can 
cause a form of alpha thalassaemia that is associated with mental retardation. This is 
described as ATR syndrome (Wilkie, Zeitlin et al. 1990). A related condition with a 
distinct phenotype has also been reported, which is associated with a deletion on the X 
chromosome (ATR-X) posited to contain a trans-acting factor which effects the 
expression of the alpha globin genes (Gibbons, Suthers et al. 1992). 
Beta Thalassaemia 
Beta Thalassaemia is caused by mutations that remove or inactivate the beta globin 
gene, reducing availability of beta globin chains. The majority of variants causing beta 
thalassaemia are point mutations and different populations have different and 
overlapping subsets of pathogenic variants. Deletions are rare, except for the 619 bp 
deletion found within some Indian ethnic groups and the Middle East. Heterozygous 
carriers of beta thalassaemia are normally symptomless with microcytic hypochromic 
indices and a raised HbA2 and follow a recessive mode of inheritance (Cao A 2000).  
The disease state occurs when a person is homozygous for beta thalassaemia or 
compound heterozygous for beta thalassaemia and another variant. As there is such a 
wide number of different variants, with varying clinical effects, the severity of the 
condition is a spectrum. At the genetic variant level beta thalassaemia causing variants 
are classified as either β0 or β+ which reduce expression from the allele entirely or 
partially, respectively. Individuals that inherit two β0 variants would be expected to have 
a severe beta thalassaemia condition and all other combinations would be less severe. 
The clinical diagnosis uses the term thalassaemia major or transfusion dependent beta 
thalassaemia (TDBT) and requires a complete clinical picture before classification. It is 
possible for an individual to be homozygous for two β0 variants and not present with 
beta thalassaemia major as the lack of beta globin is substituted by HbF, leaving them 
clinically well. Milder forms of beta thalassaemia – termed thalassaemia intermedia or 
non-transfusion dependent thalassaemia (NTDT) – arise when there is some beta 
globin gene expression. Currently, blood transfusion is used to manage beta 
thalassaemia patients and the additional red cells contain iron which causes iron 
overload. Therefore these individuals also require iron chelation therapy to manage 
their excess iron, which if left unchecked can cause organ damage. In rare cases, beta 
thalassaemia can be an autosomal dominant condition, where individuals with only one 
affected allele also experience a disease state. Hyper unstable haemoglobin variants 
causing autosomal dominant thalassaemia are limited to the third exon of the beta 
globin gene as these escape clearance by nonsense mediated decay (Thein 1992). 
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The HbVar database currently lists 279 reported variants causing beta (or variants on, 
e.g. delta-beta) thalassaemia (Patrinos, Giardine et al. 2004).  
The symptoms of beta thalassaemia begin to appear around six weeks after birth 
where adult haemoglobin production surpasses foetal haemoglobin production. The 
primary clinical feature of beta thalassaemia is chronic hypochromic microcytic 
anaemia due to insufficient globin chain synthesis and ineffective erythropoesis. In 
addition to this, aggregates of unused alpha globin subunits collect inside red blood 
cells. The presence of these aggregates (termed ‘inclusion bodies’) reduces the 
lifespan of mature red blood cells, worsening the person’s anaemia (Shinar E 1990). 
Individuals who are homozygous for beta thalassaemia produce little or no functional 
adult haemoglobin and their survival is usually dependent on receiving frequent blood 
transfusions (Weatherall 2001). Beta thalassaemia intermedia has lower clinical 
severity than beta thalassaemia major. This group produce a greater amount of 
functional haemoglobin than those with thalassaemia major, which may be due to the 
inheritance of ameliorating functions or less severe thalassaemia variants (Thein 
1993).  
The chronic anaemia beta thalassaemia causes can have many downstream clinical 
consequences. In most countries thalassaemia major is treated with frequent blood 
transfusions, which results in a different disease natural history. The clinical features of 
thalassaemia in countries providing transfusions are as follows: Common clinical 
symptoms of beta thalassaemia are pallor, fatigue, irritability, feeding problems, 
diarrhoea and splenomegaly. Consequences of iron overload resulting from repeated 
treatment by blood transfusion in early life include growth retardation; failure of sexual 
maturation ; issues with the heart, liver (such as hepatitis, fibrosis cirrhosis), and 
endocrine glands (resulting in the abnormal hormone production which may create 
various other knock-on effects); hypersplenism (and subsequently reduced immune 
response); venous thrombosis; osteoporosis and hypogonadism (Cao and Galanello 
2010). In countries where frequent blood transfusions are not available, thalassaemia 
major is characterised by growth retardation, pallor, jaundice, poor musculature, 
hepatosplenomegaly, leg ulcers and skeletal changes  (Galanello and Origa 2010). 
Without regular transfusions the life expectancy for individuals with beta thalassaemia 
major is less than a year. With regular transfusions and iron chelation therapy, life 
expectancy is normal. In 71% of patients who receive regular blood transfusions the 
eventual cause of death is cardiac complication as a result of iron overload 
(Borgna‐Pignatti, Cappellini et al. 2005). Bone marrow transplant can cure beta 
thalassaemia but is currently associated with an unacceptable risk of mortality for the 
44 
 
majority of sufferers (Trent 2006). Current research into a cure for thalassaemia 
focuses on gene therapy approaches (namely in boosting foetal haemoglobin 
production or somehow reversing the switch from foetal to adult haemoglobin 
production) (Donnall Thomas, Sanders et al. 1982). 
Beta thalassaemia carriers are symptom free, but the presence of the variant can still 
be detected from microcytic, hypochromic red cell indices accompanied by an elevated 
HbA2 level (>3.4%) . Both sickle cell disease and beta thalassaemia show a great 
amount of diversity in the clinical severity of the disease experienced by patients. A 
major factor in this is the inheritance of modifying genetic factors. These include 
concurrent inheritance of other variants affecting the same globin gene loci and 
variants affecting the globin subunit’s counterpart (concurrent alpha and beta 
thalassaemia result in a milder form of both diseases because the imbalance between 
the production of the two subunits is lessened) and many other genetic factors, yet to 
be identified, plus environmental factors. The most important modifier of disease 
severity identified to date is the level of HbF (foetal haemoglobin) produced in 
adulthood. In most adults, trace amounts of HbF persist in the peripheral blood, <1% of 
total haemoglobin. A minority, however, show elevated levels of HbF with the genetic 
cause either linked to the beta globin loci or due to variants in trans acting factors. 
Although a complete understanding of the molecular mechanism of HbF regulation is 
not yet known the complex trait is strongly genetic and is termed ‘hereditary 
persistence of foetal haemoglobin’ (HPFH) (Thein 2009). Genomic regions, or 
quantitative trait loci (QTL)  associated with HPFH have been identified on 
chromosomes 11p and 6q, but their precise mechanism has yet to be determined 
(Craig 1996) (Menzel, Garner et al. 2007). When associated with haemoglobinopathy, 
HPFH has been shown to have a positive impact on disease outcome. For this reason, 
understanding what causes HPFH is of extreme interest to understanding 
haemoglobinopathies and improving patient care.  
Other Thalassaemias 
Alpha and beta are the most commonly seen thalassaemias, but mutations can affect 
any or multiple globin genes producing conditions with varying clinical severity. 
Thalassaemias affecting only the delta globin subunit go unreported as they have no 
clinical impact although they can mask a raised HbA2 level (which is the differentiator 
between alpha and beta thalassaemia) and can cause diagnostic delays as a result  
(Bouva, Harteveld et al. 2006).  Thalassaemias affecting epsilon globin or gamma 
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globin have the greatest effect early in development and may either go unnoticed or 
require intra-uterine transfusion, but be tolerable postnatally.  
Deletions in the beta globin gene loci are rare. Deletions have various clinical effects 
depending on the breakpoints and are therefore important to identify and record 
accurately. Deletions may remove all or part of the beta globin gene and are classified 
as beta thalassaemia deletions. Deletions that remove the delta and beta globin genes 
are termed δβ thalassaemia deletions and are often associated with moderate 
increases in HbF (7-15%). HPFH deletions are larger and remove one gamma globin 
gene plus the delta and beta globin genes. These deletions result in elevated levels of 
HbF (15-30%), which is significantly higher than that in beta or δβ  thalassaemia. 
Whole beta globin loci deletions have also been documented, associated with a mild 
increase in HbF production to (2-5%).Individuals present with a haematological picture 
similar to alpha thalassaemia; microcytic hypochromic with a normal to low level of 
HbA2. These εᵧδβ thalassaemia deletions are sub classified into two groups. Group I 
are deletions that remove the globin genes and group II remove the locus control 
region which silences the globin genes that are left intact. Duplications at this locus had 
not been documented prior to this study 
The range of variants that can cause haemoglobinopathies is unusually high; many 
diseases with known genetic origins are associated with specific variants. Identifying 
the underlying variants in haemoglobinopathies can be clinically useful, but also 
demanding given their variety. How do mutations that cause haemoglobinopathies 
come about, what causes such a range of variants at these loci, and why are they so 
prevalent in African, South East Asian and Mediterranean populations?  
Mutation 
Mutations are changes to the genetic code that can occur anywhere in the genome and 
have an associated connotation that they will have a negative impact on the host. 
Mutation is a process that mostly occurs during meiosis, where mistakes can be made 
during DNA replication. Many mutations result in variants that are considered to be 
‘silent’ where they fall outside gene coding regions, or occur within the coding region 
but do not cause any changes to the gene’s function or product. Since the advent of 
next generation sequencing the amount of genetic variation under investigation has 
increased and the use of the term mutation has changed, with the journal Human 
Mutation tightly limiting its use to explain a process. All genetic differences resulting 
from mutation should be described as genetic variation such as sequence variants, 
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pathogenic variants or structural variants. NB: some of the analysis tools used in this 
study have yet to adopt this change, and still refer to variants as “mutations”.   
Single Nucleotide Changes 
Single nucleotide changes (often called ‘single nucleotide polymorphisms’ or ‘SNPs’) 
can be as phenotypically severe as a large deletion that removes a megabase of 
sequence. When nucleotide changes occur in the coding region of a gene and change 
its amino acid sequence they are described as non-synonymous gene variants. These 
can have detrimental consequences for the structure and function of the protein the 
gene produces. Single base changes in the beta globin gene are responsible for 
structural haemoglobinopathies including sickle cell disease (Steinberg M.H. 2001), 
HbC disease and HbE disease. Single base changes can also reduce or prevent the 
production of any functional protein by the affected gene if they are within splice sites 
or promoters. Changes such as these that affect the dosage of globin genes cause 
thalassaemia. Single nucleotide changes causing beta thalassaemia such as the IVS-
II-1 (G>A) variant and Sardinian codon 39 nonsense variant are common (Najmabadi, 
Karimi-Nejad et al. 2001). Single nucleotide changes causing alpha thalassaemia also 
occur but are rarer. Small genetic changes such as single base substitutions and small 
deletions lend themselves well to the HGVS naming nomenclature used to document 
thalassaemia-causing variants. In this system all genetic variants are called against a 
standard transcript or a genomic reference sequence. This standardises how the 
majority of genetic variation described and allows instant understanding of the position 
of the variant within the gene. For example, a mutation described as 
“HBB:c.315+1G>A”, affects the gene HBB, with the +1 indicating the variant is 1bp 
within the intron (after codon 315) changing a base from guanine to adenine. From this 
information, the variant can be surmised to affect mRNA splicing.   
Structural Rearrangements 
Recombination is an exchange of genetic material between two chromosomal regions, 
which is used to repair double stranded breaks (DSBs) in DNA which occur during cell 
division. Homologous recombination (HR) is an exchange of similar or identical 
nucleotides which generates sequence variation in gametes and is an important 
mechanism for evolution (Schleif 1993). In non-allelic homologous recombination 
(NAHR), a double stranded break is repaired via an unequal exchange of genetic 
material which can result in a structural rearrangement (Stankiewicz and Lupski 2002). 
Structural rearrangements include duplications, deletions, translocations and inversions 
of DNA sequence. These are currently defined as “sequence variants of at least 50bp 
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in size” (Mills, Walter et al. 2011). Smaller sequence variants are known as ‘SNPs’ 
(single base changes) or ‘indels’ (insertions, inversions or deletions of up to 50bp of 
sequence). Structural rearrangements can affect multiple megabases of DNA. Deletion 
variants are a common cause of alpha thalassaemia (Trent, 2006) and occasional 
cause of beta thalassaemia. While structural rearrangements can happen anywhere in 
the genome, they are reported more frequently in some regions than others. The 
number of rearrangements associated with alpha thalassaemia is higher than many 
other genetic diseases. It has been suggested that the large number of globin genes 
we possess may be due to historic duplication and gene conversion events, mediated 
by elements at this locus that encourage recombination events (Michelson and Orkin 
1983, Steinberg and Adams 1991). Elements within the DNA sequence that caused 
these events could be responsible for the structural rearrangements we see in 
thalassaemia.  
Certain features of DNA sequence can affect its chance of being involved in a 
recombination event by influencing the 3D structure of the chromosome on which it is 
situated. Features such as mirror repeats, palindromic sequences and z-DNA motifs 
can result in the formation of Non-B (or non-canonical) DNA structures which are 
associated with non-homologous recombination (Bacolla 2009). As non-homologous 
recombination is often associated with detrimental phenotypic consequences, evidence 
of regions with a high rate of non-homologous recombination may not be reflected in 
the general ‘recombination rate’ as calculated based on the inheritance of broadly 
functional chromosomes in the normal population. In fact, only 60% of identified 
recombination events are linked to known recombination hotspots, as our 
understanding of where and how DNA recombines is not yet complete (Mills 2012).   
Non-homologous recombination is probably responsible for most alpha zero deletion 
events – the break-points for these tend to involve small partially homologous 
sequences which are known to be important for some mechanisms of non-homologous 
repair of double stranded DNA breaks which occur during meiosis (Nicholls, Fischel-
Ghodsian et al. 1987). Alu repeats are associated with deletion breakpoints and are 
frequent around the alpha globin gene cluster. They may have structural significance or 
just provide the regions of partial homology. Where these occur around the beta globin 
gene loci, their association with structural rearrangements is substantially lower than 
the alpha globin gene locus (Henthorn, Smithies et al. 1990).  
The alpha globin gene cluster may be situated in an area particularly prone to non-
homologous recombination (alternatively, the location may just be particularly tolerant 
of rearrangements, as many resulting phenotypes such as duplications have no clinical 
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affect). The cluster is located near the telomere on the short arm of chromosome 16. In 
males, chromatin forms tighter loops towards the telomeres. These smaller loops are 
associated with an increased rate of recombination, where DNA from different loops 
which are brought into close physical proximity to one another can recombine (Paigen, 
Szatkiewicz et al. 2008) (Paigen and Petkov 2010). Non-homologous recombination 
events in these regions could create gene deletions. The entire alpha globin gene 
cluster (both the genes and surrounding DNA) also has a high (60%) GC content 
(Fischel-Ghodsian 1987) which could influence the recombination rate of the region. 
Recombination events can be difficult to characterise: their breakpoints are often 
situated in repetitive regions that are hard to sequence, they may affect very large 
regions of DNA, and in the case of balanced rearrangements (inversions, insertions 
and translocations), the standard techniques used in molecular diagnostic laboratories 
may not detect them at all. For this reason, it can be difficult for diagnostic laboratories 
to identify characterise novel rearrangements causing thalassaemia or develop tests to 
detect further instances of the variant in the future. In addition, diagnostic labs may only 
need to detect the presence of a variant and do not need to completely characterise 
the it for patient management.  Where these rearrangements are phenotypically silent 
(as duplications and inversions often are) they may go undetected in the normal 
population, so estimating the rate at which these events occur can be challenging 
(Nobrega, Zhu et al. 2004) (Weischenfeldt, Symmons et al. 2013) (Firth, Richards et al. 
2009). Rearrangements recorded on the alpha and beta globin gene loci to date are 
illustrated in Figure 5 and Figure 6.  
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Variants in HbVar Affecting the Beta Globin Gene Cluster
 
Figure 5: Variants in HbVar Affecting the Beta Globin Gene Cluster. Variants (blue lines) are 
displayed in the UCSC genome browser, with gene positions shown at top of image. The Globin 
gene cluster is highlighted in yellow and position of the beta globin gene is also highlighted in red. 




Variants in HbVar Affecting the Alpha Globin Gene Cluster 
 
Figure 6 Variants in HbVar Affecting the Alpha Globin Gene Cluster. Variants (blue lines) are 
displayed in the UCSC genome browser, with gene positions shown at top of image. The Globin 
gene cluster is highlighted in yellow and position of the alpha globin genes are also highlighted in 




Some parts of the genome are subject to a higher rate of recombination than others. 
These regions are called recombination hotspots. The rate of recombination can be 
calculated by studying the haplotypes that exist in different regions. A haplotype is the 
precise sequence of nucleotides on a single chromosome. A chromosome can have 
many different possible haplotypes even in healthy individuals, as new variants with no 
functional consequences accumulate over generations. As some regions of the 
genome have a high rate of recombination, chromosomal haplotypes tend to split into 
smaller ‘blocks’ (Paigen and Petkov 2010). The pattern of SNPs within a block is highly 
conserved and they are almost always inherited together. The pattern of blocks making 
up a chromosome, however, can change significantly between populations. By 
comparing the haplotypes of different chromosomes across a region of interest, the 
rate of recombination can be calculated based on the number of points at which 
different haplotypes with a common ancestor diverge from one another (Lupski 2004). 
From this, clear ‘hotspots’ where recombination has occurred frequently in the past can 
be seen. These regions are typically surrounded by large areas of ‘linkage 
disequilibrium’ where the recombination rate is significantly lower than average. A 
recombination hotspot has been previously reported in the beta globin gene cluster, 
between the HBB and HBD genes. The alpha globin gene cluster on the other hand, is 
>30Kb from the closest calculated recombination hotspot (Chakravarti, Buetow et al. 
1984, Ardlie, Kruglyak et al. 2002, Gabriel, Schaffner et al. 2002).   
Spread and Distribution of Haemoglobinopathies 
The areas where haemoglobinopathies are most common are all regions where the 
virulent malaria strain p.falciparum was once endemic (Weatherall 2008). Evidence 
suggests that carriers of haemoglobinopathies have partial resistance to malaria 
infection, which is why the variants became common in these areas as they conferred 
a selective advantage (Taylor, Parobek et al. 2012). The mechanism by which 
haemoglobinopathies might provide malaria resistance is not fully understood. 
Evidence suggests that because haemoglobinopathies reduce the lifespan of red cells, 
the malaria parasite is unable to complete the stage of its life cycle that occurs within 
red blood cells, which prevents systemic infection of the individual. Haemoglobinopathy 
carriers may also experience a partial benefit from this (Ayi, Turrini et al. 2004). Sickle 
Cell disease and HbC disease are also hypothesised to protect against malaria through 
their disruption to intracellular trafficking networks that the parasite needs to modify to 
propagate (Cyrklaff, Sanchez et al. 2011).  
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Migration of people between these areas was once rare. Most populations which have 
high rates of haemoglobinopathies due to a selective pressure have a distinct set of 
variants that arose, and then remained within that area. The population of Sardinia is a 
good example, where 95.7% of persons who carry a beta thalassaemia variant have 
the same codon 39 nonsense variant (Rosatelli, Dozy et al. 1992). Migration between 
all countries has increased enormously over the last century. London has a particularly 
diverse population in which 50 nationalities are represented by at least 10,000 
individual residents, and over 301 languages were reported to be spoken in the 2005 
census (Statistics 2011). This diversity means that hospitals must be prepared to test 
for pathogenic variants that would not be common in the native population. In addition, 
ethnicity is difficult to collect and in a metropolitan city it is an unreliable guide to the 
variants that may be detected (Clark and Thein 2004). Therefore tests must detect all 
types of thalassaemia causing variants which cannot be predicted by ethnicity.  
Routine Diagnosis of Haemoglobinopathies in the UK 
Diagnosis of haemoglobinopathies in the UK can occur at any time in an individual’s life 
depending on how and when they present with symptoms. Most diagnoses are made 
as a new-born or antenatally due to two major screening programmes. The new-born 
screening programme is universal and aims to detect neonates affected by sickle cell 
disease. As a consequence of the methods used this screening program can also 
detect the absence of HbA and therefore severe forms of beta thalassaemia. The first 
line screening method is either High performance liquid chromatography (HPLC) or 
mass spectrometry, both of which abnormal protein chains. Antenatal screening aims 
to detect mothers affected by a haemoglobinopathy and the first line screening 
methods are HPLC and a full blood count (FBC). Screening is divided into high and low 
prevalence regions depending on the affected birth rate. Mothers that are detected as 
carriers or affected by a haemoglobinopathy have their partners called for testing and if 
they are positive, the couple have counselling so they are aware of the implications and 
their options. The majority of individuals tested are unaffected and are reported as 
normal. Genetic testing is only required when the screening results from the analysis 
are not clear, variants need to be identified to allow informed counselling, and in the 
assessment of alpha thalassaemia. Genetic testing is also required for prenatal 
diagnosis which is offered on the NHS, to couples at risk of an affected child. It is best 
practise to identify the pathogenic variants in the parents prior to foetal sampling, 
however this does not happen for cases of sickle cell disease as the penetrance of the 
variant is close to 100%, and the protein screening test represents the genotype. 
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Genetic investigations follow a diagnostic algorithm looking for common variants first 
and then moving on to rarer causes if the first test is negative. The investigation is 
guided by the phenotype or the primary screening results using it as a guide to look for 
alpha or beta thalassaemia or an alpha or beta globin gene variant. The diagnosis of 
thalassaemia can be time consuming, particularly if the variant is rare. For example, if 
an individual has εᵧδβ thalassaemia the screening results will appear like alpha 
thalassaemia. A screen for common alpha deletions is started and then the HBA1 and 
HbA2 genes are sequenced. Upon review an MLPA assay will be carried out to detect 
rare deletions and only once this is negative will an MLPA assay be carried out on the 
beta globin loci to detect the causative structural variant. This diagnosis could take up 
to one month to complete at a time when mothers may be anxious about their 
pregnancy and haemoglobinopathy risk. 
A description of these routine diagnostic techniques is provided in Table 1 These 
techniques still have limitations leaving a very small proportion of cases undiagnosed. 
These include balanced translocations and small point mutations in the LCR that may 
affect globin gene transcription. The main drawback is the approach to testing which 
favours individuals with common variants and penalises those with rare variants. In 
addition, some individuals will have multiple haemoglobinopathy variants requiring 
multiple tests. Managing this workload is complex and requires dedicated staff and 
processes within a molecular diagnostic facility aimed at providing services for a 
repertoire of conditions. Having a single technique that detects all the genetic variation 
in one assay would standardise the workflow, provide an equitable service to all and 
detect all genetic variation allowing it to be related to the referring phenotype, thereby 
giving a better diagnosis (Clark 2004). 
Newborn Screening 
The new-born screening program aims to identify babies born with sickle cell disease. 
In 94% of cases, children born with sickle cell disease will develop functional asplenia 
within 5 years of birth due to vaso-occlusion of small vessels within the spleen by 
sickled red blood cells (Milne 1991, Pai and Nahata 2000). Functional asplenia is a 
form of immunodeficiency that is associated with increased risk of infection, and 
increased severity of infections. Initiating penicillin prophylaxis soon after birth has 
been found to significantly reduce mortality associated with a number of infections in 
patients with sickle cell disease (Gaston, Verter et al. 1989).  Fast and accurate new-
born screening for sickle cell disease can therefore have a significant impact on patient 
health. Early diagnosis is also beneficial to children with beta thalassaemia major, 
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where regular blood transfusions maintaining a haemoglobin concentration of >95-105 
g/L can prevent splenomegaly (Cao and Galanello 2010).  
Antenatal Screening and Prenatal Diagnosis of 
Haemoglobinopathies 
The NHS Sickle Cell and Thalassaemia Screening Programme aims to allow people to 
make informed choices before conception and during pregnancy. 
Women are screened from 8 weeks of gestation and if they are affected or carrying a 
haemoglobinopathy, the partner is also screened. If they are both carrying a 
haemoglobinopathy, the couple are counselled and offered prenatal diagnosis (PND). 
The antenatal screening plan aims to offer diagnosis to all women in the UK to allow 
informed decision making, and to perform at least 50% of diagnoses before 12 weeks 
and 6 days of pregnancy.  
PND requires foetal sampling, either by chorionic villus sampling (CVS) in early 
pregnancy (9.5-12.5 weeks of gestation) or by amniocentesis (14-20 weeks of 
gestation). Accurate testing is crucial at this stage, as the results may determine 
whether the mother decides to continue with the pregnancy or not.  
The diagnostic workflow depends on the availability of the father for testing. In PND of 
sickle cell disease, if the father is available two tests are performed: A TaqMan real 
time PCR assay and a restriction fragment length polymorphism (RFLP) assay are 
used to directly detect the presence or absence of the sickle cell mutation. 
Microsatellites are analysed as a third assay to detect maternal cell contamination in 
the gDNA prep. If the father is unavailable for testing, beta globin gene sequencing is 
also performed to detect the presence of compound heterozygous states that could 
result in a sickle cell disease genotype. In prenatal diagnosis of thalassaemia, either 
alpha genotyping or beta sequencing are performed, depending on the variant 
identified in the parents. MLPA is also performed to support the diagnosis. This 
workflow is most accurate when both parental samples are available but in the absence 







Table 1 Techniques used in the diagnosis of Haemoglobinopathies 
Blood/Molecular/Protein laboratory techniques used in the screening and 





A full blood count counts the number of red blood cells, white 
blood cells and platelets in a blood sample and also calculates red 
cell indices: mean corpuscular volume and mean corpuscular 
haemoglobin. An automated blood count analyses the contents of 
blood by the number, size and light absorption of the cells in a 
standard volume of blood. Low MCV and MCH are indicative of 
haemoglobinopathy.  
HPLC High performance liquid chromatography is used to separate out 
and identify the different forms of haemoglobin present in a blood 
sample. Red blood cells are lysed to release their haemoglobin, 
which is then electrophoresed through a gel. Differences in mass 
and charge alter the rate at which different molecules cross the 
gel.   
Sickle solubility 
test 
A blood sample is treated with a reducing agent such as sodium 
dithionite which reduces the available oxygen in the blood. Lysis is 
induced in the red blood cells, releasing their haemoglobin. HbS 
will form liquid crystals when released, giving the mixture a cloudy 
appearance. In the absence of HbS the mixture will remain clear. 
The test detects the presence of HbS but not whether the subject 
is a carrier, compound heterozygous or homozygous for the 
condition.  
CAE /IEF gel 
test 
A Cellulose acetate electrophoresis (CAE) test identifies HbS in a 
blood sample by its migration across a cellulose acetate strip 
when exposed to an alkaline pH. HbS migrates noticeably more 
slowly across the gel than other haemoglobins, due to an extra 
positive charge.    
Isoelectric focussing (IEF) separates out the different haemoglobin 
variants present in a sample by their migration across a gel with a 
pH gradient to their isoelectric point, which is determined by their 
molecular charge. This can detect differences of 0.02pH units 
between different haemoglobin variants. This is more costly than a 
CAE test, but allows differentiation of the isoelectrically similar Hb 
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When a genetic variant causes a sequence change that affects a 
restriction enzyme recognition site it may be detected using a 
RFLP assay. The region is amplified by PCR and then digested 
with the restriction assay. The digested fragments are then 
resolved on an agarose gel and the presence of specific size 
fragments will indicate if the variant is present and its zygosity.  
CGH Array Comparative Genomic Hybridization is used to detect dosage 
changing variants. DNA from a test sample and a reference 
sample are labelled with different fluorophores. the comparative 
levels of hybridization (which releases the fluorescent tag) of DNA 
from these samples to DNA probes corresponding to a region of 
interest is measured. Regions were a deletion or duplication has 
occurred are identified by their decreased or increased, 
respectively, binding to probes in the affected region. (NB: CGH 
array is performed in some laboratories, but not at the Dept. 
Molecular Pathology at KCL, where Next Generation Sequencing 
strategies are being perused instead) 
MLPA Multiplex ligation dependent probe amplification uses a single 
primer set to amplify multiple oligonucleotide pairs from across a 
genomic region of interest. Each separate probe group creates a 
different sized product. The amplified products can be separated 
out by capillary electrophoresis. Any products which are absent 
due to deletions affecting the target sequence are quickly 
identified, and the approximate size of the deletion can be 
estimated by the number of probe groups affected.   
Gap-PCR A Gap-PCR uses primers to amplify the break-point product of a 
known deletion via PCR. Primer sets for multiple variants can be 
pooled together in a multiplex reaction, providing they amplify 
under the same thermal cycling conditions. Multiplex Gap-PCR is 
used to quickly test for multiple common deletions in alpha 




Dye-terminator sequencing uses the sanger-sequencing method 
to establish the precise sequence of PCR products amplified from 
patient DNA. Fluorescent dyes are used to label free nucleotides 
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which fluoresce upon incorporation into DNA fragment, revealing 
its sequence. This can identify point mutations and small indels 
which are commonly associated with beta thalassaemia and 
haemoglobin variants.  
Real time PCR/ 
Taq Man assay 
TaqMan qPCR is used to detect known genetic variants in a DNA 
sample, and to determine whether it is present in a homozygous or 
heterozygous form. Fluorescent probes bind specifically to the 
target alleles and are detected when the extended primer releases 
the fluorophore during amplification.  
STR analysis for 
Maternal 
contamination  
Short Tandem Repeats (STRs) are highly variable sequences with 
multiple alleles in the population, so it is likely the mother and 
father will have different alleles. Amplifying the repeats with a 
fluorescent primer and sizing the PCR product allows detection of 
the maternal and foetal genotypes. Maternal contamination of the 
foetal sample can be detected when the mother heterozygous and 
the allele not inherited by the foetus appears in the foetal sample. 
 
New techniques for DNA sequencing and analysis are constantly emerging, and have 
become increasingly sophisticated over the last century. Techniques used today can 
produce a wealth of information, making interpretation and storage of this data 
challenging. Wet laboratory DNA analysis techniques are becoming increasingly 
supported by computational tools for data handling, and as laboratory techniques have 
evolved, so have the fields of computational biology and bioinformatics.   
The Technological Evolution of DNA Sequencing and 
Analysis  
Bioinformatics 
The classical definition of bioinformatics is “The mathematical, statistical and 
computing methods that aim to solve biological problems using DNA and amino acid 
sequences and related information“ - attributed to Fredj Tekaia - Institut Pasteur 
(Fenstermacher 2005) 
Bioinformatics differs from the equally important field of computation biology, which is 
defined as “The development and application of data-analytical and theoretical 
methods, mathematical modelling and computational simulation techniques to the 
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study of biological, behavioural, and social systems” - NIH Biomedical Information 
Science and Technology Initiative Consortium.  
The boundaries between these two disciplines are blurred and elements of both are 
usually used together in biological research.  
The discipline of bioinformatics grew out of the increasing importance of protein 
modelling, and also the need to handle large amounts of data produced by sequencing 
technology. Bioinformatics governs how large datasets are acquired, stored, evaluated 
and analysed. A crucial element of the field is successfully combining the findings of 
multiple fields together – often taken from huge databases – to discover new 
relationships between one finding and another. These studies were quick to produce 
data: such as the relevance of the 3D structure of mRNA on its natural selection 
(Konings, Hogeweg et al. 1987). 
DNA Sequencing Technology 
The first genome to be completely sequenced was that of the ΦX174 bacteriophage, 
stored in notebooks and then hand-typed for publication. Using data in this format was 
unwieldy, and the sequence was transferred to a punch card computer by scientists at 
Cambridge. Scientist Rodger Staden then created an interactive program (The Staden 
Package) which allowed biologists with little knowledge of computer science to access 
the data. This is arguably the first use of bioinformatics in the field of genomics 
(Krawetz and Womble 2003) (Fenstermacher 2005).  
The ΦX174 bacteriophage genome was sequenced using the ‘plus and minus’ method 
developed by Frederik Sanger (Sanger, Coulson et al. 1982). In this method, two 
polymerase chain reactions were performed: the first amplified fragments into random 
lengths, and then terminated synthesis with the incorporation of a 32P labelled 
nucleotide.  The product was then divided into aliquots, to which a single type of 
nucleotide base was added for a second reaction. The products were all 
electrophoresed on an acrylamide gel. If the sequence was a single base longer in one 
of the reactions, this was concluded to be the nucleotide present at that position in the 
fragment. Problems arose where homopolymers occurred and the number of bases 
incorporated had to be estimated based on the position of the band on the gel. This 
slow process was eventually sufficient to sequence the entire bacterial genome. Two 
years later, Sanger published an improved, faster sequencing method which has the 
same underlying chemistry as methods used today (Hutchison 2007).  
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DNA sequencing became more rapid after the development of the dideoxy sequencing 
method by Frederik Sanger in 1977. Dideoxy or ‘chain termination method’ sequencing 
initially sequenced only single stranded DNA cut into small fragments (~100bp) by a 
restriction enzyme. The fragments were mixed with a DNA polymerase enzyme, a short 
specific primer and free nucleic acids. This mixture was then divided into four separate 
reactions. To each of these, a different radioactively labelled chain-terminating 
nucleotide was added. At some point, one of the fragments in the reaction tube would 
incorporate one of these bases, rather than an unlabelled base, into the DNA fragment. 
The lack of a 3’ group attached to this base prevented further replication of the 
fragment. The products of each of the four reactions were added to separate lanes on 
an acrylamide gel. Small fragments (which had been incorporated a terminating base 
early in synthesis) travelled further down the gel than slower moving large fragments. 
Comparing fragment sizes in different lanes showed the relative positions of different 
bases. From this, the entire sequence of the fragment could be deduced (shown in 
Figure 7). This method originally required single stranded DNA, but was later modified 
to work for double stranded molecules. Shortly after the publication of the Sanger 
method of sequencing, the Maxam-Gilbert Method was also released. This method 
used similar mechanism but different underlying chemistry, with the advantage that a 
cloning step was not required. The method became highly popular for this reason, but 
fell out of favour due to improvements to the sanger-sequencing method, coupled with 





Dideoxy/Chain Termination Sequencing 
 
Figure 7: Dideoxy or ‘chain termination’ sequencing, developed by Fredrik Sanger. The different 
positions at which chain termination occur in the different reactions show positions where that 
base appears in the sequence. For a 10bp sequence for example, if the reaction containing ‘A’ 
chain terminating nucleotides created products that were 3, 4 and 5bp; the ‘G’ reaction created 
products that were 1, 2 and 6 bp; the ‘C’ reaction an 8bp product and the ‘T’ reaction 7, 9 and 10bp 
products, the sequence of the original fragment would be determined to be ‘GGAAAGTCTT’ 
The completion and digital recording of the first bacteriophage genome was quickly 
followed by the completion of other small genomes. This eventually led to the creation 
of an international digital database to store the information, called GenBank in 1982. 
The availability of this data to other scientists led to the rapid development of tools to 
analyse and manipulate the data, such as the FASTA format for storing and searching 
for sequence information. Improved computing technology also allowed increased 
automation of the Sanger method, resulting in platforms such as the Life Technologies 
Genome Analyser, which is capable of sequencing hundreds of base pairs of multiple 
samples in a few hours.  
Milestones in Genome Sequencing 
As the number of small genomes that had been sequenced successfully grew, so did 
the attraction of the challenge of sequencing the human genome. Plans to sequence 
the human genome were officially made in 1985, with the project starting in 1990. The 
project was completed in 2003, covering 99% of the genome, 92% of that with an 
accuracy of 99.99% (Schmutz, Wheeler et al. 2004). The project started out using 
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sanger-sequencing methods, but adopted more sophisticated approaches as new 
technology became available. A significant portion of the project was carried out via 
shotgun-sequencing, developed in principle in 1977.  
Shotgun sequencing combined sanger-sequencing with clonal amplification and also 
introduced paired-end sequencing.  The technique was cumbersome and 
computationally more taxing than its predecessors, but invaluable for novel genome 
assembly. DNA is sheared randomly into fragments, normally >2 and <150Kb in length. 
A particular size is amplified clonally in a vector (such as bacterial artificial 
chromosomes (BAC)) and then each fragment is sequenced by chain-termination from 
both ends. The sequencing of both ends of each fragment is a crucial aspect of this 
technique: it allows two distant sequences to be linked, as they are known to be (i) 
orientated in opposite directions from one another and (ii) a distance from one another 
that is approximately equivalent to the fragment length.  Multiple clonal fragments from 
circular vectors can be cut into linear molecules with different start and end positions. 
By sequencing both ends of each of these fragments (sanger-sequencing can now 
sequence up to 1000bp DNA), the entire sequence of the fragment can eventually be 















Shotgun Sequencing Methodology 
 
Figure 8: Shotgun Sequencing Methodology. Genomic DNA is sheared at random into small 
fragments (2-150Kb). Specific size selected fragments are added into a vector such as BACs and 
clonally amplified. The clonal copies are cut at random positions to create linear DNA strands. The 
fragments are sequenced from both ends. The original sequence can be resolved by compiling 
overlapping sequences into ‘contigs’.  
The human genome project was completed ahead of schedule and under budget, 
thanks to the boom in sequencing technology and bioinformatics that it created. Data 
from the project is freely available online or to download and several newer builds 
improving on the initial assembly have been released. The data, hosted by the UCSC 
Genome Bioinformatics Site and Ensembl Genome site, have since been cited by 
innumerable research papers. The completion of this project inspired even more 
ambitious sequencing challenges, many of which have already been completed: the 
1000 genomes project; the compilation of the Neanderthal genome; the $10,000 
genome project. The $1000 human genome challenge was to sequence a human 
genome for less than $1000 dollars and was completed by Illumina when they released 
their X10 sequencing instrument (Sheridan 2014). The 100,000 genomes project 
(sequencing 100,000 genomes from people with rare disease or cancer) is still 
underway. These sequencing milestones have been accompanied by the development 
of many different bioinformatics tools to analyse the data (Baird, Driscoll et al. 1981, 
Conesa, Götz et al. 2005, Li, Yu et al. 2009, McKenna, Hanna et al. 2010). The 
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projects themselves have been made possible by the development of increasingly 
sophisticated sequencing technologies: namely the development of Next Generation 
Sequencing.  
Timeline of Significant Advances in Genome Sequencing 
 
Figure 9 Timeline of Significant Advances in Genome Sequencing. The Human Genome Project. 
1990-2003; The $1,000 Genome Project, 2004-2014; The first individual genome sequenced, 2007; 
The 1,000 Genomes Project, 2008-2012 (Consortium 2012); The completion of the Neanderthal 
genome in 2013 (Prufer, Racimo et al. 2014); The $100 Genome Project, started by Genia in 2011 
and ongoing; The 100,000 Genomes Project, started in 2012 by Genomics England and ongoing 
NGS sequencing 
Next Generation sequencing platforms are united by their ability to sequence many 
thousands of DNA fragments, from multiple samples, simultaneously. Many different 
platforms have been developed, with different advantages and disadvantages for 
various sequencing applications. Three companies produce the majority of NGS 
platforms currently used: 
Illumina 
Illumina platforms operate through ‘sequencing by synthesis’. DNA is prepared for 
sequencing in advance by shearing it into small fragments, blunt ending and 
adenylating the fragments and then ligating adaptors and identifying index tags to the 
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ends of the fragments. The DNA fragments are denatured to single stranded and 
ligated to a glass slide called a ‘flow cell’. The flow cell has eight deep channels to 
maximise its surface area. It is coated with adaptors complimentary to those of the 
DNA fragments, which are able to ligate to them. The DNA fragments are then ‘bridge 
amplified’: they bend over forming a bridge shape between two of the adaptor 
molecules on the flow cell. The fragment is then amplified, beginning from the end of 
the ligated adaptor to which the DNA molecule has attached and extending across the 
bridge. Both molecules break away from one another and straighten out through 
another denaturing step. The process is repeated, and both clonal fragments undergo 
new bridge amplifications. Each amplification cycle doubles the number of clones 
produced. The result is many clusters of identical single stranded DNA fragments in 
very small, localized area. This allows detection of the florescent signal generated from 
the clone.  
The actual sequencing of the fragments employs a ‘sequencing by synthesis’ 
technique. Fluorescently labelled nucleotides are washed over the flow cell. Different 
fluorescent tags are attached to the four different nucleotides. The nucleotides 
polymerase against the single stranded DNA fragments ligated to the flow cell to create 
double stranded molecules. Each time a nucleotide is incorporated into a new 
molecule, it release its fluorescent label. A high definition camera within the instrument 
records the combined signal emitted by each clonal cluster of DNA fragments, and 
interprets this as the fragment sequence. It also assigns a quality score to each 
nucleotide it calls.  
Thermo Fisher Scientific (formerly Life Technologies) 
Ion torrent platforms (Thermo Fisher Scientific) employ semiconductor sequencing and 
emulsion PCR. DNA is sheared into small single stranded fragments. Each fragment is 
ligated to a magnetic bead. An emulsion PCR is performed that creates an isolated 
PCR reaction for each bead. The PCR reaction continues until the bead is completely 
covered with clonal copies of the original DNA fragment. The beads are then added to 
an ion-chip covered with wells large enough for only a single bead. Different DNA 
bases are washed sequentially over the chip. If that base is incorporated into the DNA 
fragments on the bead, they release a hydrogen ion. The change in pH this causes in 
the solution surrounding the chip is detected by an ion sensitive layer at the base of the 
well. A different nucleotide is then washed over the chip and the process is repeated. 
Homopolymers cause release of a larger number of ions, and can be identified the pH 




Single molecule sequencing is an emerging technology, with the first platform operating 
using this chemistry – the MinION (Oxford Nanopore, UK) released this year. 
Sequencing produces ‘2D’ reads of DNA molecules: one read of the forward strand 
followed by a read of the reverse strand connected to it by a hairpin structure, to 
produce a consensus for each base position. The platform is extremely small and low 
cost; library construction is simple and doesn’t involve amplification steps (Cherf, 
Lieberman et al. 2012). Sequencing single molecules is a potentially enormous 
advance for sequencing technology which could allow accurate sequencing of 
repetitive regions and immediate resolution of novel variants. Recent studies examining 
the potential of the MinION platform to sequence the phage lambda genome reported 
achieving an average read length of 5Kb, but with a high base call error rate (Quick, 
Quinlan et al. 2014). Work is currently underway to improve the accuracy of MinION 
sequencing, but it is not yet at a stage where it can be used as a reliable diagnostic tool 
(Madoui, Engelen et al. 2015).  
Next generation sequencing has many advantages compared to previous sequencing 
technologies: its high sequencing capacity can be used to assemble an entire genome, 
to sequence a targeted region of interest from multiple samples, or to sequence target 
regions in individuals at a very high read depth. High read depth can allow detection of 
non-germline, minor allele and low copy sequences normally masked by the genomic 
background. NGS also has the advantage that while regions of interest can be targeted 
specifically, this can be done with a high tolerance for novel sequences that might exist 
within those areas. This is something that cannot be done in PCR-based technologies, 
where prior knowledge of the target sequences is necessary for primer design. The 
technology has huge diagnostic potential, and in the context of haemoglobinopathy 
diagnosis could potentially replace the battery of tests currently employed. In addition 
to matching the accuracy of the current diagnostic standard, NGS has the scope to 
improve upon it by allowing other clinically important variants outside the globin genes 
to be included in diagnosis, such as those associated with risk of preeclampsia and 
modifiers of haemoglobinopathy disease state, as well as sex determination.    
Although NGS platforms represent a great advance in sequencing technology they still 
have some shortcomings: platforms are costly; PCR contaminants and excessive PCR 
duplicates can hinder results; semiconductor and pyrosequencing platforms have 
issues with accurate sequencing of homopolymer repeats; base calling accuracy tends 
to diminish with read length; false positive and negative rates can be high if data is not 
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treated with appropriate stringency; long repetitive regions cannot be targeted 
accurately. The sequencing capacity of the machine also means a trade-off is required 
between number of samples sequenced, size of region sequenced, and read depth 
produced. Many of these problems may cease to be with the development and 
refinement of new ‘third generation’ sequencing technologies such as nanopore 
sequencing.  
Data analysis itself is also an issue: alignment programs struggle to correctly align 
reads situated in highly homologous sequences such as repeats or very similar genes, 
such as HBG1 and HBG2. Analysis can also be hindered by the bulk of sequence that 
these platforms produce, which many non-specialised centres many not have the 
computing capacity to store or manipulate.  
Summary, AIM 
At the outset of this project NGS sequencers were just becoming widespread in 
diagnostic labs. Their application to haemoglobinopathies was questionable as not all 
globin genes need to be sequenced diagnostically and the clinically relevant genes and 
regions are small, lending themselves well to Sanger Sequencing. CGH array had 
been investigated by the diagnostic group at Kings College Hospital and others 
(Phylipsen, Chaibunruang et al. 2012) looking at mapping and characterising large 
structural haemoglobinopathy variants. CGH array technology was effective at 
identifying deletions and duplications but breakpoint mapping was not possible in every 
case and balanced translocations could not be detected. CGH array was applied to 
haemoglobinopathies as another methodology in the battery of techniques used for 
diagnosis, whereas NGS had potential to replace all tests, with a single methodology, 
which would give a definitive diagnosis in all cases. The benefits of streamlining the 
diagnosis could standardise the diagnostic approach and align with other genetic tests 
carried out in the lab for other diseases. This could therefore make the lab more 
efficient and ensure all variants are identified within the 10 working day turnaround time 
for antenatal assessment, irrespective of how common they are.  
Before starting the project it was assumed that small sequence variants would be 
detected and that the large structural variants would be a challenge, although the lab 
had no experience of NGS data generation or analysis. Once this assessment of NGS 
is complete, the aim will be to implement it into routine diagnosis. This thesis describes 
the technological assessment of NGS as applied to haemoglobinopathies, a disease 
group that covers a complete range of mutation types and would therefore have 






Ethics approval: Use of Residual Clinical Samples 
Extracted DNA, residual from clinical testing, does not contain cells and therefore does 
not come under the Human Tissue Act (2004) but falls under common law and 
professional guidance, this is provided by the Royal College of Pathologists.  
In accordance with the Royal College of Pathologists guidance:  
 The retention and storage of pathological records and specimens (5th edition, 
April 2015) 
 Guidance on the use of clinical samples for a range of purposes that are not 
within the remit of Research Ethics Committees (RECs) (3rd edition) 
 Consent and confidentiality in clinical genetic practice: Guidance on genetic 
testing and sharing genetic information 
Prior consent was obtained for genetic testing, long term storage of DNA samples and 
use of residual DNA samples for controls or test development. 
The Sample Cohort 
Residual clinical samples came from patients who had undergone genetic testing for 
haemoglobinopathies at King’s College Hospital. These samples came from individuals 
of both genders, all ages and a variety of ethnic backgrounds. In most cases a deletion 
or duplication had previously been identified by MLPA or Sothern blotting. Therefore 
the genetic cause for the haemoglobinopathy had been identified but the structural 
variant had not been characterised.  
Red Cell Indices 
For some samples, haematological data was available which could be used to predict 
whether the variants in the sample affected the alpha or beta globin gene loci. This 
data and its normal interpretation are summarised in Table 2. Globin percentage data 
is obtained through an HPLC assay, and the other indices through a full blood count 
(FBC). For details of these, refer to Table 1.The ‘normal’ reference ranges vary 




Table 2 Red cell indices 
Metric Meaning Diagnostic use 
HbA2 % Percentage of HbA2 in blood 
(composed of alpha and delta globin) 
Raised in beta thalassaemia 
trait (>3.4%) reference range 
is generally set at 2-3.4% 
HbF % Percentage of foetal haemoglobin in 
blood (composed of alpha and gamma 
globin) 
May indicate 
diserythropoesis. Raised in 
some conditions, including 
some forms of beta 
thalassaemia Noted when 
above 5%. 
RBCx1012/L Red Blood Cell Count Raised in thalassaemia 
(varies with age, gender and 
other factors). The normal 
ranges used for men and 
women are: 
4.5-6.5 males 
3.8-5.8 women  
Hb Concentration of haemoglobin in the 
blood 
Haemoglobin less than 100 
g/L indicates anaemia, which 
can be caused by 
haemoglobinopathies or iron 
deficiency 
MCV Mean corpuscular volume (volume of 
red blood cells) 
Normal range is 78-100 fL 
Less than this indicative of 
thalassaemia  
MCH Mean corpuscular haemoglobin 
(amount of haemoglobin within red 
blood cells) 
Normal range is 27-32 pg 
Less than this is indicative of 
thalassaemia  
 
Automated DNA extraction 
DNA processed by the Molecular Pathology laboratory at King’s College Hospital was 
extracted using the QIAsymphony (Qiagen, Germany). Extraction was performed in 
accordance with the manufacturer’s protocol, as part of standard laboratory practice. 
The primary blood collection tube was loaded onto the instrument with a pre-labelled 
2ml DNA collection tube in a corresponding rack. 1ml of EDTA blood was extracted, 
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using the Qiagen Midi kit eluted into 200 µL of buffer yielding 30-150 ng/µL gDNA. If 
more DNA was required then the programme was run multiple times eluting into the 
same 2ml screwcap collection tube. 
Phenol-Chloroform DNA Extraction (manual)  
Solutions referred to throughout ‘Methods’ are listed in Appendix 2: List of Solutions 
Phenol-Chloroform DNA extraction was used to purify DNA from blood samples 
collected from outside the routine diagnostic route at King’s College Hospital. This 
procedure was performed by Mrs Helen Rooks, Department of Molecular Haematology, 
King’s College London. The details of the procedure are given in Appendix 4.  
DNA Quantitation 
Before the DNA was used in any downstream reactions a number of quality metrics 
were assessed including concentration and purity. This checks that the extraction 
process has been successful and ensures the quality of the extracted DNA is of a high 
standard and reduces the downstream failure rate. Assessing the size range and 
distribution of DNA fragments in the sample was also important during NGS library 
preparation and was measured in a few ways depending on the availability of 
apparatus.  
Nanodrop 
The Nanodrop Spectrophotometer ND-8000 (Thermo Scientific, USA) was used to 
quantify DNA extracted from blood as part of routine laboratory practise. The 
concentration of a dsDNA sample (in ng/µL) is made based on its absorbance of light in 
a 260 nm wavelength over 1-2 ms with the assumption that a DNA concentration of 50 
µg/ml absorbs 1 unit. The Nanodrop calculates the purity of a DNA sample based on 
the ratio of the sample’s absorbance of 260 nm and 280 nm light wavelengths. A ratio 
of >1.8 was considered acceptable with minimal contamination. 
The Nanodrop was initialized upon power-up by adding 2 µL water to each pedestal 
and selecting ‘Initialize’ in the software. The pedestal was wiped clean with a lens 
cleaning tissue and a 3 µL blank (molecular grade water or AE buffer for Qiagen 
Symphony extracted DNA) was added to the pedestals. After a blank measurement 
was taken the pedestal was wiped clean again. 3 µL of DNA sample was placed on the 
pedestal and its concentration was measured. Results were displayed in a table and 
stored electronically and automatically. The pedestal was cleaned between different 




The QuBit 2.0 Fluorometer (Life Technologies, USA) Broad Range and High Sensitivity 
kits were used according to the manufacturer’s protocol.  The QuBit measures the DNA 
concentration of a sample by measuring the fluorescent signal emitted by the QuBit 
reagent, which fluoresces only when bound to DNA. The High Sensitivity kit was used 
when sample concentration was expected to be <5 ng/µL. For other applications the 
Broad Range kit was used. For each use of the instrument, a fresh QuBit Assay Mix of 
1:100 QuBit Reagent : QuBit Sample Buffer was made up. ~200 µL per sample is 
required, plus 380 µL to make up the two standards necessary for quantitation. 5 µL of 
dsDNA was added to 0.5 ml QuBit assay tubes. 195-198 µL QuBit Assay Mix was 
added to make a final volume of 200 µL. The DNA and Assay Mix were mixed by 
pipetting and vortexing briefly. Two standards (Standard #1 and Standard #2, provided 
with the kit) were made up by mixing 10 µL of each standard with 190 µL of the Assay 
Mix in a QuBit Assay Tube. The QuBit was turned on and the desired assay function 
was selected. Both standards were placed in the QuBit and measured for calibration. 
These two standards are used to draw a standard curve from which unknown samples 
were calculated. Assay tubes containing sample DNA were then measured. The 
dilution factor was programmed into the machine in order to calculate the concentration 
of the original sample by reading from the standard curve. This technique is more 
accurate than UV absorbance measurement by the Nanodrop, as there is no 
interference from proteins and other contaminants and does not measure single base 
nucleotides. Qubit concentrations are particularly useful at low DNA concentrations 
where other techniques are less accurate.   
Agarose gel electrophoresis 
For a 1.5% gel, 1.5 g agarose powder (BioGene, UK) was added to 100 ml 1x TBE 
Buffer and heated in a microwave on full power until the agarose had dissolved and the 
solution was clear (approx. two minutes). The dissolved agarose was cooled by holding 
the flask under a running cold tap until it was comfortable to hold by hand. 5 µL of 10 
mg/ml ethidium bromide was added to the agarose solution (final concentration 0.5 
ng/ml). The solution was poured into a gel tray and left to set with a comb with 
appropriate number of slots for the number and volume of the samples. DNA samples 
(2-5 µL) were made up to 10 µL with nuclease free water and 1.5 µL 6x bromophenol 
blue gel loading dye (Sigma, USA). Once the gel was set it was submerged in a gel 
tank containing 1x TBE Buffer. The DNA samples were loaded into the slots, along with 
an appropriate sized DNA ladder, often 50 ng of 1 Kb DNA ladder (Invitrogen). The gel 
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was run at 100 V for 1-2 hours until the individual fragments had resolved, separation 
was viewed using a gel documentation system (Syngene, UK?). DNA fragment size 
was estimated by comparison to the DNA ladder electrophoresed in parallel with the 
samples. Gel images were saved as (.SGD and .JPEG file types) using GeneSnap 
software (Syngene). 
Bioanalyser 
The 2100 Bioanalyser (Agilent, USA) measures DNA fragment size, distribution and 
concentration by digital electrophoresis. In principle, the DNA is labelled and 
electrophoresed through a gel-dye matrix to separate the different sized fragments and 
the electrophoresis is visualised in real time. This method is very accurate at visualising 
small fragments of similar size <500 bp which can be difficult to resolve by agarose gel 
electrophoresis. The Bioanalyser also has the added advantage that it can measure 
the concentration of the various size fractions by comparing to known standards run in 
parallel.  All reagents were equilibrated to room temperature for 30 minutes before use. 
The reagents are light sensitive and were kept out of bright light in a box for this period. 
If necessary, a new aliquot of gel-dye mix was prepared: The DNA Dye Concentrate 
was vortexed and 25 µL was added to a DNA Gel Matrix vial. The solution was 
vortexed and centrifuged at 2240 x g briefly in a micro centrifuge. The mixture was 
transferred to a supplied spin filter tube. The spin filter tube was centrifuged at 2240 x g 
for 15 minutes. The gel-dye mix was stored in aliquots for use for up to 2 weeks. 
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Setting up the Bioanalyser Chip Priming Station 
 
Figure 10: Setting up the Chip Priming Station. Figure modified from images in the Agilent DNA 
1000 Kit Quickstart Guide G2938-90015 (for URL, see appendix 2) 
A new DNA chip was removed from its packaging and the glass was inspected for any 
cracks. The chip was placed in the chip priming station. The base of the chip priming 
station was set to position ‘C’ and the syringe holder was set to the lowest position 
(See Figure 10). Nine µL of the Gel-Dye Mix was added to the well, marked with a 
circled ‘G’ (See Figure 11). 
A Bioanalyser Chip 
 
Figure 11: A Bioanalyser Chip. Positions of sample wells, ladder well and well ‘G’ labelled.  
Any bubbles in the gel were removed by pipetting. Ensuring the syringe plunger was 
fully retracted, the gel priming station was locked into place on top of the chip. The 
plunger was slowly depressed until it could be secured under the catch. After exactly 
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one minute, the catch was released. After 5 seconds, the plunger was pulled back to its 
starting position and the chip was removed from the chip priming station. A further 9 µL 
of Gel-Dye Mix was added to the two additional wells marked with ‘G’. Five µL of 
Marker was added to all the 13 wells of the chip (12 sample wells and ladder well) that 
were not marked with ‘G’. One µL of DNA ladder was added to the well with the ‘ladder’ 
symbol. One µL of sample was added to each of the sample wells, or if less than 12 
samples were being run, 1 µL of deionised water was added to any unused wells. The 
chip was placed horizontally in the provided chip vortex adapter and vortexed at 2400 x 
g for exactly one minute. The chip was placed in the Bioanalyser and ‘start run’ was 
selected. It was necessary to start the run within five minutes of removing the chip from 
the vortex for best results.  
Closing the lid of the Bioanalyser lowers an electrode into each well. The electrodes 
are activated one well at a time. The electrodes produce a charge which causes the 
polar DNA molecules to migrate through the gel. A laser shone on the well causes the 
dye in the gel to fluoresce if it is bound to a DNA molecule. The size of the fragments in 
the well is measured by the speed at which they migrate through the gel, and their 
concentration is measured by the strength of fluorescence the sample emits.  The 
Bioanalyser 2100 Expert Software produces an electropherogram of the sample. The 
size and concentration of the DNA in the sample can be determined by comparison to 
a DNA ladder run in a separate well and to lower and upper size markers included in 
the sample buffer which is added to each well. The results were exported as .xad run 
file and a .pdf report file.  
Tapestation 
DNA fragment length was calculated using the 2200 Tapestation (Agilent, USA). The 
D1000, D1000 High Sensitivity and Genomic DNA kits were used according to the 
manufacturer’s protocol. The D1000 High Sensitivity kit was used when sample 
concentration was expected to be <5 ng/µL. The Genomic DNA kit was used when the 
mean DNA fragment size was expected to exceed 500 bp. For all other assays the 
DNA 1000 kit was used.  
The reagents and screen tape were equilibrated to room temperature for 30 minutes 
before use. As the reagents are light sensitive, they were kept in a box away from 
bright light during this time. For the D1000 and gDNA assays, 3 µL of Sample Loading 
Buffer was added to an 8 well PCR strip tube (Starlab). One µL of D1000 ladder was 
added to the first tube. One µL of DNA sample was added to each other tube. For the 
High Sensitivity kit, 2 µL Sample Loading Buffer was added to the 2 µL of Ladder and 2 
74 
 
µL DNA samples. The tubes were centrifuged briefly in a minifuge to bring all liquid to 
the bottom, then placed in a 96 well plate adapter on a vortex mixer and vortexed at 
2400 x g for one minute. The tubes were centrifuged again to return all liquid to the 
bottoms of the wells. The tubes were placed in the Tapestation in the strip tube 
adapter, with the ladder in the top right position. The tip rack was filled with Agilent 
Tapestation tips, and the used tip tray was emptied prior to the run. The tape was 
placed in the tape reader with the barcode at the front, on the left hand side where it 
could be scanned by the instrument. Lids were removed from the strip tubes. The 
instrument was closed and the run was initiated. The Tapestation measures the size 
and concentration of DNA fragments in the sample using a similar methodology to the 
Bioanalyser, but each sample migrates through a lane in the screentape, rather than 
across a well. The Tapestation produces an image of the electrophoresis through the 
screentape that is converted into an electropherogram trace whereas the Bioanalyser 
produces an electrophoresis trace as its primary output. As a result the Bioanalyser is 
more accurate at sizing fragments but is slower and prone to more issues.  The results 
from the Tapestation were saved as instrument/tape specific file types (.D1K, .D1KHS, 
etc.) and exported as a .doc report file.  
Sample Fragmentation 
Covaris 
The Covaris E220 (Covaris, USA) was used to shear genomic DNA into fragments of 
various size ranges by sonication. Three to five µg of high molecular weight genomic 
DNA for each sample was made up to a total volume of 130 µL in nuclease free water 
and then placed in AFA fibre crimp cap 6x16 mm microtubes (Covaris). The Covaris 
E220 tank was filled with Millipore water up to level 6, so that tubes would be immersed 
in the water during sonication. The chiller and pump were switched on and left for 45 
minutes to degas and cool the water to 4° C prior to use.  Samples were placed in a 96 
position rack and sheared to the desired size according to the parameters provided by 








Table 3 Shearing parameters for Covaris E220 





bp Parameter Description 
PiP The instantaneous power in Watts transmitted 
to the acoustic transducer during the “on” time 
of each acoustic burst. * 
175 140 105 
DF Percentage of time that the  
transducer is “on” and creating acoustic waves* 
10% 5% 5% 
Cycles Per 
Burst 
The number of waves generated by the 
transducer in a burst.* 
200 200 200 
Treatment 
time 
Time in seconds of treatment 180 55 80 
Temperature Temperature of waterbath in Celsius 7°C 7°C 7°C 
Water bath 
level 
Level to which waterbath is filled 6 6 6 
*Parameters for shearing as defined by the Covaris User Guide. These parameters 
were used for creating 200 bp fragments. 
Post shearing a small aliquot of samples was run on the Bioanalyser or Tapestation to 
check to size distribution of the fragments. It was important to remember the size 
limitation of the technique as some larger fragments may not be visible when run with 
specific consumables. Comparing the total estimate of DNA from the Tapestation to the 
Qubit was useful. 
Bioruptor 
This instrument is similar to the Covaris in that it shears DNA to a desired size range 
using sonication. This instrument provides less control over the shearing parameters 
and yields fragments in a broader range around the desired fragment size. 
To shear DNA into ~500 bp fragments 3.5 µg DNA was made up to 100 µL with 
molecular grade water. The DNA sample was placed in a 1.5 ml microcentrifuge tube in 
a tube holder and inserted into the bioruptor’s chilled water bath. The program used to 
shear the DNA was 15 cycles of 30 seconds ‘ON’, 30 seconds ‘OFF’ high intensity 
sonication. No other parameters were available to modify the distribution of fragments 
and this was a limitation of the apparatus. 
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Size Selection with SPRI-Select Beads (Beckman Coulter, USA) 
SPRI beads are 1.5 nm in diameter. They comprise of a polystyrene core coated with a 
layer of magnetite and an outer layer of carboxyl molecules. DNA is a polar molecule 
that can bind reversibly to the carboxyl molecules on the bead’s surface in a manner 
dependent on the concentration of polyethylene glycol (PEG) and salt to which it is 
exposed. DNA-bound SPRI beads can then be extracted from a solution via magnetic 
separation. This process is used to purify DNA from solutions that may contain PCR 
inhibitors or other impurities. The amount of DNA that can bind to a SPRI bead is 
dependent on the concentration of PEG buffer. With a concentrated buffer solution 
small fragments of DNA (≥100 bp) can be bound and as the buffer is diluted the beads 
are only able to bind larger fragments, therefore fragments <100 bp are never captured 
(See Figure 12).  
SPRI beads can therefore be used to purify DNA, concentrate it, or, by changing the 
buffer conditions, extract DNA fragments of a specific size from a wider population. 
Beckman Coulter produce a range of beads for different DNA purification applications: 
AMPure XP beads are a generic bead used to remove contaminants from a DNA 
sample and to concentrate DNA fragments or PCR products; SPRIselect beads are 
similar to AMPure beads except the buffer and bead concentrations are more 
accurately prepared, ensuring the highest consistency in size selection and purification. 
SPRI-select and pre-PCR AMPure bead steps were performed on different sides of the 
laboratory ensuring PCR product purification (using AMPure beads) never 
contaminated the NGS workflow (SPRI-Select beads). CleanSeq beads are specifically 
designed to purify small DNA fragments for Sanger sequencing, removing residual 
unincorporated labelled nucleotides. Using these beads to purify sequencing templates 
allowed the process to be easily automated on a BioMek NX (Beckman Coulter, USA).  
‘SPRIselect’ beads were used to select a specific size range of DNA fragments after 
sonication. Figure 12 shows a titration of different SPRIselect concentrations and its 
effect on the ability to recover a DNA ladder. This was used as a guide for our DNA 
selection experiments. Using two independent bead captures at different 
concentrations permitted capture of a specific size range of DNA from the broader 






DNA Size Selection using SPRISelect Beads
 
. 
Figure 12: Size selection using SPRIselect beads. Upper image: DNA fragment ranges selected by 
different ratios of SPRI beads to sample (See Appendix 1 for URL).  
Lower image: A DNA sample contains DNA fragments of various sizes at different concentrations. 
SPRI-select beads can be added to the DNA sample. The beads bind preferentially to larger 
fragments. The range of fragment sizes bound to the beads depends on the amount of beads 
relative to the concentration of the DNA sample. This attribute is used to select specific size ranges 
of DNA fragments: a right handed size selection binds unwanted large fragments to the beads, 
then discards the bead pellet leaving the desired smaller fragments in the supernatant. A left-
handed size selection removes unwanted small fragments by discarding the supernatant and 
purifying the bead-bound DNA. A double size selection can be performed to acquire a specific 
range of fragment sizes by removing and discarding large fragments in a right handed size 
selection, followed by removing and discarding small fragments in a left handed size selection. The 




The beads were shaken thoroughly to re-suspend them in the PEG buffer solution. A 
0.4x to 2x ratio of beads to DNA sample volume was added to DNA in 1.5 ml tubes. For 
example, if a 0.6 x concentration was required for 100 µL DNA, 60 µL SPRIselect 
beads were added. The solution was mixed briefly by vortexing and then left at room 
temperature for five minutes. The tubes were then placed in a magnetic rack and left 
for 3-5 minutes until the solution was clear and the beads had formed a pellet on the 
side of the tube against the magnet.  
For right-handed size selection the supernatant was aspirated and discarded 
(containing small unbound DNA fragments). Keeping the tubes with the bead pellet in 
the rack, 500 µL of 85% ethanol (EtOH) was added to the tube and left to stand for one 
minute without mixing. The ethanol was aspirated and discarded. This was repeated for 
a total of two washes. The pellet was left to dry at room temperature for 10 minutes. 
Once the bead pellet was dry, the tubes were removed from the magnetic rack and the 
pellet re-suspended in the desired volume of molecular grade water.  
Left-handed size selection can also be performed. As with right-handed selection, the 
DNA and beads were mixed together and incubated at room temperature for five 
minutes, then placed in a magnetic rack. Once the beads have formed a pellet against 
the magnetic rack and the solution had cleared, the solution was aspirated and 
retained while the beads (which had bound the larger DNA fragments) were discarded. 
Additional beads are then added to the solution (taking into account the PEG it already 
contains) to bind to the remaining small DNA for purification. 
Higher throughput bead size selection can be performed in a 96 well plate, using 200 
µL rather than 500 µL of EtOH to wash the bead pellet. This process can be carried out 
by a liquid handling robot. 
AMPure XP Bead Purification 
AMPure XP beads (Beckman Coulter, USA) are identical to SPRIselect beads except 
that the bead and buffer concentrations are less accurately made so they are not 
suitable for fragment size selection.  
AMPure beads were vigorously re-suspended and allowed to equilibrate to room 
temperature for 30 minutes before use. Fresh 80% ethanol was made up using pure 
ethanol and molecular laboratory grade water. The beads were shaken again before 
use to re-suspend. The beads (at a volume of 1.8 x beads to the volume of the sample) 
were added to tubes/plates containing the sample. The beads and sample were mixed 
by vortexing or pipetting and incubated at room temperature for five minutes. The 
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samples were transferred to a magnetic plate or rack, where they were incubated for a 
further 3-5 minutes, until a pellet of beads had collected on the side of the tube against 
the magnet and the supernatant had cleared. The supernatant was removed and 
discarded. 500 µL 80% ethanol (for 1.5 ml tubes, or 200 µL for 300 µL 96 well plates or 
strip tubes) was added to the tube, left for one minute and then aspirated and 
discarded. This step was repeated for a total of two washes. The sample tubes 
remained in the magnetic rack during this time and care was taken not to disturb and 
aspirate any of the pellet. The samples were removed from the magnetic rack and 
added to a 37°C heat block, or left at room temperature until any trace remnants of 
ethanol had evaporated. The pellet was then re-suspended in 15-50 µL of nuclease 
free water.  
Vacuum Concentration 
Prior to use, the Vacuum Concentrator Plus (Eppendorf, USA) was run for 30 minutes 
with no samples in it to heat it to 30°C. Samples in open microcentrifuge tubes or PCR 
plates covered with perforated seals were then placed in the concentrator. Once 
started, the evaporation status of the samples was inspected every 10 minutes. The 
samples were removed once all DNA was completely lyophilized. The settings for 
concentration were: Break ON, Temperature 30°C, Mode V-AQ. The rotor speed was 
530 x g. Care was taken to ensure the concentrator was well balanced, with equal 
volumes of liquid to be evaporated from complimentary positions. 
Next Generation Sequencing 
For the experiments performed Agilent SureSelect XT library preparation was used in 
conjunction with Agilent “in-solution” bait capture target enrichment. These DNA 
fragment libraries were then sequenced on either the Illumina HiSeq 2000 or the 
Illumina MiSeq. The methodology was well suited to capturing a large contiguous 
genomic region in a single step without the need for multiplex PCR, therefore the 
relative proportions of DNA fragments would be preserved during the process allowing 
identification of copy number variants by relative coverage analysis.     
Samples were prepared for sequencing as described in Figure 13. Samples from 
different individuals were tagged with a 6-8 bp nucleotide index and pooled at an 
equimolar concentration prior to sequencing. The instrument performs three ‘reads’ of 
the base sequence of each DNA fragment: one read of the index tag and two reads of 
the DNA fragment sequence (one forward and one reverse). The instrument outputs 
the base calls of each individual DNA fragment sequenced and assigns them a quality 
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score. The 6-8 bp index sequences are read and the various samples are segregated 
by the sequencing instrument. The output from the sequencer is two FASTQ format 
files for each indexed sample, one containing the forward fragment sequences and the 
other containing the reverse sequences. The analysis and interpretation of this data is 
described later.  
Sample Preparation Process for Illumina Sequencing 
 
Figure 13: Sample Preparation Process for Illumina Sequencing. DNA is sheared into small 
fragments, blunt ended, adenylated and ligated to adaptors. Fragments that originated from the 
target region of the genome for this study were selected for via hybridization to a custom library of 
oligonucleotide probes, with sequences corresponding to sequences from the target region. These 
fragments were then isolated from the remainder of the sample through successive wash steps. 
Index tags were ligated to the fragments and then samples were pooled at an equimolar 
concentration for sequencing on the Illumina sequencing platforms.  
Agilent SureSelect Bait Capture Library Design 
RNA baits, 120bp in length, were designed to be complimentary to the region of the 
human genome that we wanted to sequence. The RNA bait length was automatically 
adjusted to ensure the Tm between baits did not vary significantly. Baits could be 
designed to cover the region of interest (ROI) at 1x tiling - so that every base is 
covered by one bait - or at greater depth up to 5x tiling (every base in the ROI is 
covered by 5 different baits).  For an RNA bait to bind a DNA fragment at a Tm 65°C 
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they must share at least 40 bp of complimentary sequence. Therefore, baits can 
capture DNA fragments with sequences extending beyond the bait covered region. 
This is a helpful feature when trying to sequence through short repetitive regions. The 
RNA baits are biotinylated and therefore after the baits have hybridised to the DNA 
they are mixed with iron-containing streptavidin beads, which can be selected for with a 
magnet. Off-target DNA fragments not bound to the beads are washed away, allowing 
for enrichment of the ROI. The selected fragments are then sequenced (Figure 14). 
SureSelect Target Enrichment Workflow 
 
Figure 14 SureSelect Target Enrichment System Workflow. Taken from Agilent web page: 
‘SureSelect Process – how it works’ (For URL see Appendix 1) 
Initial Library Design 
Bait Capture Library 1 was designed using the in-browser application eArray (Agilent). 
It targeted 2 regions – one on chromosome 11 and one on chromosome 16 – covering 
both globin gene loci in two contiguous regions. Non-exonic regions were also included 
in the design which covered a total of 4.7 Mb: 260 Kb of the alpha globin loci on 
chromosome 16 and 4.4 Mb on chromosome 11. The small region on the alpha globin 
gene locus was an error not detected until after submission. The library was designed 
with a 1x tiling frequency throughout, meaning the baits were head to tail and did not 
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overlap. Each design can have up to 57,750 baits and therefore this bait limit caused a 
design constraint.  Baits were not designed against repetitive regions because it would 
not be possible to target sequences specifically from the region of the chromosome we 
were interested in, as it would capture sequence from every location in the genome 
where the repeat sequence occurred.  
Baits were permitted to extend 20 bp into repetitive regions. Hybridization between 
RNA baits and DNA fragments required a minimum 40 bp match, so this was expected 
to be enough to specifically capture sequence from repetitive regions without also 
picking up large amounts of off target repetitive sequence. By including some of the 
repeat sequence we hoped to be able to sequence through some of the smaller 
repetitive regions. A summary of the library design parameters is shown in Table 4.  
Table 4 eArray design parameters for Bait Capture Library 1 
Parameter Selection 
Sequencing Technology Illumina 
Sequencing Protocol Paired-end long read 
Bait length (bp) 120 
Bait tiling frequency 1x 
Allowed overlap into avoided regions (bp) 20 
Strand Sense 
Species H. Sapiens 
Genome Target Intervals Chr11: 3,244,823 – 7,264,822 
Chr16: 0-260,000 
Avoid Standard Repeat Masked Regions Window masker and repeat masker 
The library was ‘boosted’ to compensate for high GC baits which were predicted to 
perform poorly. The degree of boosting was taken from SureSelect sequence data 
which showed lower coverage in GC rich regions (Guy’s Regional Genetics 
Laboratory). The boosting parameters are detailed below in Table 5. The GC content of 
each bait was calculated using an online pipeline at http://galaxyproject.org/ and 
separated into different percentage groups. The baits in each group could then be 
amplified accordingly. ‘Orphan baits’ are baits which are >20 bp from their nearest 
adjacent bait. These were also boosted to ensure they captured their region efficiently. 
These orphan baits were further boosted according to their GC content. Low GC/ high 
AT content was considered less of an issue at the time as the dataset used was from 
exon targeted panel and genes are considered to be more GC rich. The final baits 
included in the library design are shown in Figure 15. 
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Table 5 Boosting parameters for baits in Bait Capture Library 1 
GC content Boost for Non-Orphan Baits Boost for Orphan Baits 
<50% 1x 4x 
50-55% 1x 4x 
55-60% 2x 6x 
60-65% 5x 6x 
65-70% 6x 8x 
>70% 10x 10x 
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Bait placement in Bait Capture Library 1 
 
Figure 15 Baits Placement in Bait Capture Library 1. Baits displayed in the UCSC Genome Browser. 
Panels for each chromosomal region show baits in red, genes in blue and repeats in black. Orange 
bars highlight the positions of the globin genes.  
Second Library Design 
The second bait design (Bait Capture Library 2) targeted different regions and used 
different bait selection parameters to the first design. This was performed using 
SureDesign (Agilent), the next version on from eArray.  
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The design was extended to cover a larger region of chromosome 16. Regions on 
chromosomes 2 and 6 that influence the level of HbF in adults at steady state and can 
influence the severity of haemoglobinopathies were also included in the design. The X 
and Y chromosome were also targeted so that the assay could also be used for sex 
determination (which can be helpful in resolving or confirming sample mix-ups). The 
covered regions are listed in Table 6. 









Beta globin gene 
cluster 
chr11 4000078 7000522 3 Mb 
Alpha globin gene 
cluster 








chr6 135374939 135505003 130 Kb 
Sex determination chrX 11312846 11318819 6 Kb 
Sex determination chrY 2655007 2655666 600 bp 
 
We relied on Agilent’s newly developed boosting parameters to the library design. 







Table 7 Max Performance boosting parameters for Bait Capture Library 2 as 
recommended by manufacturer 
GC content Boost for Non-Orphan Baits Boost for Orphan Baits 
<30% 2x 4x 
30 - 60% 1x 2x 
60 - 66% 3x 3x 
66 -72% 8x 8x 
> 72% 16x 16x 
 
Tiling density and boosting parameters varied between different regions of the design, 
depending how crucial we expected that region to be for diagnosis: baits were placed 
most densely in the regions of the globin genes where thalassaemia-causing variants 
were most likely to occur. The regions covered by the design and the bait placement 
strategy assigned to the regions are outlined in Table 8. The new design covered 
approximately 2.8 Mb of sequence, falling into the <3 Mb library category (which 
requires a slight adjustment to the hybridization stage of sample preparation). The 
positions of baits on chromosomes 11 and 16 is shown in Figure 16 and the additional 
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Total 2,359,562 57,477 
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*Tiling density is the number of baits tiled over each base position in the target region. 
1x tiling covers each base once. 2x tiling overlaps bait positions by 50%, so each base 
is covered by 2 baits. 
**The bait placement algorithms avoid tiling over repetitive regions. The stringency with 
which repetitive regions are avoided can be: ‘least’ (3 separate repeat-masking tools 
mask avoided regions); moderate (2 separate repeat-masking tools mask avoided 
regions) or ‘most’ (any sequences masked by the Repeat Masker repeat-masking tool 
are avoided). 
***Boosting parameters determine the number of replicates of high-GC baits which are 
included in the library: ‘Max Performance’ boosts all probes in the design region 
according to the parameters in Table 7; ‘Balanced’ uses less probes and only applies a 




Bait Capture Library 2 Bait Locations: Chromosomes 11 and 16 
 
Figure 16: Bait Capture Library 2 Bait Locations: Chromosomes 11 and 16. Genes are shown in 
blue, baits are shown in green and repeats are shown in black. NB: Green lines appearing on the 
graph are due to incorrect rendering of all dense tiling in the genome browser.  
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Bait Capture Library 2 Bait Locations: Chromosomes X, Y, 6 and 2 
 
Figure 17: Bait Capture Library 2 Bait Locations: Chromosomes X, Y, 6 and 2. Bait positions are 
shown in the UCSC Genome Browser. Genes are shown in blue, baits are shown in green and 
repeats are shown in black. NB: Green lines appearing on the graph are due to incorrect rendering 
of dense tiling in the genome browser.  
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Manual Library Construction Process 
Experiments were performed in accordance with SureSelect Library Preparation kit 
(Agilent, USA) protocol version G7530-90000 (2012). For an overview of this process, 
refer to Figure 13 and Figure 14. Reagents from the following kits were used: Agilent 
SureSelect Library Preparation Kit (Part #G9612A), Agilent SureSelect Custom Target 
Enrichment Kit (Bait Capture Library 1 Part # 5190-4827; Bait Capture Library 2 Part 
#5190-4817), Agilent Herculase II Fusion Kit (Part #600675). The contents of reagent 
mixes are listed in ‘Appendix 1: List of Solutions’. 
DNA samples 
Non-degraded genomic DNA (3 – 5 µg) was sheared into fragments (variously 150 bp, 
500 bp, 600 bp) using the Covaris or Bioruptor in accordance with the manufacturer’s 
protocol. Shearing was checked using the Tapestation or Bioanalyser.  
The sheared product was purified using AMPure XP beads, with an input volume of 
180 µL beads, eluting in 50 µL nuclease-free water.  
End repair 
End repair reaction mix was made up on ice for each DNA sample (see appendix). For 
multiple samples, a master mix was made with 0.5 reactions excess. The end repair 
mix (52 µL) was added to 48 µL DNA sample and mixed by pipetting.  The reaction mix 
was incubated in a thermal cycler for 30 minutes at 20°C without a heated lid.  
This step is followed by an AMPure XP bead clean-up with using a bead volume 
equivalent to 1.8x the reaction volume, eluting in 32 µL nuclease-free water. This 
ensured recovery, clean-up and concentration of all DNA fragments from the reaction 
with no size selection. 
Adenylation 
Adenylation reaction mix was made up on ice for each DNA sample (see appendix). 
For multiple samples, a master mix was made with 0.5 reactions excess. 20 µL 
reaction mix was added to 30 µL DNA sample and mixed by pipetting. The mix was 
incubated on a thermal cycler for 30 minutes at 37°C without a heated lid.  
This step is followed by an AMPure XP bead clean-up with using a bead volume 
equivalent to 1.8x the reaction volume, eluting in 15 µL nuclease-free water. This 
ensured recovery, clean-up and concentration of all DNA fragments from the reaction 




Adaptor ligation reaction mix was made up on ice for each DNA sample (see 
appendix). For multiple samples, a master mix was made with 0.5 reactions excess. 37 
µL reaction mix was mixed with 13 µL DNA sample and mixed by pipetting. The mix 
was incubated for 15 minutes at 20°C on a thermal cycler without a heated lid.  
This step is followed by an AMPure XP bead clean-up using a bead volume equivalent 
to 1.8x the reaction volume, eluting in 32 µL nuclease-free water. This ensured 
recovery, clean-up and concentration of all DNA fragments from the reaction with no 
size selection 
Library amplification 
The optimal quantity of DNA for this reaction is 250 ng which was quantified on the 
QuBit. Surplus DNA was stored at –20°C. Pre-Hybridization PCR mix was made up on 
ice for each DNA sample (See appendix). For multiple samples, a master mix of the 
reactants was made with 0.5 reactions excess. The thermal cycler program was started 
(Table 9). 
Table 9 Thermal Cycler program for Library Amplification 
Step: Step 1 Step 2 (x6) Step 3 Step 4 
Temperature: 98°C 98°C 65°C 72°C 72°C 4°C 




1 minute 10 
minutes 
Hold 
 NB: Step 2 was repeated for a total of 5 cycles for QIAsymphony extracted samples 
and a total of 6 cycles for phenol-chloroform extracted samples due to their different 
amplification efficiencies  
This step is followed by an AMPure XP bead clean-up using a bead volume equivalent 
to 1.8x the reaction volume, eluting in 30 µL nuclease-free water. This ensured 
recovery, clean-up and concentration of all DNA fragments from the reaction with no 
size selection 
During library preparation the size and concentration of the fragments was measured 
on a Bioanalyser or a Tapestation (D1000 kit). As adapters were ligated to the DNA 
fragments they increased in size. Unincorporated adapters or non-ligated fragments 
could be seen and measured in the analysis therefore assessing reaction efficiency. 
Small peaks (<100 bp ) indicate the presence of primer dimer which must be removed 
by further AMPure purification. A ‘hump’ in the peak can indicate over amplification of a 
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subset of DNA fragments within the library (See MiSeq Sample 5 for an example of 
this).  
The concentration of prepared libraries was calculated using the QuBit (Broad Range 
Kit). 500 ng of DNA was used for library hybridization.  
Hybridization 
To avoid library evaporation, the labware for hybridization was tested prior to use: The 
combination of PCR plate, thermal cycler and sealing caps to be used were incubated 
at 65°C for 24 hours with wells containing 30 µL of water. Labware combination was 
changed if evaporation exceeded 33%. NB: This step of the process is complex and for 
clarity key terms have been colour coded. 
Five hundred ng of adapter ligated DNA was placed in 96 well plate and then 
completely lyophilized using a Vacuum Concentrator Plus (Eppendorf). A SureSelect 
Custom Target Enrichment Kit was used to hybridize the DNA to a custom bait library. 
The process is summarised below in Figure 18. 
Hybridization Buffer was prepared at room temperature for each reaction Occasionally 
a precipitate formed in the mix, in which case it was incubated at 65°C for 5 minutes. 
SureSelect Capture Library Mix was prepared on ice in a separate tube. The solution 
was mixed by pipetting and kept on ice until use. SureSelect Block Mix was prepared 
on ice in a separate tube (for reagents used to make each mix, see Appendix 1: List of 
Solutions)..  
The lyophilized DNA libraries were reconstituted in 3.4 µL of molecular grade water in 
separate wells of a PCR plate. 5.6 µL SureSelect Block Mix was added to each DNA 
sample. The DNA and Block Mix were mixed by pipetting up and down. The wells were 
sealed firmly with caps and placed in the thermal cycler. The thermal cycler program 
(Table 10) was started.  
Table 10 Thermal Cycler Program for Hybridization 
Step: Step 1 Step 2 
Temperature: 95°C 65°C 
Time: 5 minutes Hold 
Lid Temp: 105°C 
 
Reagents were loaded into the plate as illustrated in Figure 18: Once the thermal cycler 
reached 65°C, 40 µL Hybridization Buffer for each sample was loaded into separate 
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wells of the PCR plate in the thermal cycler and firmly sealed with caps. After the 
Hybridization Buffer had been incubated in the PCR plate at 65°C for 5 minutes, 7 µL 
of the Capture Library for each sample was added to separate wells of the PCR plate in 
the thermal cycler. The wells were sealed firmly with caps and the program allowed to 
run for a further 2 minutes. The lids were then removed and using a multichannel 
pipette, 13 µL of Hybridization Buffer was transferred into each of the wells containing 
the Capture Library. With the plate remaining in the thermal cycler, the lids were then 
removed from the wells containing the prepared DNA Library and SureSelect Block 
Mix. The entire contents (7 µL) of the wells were transferred to the wells containing the 
Capture Library and Hybridization Buffer using a multichannel pipette and mixed by 
pipetting slowly up and down 10 times before being sealed. A thermal mat was placed 
on top of the plate to improve the seal and reduce evaporation. The thermal cycler was 
then closed, and the reactants left to incubate at 65°C for 24 hours.  
PCR Plate Setup for SureSelect Hybridization
 
Figure 18 PCR Plate Setup for SureSelect Hybridization. Reagents and the wells to which they 
should be added in a 96 well plate are colour-coded.  
Separation of bait-bound DNA using Streptavidin beads 
Washing the beads 
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Streptavidin beads bind to the biotinylated baits which are hybridised to the DNA 
fragments of interest. The Streptavidin beads contain iron and can be held by a 
magnet, therefore while the beads bind the DNA fragments from the region of interest, 
the unwanted DNA fragments are washed away.  
The Streptavidin beads were prepared 30 minutes prior to the completion of the 24 
hour hybridization stage by washing them to remove preservatives: Dynalbeads, 
MyOne Streptavidin T1, were vigorously re-suspended on a vortex mixer. For each 
hybridization, 50 µL of beads were pooled in a single 1.5 ml microcentrifuge tube (max 
250 µL or 5 reactions). The beads were washed by adding 200 µL (per 50 µL beads) of 
SureSelect Binding Buffer, vortexed for 5 seconds and then placed in a magnetic rack. 
Once the beads had collected against the magnet, the supernatant was removed and 
discarded. After this had been repeated for a total of three washes, the beads were re-
suspended in 200 µL (per 50 µL beads) SureSelect Binding Buffer and divided into 
separate tubes for each hybrid capture.  
Binding the Hybridized library to the beads 
The hybridized libraries were added directly from the thermal cycler at 65°C into the 
microcentrifuge tubes containing 200 µL of room temperature beads and buffer. The 
tubes were inverted 3-5 times to mix and then attached to a Nutator and mixed gently 
at room temperature for 30 minutes. SureSelect Wash Buffer 2 was added to a 65°C 
heat block during this time for use later. After 30 minutes the microcentrifuge tubes 
were centrifuged briefly to remove any liquid from the lid. The tubes were then added to 
a magnetic separator rack and the supernatant was removed from the beads after 
standing for five minutes.  
Wash stage one 
The tube was removed from the magnetic rack and the bead pellet was re-suspended 
in 500 µL SureSelect Wash Buffer 1 (room temperature) by mixing on a vortex mixer 
for five seconds. The sample was then incubated for 15 minutes at room temperature 
and mixed briefly on a vortex mixer every three minutes. The microcentrifuge tubes 
were briefly spun in a centrifuge, and the supernatant was removed and discarded. 
This was repeated twice for a total of 3 washes in SureSelect Wash Buffer 1.  
Wash stage two 
The bead pellet was resuspended in 500 µL Wash Buffer 2 (pre warmed to 65°C) by 
vortexing for five seconds. The samples were incubated 65°C for 10 minutes, vortexing 
briefly every three minutes. The samples were placed in a magnetic rack. Once the 
supernatant cleared it was removed and discarded. This was repeated for a total of 
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three washes in pre-warmed Wash Buffer 2. The DNA was eluted with 30 µL nuclease 
free water. 
Selecting optimal bar codes for sequencing runs 
The barcodes used to identify different samples in a pool are supplied within the Agilent 
XT Library Preparation kit. When low numbers of barcodes are being used some 
combinations perform better than others. This is because the MiSeq camera uses the 
first cycles of sequencing by synthesis (which read the barcodes) to calibrate the 
camera and this requires it to see each different base fluoresce in each cycle. If neither 
the red nor green channel is activated for any of the samples at one base position, it 
will not be recorded. This causes the MiSeq to record incorrect barcode sequences 
which may inhibit de-multiplexing. Pooling recommendations distributed by Agilent 
were followed for low-plexity pools. These are outlined in the Table 11.  
Table 11 Optimal index combinations for low sample pools 
Pool of 2 samples: 
Index #6 GCCAAT 
Index #12 CTTGTA 
Pool of 3 samples: 
Index #4 TGACCA 
Index #6 GCCAAT 
Index #12 CTTGTA 
Pool of 6 samples: 
Index #2 CGATGT 
Index #4 TGACCA 
Index #5 ACAGTG 
Index #6 GCCAAT 
Index #7 CAGATC 
Index #12 CTTGTA 
 
Add index tags to library  
Indexing PCR mix was prepared using kit reagents (See appendix) on ice. For multiple 
samples, a master mix of the reagents with 0.5x excess was prepared. 35 µL was 
added to 14 µL captured on-bead DNA with 1 µL of the appropriate indexing tag for a 
total reaction volume of 50 µL. The thermal cycler program (Table 12) was started. 
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Table 12: PCR program for post-capture indexing PCR 
Step: Step 1 Step 2 (x12) Step 3 Step 4 













This step is followed by an AMPure XP bead clean-up with using a bead volume 
equivalent to 1.8 x the reaction volume, eluting in 32 µL nuclease-free water. The 
clean-up was performed in a designated post-PCR area. Recovery, clean-up and 
concentration captured all DNA fragments with no size selection. 
Quantifying and pooling the DNA 
The optimal amount of sequencing data per sample depends on the capture library 
size. Bait Capture Library 1 is a custom library of 4.26 Mb and the optimal output per 
sample is 426 Mb. For Bait Capture Library 2 which covers 2.78 Mb the optimal output 
per sample is 278 Mb.  
The Bioanalyser or Tapestation High Sensitivity kit was used to determine the quality 
and size range of DNA fragments in each sample, and to detect any primer dimer (if 
primer dimer was found additional clean-ups with the AMPure XP beads were 
performed until the dimer disappeared). The QuBit High Sensitivity kit was used to 
determine the concentration of the DNA samples and the pM concentration could be 
calculated using the molecular weight of an average nucleotide base pair and the mean 
fragment size taken from the Tapestation.    
Samples were pooled together to make an equimolar 2 nM pool in molecular grade 
water. These prepared libraries were stored at -20°C if not being sequenced 
immediately.  
Sequencing on HiSeq 2000 (in collaboration with Alexander 
Smith) 
Cluster generation and sequencing on the HiSeq 2000 was performed off site at the 
Department of Haematological Medicine, Rayne Institute, King’s College London by Dr 
Alex Smith. One 12 Sample Run was performed. Cluster generation was carried out  
using reagents from the Illumina HiSeq PE Cluster Kit (v2) (Illumina part # PE-401-
4001). Sequencing was performed using the HiSeq PE Sequencing Kit (v2) (Illumina # 
FC401-4001).Tris-Cl and NaOH were obtained from generic laboratory suppliers.  The 
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steps involved in cluster generation and HiSeq setup according to the current version 
of the protocol supplied by Illumina are outlined in Appendix 3.  
Sequencing on MiSeq  
The following steps are in accordance with the protocol provided by Illumina “Preparing 
Libraries for MiSeq (protocol part number 15039740 D)”. The MiSeq could produce 
7Gb data using the V2 2x 250 bp reagent kits and 13.2-15 Gb data using the V3 2x 300 
bp reagent kits.  
Denaturation and Dilution of DNA Sample Pool 
DNA samples that had been prepared for NGS were pooled together at a 2 nM 
concentration. 4-6 samples were pooled per run.  
The reagent cartridge was removed from -20°C storage and placed in a room 
temperature water bath up to the ‘max’ line on its’ side (approximately one hour to thaw 
and stabilise). The tube of HT1 Buffer packaged with the cartridge was set aside at 
room temperature until thawed. Once thawed, both were stored at 2-8°C until used.  
0.2 M NaOH was prepared freshly. Mixing 800 µL molecular grade water  with 200 µL 
of 1.0 M NaOH stock. The tube was inverted to mix. The dilution can be used for up to 
12 hours after preparation.  
2 nM pooled DNA library (5 µL) and 0.2 M NaOH (5 µL) were added to a 
microcentrifuge tube and vortexed briefly to mix. The sample was then micro 
centrifuged for 1 minute at 280 x g and incubated for 5 minutes at room temperature to 
denature the double stranded DNA. HT1 Buffer was removed from 2-8°C storage and 
990 µL of the buffer was added to the DNA/NaOH mix. This diluted the DNA to form a 
10 pM denatured library in 1mM NaOH, which was placed on ice.  
The library could be retained at a 10 pM concentration, or further diluted using pre-
chilled HT1 to 6 pM (360 µL DNA : 240 µL HT1) or 8 pM (480 µL DNA : 120 µL HT1) 
depending on desired clustering density. Dilution was followed by pulse mixing and 
brief centrifugation, and the denatured diluted library was stored on ice until use.  
Denaturation and Dilution of Phi-X Control 
2 µL of the Phi-X control was combined with 3 µL 10 mM Tris-Cl PH 8.5 with 0.1% 
Tween 20 in a microcentrifuge tube. 5 µL 0.2 M NaOH (prepared within the last 12 
hours) was added to the Phi-X control. The mixture was vortexed briefly and 
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centrifuged at 280 x g for 1 minute. The tube was then incubated for 5 minutes at room 
temperature.  
Pre-chilled HT1 (990 µL) was added to the 10 µL Phi-X library. The denatured library 
can be stored at -20°C for further use.  
For a v3 reagent kit, Phi-X control is used at this concentration (20 pM). For a v2 
reagent kit, a final dilution was performed prior to running, by combining 375 µL Phi-X 
with 225 µL pre-chilled HT1 to give a final working concentration of 12.5 pM and 
inverted several times to mix.  
Spiking the Denatured DNA Library with Phi-X 
Diluted denatured Phi-X control (6 µL) was added to 594 µL diluted denatured DNA 
pool, resulting in a 1% Phi-X spike. The mixture was stored on ice until use.  
Setting up a Run on the MiSeq 
The following steps are in accordance with the protocol provided by Illumina “MiSeq 
System User Guide (part #15027617)” 
Before removing reagents from cold storage, ensure that any pre-run washes required 
by the MiSeq have been carried out, with the wash cartridge filled with laboratory grade 
water.  
The thawed reagent cartridge was removed from 4°C storage. A lint free lab tissue was 
used to clean the foil seal over the reservoir labelled ‘load samples’. The foil was then 
carefully pierced using a 1 ml pipette tip. 600 µL prepared library with Phi-X spike was 
loaded into the opened reservoir, with care taken to avoid getting any sample on the 
foil seal.  
On the MiSeq instrument screen: 
Open ‘Manage Instrument’ and select ‘Reboot’ to restart the software. Reopen 
‘Manage Instrument’ and select ‘Sequence’. On the first screen – BaseSpace Options – 
select ‘Use BaseSpace for Storage and Analysis’ and click ‘NEXT’. A prompt appears 
to load the flow cell.  
Remove flow cell from cold storage at 4°C. Carefully extract flow cell from container 
using tweezers. Avoid touching glass with tweezers. The flow cell was carefully rinsed 
with laboratory grade water. The cell was then dried with lint-free lens cleaning tissues. 
The flow cell compartment was opened. A button releases the latch for the flow cell 
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stage. The flow cell was placed carefully on the stage, without touching the glass and 
the latch closed to hold the cell in place. The compartment was then closed.  
Once the flow cell is in place, the next prompt on the MiSeq instrument screen instructs 
the user to load the reagents and reagent cartridge. 
PR2 reagent bottle was removed from cold storage and inverted gently to mix. Reagent 
compartment was opened. Sipper handle was raised and locked into place. PR2 bottle 
was placed in right side of upright reagent chiller with lid removed. The waste bottle on 
the right of the upright reagent chiller was emptied and replaced. The lever was then 
lowered 
Reagent Cartridge was inserted into cartridge space on left hand of reagent chiller and 
the door was closed. Screen must show cartridge RFID has been read. 
A sample sheet was uploaded to the Experiment manager. Sample sheets can be 
created in advance with experiment manager or for experienced users as .csv files. 
Run parameters listed in sample sheet are shown in (Table 13). 
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After checking all the run parameters are correct the user tells the instrument to 
perform a pre-run check. Once this check is completed, the run can be started. 
Various MiSeq kits were used according to their availability and the practicalities of 
each kit for the experiment at hand. Variously, the V2 2x150, 2x500, V3 2x150, V3 
2x250 and V3 2x300 kits were used.  
All sequencing data produced from the MiSeq was stored on BaseSpace, a cloud 
computing environment provided by Illumina.  Three reads are taken of each fragment 
cluster: an identifying read (that reads the indexing barcode), a forward read of the 
DNA fragments (length of which depends on sequencing kit used) and a reverse read 
of the fragments (Figure 19). The 2 main sequencing files generated for each sample 
are FASTQ forward and a FASTQ reverse read. FASTQ format uses one ASCII 
character to denote both the nucleotide and quality score of each position in a 
sequence read. Illumina machines output data in FASTQ format which also includes 
sequence identifiers, such as flow cell lane and X-Y co-ordinates of the cluster of origin 
within flow cell. Format conversion removes reads where the quality scores for the 
reads do not meet user defined criteria. The quality information is stripped from the 
remaining sequences, converting them into sequence-only FASTA format.  
Illumina sequencing platforms sequence each DNA fragment on the flow cell in a 
forward and reverse direction (see Figure 19). This creates 2 ‘reads’ for each DNA 
fragment which are linked by their names. ‘Read one’ reads the fragment in a 5’ to 3’ 
direction and ‘Read 2’ reads in a 3’ to 5’ direction. If one read from a DNA fragment 
does not pass format conversion its partner is also removed at this stage.  
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Generation of Read 1, Read 2 and Read 3 on Illumina Sequencing Platforms
 
Figure 19: Generation of Read 1, Read 2 and Read 3 on Illumina Sequencing Platforms. Three reads 
are taken of each DNA fragment ligated to the flow cell: Read 1 and Read 2 read the sequence of 
the DNA fragment from opposite directions for (n) bases depending on the reagent kit used. Read 3 
reads the index tag so that the fragment sequences can be attributed to the correct sample from 
the DNA pool. The Read 1 and Read 2 data is then output as a pair of linked files in FASTQ format 
grouped by the index identified in Read 3.   
The PhiX control that is spiked into the pooled DNA samples is used by BaseSpace to 
produce quality metrics about the run according to the alignment of read data 
generated by the PhiX control to the PhiX reference genome (Table 14). This quality 
data can be used to make inferences about the quality of the run for the pooled DNA 
samples. These values are updated throughout the progress of the run, thus inspection 
of the values after the run has completed will indicate values for either cycle 300, or 
cycles 1-300. Quality scores are calculated for each base call generating logarithmic 
values of call certainty (Q10 = 10% chance of wrong base call; Q20 = 1%, Q30 = 0.1%, 






Table 14 MiSeq Run Quality Metric Details, from the BaseSpace User Guide 
(Illumina) 
Metric Explanation 
Yield total Number of bases sequenced in total 
Yield perfect Number of reads that contain no base 
calling errors in the PhiX control 
Yield >=3 errors Number of reads containing three base 
call errors or less in the PhiX control  
Aligned Percentage of total reads on flow cell 
that aligned to the PhiX genome 
Perfectly Aligned (%) Proportion or bases in PhiX reads that 
align perfectly to the reference 
sequence (at read cycle indicated in 
square brackets) 
>=3 errors (%) Proportion or reads in PhiX reads that 
align with three base call errors or less 
to the reference sequence (at read 
cycle indicated in square brackets) 
Error rate Overall error rate in all reads aligning to 
the PhiX genome 
Q >=3- (%) Percentage of bases with a quality 
score >30 
Tiles The flow cell is divided into strips which 
are subdivided into ‘tiles’. Tiles are the 
data unit of processing corresponding to 
an imaging area of the flow cell. 
Density Number of clusters (thousands per 
mm2) detected. Optimal cluster density 
for 865-965 k/mm2 for v2 chemistry and 
1200-1400 k/mm2 for v3 chemistry 
PF Number of clusters that pass filtering 
(+/- one standard deviation) 
Phas./Prephas Number of DNA molecules within a 
cluster that fall out of phase (by jumping 
ahead or lagging behind) the rest, 
based on the first 25 cycles.  
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Reads Number of clusters (millions) 
Reads PF Number of clusters passing filtering 
(millions). Filtering removes clusters 
that cannot be consistently identified in 
the first 25 cycles of sequencing.  
Q>=30 Bases with a quality score greater or 
equal to 30. 
Scores expected per kit:  
MiSeq Reagent Kit V2 
2x150bp >80% >Q30 
2x250bp >75% >Q30 
MiSeq Reagent Kit V3 
2x300 >70% >Q30 
   
Yield Number of bases passing filtering 
Cycles error rated Cycles error rated by PhiX control 
Aligned Percentage of reads aligned to PhiX 
genome 
Error rate Error rated determined by PhiX 
alignment during cycles 1-35, 1-75 and 
1-100 
Intensity cycle 1 The intensity of the wavelength of light 
detected by the MiSeq for each base. 
This data can have diagnostic use if a 
run performs unexpectedly poorly.   
Intensity cycle 20 
 
Data Analysis (NextGene) 
Format conversion 
Raw sequencing data was converted from FASTQ format to FASTA format for 
alignment to the reference sequence (Hg19).  
Format Conversion was performed using the standard quality filtering settings 
recommended by NextGene which are listed in Table 15.  
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Table 15 Default format conversion settings in NextGene 
Parameter Setting 
File Format Type Illumina 
Median Score Threshold  >= 20 
Max number of uncalled bases <=3 
Called Base Number of Each Read >=25 
Trim or Reject Read when  >= 3 bases score <= 16 
Paired Reads Data TRUE 
Alignment settings 
Alignment settings for HiSeq data are listed in Table 16 Alignment Settings for HiSeq 
Data. Whole genome alignment settings, which were adopted later and also used for 
alignment of MiSeq data are listed in Table 17. 
Table 16 Alignment Settings for HiSeq Data 
Parameter Setting 
Reference Sequence Human v37_2 
Instrument Type  Illumina 
Application Type  SNP/Indel Discovery 
Steps 
Do Condensation  FALSE 
Do Assembly  FALSE 
Do Alignment  TRUE 
[Sequence Alignment] 
Whole Gene Project  TRUE 
Directory of Index C 
Do WGA With Paired Index  FALSE 
Do Methylation Detection FALSE 
Reads Allowable Mismatched Bases 2 
Allowable Ambiguous Alignments 500  
Seed  35 Bases, Move Step 
Allowable Alignments 500  
Overall  Matching Base Percentage >= 80.0 
Detect Large Indels FALSE 
Sequence Range Checked  FALSE 
Hide Unmatched Ends  FALSE 
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Mutation Percentage <= 15.00  
SNP Allele <= 3 Counts  
Total Coverage <= 30  
Except for Homozygous TRUE 
Mutation Filter Use Original TRUE 
Allow Software to Delete Mutations FALSE 
Forward and Reverse Balance FALSE 
Forward and Reverse Balance Value <= 
0.050 
 
Load Assembled Result Files  FALSE 
Load Sage Data FALSE 
Delete Small Homopolymer Indels if F/R <= 
0.25 
 FALSE 
Load Paired Reads FALSE 
Save Matched Reads TRUE 
Highlight Anchor Sequence FALSE 
Ambiguous Gain/Loss FALSE 
Detect Structure Variations FALSE 
Check Mismatch Base Number  TRUE 50 Bases 





Table 17 Whole Genome Alignment Settings 
Parameter Setting 




Reads: Allowable Mismatched Bases 2 
Reads: Allowable Ambiguous 
Alignments 
500 
Seeds: Bases 80 
Seeds: Move step 5 
Seeds: Allowable Alignments 500 
Overall: Matching base percentage 80 
Detect Large Indels TRUE 
Sample Trim FALSE 
Mutation Filter: Except for homozygous TRUE 
Mutation Filter: Mutation Percentage SNPs Indels Homopolymer 
Indels 
20 20 20 
Mutation Filter: 
SNP Allele Count 
3 3 3 
Mutation Filter: 
Total Coverage Count 
5 5 5 
Mutation Filter:  





F = 80 
BR = 0.8 
F = 80 
File Type:  
Paired Reads 
TRUE 
Size range 0 bases to 600 bases 
Saved Matched Reads FALSE 
Highlight Anchor Sequence FALSE 





Visualisation of alignment in NextGene Viewer 
The NextGene Viewer provides read-by-read visualisation of the data aligned to the 
reference sequence.  
The NextGene Viewer 
 
Figure 20: The NextGene Viewer.  (A) Shows reference position. (B) Shows a rainfall chart of 
alignment across a scalable region, where grey bars indicate the level of coverage. Grey, purple 
and blue points on the chart show  positions where the sample sequence differs from the reference 
(grey: dismissed as misalignment, purple: accepted known variant, blue: accepted novel variant). 
(C-G) show an enlarged region of the reference sequence above, corresponding to the position of 
the blue + in (B). (C) Shows position on the chromosome, (D) Indicates if the region is translated, 
(E) shows the same mutation calls as seen in (B) for the enlarged region, (F) shows the reference 
sequence, and below it the consensus sequence from the reads that align to the position (G) 
shows the pileup of reads aligning to the reference sequence. A known/accepted SNP 
(heterozygous G>A) is highlighted in purple in the window. Several bases of mismatch that have 
not been accepted as a genuine deletion in one read are highlighted in grey.   
Expression Report 
The expression report contains data related to the number of sequences aligning to the 
reference sequence. The report takes a .BED file as input. A .BED file containing the 
locations of all the baits in the bait capture library was used. This had the advantage of 
excluding repetitive regions near our design where varying amounts of off-target 
sequence in different samples could skew data interpretation. Data collected in the 
expression report is outlined below in Table 18.  
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Table 18 Data included in Expression Report 
Data Description  
Chromosome 1-23, X/Y 
Chromosome Position 
Start 
Start of region covered by bait 
Chromosome Position 
End 
End of region covered by bait 
CDS Gene, if region contains sequence that is transcribed 
Average Read Count Average of coverage at each base position within the region 
Read Count Total number of reads where the central base of the read is 
between ‘Chromosome Position Start’ and ‘Chromosome 
Position End’ 
RPKM ‘Reads per kilobase exon model per million mapped reads’ 
– a normalised measure of coverage calculated based on 
the size of the reference sequence, the average coverage 
of the position in question, and the coverage of the 
sequence surrounding it for 1 kilobase  
Rejected reads 
Reads are rejected from the alignment if they don’t fit the alignment criteria in Table 17. 
Rejected reads are stored in separate FASTA files according to the criteria on which 
they were rejected from the alignment. Rejected read files and the criteria under which 
reads are assigned to them are listed below in Table 19. 
Table 19 List of files produced to which rejected reads are assigned 
File Basis of rejection from alignment 




Both reads in pair match the reference in the correct orientation from 
one another (i.e. they are read from ‘opposite directions’ and match 
the sequence as expected) but do so outside the expected gap 




Same direction reads both match the reference sequence, but in the 
same orientation as one another. Normally, one read needs to be 
‘flipped’ to match the reference because it aligns in the opposite 
direction 





Variants in the aligned sequences are filtered and scored by NextGene. Any variants 
that pass the filtering criteria defined in Alignment Settings (Table 17) are included in 
the variant report. The data included in the Variant Report is listed below in Table 20. 
Table 20 Data included in Variant Report 
Data Description  
Chromosome 1-23, X/Y 
Chromosome Position 
Start 
Start position of variant 
Chromosome Position 
End 
End position of variant 
CDS Gene, if variant occurs within its coding region 
Coverage Number of reads that cover position of variant 
Score Phred score assigned to mutation 
Reference Nucleotide Expected sequence at position of variant 
SNP db_xref dbSNP reference number, if variant has been reported 
previously 
Genotype Genotype of individual at position of variant 
Mutation Nature of mutation (insertion, substitution, deletion) 
Mutant allele frequency Percentage of reads covering position that show variant 
rather than reference sequence 
A% Ratio Percentage of reads at position showing ‘A’ at position of 
variant 
G% Ratio Percentage of reads at position showing ‘G’ at position 
of variant 
C% Ratio Percentage of reads at position showing ‘C’ at position of 
variant 
T% Ratio Percentage of reads at position showing ‘T’ at position of 
variant 
Amino Acid Change If variant occurs within CDS, expected amino acid 
change at position brought about by variant 
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In-Browser Bioinformatics tools 
BLAST 
The National Centre for Biotechnology Information (NCBI) Basic Local Alignment 
Search Tool (Nucleotide) was used to search for sequence motifs <20bp in the human 
genome.   
http://blast.ncbi.nlm.nih.gov/Blast.cgi 
University of California Santa Cruz Genome Bioinformatics Site 
The UCSC Genome Browser  
The UCSC Genome Browser was used obtain information about sequences of interest, 
such as the genomic co-ordinates of genes, the sequences of repeat elements and 
locations of SNPs. FASTA files for regions of interest were downloaded from this site. 
Custom information (such as the positions of baits in a capture library design) were 




The UCSC BLAT Tool was used to query sequences >20bp in length and map them to 




The UCSC In-Silico PCR tool was used to check primers for correct location, product 
length, Tm and specificity/uniqueness. 
https://genome.ucsc.edu/cgi-
bin/hgPcr?hgsid=445223818_NkJ0R0XwzfRU4JRvb4aAe5EglBSQ 
EMBL-EMI Pairwise Sequence Alignment 
Pairwise sequence alignment was used to compare multiple FASTA sequence files and 





Gap PCR primers were used to confirm the breakpoints of variants found by NGS data 
analysis. A FASTA sequence of the expected break point region was uploaded to 
primer3plus as the target region. FASTA sequence was obtained from the UCSC 
Genome Bioinformatics Site. Repetitive elements were masked to lower case. The 
FASTA sequence typically included 500 bp of sequence upstream and downstream 
from the breakpoint. If the regions were highly repetitive a larger target sequence was 
used to ensure the primers produced a unique product. The breakpoint position was 
highlighted as the target region. The Tm range for the primers was set to 57-62°C. 
Primer pairs with similar melting temperatures, with at least 3 gua9 nucleotides in the 
last 5 5’ bases were selected preferentially. Selected primers were evaluated in the 
UCSC in-silico PCR tool.   
http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/ 
Break Point Confirmation: 
Gap-PCR 
Gap-PCR was used to confirm the breakpoints of variants identified using NGS. Gap 
PCR primers were designed in Primer3Plus. If the primers targeted a rearrangement 
which meant they would not product a product in DNA samples from control subjects, 
additional ‘control’ primer pairs were designed. These would create 2 PCR products in 
a normal control, each using one of the ‘test’ primers for use with the test DNA sample 
in which the variant occurred. This allowed the primers to be tested and their reaction 
conditions optimized. Upon receipt 10 mM working dilutions were made of all primers 
using nuclease free water and the stocks and dilutions were stored at -20°C.  
The optimal reaction conditions for the primers were determined. The initial 
optimization PCR amplification experiment reaction conditions are as follows: Optimal 
Tm as buffer is not optimised 
A PCR mastermix was made for 4 PCR conditions, using two control samples plus no 
template controls, for each primer set (10 reactions). For each reaction: 10 µL Qiagen 
Multiplex PCR MasterMix (Qiagen, Germany), 1 µL 10mM forward/ reverse PCR 
primer, 1-2 µL template DNA (30-200ng/ µL) and nuclease free water to make a total 
volume of 20 µL. 
The reagents and DNA were mixed briefly on a vortex mixer and centrifuged to bring all 
liquid to the bottom of the tubes or plate. The tubes or plate were then placed in a 
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Verity Veriflex thermal cycler (Thermo, USA). The thermal cycling program used is 
outlined in Table 21. 
Table 21 Thermal cycling conditions for optimizing Gap PCR conditions. A 
different annealing temperature is used for each of the 4 reactions prepared for 
the samples. The temperatures used are the primer Tm -4°C, primer Tm +2°C, 
primer Tm, primer Tm +2°C, primer Tm +4°C. 
Step 1 2 (35x) 3 4 
Temperature 95°C 95°C [Veriflex 
Step] 







1 minute (or 1 






The PCR products were electrophoresed in a 1.5% agarose gel. The optimal annealing 
temperature was selected and used for amplification of the novel PCR product in the 
test sample.  
PCR products >1Kb did not amplify well under these conditions. These products were 
amplified using the following reagent mix (for one reaction): 5 µL LongAmp Taq 
Reaction Buffer (NEB, USA), 1 µL 10mM forward/ reverse primer, , 0.75 µL dNTPs, 1-2 
µL 30-200ng/ µL template DNA, nuclease-free water to make a total volume of 25 µL. 
Reactions using this kit were amplified in a Verity Veriflex thermal cycler using the 
program outlined in Table 22. This process may also require optimisation to 
successfully amplify a product, through trial of multiple annealing temperatures and 
extension times 
Table 22 PCR reaction conditions for LongAmp Taq Polymerase reaction kit 
Step 1 2 (35x) 3 4 












Dye Terminator Sequencing 
Dye-terminator sequencing was used to confirm the precise breakpoints of variants 
found by NGS after successful amplification of a Gap-PCR product covering the break 




The Gap PCR product was purified using AMPure beads on the BioMek NX robot 
platform: 80 µL AMPure XP beads were added to the reaction and mixed by pipetting 
up and down. The mixture was left to incubate for 5 minutes at room temperature. The 
mixture was then transferred to a magnetic rack. After 4 minutes, the supernatant was 
aspirated and discarded. 150 µL 85% Ethanol was added to the tube, left for one 
minute and then aspirated and discarded. This step was repeated once, for a total of 
two ethanol washes. The pellet was left to dry on the magnet for 5 minutes at room 
temperature. The samples were then removed from the magnetic rack and eluted in 35 
µL nuclease-free water. The mixture was left to incubate for 3 minutes at room 
temperature and then transferred to a magnetic rack. The samples were left to incubate 
on the rack for 5 minutes at room temperature. 30 µL of the supernatant was then 
removed and transferred to a fresh PCR plate.  
Dye-terminator PCR reaction 
Purified PCR products were prepared for dye-terminator sequencing in triplicate, with 
separate reactions for forward and reverse sequencing of the product. The following 
reagent mix was prepared per reaction: 0.5 µL Dye-Terminator Ready Mix, 0.5 µL Dye-
Terminator Buffer, 4 µL DNA, 4 µL nuclease free water, 1 µL 5pM forward or reverse 
PCR primer, total volume 10 µL.  
The reactants were mixed by vortexing and centrifuged briefly to bring all liquid to the 
bottoms of the tubes. The reactants were placed in a Verity thermal cycler and the 
program outline in Table 23  was initiated. 
Table 23 Thermal cycling program for preparation for dye-terminator sequencing 
Step 1 (40x) 2 
Temperature 95°C 52°C 60 °C 10 °C 
Time 30 seconds 15 seconds 2 minutes 10 minutes 
CleanSeq Purification 
The PCR product was returned to the BioMek NX for purification with CleanSeq beads: 
30 µL CleanSeq beads were added to the reaction and mixed by pipetting up and 
down. The mixture was left to incubate for five minutes at room temperature. The 
mixture was then transferred to a magnetic rack. After 5 minutes, the supernatant was 
aspirated and discarded. To wash the bead pellet, 150 µL 85% EtOH was added to the 
tube, left for one minute and then aspirated and discarded. This step was repeated 
once, for a total of two ethanol washes. The pellet was left to dry on the magnet for five 
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minutes at room temperature. The samples were then removed from the magnetic rack 
and eluted in 35 µL nuclease-free water. The mixture was left to incubate for three 
minutes at room temperature and then transferred to a magnetic rack. The samples 
were left to incubate on the rack for five minutes at room temperature. Ten µL of the 
supernatant was then removed and transferred to a fresh MicroAmp Optical 3130 plate 
(Life Technologies).  
Dye-Terminator Sequencing 
The MicroAmp Optical 3130 plate was fitted with a rubber septa and placed in the ABI 
Genetic Analyser 3130. Dye-terminator sequencing was performed using standard 
laboratory parameters. 
Dye Terminator sequence data was analysed using Mutation Surveyor software 
(Biogene USA) or Sequencher Software (Gene Codes, USA). In both cases dye 
terminator sequences were aligned to reference sequences. When using Sequencher, 
the reference sequence for the region that was amplified was downloaded from the 
UCSC Table Browser application (Hg.19). Mutation Surveyor was more aligned with 
diagnostic applications while Sequencher was useful for building contigs and identifying 
breakpoint sequences. 
Automation of Sample Preparation Process on BioMek FXP 
During the course of the project the BioMek FXP liquid handling robot was purchased 
with the aim of automating the library preparation and target enrichment steps of the 
sequencing process. This system was selected over the Agilent Bravo system as it was 
a more flexible platform and was not tied in to a single companies chemistry. It also 
had the potential to automate the entire process while the Agilent Bravo required some 
manual intervention steps. The cost of both instruments was similar but the Bravo 
would work almost out of the box while the methods needed to be developed on the 
BioMek. Developing an automated method sounded relatively straight forward but with 
limited experience of automation this proved challenging. 
After the robot install and initialisation a programme, developed by Beckman, was 
installed on the robot. This was modified on site by a field application specialist to 
accommodate the deck layout and specific laboratory requirements.  The process of 
establishing a method was estimated to take 3 months. In reality this took almost 9 
months with three different application specialists trying three different programmes. 
Each programme was divided into library preparation, pre hybridisation and post 
hybridisation. Library preparation was relatively easy to automate and was working 
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within 2 months. The target enrichment process which included 24 hour incubation at 
65 °C and a complex arrangement of washes was much more difficult to automate. 
After sequencing the libraries the off target sequence was very high indicating that little 
or no target enrichment had taken place. Examining this process, taking it apart and 
reprogramming the robot took time and various strategies were taken to best reproduce 
the manual steps, which used volumes exceeding those possible on the robot.  
Due to the time lost on the automation of the library prep and the focus of my PhD 
studies routine diagnostic staff took on the responsibility of developing the automated 
solution with Beckman. Once it became available it was towards the end of my 






Results Chapter One: Preliminary Investigation 
 
The initial sequencing experiments in this study were performed before on-site facilities 
for sample preparation and sequencing had been established. Sample preparation was 
performed at the Genomics Facility at Guy’s and St Thomas’s Hospital, London. The 
facility has previous experience in preparing samples for NGS and were able to provide 
advice and all necessary equipment for the procedure.  
Samples were then sequenced on the HiSeq 2000 platform at the Rayne Institute, 
London, by Dr A. Smith from the Department of Haematological medicine who was the 
operator of this platform.  
Data obtained from Dr Smith in FASTQ format was then analysed using the NextGene 
(SoftGenetics) package that was acquired by the KCL Department of Molecular 
Pathology for this purpose. Multiple approaches to analysis were investigated in order 
to determine the best way to use this software for the targets of this investigation.  
This initial experiment investigated the ability of this combination of sample preparation, 
sequencing and analysis to characterise the variants and rearrangements present in a 
range of DNA samples, including known and novel variants. The chapter describes and 
evaluates the strengths and weaknesses associated with each step of this process. 
This information was used to modify these processes in subsequent chapters to 
optimize the process for diagnostic use. The novel variant cases came from a 
collection amassed by Prof Swee Lay Thein over a period of 30 years. Throughout this 
period, when new sequencing technologies became available Professor Thein and 
researchers in her laboratory attempted to use these techniques to resolve the 
breakpoints of these novel variants. The cases examined in this investigation were not 
resolvable using MLPA, CGH array, Southern blotting or qPCR.  
As this investigation went on, more resources became available for use in preparing 
the DNA samples and analysing the data. When the project started, both sequencing 
and sample preparation had to occur off-site, due to the lack of suitable equipment on 
site, and lack of experience with the techniques used. Data analysis was performed 
using an off-the-shelf software package with which no one on site was familiar, and 
determining the best way to use this software to interpret our data was a significant 
undertaking. Figure 21 shows a timeline of the resources used over the course of the 





Figure 21: Timeline of Experiments. Different locations for sample preparation and sequencing, 
different platforms, different capture libraries and manual and automated sample preparation 
protocols were used in various combinations as they became available.  The preliminary 
investigation involved HiSeq Run 1 and MiSeq Run 1 and 2 (Years 2 and 3). 
HiSeq Sample Preparation: Run 1 
Sample Details 
HiSeq Run 1 sequenced 12 DNA samples obtained from the diagnostic laboratory. The 
batch included negative control samples, positive control samples, and test samples 
from patients with unknown, uncharacterised structural rearrangements (Table 24). 
Southern Blots or MLPA had been performed by the diagnostic laboratory and gave a 
rough idea of the size and type of the unknown rearrangements, and confirmed that no 
structural rearrangements existed in the negative controls. To increase negative control 
data available, samples known not to have variants affecting one of the globin gene 
clusters were used as negative controls for the region of their unaffected cluster. 
Therefore, alpha thalassaemia samples could be used as negative controls for beta 
globin gene analysis, and vice versa. HiSeq Sample 12 (a duplicate of HiSeq Sample 
11) was used as an additional control for the alpha globin region, but not analysed 
further for the beta globin locus.   
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Table 24: Sample Details for HiSeq Run. 
Sample Beta Globin Locus Alpha Globin Locus 
HiSeq Sample 1 Negative Control Test (Duplication) 
HiSeq Sample 2 Negative Control Negative Control 
HiSeq Sample 3 Negative Control Test (Duplication) 
HiSeq Sample 4 Negative Control Negative Control 
HiSeq Sample 5 Test (Deletion) Negative Control 
HiSeq Sample 6 Positive Control (-Asian Indian Indel/) Negative Control 
HiSeq Sample 7 Test (Duplication) Positive Control (α-3.7/) 
HiSeq Sample 8 Negative Control Test (Duplication) 
HiSeq Sample 9 Negative Control Test (Deletion) 
HiSeq Sample 10 Test (Deletion) Negative Control 
HiSeq Sample 11 Test (Deletion) Negative Control 
HiSeq Sample 12 N/A  Negative Control 
Sample Preparation 
The samples were prepared for sequencing in two batches of six for ease of handling. 
Sample preparation took place in the Genomics Centre at Guys Campus, under the 
guidance of the experienced staff at this facility. Sample preparation was in accordance 
with the protocol as outlined in Methods. The samples were run on the Tapestation 
prior to sequencing using the D1000 DNA kit, to check concentration and fragment size 
distribution (Figure 22). The size of fragments in each sample ranged from 200 bp – 
500 bp, all with a mean peak at approximately 350 bp. This is the expected product 
size range with an input fragment size of ~150 bp, after the addition of adapters and 
index tags (200 bp). The size distribution of the products for all 12 samples was 
extremely uniform.  
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Tapestation Data Showing Results of Library Preparation for HiSeq Samples 1-12
 
Figure 22: Tapestation Data Showing Results of Library Preparation for HiSeq Sample 1-12. (S1-12, 
lanes 1 to 12). Top panel shows each trace as a band, next to a DNA ladder (lane L). Lower panel 
shows individual traces for each sample. Sample yield is broadly similar (1000-2000 pg/μl) in all 




Samples were sequenced on the HiSeq 2000 in a batch of 12. The HiSeq platform had 
been recommended over other available platforms (MiSeq and Genome Analyser) for 
its high sequencing capacity. The samples were sequenced off-site at the Department 
of Haematological Medicine, Rayne Institute, King’s College London and run quality 
data, including cluster density, was not provided with the raw data. The HiSeq 2000 
platform generates two 97 bp reads of each DNA fragment ligated to the flow cell: 
‘Read 1’ (R1) and ‘Read 2’ (R2) along with addition to a 6bp index read (Figure 19). 
The sequencing data is in FASTQ format. Multiple FASTQ files were generated for 
each sample. These were condensed into a pair of files for each sample, the first 
containing ‘Read 1’ (R1) of each DNA fragment that was sequenced, and the second 
file containing ‘Read 2’ (R2) of each fragment. Read 3 data is not employed for any 
further analysis after it has been used to separate the R1 and R2 data into individual 
sample files. The R1 and R2 sequences from each DNA fragment are given unique 
identifying names that relate them to one another using the format 
“XXXX:XXX:XXX_1”/”XXXX:XXX:XXX_2”. 
FASTQ (read names, base calls, base quality scores) format files were converted into 
FASTA (read names, base calls) format. The conversion program also removes any 
reads that do not meet a series of user-defined quality score thresholds based on the 
base quality and score information. Remaining bases called as ‘N’ in reads that pass 
quality filtering are later ignored during alignment, which is performed based on the 
sequences of the bases in the read that were called successfully. Standard parameters 
(see Methods) were used for format conversion (please refer to Methods for more 
detailed descriptions of these metrics).The results of format conversion for HiSeq Run 
1 are shown in Table 25 as averages of the entire sample cohort. The majority of reads 
in all samples passed the standard quality filters. Of those that fail, the majority are 
rejected based on their ‘median score’, i.e. the median quality score of each base 
position in the read. A minority of reads are filtered out by “uncalled bases”. Some 
reads in which bases have a low quality score towards the end of the read (a common 
issue with Illumina sequencing platforms) can be ‘trimmed’ so that the remainder of the 






Table 25: Success of Format Conversion. Average for 12 samples. 









Total Reads in the Input File 15392225 6770274 19250149 11371742 








Reads Failed to Convert 1168373 548447 1162921 665870.9 










Reads Filtered by "Uncalled 










Reads Filtered by "Called 
Base Number in Read" (not 








Reads Filtered After Trimming 17899.67 7982.387 38673 22434.98 
Reads Trimmed 2286045 1018293 3261744 1874167 
Reads Trimmed by "Quality 
Score" 
2286045 1018293 3261744 1874167 
Trimmed Bases 53106560 23823152 61581995 35274987 
Trimmed Bases by "Quality 
Score" 
53106560 23823152 61581995 35274987 
 
The average quality score for each base position in each read (from base 1-96) is 
calculated per sample: a score >30 is classed as ‘good’; a score >20 and <30 is 
classed as ‘acceptable’; a score <20 is classed as ‘poor’. This data is shown in Figure 
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23. The majority of positions in both R1 and R2 reads obtained a ‘good’ score. In both 
reads, quality scores deteriorate for the last 10 called positions. This drop in quality 
towards the end of the read was seen in all runs performed on Illumina instruments.   
 
Figure 23: HiSeq Run 1: Quality of Base Calls Along Length of Read. A score >30 is deemed ‘good’; 
<30 and >20 is deemed ‘acceptable’ and <20 is deemed ‘poor’.  
Alignment of FASTA Data to the Reference Sequence 
Read data was aligned to a reference sequence of the human genome. Hg.19 v.37.3, 
dbSNP v135. NextGene attempts to align each FASTA format read to the position in 
the reference that has the closest match to its sequence. If the read can be aligned to 
multiple positions in the reference with equal accuracy, ‘ambiguous alignment’ is 
allowed which assigns the read to all the positions at which it is an equally good match. 
Reads that do not perfectly match the reference sequence are aligned to the position 
that they best fit. The mismatch in the read sequence compared to the reference is 
noted. If it fits certain parameters (such as the same mismatch being present in a large 
proportion of the reads. - see later section for more details), it will be recorded as a 
variant. If a mismatch does not fit these parameters, it is considered to be a spurious 
result and while the read may not be rejected from the alignment, the mismatch will not 
be recorded as a variant. Reads in which a certain percentage of bases do not match 
the reference sequence are rejected from the alignment entirely. The alignment 
parameters for all these conditions are user defined, so alignment stringency can be 
tailored to the needs of an individual project.  
Opting for a ‘paired read alignment’ instructs the software to match R1 and R2 
sequences from each fragment in pairs. The two reads in each pair must align in 
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not align in opposite orientations are rejected from the alignment (see later section: 
Same Direction Reads). The paired reads must also align at a set distance from one 
another, based on the size of the DNA fragments that were sequenced. For example, 
according to Figure 22 the fragment size range for this run is 100-500 bp, therefore the 
two reads of each fragment are expected to align within this distance of one another 
along the reference sequence). Reads that align to the reference in the correct 
(opposite) orientation, but exceed the acceptable distance are also rejected from the 
alignment (see later section: Opposite Direction Reads). 
Optimizing Alignment Settings 
The FASTA data from the samples in HiSeq Run 1 was subjected to multiple 
alignments with different stringencies to determine the best alignment parameters for 
this study.  
Initially, the data obtained from the Rayne Institute was not formatted in the manner 
expected for paired read data (i.e. one file for all R1 data and another file for all R2 
data) and so paired read alignment was not successful. Instead, each read was aligned 
individually to the reference sequence. This increased the number of ambiguous and 
spurious alignments for each sample, as only half of the data that was available to aid 
accurate alignment was used. This also meant reads could not be rejected from the 
alignment based on read or gap distance requirements. Once this issue was identified, 
the data was re-ordered using the ‘merge files’ and ‘arrange paired reads’ tools in the 
NextGene package. Analysis was then restarted using paired read alignment.  
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Several rounds of analysis attempted to align the read data to the specific region of 
interest targeted by the bait capture library (chr11:3,500,000-7,500,000, chr16:0-
260,000). This proved to be unhelpful, as off-target reads that had evaded elimination 
during the hybridization stage of sample preparation were ‘shoehorned’ into partial 
alignments within the region of interest. This created false positive variant calls where a 
large number of reads from another part of the genome showed the same deviations 
from the part of the truncated reference sequence that they best aligned to, and were 
therefore counted as legitimate variants.  
Preliminary alignments were performed using the standard alignment parameters 
described in Methods. Higher and lower stringency alignment options were explored, 
but were found to be less suitable for the requirements of this study (discussed later). 
Statistics from alignment using standard parameters for all samples and the run 
average are shown in Table 26. An average of 96.54% of reads that passed format 
conversion were successfully aligned to the reference sequence. Hybridization was 
found to have achieved only 53% specificity for sequences originating from the target 
region. The high sequencing capacity of the HiSeq 2000 platform meant that despite 
this, the targeted region was still sequenced at a high read depth (average coverage 
400x).  
Alignment Results 
Once alignment is complete, NextGene produces several reports that were useful for 
data analysis in this investigation. Additionally, the NextGene Viewer allows exploration 
of the exact base sequence of the reads aligning across the reference sequence.  
Variant characterisation for diagnostic use follows two different pathways using 
different outputs from NextGene: one for indel/single nucleotide variant detection and 
another for structural rearrangement detection (Figure 24). Indel/single nucleotide 
variant detection is provided by the Mutation Report. Structural rearrangement 
detection begins with gross identification of dosage changes utilising the Expression 
Report, followed by breakpoint identification. The NextGene Viewer may provide 
sufficient data to determine the rearrangement breakpoints, but if this is not possible 
resolution variously requires the use of the Mutation Report, Opposite Direction Read 
Report or Same Direction Read Report. A ‘Structural Variant’ report provided by later 
releases of the software included an extremely high amount of spurious data from 
misalignment of off-target reads, and failed to include any of the genuine 
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rearrangements found (and confirmed via Gap PCR) in these sequencing experiments. 
This report was disregarded in favour of the strategy described here.  
NextGene Variant Detection Workflow
 
Figure 24: NextGene Variant Detection Workflow. The NextGene outputs required to detect and 
characterise Indels, single nucleotide changes and structural rearrangements.  
Mutation Report (for characterising single nucleotide variants and indels) 
A mutation report was generated for each sample. The report contained a list of all 
positions where a given proportion of reads contained sequences that differed from the 
reference sequence (to be included, a position must be covered by at least 15 reads, 
and at least 3 must exhibit the same deviation from the reference sequence). The 
mutation report includes the chromosome, position, base change, mutant allele 
frequency, CDS and score. If the variant is already published in the dbSNP database, 
its identifying number is also listed. The ‘score’ is a phred score determined by a 
number of factors including penalties for whether the variant is only recorded in the end 
of reads, only in forward or only reverse reads, or within homopolymer sequences. 
Mutation scores are considered to be reliable if they are >20. Scores of >15 should be 




Haemoglobinopathies such as sickle cell disease – and many cases of beta 
thalassaemia – are caused by single nucleotide changes, so for diagnostic use it is 
crucial that these variants can be reliably identified and mapped to the correct globin 
gene. Two samples in the patient cohort sequenced in HiSeq Run 1 had known single 
nucleotide variants: a codon 44 deletion in one sample, and rs334 (sickle cell variant) 
in another. Both these variants were successfully identified in the mutation report (see 
individual sample analysis). 
The ability of NGS sequencing to detect single nucleotide variants has been widely 
investigated and many publications report that the technique is extremely sensitive to 
these variants.  This will not be explored further in this analysis then confirming the 
presence of mutations previously confirmed in the samples.  
Expression Report 
The expression report is designed primarily for use in RNA sequencing, where the 
relative proportion of different sequences indicates the level to which those genes are 
expressed. In this study, the report was used to identify DNA dosage changes that 
increased or decreased the number of reads aligning to the reference sequence. 
Relative increases in the amount of sequence aligning to a position indicated a 
duplication had occurred in the sample, while a relative decrease indicated a deletion.  
Bait performance varies widely across bait capture libraries, so rather than directly 
comparing the coverage achieved at different positions, a relative measure, RPKM, 
was used.  An ‘RPKM value’ was calculated for each bait-covered position. This is a 
normalised measure of coverage across a region of interest (each 120 bp bait) 
expressed per million reads aligned to the reference sequence for a single sample. 
These values were used to compare coverage across the entire bait tiled region and 
between different samples. The RPKM values of each bait-covered position in test 
samples were plotted on a graph, where the X-axis showed their position on the 
chromosome and the Y axis showed the value by which the RPKM value for that bait 
differed between the sample and the average of the negative controls for that region 
(Figure 25). These values were plotted on a log2 scale as this provided direct 
comparison to CGH array data. This scale also proved to be an effective way of quickly 
identifying dosage changes: A negative value indicates lower coverage in the sample 
than in the controls. A positive value indicates higher coverage than in the controls. A 
value of 0 indicates no difference between the coverage of this position in the sample 
and the controls. To look for variations that could affect the globin genes, the coverage 
across chromosome 11p was viewed on an enlarged scale, showing positions 
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5,000,000-5,500,000. This was not necessary to inspect the smaller target region on 
chromosome 16 from positions 60,000-2,600,000.   
Plotting Variation in RPKM Values between Samples and Negative Controls
 
Figure 25: Plotting Variation in RPKM Values between Samples and Negative Controls. RPKM 
values according to chromosomal position (X axis), and deviation from negative control average (Y 
axis). RPKM values are used as a normalised measure of the number of reads aligning to each part 
of the genome covered by a bait in the capture library. The difference between the amounts of 
sequence obtained for test samples compared to normal controls are plotted on a log2 scale.   
The coverage of some regions varied greatly in both the samples and the negative 
controls. Presence of this variation in the controls indicates that it is not clinically 
significant, and may be due to CNV events or differences in the hybridization efficiency 
or specificity of different baits. To identify sample specific coverage differences which 
are likely to be clinically significant, the coverage graph was overlaid with standard 
deviation data derived from the mean RPKM from the negative control samples (“NegC 
StDev”) (see Figure 26). Deletions in test samples were quickly apparent when their 
coverage data was graphed using this method (graphs shown below). The start and 
end positions of the deletions as indicated by the RPKM data were then investigated in 
the NextGene viewer, which shows all the aligned reads, their genomic location and 




Variation in RPKM Values across Bait Tiled Region on Chromosome 16
 
Figure 26: Variation in RPKM Values Across Bait Tiled Region on Chromosome 16.  X axis shows 
position on chromosome 16 and Y axis shows deviation from the negative control RPKM average 
on a log 2 scale. Black diamonds indicate individual bait values, plotted according to their position 
and on the chromosome, and the deviation from the negative control average at that position. 
Increases in RPKM values relative to the negative control average can indicate duplications, while 
decreases can indicate deletions. The standard deviation in negative control samples from their 
average is shown by a grey line. The negative control standard deviation values can be used to 
distinguish random variation in common in the assay from genuine variants.  
(A) shows a region where the sample RPKM values decrease relative to the negative control 
average. However, this variation is also seen in the standard deviation from the negative controls, 
therefore this can be dismissed as random variation in the assay.   
(B) Shows a sustained region where RPKM values for the baits in the sample are lower than the 
negative control average. This indicates a deletion of this region the sample that is not present in 
the negative controls.  
(C) Shows a sustained region where the RPKM values of the baits are lower than the negative 
control average. This implies a deletion of this region, but the same region also appears to be 
commonly deleted in the controls, which is therefore likely to be unrelated to the sample 
phenotype. Figure taken and adapted from(Shooter 2014).  
NextGene Viewer 
Once the broad region affected by a structural rearrangement has been identified using 
RPKM data, the NextGene Viewer is used to locate the precise breakpoints. Visually 
inspecting the read pileup at the approximate start and end positions of the 
rearrangement can reveal reads that have crossed the breakpoint position. These 
reads are identified by strings of misaligned bases, all originating from the same 
position (indicating the first breakpoint of the rearrangement) and showing the same 
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alternate sequence to the reference. In order to be accepted into the alignment, these 
reads may only contain a few bases of breakpoint sequence, as otherwise they are 
trimmed or rejected from the alignment. In this case, the entire read sequence can be 
retrieved from the original FASTA files by looking up the read name. Once the whole 
R1 and R2 sequences are obtained, a BLAT query of their sequences can be used to 
reveal the deletion breakpoints (Figure 27). BLAT (Blast-like alignment tool) is a 
pairwise sequence alignment algorithm hosted by the UCSC genome bioinformatics 
site which finds matches in the human genome to FASTA format sequences. It 
provides quality scores based on the quality of each match it returns. Misaligned reads 
at breakpoint positions are often not included in the mutation report. This is because 
many reads that cover the position may be rejected on the basis of (i) the amount of 
sequence within the read that misaligns; (ii) the position to which the second read 
aligns (see opposite/same direction reads). The alignment process will also attempt to 
‘shoehorn’ the read sequence into the best possible alignment to the reference 
sequence, attempting to match as many bases in the misaligned sequence as possible 
to the reference. If any part of the misalignment is accepted into the mutation report, it 
does so as a series of disjointed small variants, rather than as one large variant.  
Appearance of Break-point Crossing Sequences in the Alignment
 
Figure 27: Appearance of Break-point Crossing Sequences in the Alignment. Diagram shows a 
hypothetical deletion (upper panel), and how reads covering the deletion break point are identified 
in the alignment (lower panel). Reads crossing the deletion breakpoint lack the green coloured 
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bases, so in the alignment strings of unmatched bases will appear either side of the region that is 
deleted in the sample. NB: If a read contains too many bases that do not correspond to the 
reference sequence, it may be rejected from the original alignment.  
Mutation Report (for characterising structural variants) 
The mutation report includes mutant allele frequencies for each listed variant. If there is 
doubt about the presence or start/end points of a rearrangement based on the RPKM 
data, this can provide additional evidence of whether a rearrangement has occurred, 
and what region it covers. In balanced sequences, mutant allele frequencies should 
either be 1:1 (heterozygous) or 0:1 (homozygous). A long stretch of 0:1 mutant allele 
frequencies strengthens the suggestion that a particular region is deleted. A stretch of 
mutant allele frequencies with ratios of 1:2 or 1:1:1 indicate duplicated regions. 
However, SNPs occur at a low frequency of approximately one per kilobase, and many 
are common enough in the general population that homozygosity can be expected. As 
such, this report is only occasionally informative in characterising structural variations.  
Opposite Direction Read Report 
Reads can be rejected from the alignment because they align to the reference 
sequence in the correct (opposite) orientation from one another, but at an unexpected 
gap distance (Figure 28). These reads are stored in an ‘opposite direction reads’ file, 
which lists the name of each rejected read pair, the positions in the reference sequence 
the reads align to, and the distance between them. Large numbers of reads are 
rejected on this basis from across the reference sequence, including in negative 
controls. These dispersed reads are dismissed as noise. 
Structural rearrangements bring together two positions in the genome that are not 
normally adjacent to one another. If DNA fragments that cross a deletion breakpoint 
are captured, the two reads will align at unexpected distances from one another. As 
such, many breakpoint reads may be rejected from the alignment and stored in the 
opposite direction reads report. This report can be inspected to identify any ‘pile up’ of 
multiple rejected reads that align between the same two normally distant genomic 
positions. Overlaying RPKM data with the positions at which these reads align can help 
determine the precise breakpoints of a rearrangement which can then be identified in 
the NextGene Viewer, or by BLAT query of the reads listed in the opposite direction 
read report.  
Same Direction Read Report 
Same direction reads are rejected from the alignment because although they match the 
reference sequence, they are aligned in the wrong (i.e. the same) orientation to one 
another (Figure 28). Reads that cross the breakpoints of an inversion are rejected by 
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this condition and so this is a crucial report for detecting these rearrangements. 
Inversions are balanced rearrangements, so they cannot be detected using expression 
data. It is important to detect these rearrangements as they can have clinical 
significance. Complex inversion-deletion events have also been reported in 
thalassaemia, so knowing whether an inversion is involved in a rearrangement is 
critical for designing primers to fully characterise it.  
Successful/Unsuccessful Alignment of Read Pairs
 
Figure 28: Successful/Unsuccessful Alignment of Read Pairs. A DNA fragment that cannot be 
aligned correctly to the reference sequence may be rejected as Opposite Direction (correct 
orientation of Read1 and Read 2 from one another but incorrect gap distance) or Same Direction 





HiSeq Run 1 Coverage Graphs: Chromosome 11 
 
Figure 29: HiSeq Run Coverage Graphs Chromosome 11. Part 1- RPKM plots across Chr11 for 








Figure 29 continued: RPKM plots across Chr11 for HiSeq Samples 9-11. 
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HiSeq Run 1 Coverage Graphs: Chromosome 16 
 
Figure 30: HiSeq Run Coverage Graphs: Chromosome 16. Part 1 - RPKM plots across Chr16 for 








Figure 30 continued: RPKM plots across Chr16 for HiSeq Samples 9-11. 
Data Analysis in Negative Control: HiSeq Sample 4 
HiSeq Sample 4 in the sample cohort was a negative control. MLPA had confirmed that 
the individual did not carry any structural rearrangements at either the chr11 or chr16 
globin gene locus. This individual has no family history of haemoglobinopathies and is 
not expected to carry any variants related to haemoglobinopathy.  
Mutation Report for HiSeq Sample 4 
The mutation report for HiSeq Sample 4 listed 4,091 variants within the region of 
interest. 1,049 of these were in the CDS, and 35 caused an amino acid change with a 
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score >15. In the globin genes, 37 variants were recorded, of which 2 occurred in the 
CDS, neither of which caused an amino acid change (Table 27).   
Table 27: Contents of Mutation Report for Negative Control: HiSeq Sample 4. 





Total Variants 4091 - 
Within Genes 1049 37 
Within CDS 228 2 
Amino Acid Changing 
    Score >15 








Detection of structural variants for HiSeq Sample 4 
Chromosome 11 
Coverage appeared uniform for the negative control sample across the region of 
interest on chromosome 11. This indicated that, as expected, no dosage changes had 
occurred in the sample at this position. A small number of bait-covered positions 
exceeded the negative control standard deviation. This is likely to be due to noise in 
the assay: there were no positions where this deviation was sustained across a 
continuous region, and there was no evidence of break point reads in the NextGene 
viewer at these regions.  
Chromosome 16 
Like chromosome 11, coverage across chromosome 16 in the negative control was 
uniform with no evidence of dosage changes. A significant increase in coverage was 
recorded at one position (~chr16:235,000). High variation in this region across the 
sample cohort was reflected in the negative control standard deviation recorded at this 
position. This position was evidently duplicated or deleted with a high frequency in the 
sample cohort, and was therefore likely to be a copy number variant. Query of the 
position in dbVAR revealed a copy number variant had been reported at this position 
which matched the data: esv2662940 frequently causes deletions at this position. The 
frequency of deletions in samples used to calculate the negative control average 
caused samples where this position was intact (such as in negative control sample 4) 
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to appear to show a duplication at the position, due to their relatively increased 
coverage.  
Opposite and Same Direction Read Reports 
Both reports contained a large number of entries from positions across the genome. 
Many entries had partial alignment to the regions of interest on chromosome 11 and 
16, but with the other read aligning to other positions across the genome. It is likely that 
these fragments are from other regions of the genome, but were captured based on 
their partial alignment to the reference region covered in the bait library. Other 
fragments were the result of incomplete target enrichment during sample preparation, 
which resulted in 47% of sequence reads aligning outside the target regions (Table 26). 
These reads were dismissed as noise. There was some ‘pile up’ of opposite and same 
direction reads on chromosome 11 between HBG1 and HBG2, and on chromosome 16 
between HBA1 and HBA2. This is due to the extremely high homology of these genes, 
which causes issues with correctly aligning reads from these locations to the correct 
position in the reference sequence. These were also considered to be noise and 
ignored. No other pile-ups of multiple reads showing alignment to the same two 
locations were identified in the control data.  
Characterising Structural Variants in HiSeq Sample 6 Positive 
Control: Asian Indian Inversion-Deletion (Figure 29.6)  
HiSeq Sample 6 is a positive control for a known variant causing thalassaemia with an 
elevated level of HbF: HbVar 1038; commonly known as the Asian-Indian Inversion 
Deletion (“AI Indel”). This variant consists of two deletions (0.6 Kb and 7.5 Kb) flanking 
an inversion (15.5 Kb). The two deleted regions are clearly visible in the RPKM plot 
(the smaller deletion is harder to see as it is only represented by four consecutive 
baits). Three of the four break points these two deletions create were clearly visible in 








Detection of the Asian-Indian Inversion-Deletion in Sequencing Data 
Positive Control: HiSeq Sample 6
 
Figure 31: Detection of the Asian-Indian Inversion-Deletion in Sequencing Data. RPKM values 
across the bait-tiled region across chromosome 11 for HiSeq Sample 6 (Asian Indian Inversion-
deletion). Graph: The two deletions identified in the upper panel (circled in blue) result in four 
breakpoint locations (1-4). Below: At three of the four locations, reads containing breakpoint 
sequence could be identified in the NextGene Viewer at locations shown in graph (highlighted in 
grey and blue). Breakpoint 3 occurs in a repetitive region and was not captured.  
The two deletions involved in this variant are clearly visible in the RPKM plot. 
Inspecting the breakpoint regions as indicated by this plot in the NextGene Viewer 
revealed that three of the four breakpoints of this rearrangement had been included in 
the alignment. The remaining breakpoint could be determined by retrieving full read 
sequences from reads that aligned to the reference at the other side of this 
rearrangement, and querying them in BLAT. This revealed the co-ordinates of the two 
sequences brought together by the rearrangement (Figure 32).  
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BLAT Query of Sequences Aligning to AI-Indel Breakpoint Positions
 
Figure 32: BLAT Query of Sequences Aligning to AI-Indel Breakpoint Positions. Multiple matches 
are listed for each query. The BLAT query returns (left to right) query name, score, start and end of 
match, length of query, proportion of query that matches the reference sequence, chromosome, 
direction, start and end point of sequence match in genome.  
Although in this instance the breakpoint sequences identified in NextGene were 
sufficient to characterise the entire inversion deletion (as BLAT indicates the orientation 
of the sequences conjoined at both breakpoints), whether or not it could be detected in 
the opposite/same direction read reports was also investigated.  
Opposite Direction Reads 
The RPKM data plot was overlaid with the locations of read pairs from the opposite 
direction read report (Figure 33). Reads were dismissed as noise where one half 
aligned to a position on another chromosome in this case, because we knew that these 
were spurious in this rearrangement. Each read pair was assigned an arbitrary Y-Axis 
value; this facilitated visual identification of clusters of reads pairs with similar start and 
end positions. The plot does not reveal any pile-up of pairs of opposite direction reads 
at the break-point locations of this rearrangement. This is due to the inversion of the 
intervening sequence, which means that reads covering the deleted region are in fact 





Locations of Opposite Direction Reads in the AI-Indel 
 
Figure 33: Locations of Opposite Direction Reads in the AI-Indel. Opposite direction reads (grey 
crosses) are overlaid on the RPKM plot for HiSeq Sample 6 (an enlarged version of the 
rearrangement region is shown here). The X-axis value shows the position on the reference 
sequence each read aligns to. Each read pair was assigned an arbitrary Y axis value. Thus, crosses 
with the same Y axis value are different halves of the same read. 
Same Direction Reads 
The sequence between the two deleted regions in the AI Indel is inverted. Therefore, a 
certain pattern of same direction reads covering the area should be expected, outlined 
in Figure 34.1. Each deletion is covered by one set of DNA fragments. The two reads 
taken from each fragment align either side of the deleted region. With two deletions, 
this means there are a total of four break point regions. The inversion covers the region 
between the two deletions, and therefore includes one breakpoint from each of the 
deletions. This means that each set of reads covering the deletion breakpoints are 
same direction reads, as one read has been inverted. The pattern this produces is 
shown below, where pink lines indicate fragments covering one deletion, and blue lines 
indicating fragments covering the other. The way NextGene attempts to align these 
fragments to the reference sequence, and the resulting same direction read pairs is 
also shown.  
Figure 34.2 shows the actual clustering of same direction reads overlaid over the 
RPKM data plot. For clarity, the clustered reads that conform to the predicted read pile-
up are also indicated in pink and blue. Other same direction reads which occur as 
background noise are in grey. An additional region of read pile-up is noticeable for 
reads aligning to the blue breakpoint pair. This due to ambiguous alignment between 
HBG1 and HBG2 that confounds the data at this position.  
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Predicted and Observed Positions of Same Direction Reads in the AI Indel
 
Figure 34:  Predicted and Observed Positions of Same Direction Reads in the AI Indel.  
1: Same direction read data for the Asian-Indian inversion deletion. The layout of the Asian-Indian 
inversion deletion is described in the upper panel (1). 1A: normal organisation of the globin gene 
loci. 1B: the rearrangement occurs, and two regions (outlined in red) are deleted, and the 
intervening region (outlined in blue) is inverted. 1C: This results in a rearranged allele that 
truncates HBB, HBD and HBG1, also inverting the remaining sequence of HBD and HBG1. 1D: 
When DNA from this region is sequenced, most of the captured fragments will align normally to the 
reference sequence (1E). Reads that originate from fragments that cross the inversion-deletion 
breakpoints (pink and blue) will be rejected from the alignment as same-direction reads.  
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2: Plotting the positions of these reads against the positions they align to on the reference 
sequence results in two clusters of linked reads (pink and blue) that straddle each break point of 
the inversion deletion. The observed distribution of same direction reads across the region of the 
globin gene loci each pair of same-direction reads are assigned the same arbitrary Y-axis value so 
that linked values can be identified. Grey crosses show same direction reads that are spurious 
noise. Pink crosses show a group of reads where the two halves cluster around the same regions: 
the first break point of the inversion deletion, as predicted in 1D. A second group shows same 
direction reads that cross the second inversion deletion break point. Some of these reads have 
been erroneously aligned to HBG2 instead of HBG1 due to the extremely high homology between 
these two genes.   
To-the-base resolution of this variant was possible, as three of the four breakpoints 
were successfully identified and the two regions affected by the deletion were clearly 
visible. Characterisation of this variant was complicated by the presence of the inverted 
region, as same direction reads related to this variant were obscured by the noise 
occurring between the two gamma globin genes. In this patient an additional variant 
was identified by looking through the NextGene Viewer, a 17 bp deletion was clearly 
visible within HBG1 (Figure 35). This deletion is a known polymorphism recorded in the 
dbSNP database, named Rs72324537 (Intron variant; Clinical significance N/A (Sherry, 
Ward et al. 2001)). Multiple positions are visible where NextGene has attempted to 
‘shoehorn’ the deletion containing sequences into aligning. Correctly aligning data at 
this position may have been particularly challenging for the software due to the 
repetitive nature of its surroundings. This software, or perhaps the settings used in this 
alignment, may not be reliable in detecting small indels which it is unable to align 
correctly, and are too small to be identified by inspecting the coverage reports.  
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An Indel in the AI Indel Alignment not Called by NextGene
 
Figure 35: An Indel in the AI Indel Alignment not Called by NextGene. Upper: A 17 bp deletion is 
clearly visible in the NextGene Viewer, but is not called by the software. The variant occurs in a 
simple repeat. Lower: The deletion as recorded in dbSNP, displayed on the UCSC genome browser. 
Characterising Structural Variation in the Test Samples 
All test samples showed clear regions where their coverage was substantially higher or 
lower than the range seen in negative controls. It was possible to estimate the size and 
dosage of the rearrangements in these samples based on the number of baits affected 
by the rearrangement (Table 28). 
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Table 28: Rearrangements identified in sample cohort from RPKM plots. Where 
available, HbVar database ID numbers are included for positive control samples 
for previously reported rearrangements. “+ Cntrl” = Positive Control; “-C =” 
Negative Control. 


















Test Sample 1 
Figure 30.1 
Het Deletion 
Alpha Globin Gene Cluster 
Chr16:  
112,159 - ? 
Cannot be 
estimated 













+Cntrl Het Deletion 
Alpha Globin Gene Cluster 
Chr16:  
223,197-226,313 
2,759 - 3,236 
Test Sample 8 
Figure 30.8 
Het Duplication 
Alpha Globin Gene Cluster 
Chr16:  





+Cntrl Het Deletion 
“British Deletion”  
Alpha Globin Gene Cluster 
Chr16:  
205,187- 234, 194 





























+ Cntrl Het Inversion-
Deletion 
HbVar.1038 (AI InDel) 





1,028  and 472 





5,226,289 - 5,372,652 
146,0363 







28,767 - 29,247 





5,232,355 - 5,258,687 
21,572 - 26,322 
 
Variant Characterisation: HiSeq Samples 1, 8 (Figure 30.1, Figure 30.8) 
The duplication on chromosome 16 in HiSeq Sample 1 extended beyond the region 
covered by the bait design (See Figure 30.1). The start position of the duplication (as 
indicated by the change in coverage relative to the negative control samples) is 
~chr16:112,164. HiSeq Sample 8, a related individual, showed a similar RPKM plot 
(See Figure 30.8) as expected. The pile-up of sequences aligning to the reference at the 
duplication start point was examined in the NextGene Viewer. Numerous reads that 
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had aligned to the reference sequence at this position contained a string of bases that 
did not match the reference sequence (Figure 36 B). The ID numbers of these reads 
were recorded and identified in the original FASTA files for the sample to obtain the full 
Read 1 and Read 2 sequences for these DNA fragments (Figure 36 C). The Read 1 
and Read 2 sequences of these reads were queried using the BLAT tool hosted by the 
UCSC Genome Browser to identify matches to these sequences within the human 
reference genome. A number of matches were obtained for the sequences (Figure 36 
D), only two merited high confidence scores (based on the high percentage of bases 
from the query included in the match and the number of bases matching in continuous 
sequence).  
Characterising a Novel Rearrangement in HiSeq Sample 1
 
Figure 36: Characterising a Rearrangement in HiSeq Sample 1. (A) The start point for the 
duplication (circled in blue) (B) Read pile-up at the estimated duplication start position (C) The 
whole read sequence is obtained from the original FASTA files for the sample (D) The read 
sequence is queried in BLAT.  
The confidence score UCSC assigns to query results is based on the absolute number 
of bases in the query that match the reference sequence at this location, the number of 
bases that match the reference sequence continuously, and the number of mismatches 
between the query sequence and the reference sequence. A blanket threshold for 
acceptable scores for all queries could not be established, as the length of sequences 
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queried varied greatly and this has a significant impact on the score a query is 
assigned. For this reason, as a general rule, the matches with the three highest scores 
for each read were considered as possible sources for the original sequence. If other 
matches had a similarly high score, these were also considered. 
UCSC BLAT showed that these reads from the rearrangement breakpoint region in 
sample 1 contained sequences from two different points in the reference genome, 
which had been brought together by the rearrangement. Part of each read aligned to 
the reference sequence beginning from position chr16:112,164 (where these reads 
were identified in the NextGene Viewer); while the remaining read sequence was a 
positive match to a region 118Kb downstream, ending at position chr16:300,927. This 
meant that the sequence normally found at position 112,164 was repeated after 
position 300,927 in the genome, the intervening sequence having been duplicated. 
Both portions of the sequence in each read matched either the positive or negative 
strand of the UCSC reference sequence, meaning that the rearrangement was top-to-
tail in orientation, rather than inverted (where one match would be to the positive 
strand, and the other to the negative strand). The duplication size is 118,763 bp. The 
layout of the rearrangement is shown in Figure 37A. 
The novel duplication was confirmed by Gap-PCR. Primers were designed to capture 
the duplication breakpoint indicated by the NGS data: Pr1: 5’-
GCTGCTTGGGTTTAATGAGG-3’ 5’-AAGTCAGTGTGTCCCCGTTC-3’. These primers 
were expected to make a unique product of approximately 700 bp across the 
duplication break point. PCR amplification produced a single band of the expected size 
in the patient, and no band in a negative control (Figure 37B). The PCR product was 
sequenced (Figure 37C) and confirmed the same break points of the duplication (as 
suggested by the NGS data) in both HiSeq Sample 1 and HiSeq Sample 8, both 
showing identical break points for the rearrangement in both family members.  
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Schematic of a Novel Duplication in HiSeq Samples 1 and 8
 
Figure 37: Schematic of a Novel Duplication in HiSeq Samples 1 and 8. (A) Schematic of 
rearrangement, showing primer locations on normal and duplicated allele (B) Gel image for Gap 
PCR. Lanes 1-6: (1) 1Kb+ DNA Ladder (2) HiSeq Sample 1 (3) HiSeq Sample 8 (4) HiSeq Sample 2 
(unaffected relative) (5) Negative control (6) No template control (NTC). (C) Chromatogram showing 
sequence of PCR product from HiSeq Sample 1. 
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Variant Characterisation: HiSeq Sample 3 (Figure 30.3) 
HiSeq Sample 3 shows a duplication that extends from approximately chr16: 83,214 to 
outside the bait-covered region. Inspection of the estimated start point of the 
duplication in the NextGene Viewer did not reveal any reads showing mismatched 
sequences at this position. One nearby region did show strings of mismatched bases, 
but the region was repetitive and BLAT query of these reads produced multiple high-
scoring matches across the genome.  
Opposite and same direction read analysis 
To investigate whether any reads that contained the variant sequence had been 
rejected from the alignment outright, both the opposite and same direction read reports 
were examined. The opposite direction reads report data contained thousands of 
entries derived from off-target regions and alignment errors. As such, the report was 
filtered to only include entries where at least one part of the read pair was within 5Kb of 
the suspected duplication breakpoint covered by the bait design. No read ‘pile-up’ like 
that seen in the positive control sample was revealed that could represent reads 
crossing the duplication break points. The same direction reads report was filtered in 
the same way. This revealed nine individual read pairs where one half aligned to the 
approximate region of the duplication start point (66,635-68,951) and the other half 
aligned in the same orientation to the same region on chr15. This may indicate that a 
translocation had occurred, resulting in an additional copy of this region of 
chromosome 16 situated on chromosome 15. These reads appear in the same 
direction read report, which would also indicate that the translocation was inverted. 
Comparison to the negative control same direction report revealed similar reads, 
however, so this was dismissed as noise due to homology between the regions.  
Single nucleotide variant analysis 
The mutation report generated by the NextGene software for the region was inspected. 
No mismatches that could represent the duplication breakpoints had been recorded in 
the report. The mutation quality score cut-off point was reduced from >20 to >10. This 
leniency is used in order to account for penalties that the software may apply to 
genuine variants which are affected by the duplication. In reports from negative control 
samples that are known to be balanced, variants show a mutant allele frequency of 1:0 
for homozygous variants or 1:1 for heterozygous variants.  In the patient sample, from 
position chr16:60,842 onwards many heterozygous SNPs were recorded with allele 
frequencies of 1:2 indicative that three copies of the DNA at the positions of these 
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SNPs are present. In the patient, 80% of heterozygous variants recorded after position 
chr16:60,842 from the telomere show this ‘duplicated’ allele frequency (i.e. 1:2 or 2:1). 
No variants were present at a 1:1:1 ratio, which would imply three separate genotypes 
for this region (although SNPs where >2 possible genotypes exist are rare). This 
suggests that one of the two normal alleles present in this individual has been 
identically duplicated due to an intrachromosomal recombination event.  
Variant Characterisation: HiSeq Sample 5/Sample 10 (Figure 29.5, Figure 
29.10) 
The RPKM plots for HiSeq Samples 5 and 10 indicate they have the same - or a very 
similar - deletion on chr11. This was expected, as these two individuals are related. 
The deletion removes exon 3 of HBG2, HBE and the beta globin ‘Locus Control 
Region’ (LCR), thus down regulating the expression of all the globin genes on the 
chromosome. The RPKM plot indicates the variant is 118,129 – 126,342 bp in size. A 
more accurate estimation could not be made as one breakpoint fell within a 6 Kb 
repetitive region that was not included in the bait capture. Investigation of the known 
breakpoint showed some reads with a small amount of mismatch. A BLAT query of the 
original reads revealed multiple (>50) matches for the non-aligning sequence. The 
highest scoring of these was for a region of HBG1 that was highly homologous to this 
part of the HBG2 gene. The other match on chr11 was located 58 Kb downstream of 
the breakpoint. That region was covered by an orphan bait which did not appear to 
have captured any sequence at this position.  
Opposite direction and same direction read reports revealed a large number of 
misaligned reads that partially matched the suspected breakpoint position chr11: 
5,274,684 in HBG2. The majority of these appeared to result from misalignments of 
read data from HBG1. The remainder showed matches across the genome, with no 
pile-up of multiple instances of the same mismatch that could indicate a genuine link 
between two distal sequence regions.  
The mutation report confirmed the presence of a deletion between the positions 
indicated by the RPKM plot; all but two of the SNPs recorded between these two loci in 
bait-tiled regions showed allele frequencies of 90-100%, indicating there was no 
alternative allele throughout this 122Kb region. The two exceptional entries in the 
report were dismissed as spurious data: they were not located in a bait covered region, 
meaning that read pileup at these locations was more likely to include off-target 
sequences. Also, both variants were indels, for which allele frequency counts are less 
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accurate in NextGene, as some reads containing the variant are aligned to the 
reference incorrectly.  
Gap-PCR primers were designed between the known break-point at chr11:5,274,684 
and the first unaffected position after the 6 Kb repeat covered by the bait design 
(chr11:5,400,736) but these failed to create any product, even with a 10 minute 
extension time to allow for a product of up to 10 Kb (the maximum expected size of this 
product being 6.5Kb).  Without any information about the breakpoints from the 
sequence, or from the opposite or same direction read reports, this rearrangement 
could not be fully characterised. The same rearrangement was later encountered in two 
other samples sequenced on the MiSeq (with longer insert sizes), and in this case to-
the-base characterisation of the variant was achieved. The breakpoints were confirmed 
for both the MiSeq samples and the two samples discussed here. The novel 
rearrangement was reported in Human Mutation (Shooter, Rooks et al. 2015) and 
named the ‘English V’ inversion - deletion. Please see later section for detailed 
discussion of the successful characterisation of this rearrangement.  
Variant Characterisation: HiSeq Sample 7 (Figure 29.7) 
HiSeq Sample 7 was an antenatal referral from a woman who had an unusually low 
level of HbS (13%) with an HbF level of 0-2% and hypochromic microcytic red cell 
indices. Co-inheritance of alpha thalassaemia with the sickle variant was investigated 
as this is known to reduce the fraction of HbS in a sickle cell carrier. She was 
subsequently confirmed to be heterozygous for the alpha thalassaemia 3.7 deletion 
(HbVar ID: 1076), but this single alpha globin gene is not sufficient to explain the 
unusually low HbS percentage. Beta globin gene sequencing did not identify any 
thalassaemia variants which may be in cis with the sickle cell variant that could reduce 
the HbS level. A HbS Taqman assay that indicates the relative abundance of HbS and 
HbA was performed, and indicated that an additional copy of HbA could be present in 
the patient. The NextGene mutation report listed rs334 – the sickle cell disease variant 
- with a mutant allele frequency of 1:2, suggesting a duplication of the normal allele 
may have occurred (Table 29).  















Inspection of the RPKM data for the covered region on chr11 indicated the presence of 
a large duplication (146,033-146,513 bp) extending from position chr11:5,226,876 to 
chr11:5,372,562, encompassing the entire beta globin gene cluster (Figure 39). The 
mutation report assigned allele frequencies of 1:2 or 2:1 for heterozygous SNPs in this 
region. 
We would expect that a duplication would increase the coverage of the affected region 
by a third (+0.3 on a log2 scale) relative to the negative control average. We found that 
the general variability of the assay meant that bait positions from balanced regions 
frequently showed variation as great as + 0.3. For this reason, we elected to use a 
deviation of +0.5 from the negative control average as an approximate indicator of 
duplicated regions in this study rather than + 0.3. Figure 38 shows that this cut-off 
provides a clearer distinction between duplicated and balanced regions in three 
confirmed duplications from this study.  
Bait Coverage in Balanced Versus Duplicated Regions for Three Samples
 
Figure 38: Bait Coverage in Balanced Versus Duplicated Regions for Three Samples. Box and 
whisker plots show range of Log2 values in duplicated versus balanced regions for three samples.  
Black plots show range of balanced values, while red plots show range of values in confirmed 
duplicated regions. Quartile values indicated by ‘Q’ and average values indicated by ‘Av’ are 
shown for each plot.  
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Inspection of the breakpoint regions in the NextGene Viewer revealed misaligned 
sequences in the read pile-up near both locations. BLAT query of reads containing 
these sequences in the original FASTA files confirmed that these misaligned 
sequences were the breakpoints of the duplication. The precise breakpoints were 
revealed to be positions chr11:5,226,885-5,372,677. Gap PCR and sequence analysis 
confirmed that the duplication was in a head-to-tail orientation (Figure 40). Eleven bp of 
novel sequence (CACCTCCACTT) was inserted at the break point. The 11 bp 
insertion, together with two last two bases of the duplicated region created a 13 bp 
mirror repeat. Previous studies have pointed out an association between mirror repeats 
and the incidence of duplication events. This scenario is unlike other incidents where 
mirror repeats are associated with duplications, as the duplication appears to create 
the mirror repeat, rather than the initial presence of a mirror repeat causing subsequent 
duplication. The variant was reported to HbVar as Hg19.Chr11 




Characterisation of a Novel Duplication in HiSeq Sample 7
 
Figure 39: Characterisation of a Novel Duplication in HiSeq Sample 7. Upper panel shows 
duplicated region indicated by RPKM plot. Middle panel shows reads aligning to the reference 
sequence at the position of the first break point. Lower panel shows schematic of duplication 
according to BLAT query results.  
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Breakpoint Confirmation for Novel Duplication in HiSeq Sample 7 
 
Figure 40: Breakpoint Confirmation for Novel Duplication in HiSeq Sample 7 by Gap PCR. Upper 
panel: Gel image showing (Lanes 1-5): (1) 1Kb plus DNA ladder (2) NTC (3) negative control (4) 
whole blood extracted DNA sample from sample 7 (5) saliva extracted DNA sample from sample 7. 
A 350 bp product is produced in lane 4 and lane 5. Lower panel: chromatogram of sequenced PCR 
product confirming the break point sequence identified by NGS analysis.  
The RPKM plot for chr16 showed the presence of the 3.7 deletion. Inspection of the 
break point locations in the NextGene Viewer did not reveal any misaligned sequences. 
This is likely to be due to the extremely high homology between the sequences at the 
start and end points of the 3.7 deletion. There were no opposite or same direction 
reads identified in the location. This is expected, as the breakpoint is within exon/intron 
1 between HBA2 and HBA1 and both have almost identical sequence. Therefore, any 
breakpoint-spanning sequences would align across the reference like normal paired 
end reads. The 3.7 Kb deletion was only detectable by the RPKM plot, supported by 




Variant Characterisation: HiSeq Sample 9 (Positive Control for British 
Deletion HbVar.1091) (Figure 29.9) 
HiSeq Sample 9 showed a deletion of approximately 30 Kb (co-ordinates 
Chr16:205,500-234,800) removing globin genes HBA1, HBA2 and HBM. Both break-
points appeared to be situated in repetitive regions that were not included in the bait 
design. Some variation outside the normal range made the position of the 5’ break 
point particularly hard to estimate. Inspection of the region showed a large amount of 
misalignment within the region that was supposedly deleted across approximately 1 Kb 
of sequence. The misalignment in this region was not the same in all reads; several 
different sequences showed partial alignment to the reference. Although the region is 
not classed as repetitive by Repeat Masker, there was no pile-up of misaligned reads 
at either of the suspected breakpoints. The opposite direction reads report did not 
contain any reads which mapped across the breakpoint locations, with a gap distance 
equal to the estimated size of the deletion, or pile-up between either breakpoint 
position and any other region. Large numbers of same direction reads aligned to the 
regions of both break points, but no trends stood out that could indicate a legitimate 
rearrangement over the background of partial matches to similar repetitive elements. 
When the precise known co-ordinates of this deletion were investigated in the 
NextGene viewer, a mismatch of two bases could be seen in reads at the telomeric 
break point location. It was established that there was a high level of homology in the 
breakpoint region, meaning that only two bases in the breakpoint reads did not match 
what was expected in the reference sequence. These two bases had previously been 
dismissed as a SNP rather than a rearrangement breakpoint. Therefore, without prior 
knowledge of the co-ordinates of this variant, to-the-base characterisation of this 
rearrangement would not have been achieved. Having now identified this 2 bp change 
as the breakpoint for this deletion, we will be able to confirm future cases of the 
rearrangement based on the RPKM data and this signature mismatch.  
Variant Characterisation: HiSeq Sample 11 (Figure 29.11) 
The RPKM plot for Sample 11 showed a deletion removing the delta and beta globin 
gene loci. Both deletion breakpoints as estimated by the RPKM data lie in unmapped 
repeat regions. The first break point appears to be between positions chr11: 5,232,475-
5,236,266 (LINE repeat, size: 3,791 bp) and the second between positions chr11: 
5,258,078-5,258,567 (SINE repeat, size: 500 bp). The layout of this region of the 
genome is shown in Figure 41. The size of the deletion is therefore estimated as 
21,572 bp – 26,332 bp. There were no strings of mismatched bases at either region 
that could represent the breakpoint sequence. No opposite direction reads or same 
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direction reads were found to cluster around either breakpoint, or cluster significantly 
anywhere in the wider surrounding region (excluding the expected mismatch between 
the two alpha globin gene loci). This variant could not be resolved with to-the-base 
accuracy using this methodology. This case could not be investigated further via Gap 
PCR due to insufficient DNA being available.  
A Novel Deletion in HiSeq Sample 11 That Could Not Be Characterised
 
 
Figure 41: A Novel Deletion in HiSeq Sample 11 That Could Not Be Characterised. The region 
highlighted in red appears to be deleted. The flanking regions highlighted in blue are repeats (LINE 
and SINE) that are not covered by the bait design library. Lower panel shows the layout of this 
region, including repeats, in the UCSC genome browser. 
Conclusions from HiSeq 2000 (Run 1) 
The HiSeq allowed 12 samples to be sequenced simultaneously, achieving a depth of 
coverage for each sample that was sufficient to identify the structural variants they 
were expected to contain (mean coverage 400 x). Although all expected variants could 
be identified by the RPKM plots, not all of the rearrangements present could be 
resolved (Table 30). The region covered by the bait design on chromosome 16 was not 
large enough to encompass some of the structural variants identified; therefore in these 
cases only one end of the variant was mapped. Despite this, in one case, a duplication 
could be resolved with to-the-base accuracy using reads from the one captured break 
point. Other variants could not be resolved where the break-point within the target 
region occurred in a repeat sequence not included in the bait library, and thus the size 
of the variant could not be estimated. The Asian Indian inversion deletion positive 
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control sample was successfully characterised by this assay due to the fact that three 
of the rearrangement’s four breakpoints were situated in non-repetitive sequence. In 
spite of this, there was still some confusion about the position of the fourth breakpoint, 
due to the high homology between the two gamma globin genes producing additional 
read pile-up. A novel duplication affecting the beta globin gene locus was successfully 
characterised, where neither breakpoint fell within sequence that was repetitive, or 
highly homologous to another region.  
Multiple variants on both clusters could not be characterised due to their breakpoints 
falling in either repetitive and unmapped, or highly homologous sequences. This 
included the (α-3.7/) deletion, which occurs between two highly homologous sequences. 
Although two known single nucleotide variants were successfully detected by 
NextGene and included in the mutation report, another variant was identified in the 
viewer which had not been detected, giving a false negative call. The uncalled variant 
was a 17 bp indel. Although this variant is a polymorphism with a silent phenotype, the 
fact that such a variant could be missed by software intended for diagnostic use is 
concerning. It is possible that increased read length will improve the ability of the 
software to confidently align reads containing this variant to the reference sequence 

































Sample Rearrangement Co-ordinates Resolved 
HiSeq Sample 1 
Figure 30.1 
Het Deletion 
Alpha Globin Gene Cluster 
Chr16:  
112,164 - 300,927  
Yes 







83,214 - ? 
No 
HiSeq Sample 7 
Figure 30.7 
+ Cntrl Het Deletion 




HiSeq Sample 8 
Figure 30.8 
Het Duplication 
Alpha Globin Gene Cluster 
Chr16:  
112,164 - 300,927 
Yes 
HiSeq Sample 9 
Figure 30.9 
+ Cntrl Het Deletion 
“British Deletion” 




























HiSeq Sample 6 
Figure 29.6 
+ Cntrl Het Inversion-Deletion 
HbVar.1038 (Asian-Indian 
Inversion Deletion) 


























5,232,355 - 5,258,687 
No 
Inter-sample variation was high across both regions included in the design. This 
variation made it hard to identify small dosage changes reliably. In some cases the 
variation also prevented clear determination of where dosage changing variants began 
and ended in the alignment, due to noise in the surrounding region. Average deviation 
from the Log2 negative control average within the negative control cohort for 
chromosome16 was +0.199/-0.244, and for chromosome 11 was +0.16/-0.204. There 
was a particularly large degree of coverage variability in the region of the bait design 
nearest the telomere on chromosome 16:60,000-80,000Kb. In this region, the average 
standard deviation from the negative control average among the negative control 
samples was -0.47/+0.35. This variation does not appear to be the result of copy 
number variation, because the variation does not imply that clearly defined segments 
are variously present or absent, as is the case with other CNVs (Figure 26). Features 
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of the sequence at this region that may be responsible for this variability include 
elevated GC percentage (which correlates with increased coverage variation across 
the chromosome (Figure 42)), large segmental duplications that confer a high 
homology between this position and regions of other chromosomes, and human 
chained self-alignments. Multiple copy number variants are also recorded within this 
area (Figure 43). These features of the sequence may contribute to the coverage 
variability seen in this region.  
Controlling for variability is necessary to reduce noise in the assay and improve its 
ability to detect rearrangements. A longer read length will aid this, as it allows 
alignment to be performed with a higher degree of specificity. Longer fragment length 
could also improve specificity, as alignment then relies on two non-overlapping 
sequences occurring at a given distance from one another. This would improve the 
ability of this assay to reliably sequence into repetitive regions, where breakpoints are 
frequently situated.   
Although the HiSeq produced a wealth of sequencing data and good coverage, the 
read length (2x97 bp) was short and limited sequencing into repetitive regions. By 
shearing the DNA to a larger size and increasing the read length it was hoped that 
more of the adjoining repeat regions could be sequenced. The main concern of this 
approach would be the coverage read depth, as this type of sequencing can only be 
done on a MiSeq, not the HiSeq. By moving to the MiSeq platform the assay can be 
run in a diagnostic laboratory and removes the need for collaboration with large 
genomic sequencing facilities. The MiSeq platform has lower sequencing capacity than 
the HiSeq 2000, which means that fewer samples can be included in each run to 
produce the same read depth for the targeted region. High read depth is crucial to 
accurately detecting structural rearrangements, so it may be necessary to significantly 
reduce the number of samples per run for this assay to retain diagnostic use on the 





Impact of GC Content on Bait Variability 
 
 
Figure 42: Impact of GC Content on Bait Variability. Top: The GC content calculated per 500 bp of 
the bait tiled region vs. standard deviation in bait position RPKM values between negative controls. 
Bottom: Correlation between amount of standard deviation from the average RPKM value per 500 
bp segment of the covered region on chromosome 16, and the GC content of each segment.  
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Genomic Features of the Region of High Coverage Variability on Chromosome 16
 
Figure 43: Genomic Features of the Region of High Coverage Variability on Chromosome 16 
16:60,000-100,000. The region that produces highly variable coverage during sequencing is 
highlighted in blue.  
A major advantage of this assay over CGH array or MLPA is that it is capable of 
detecting inverted sequence. In the case of the positive control Asian Indian inversion 
deletion, this was accomplished with to-the-base accuracy. This technique also has the 
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potential to detect insertions and translocations, however none of the samples in this 
cohort have either form of rearrangement. It should be considered in further 
evaluations of this assay that while insertions could be theoretically detected, it would 
not be possible to determine their size if the inserted sequence did not correspond to 
any sequences included in the bait capture library.  
MiSeq Runs 1 and 2 
To investigate whether moving to the MiSeq platform would improve the capability of 
this assay to detect structural variants, two MiSeq sequencing runs were performed 
(off-site). These runs contained a smaller number of samples to account for the lower 
sequencing capacity of this instrument than the HiSeq 2000.  
Sample Details 
DNA samples were sequenced on the MiSeq in batches of four (MiSeq Run 1) and five 
(MiSeq Run 2), using 2x 250 bp read kits. Each run contained a positive control; a 
negative control and at least one test sample (see Table 31). In MiSeq Run 2, DNA 
from the same patient was erroneously prepared twice, both as MiSeq Sample 7 and 
MiSeq Sample 9. The second preparation of this DNA (MiSeq Sample 9)  was 
excluded from variant analysis. MiSeq runs 1 and 2 focussed on characterising variants 
affecting the beta globin gene locus on chromosome 11.  
Table 31: Sample Details for MiSeq Run 1 and 2. 
MiSeq Run 1 
Sample Beta Globin Locus Alpha Globin Locus 
Sample 1 Positive control (-HPFH1/) Negative Control 
Sample 2 Test (deletion) Negative Control 
Sample 3 Test (deletion) Negative Control 
Sample 4 Negative Control Negative Control 
MiSeq Run 2 
Sample Beta Globin Loci Alpha Globin Loci 
Sample 5 Positive control (-619bp deletion/) Negative Control 
Sample 6 Test (deletion) Negative Control 
Sample 7 Test (duplication) Negative Control 
Sample 8 Negative Control Positive Control (α-3.7/)  




Samples were prepared in accordance with the protocol (See methods). An issue with 
the previous run was that the read size on the HiSeq 2000 was not long enough to 
accurately align reads containing long mismatches where they covered rearrangement 
break points. Another issue was that the small read size and small overall DNA 
fragment size impaired alignment to repetitive regions, which were frequently the sites 
of rearrangement breakpoints that were subsequently not captured. MiSeq sequencing 
kits allow a longer read length than available on the HiSeq (2x150, 2x250, 2x300). To 
accommodate this, a larger starting fragment size was used. This was achieved by 
shearing the DNA samples using a Bioruptor (as a Covaris was not available on site) to 
approximately 500 bp (see methods). MiSeq Run 1 was prepared successfully; 
producing libraries with a peak fragment size of approximately 650 bp (Figure 44). Five 
samples were prepared for sequencing, but only the highest quality four preparations 
were included in this run. Sample 4 from this run was later included in MiSeq Run 2 as 
Sample 5. Due to an error, this sample was then prepared again and was included in 
MiSeq Run 2 twice (as Sample 7 and Sample 9). Sample 7 showed better data and 
was used for analysis, while the duplicate, sample 9 was excluded from variant 
analysis but used for comparing inter-run variability (see later section). Sample 
preparation took place in Dr Chris Shaw’s laboratory at the Institute of Psychiatry, 
Denmark Hill Campus, King’s College London. Dr Athina Gkazi gave assistance and 
advice with the sample preparation process. 
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Bioanalyser Traces of Samples Prepared for Sequencing in MiSeq Run 1
 
Figure 44: Bioanalyser Traces of Samples Prepared for Sequencing in MiSeq Run 1. 
Electropherograms show fragment size distribution in each sample following post-hybridization 
indexing PCR and clean-up.  
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Bioanalyser Traces of Samples Prepared for Sequencing in MiSeq Run 2
 
Figure 45: Bioanalyser Traces of Samples Prepared for Sequencing in MiSeq Run 2 Samples 5-8 
(NB: Sample 9 was prepared in previous batch). Upper panel shows gel image and lower panel 
shows electropherogram trace. Each sample shows a size distribution of 300-1,000 bp, with a peak 
fragment size of around 500 bp. Sample 6 shows a slight hump on the peak which is indicative of 
over amplification during library prep. 
Sequencing 
Samples were sequenced on the MiSeq using the v2 2x250 reagent kit. MiSeq Run 1 
had been slightly overloaded and the cluster density was higher than recommended for 
this sequencing kit (Table 32). MiSeq Run 2 achieved acceptable cluster density (Table 
33). In both runs the quality scores of the bases in R2 tail off towards in the last few 
bases of the read (Figure 47). This is a known issue with the long read lengths of the 
v2 2x250 kits. The quality drop is more pronounced in MiSeq Run 1 read 2. This is 
likely to be due to the overloading of the flow cell in this run, meaning that the amount 
of reagents remaining was a limiting factor on sequencing quality in the second half of 
the . All indexed samplesamples were represented evenly in both runs (with no one 
sample over or underrepresented by >10% of total reads), indicating that pooling had 
been carried out correctly (Figure 46).  
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Reads Sequenced per Index in MiSeq Run 1 and MiSeq Run 2
 
Figure 46: Reads sequenced per index in MiSeq Run 1 and MiSeq Run 2.  




Table 33 Sequencing Statistics, MiSeq Run 2. 
 
Format Conversion 
After sequencing, s were converted from FASTQ format to FASTA format using 
NextGene. The majority of reads passed format conversion successfully (  
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Table 34). The majority of reads that were not converted were rejected based on their 
median score. A minority of reads were removed when they exceed the limit for bases 




Table 34: Success of Format Conversion. Average for MiSeq Run 1 and MiSeq Run 2 
 
 
Figure 47: MiSeq Run 1 and 2: Quality of base calls along length of read. A score >30 is deemed 




The majority of reads in both runs aligned successfully to the reference sequence 
(Table 35). In Run 1 37% of reads were on target, yielding average coverage of the 
ROI of 200x. In MiSeq Run 2 40% of reads were on target, and average coverage of 
the ROI was 180x. The reduced coverage per sample in Run 2 is contributed to by the 
inclusion of five samples in the batch, reducing the total reads produced for each 
sample.  
Table 35: Alignment results for MiSeq Run 1 and MiSeq Run 2. 
 
Coverage data 
With only a single negative control in each run, and all the samples containing variants 
from the same chromosome 11, it was not possible calculate a negative control 
average RPKM value. Instead, potential variants were identified by a sustained 
deviation from the RPKM values of the single negative control of >0.5 on a log2 scale 





MiSeq Run 1 Coverage Graphs: Chromosome 11 
 
Figure 48: MiSeq Run 1 Coverage Graphs: Chromosome 11. RPKM plots for MiSeq Run 1 Samples 
1-3, plus raw RPKM plot for Sample 4 (normal control). Green bar indicates region of acceptable 
(+/-0.5) variation from negative control value. 
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MiSeq Run 2 Coverage Graphs: Chromosome 11 
 
Figure 49: MiSeq Run 2 Coverage Graphs: Chromosome 11. Samples 5-7, plus raw RPKM plot for 
Sample 9 (normal control). Green bar indicates region of acceptable (+/-0.5) variation from negative 
control value. 
Variant Characterisation: MiSeq Run 1, Sample 1 (Figure 48.1) 
MiSeq Sample 1 (Figure 48.1) was a positive control for the HPFH-1 (HbVar.1021), a 
deletion of 85 Kb between co-ordinates chr11: 5,174,451 - 5,259,369 removing HBB 
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and HBD. The variant is clearly visible on the RPKM plot, estimated at between chr11: 
5,174,346 (+/-240 bp) – and 5,259,047 – 5,259,874 (where a repeat of 830 bp is not 
covered by the bait design). Inspection of the 5’ breakpoint region showed multiple 
reads aligning to the reference sequence at position ~5,259,360 that exhibited the 
same mismatched string of bases. Query of reads containing this string in the FASTA 
data files showed that they spanned the deletion breakpoint, aligning partially at both 
the 5’ and 3’ breakpoints of the deletion as listed in HbVar. Despite the gap in the bait 
design across this region, the long DNA fragment length and read length allow 
alignment of multiple sequences to this region (Figure 50), and to-the-base 
characterisation for this variant.   
Detection of the HPFH1 Deletion in Sequencing Data
 
Figure 50: Detection of the HPFH1 Deletion in Sequencing Data. (A) RPKM plot showing deleted 
region relative to globin gene positions. (B) The read pile up at the 3’ break point region (circled in 
blue) reveals breakpoint reads. (C&D) BLAT query of the original sequences of these reads reveal 
deletion breakpoints.  
Variant Characterisation: MiSeq Samples 2 and 3 (Figure 48.2, Figure 48.3)  
MiSeq Samples 2 and 3 (Figure 48) were obtained on separate occasions from two 
unrelated individuals. Neither variant could be resolved via Gap-PCR, although a large 
deletion removing the LCR was clearly visible by MLPA. NGS sequencing revealed that 
the same region was deleted in both samples, removing approximately 126 Kb of 
178 
 
sequence including the last exon of HBG2, HBE and the LCR (Figure 51A). The 5’ 
breakpoint of the deletion was obscured by a 6 Kb LINE repeat which was not included 
in the bait design. Multiple reads aligning to the region of the 3’ break point showed 
strings of mismatched sequences (Figure 51B). The deletion was similar to that of 
HiSeq Samples 5 and 10, in whom the break-points of the variant could not be 
resolved. BLAT query of these sequences revealed that the first portion of the read 
matched the reference sequence up to position chr11: 5,274,684 within HBG2 (and 
also partially matched a region highly homologous to this within the HBG1 gene) 
(Figure 51C/D).  The second portion of the read matched the reference sequence 58 
Kb downstream between positions 5,215,647 and 5,215,692 on the reverse strand, and 
also aligned with high homology to an overlapping sequence (5,215,689 - 5,215,734) 
on the positive strand. The same 3’ breakpoint had also been identified in HiSeq data, 
but the shorter read length had meant that this highly homologous match downstream 
on chr11 was obscured by the many other high scoring matches to this common 
repetitive sequence.   
Characterisation of a Novel Variant in MiSeq Samples 2 and 3
 
Figure 51: Characterisation of a Novel Variant in MiSeq Run 1 Samples 2 and 3. (A) RPKM plot 
showing deletion relative to positions of globin genes (B) Reads containing breakpoint sequence 
identified at 5’ breakpoint (C&D) BLAT query of the original sequences of these reads  reveal 
multiple matches to the reference sequence including inverted break point positions.  
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Overlaying the opposite direction reads over the RPKM data did not reveal any pile up 
that could indicate the deletion break points. A single same direction read aligned 
between the two positions identified by BLAT of the misaligned sequences described 
above which suggested that an inversion may have occurred between these two 
points. Close examination of the sequence at position 5,215,647 – 5,215,692 revealed 
that the region was a 159 bp reverse-compliment palindrome (meaning that the 
sequence on the positive strand read 5’-3’ was identical to that of the negative strand 
when read in from its 5’-3’) (Figure 52). It also appeared that the bait covering this 
region – which was an orphan situated between two repeats – was not functioning 
correctly: <5 reads aligned to this position in any of the sequenced samples from the 
MiSeq or HiSeq runs. This is likely to be related to the palindromic nature of the 
sequence which may cause the bait itself or DNA fragments containing this sequence 
to take on unusual physical conformations.  
A Palindromic Sequence on Chromosome 11 Impeding Bait Performance
 
Figure 52: A Palindromic Sequence on Chromosome 11 That Impeded Bait Performance. 
Palindromic region at position 5,215,611-5,215,770. The nature of this sequence renders the bait 
that covers this position (marked in orange) non-functional 
Confirmation of Novel Inversion-Deletion by Gap-PCR  
Gap-PCR primers were designed to confirm the suspected inversion break points, and 
to identify the deletion breakpoints. A 1,031 bp product confirming the inversion 
sequence was successfully amplified using primers Pr1: 
5’AGCTGGTTGGTCCGTTTTGG-3’ and Pr3: 5’-CTCTGCATCATGGGCAGTGAG’3 
(See methods). The product was dye-terminator sequenced on the ABI 3130 platform 
and the resulting chromatogram examined in Sequencher. The chromatogram showed 
that the variant breakpoints were 5,215,690 – 5,274,684 (Two bases at the break point 
position were expected in the normal sequence at both locations, so their origin was 
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ambiguous – the variant breakpoints could also be 5,215,692-5,274,682). Additional 
primers were designed between the inverted sequence (in the closest section of 
unique, non-repetitive sequence to the break point) and the unique, unaffected 
sequence region occurring immediately after the 6 Kb LINE repeat obscuring the 5’ end 
of the deletion (Figure 53). The primer sequences were Pr2: 5’-
AGTGCAAAGGATGCCAGGAC’3 and Pr4: 5’-GAGCAAGTGCATGCAAGGAGA-’3. A 
unique Gap-PCR product of 4,499 bp was successfully amplified using a long-range 
polymerase (See Methods). These revealed that the deletion breakpoints were 
5,215,722 (inverted) – 5,397,195.  
Breakpoint confirmation for novel variant in MiSeq Samples 2, 3 and 6 and HiSeq 
Sample 10
 
Figure 53: Breakpoint confirmation for novel variant in MiSeq Samples 2, 3 and 6 and HiSeq 
Sample 10.  Gel images: (A) Inversion PCR product. Lanes 1-8: (1) 1Kb+ ladder (2) Blank (3) 
Negative Control (4) Negative Control (5) MiSeq Sample 2 (6) MiSeq Sample 3 (7) MiSeq Sample 6  
(8) HiSeq Run 1 Sample 10. (B) Deletion PCR product Lanes 1-7 (1) 1Kb+ ladder (2) MiSeq Run 1 
Sample 2 (3) negative control (4) MiSeq Run 1 Sample 3 (5) HiSeq Run 1 Sample 5 (6) HiSeq Run 1 
Sample 10 (7) Blank. Chromatogram: Sequence analysis of the inversion Gap PCR product for 
MiSeq Run 1 Sample 2 showing inversion-deletion breakpoint.  
An 82 bp section of the inverted sequence was also removed by the deletion, which 
was 122,593 bp in length. The inclusion of inverted sequence in the deletion indicates 
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that the inversion event happened before the deletion event. The rearrangement 
concatenated two normally distant, but highly homologous LINE repeats (Figure 54). 
This novel inversion-deletion was submitted to HbVar with the common name English 
V, ID 2935, and is described as: Chr11 Hg19 (build 37.3) 
g.5215690_5274684invdel5215690_5215772del5274684_5397195 (Shooter, Rooks et 
al. 2015).  
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Schematic of the Novel Rearrangement in MiSeq Samples 2, 3 and 6 and HiSeq 
Sample 10 (English V Inversion Deletion) 
 
Figure 54: Schematic of the Novel Rearrangement in MiSeq Samples 2, 3 and 6 and HiSeq Sample 
10 (English V Inversion Deletion). (A) normal layout of beta globin gene cluster and surrounding 
region of chromosome 11, plus positions of primers for Gap-PCR. (B) Inversion event (indicated by 
a light green box) occurs, followed by deletion removing 82 bp of the inverted sequence and 
122,511 bp of upstream sequence (C) rearranged chromosome (figure from Shooter et al, 2014). 
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Variant Characterisation: MiSeq Sample 5 (Figure 49.1) 
MiSeq Sample 5 is a positive control for the well-characterised 619 bp deletion (HbVar 
ID.979) which removes the sequence between chr11:  5,246,619 - 5,247,237, inserting 
7 bp of novel sequence (‘TCTACTT’) at the deletion break point. The small size of the 
variant made it difficult to identify from the RPKM data, particularly as in this case the 
cut-off used was >+0.5/<-0.5 from the negative control, rather than the more accurate 
means of detection by comparison to the standard deviation of variation from the 
average of multiple negative controls. The deletion is more prominent when the RPKM 
data is viewed at a higher resolution (Figure 55). Investigation of the read pile-up at the 
expected breakpoint regions from the RPKM data showed large numbers of reads that 
had crossed the break point had aligned to the reference sequence. BLAT query of the 
sequences of reads containing these mismatched bases showed a split alignment 
between the expected break point positions, and also the 7 base pair insertion. The 
read pile-up also shows an additional pile up of multiple reads containing a different 
sequence of mismatched bases. All of the aligned sequences containing this novel 
sequence of bases were identical in length and ended with a similar string of novel 
bases. BLAT query of this sequence indicated that they were published PCR primer 




Detection of the 619 bp Deletion in Sequencing Data
 
Figure 55: Detection of the 619 bp Deletion in Sequencing Data. (A) RPKM plot showing deletion 
relative to positions of globin genes (B) misaligning reads in the NextGene viewer at deletion 
breakpoint region (C&D) BLAT query of original FASTA sequences identifies breakpoint, including 
7 bp insertion (indicated in red).  
Identifying this PCR contaminant was important, as it shows the necessity for good 
laboratory practise and isolation of post-PCR products. As NGS is a high sensitivity 
technique, minor contaminations have the potential to influence how the results of 
sequencing are interpreted.  
Variant Characterisation: MiSeq Sample 6 (Figure 49.2) 
MiSeq Sample 6 was also identified to have the newly characterised English V 
deletion. This sample had previously been sequenced on the HiSeq 2000 (HiSeq  
Sample 5) in which the variant could not be resolved due to the shorter read length. 
Here, the variant could be resolved by BLAT query of reads aligning to the reference 
sequence at position chr11: 5,274,684 which crossed the inversion breakpoint. As with 
MiSeq Samples 2 and 3, no sequences aligned to the reference sequence at this 
position, as they had not been captured by the non-functional bait covering this region. 
The deletion breakpoints could once again only be resolved through Gap-PCR.  
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We investigated whether the rearrangement was on the same haplotype background in 
all, or whether this rearrangement had arisen independently in these people. Mutation 
reports for all three samples sequenced on the MiSeq were generated. Variant calls 
data from the HiSeq 2000 excluded from  the analysis to increase the uniformity of the 
datasets being compared. The reports were filtered to the broad region of the 
rearrangement (chr11:4,500,000-6,000,000). Variants within the region deleted by this 
rearrangement (chr11:5,215,690-5,215,722 and 5,274,684-5,399,855) were excluded, 
as any variants here would belong to the unaffected chromosome.  
For each sample, we selected variants that were (a) homozygous, and therefore 
definitely present on the rearranged allele, and (b) had a phred score of >15 (Table 
36). We searched for these variants in the mutation reports of the other two samples to 
identify any variants that were unique to the rearranged allele in that sample.  
The data showed that >98% of variants that could definitely be assigned to the 
rearranged allele were present in all three samples. This suggests that the haplotype 
background for the variant was the same in all three cases, and that it has a common 
point of origin.  
Table 36 Comparison of variants in cis with the English V deletion in three 
samples 






Number of variants recorded in region 4818 4641 4749 
Number of those variants with a Phred 
score >15 
3497 3121 3315 
Number of variants (Phred score >15) that 
were homozygous (and thus definitely 
present on rearranged allele) 
1403 1408 1514 
Number of variants (Phred score >15) 








Number of those variants (Phred score >15) 










Variant Characterisation: MiSeq Sample 3 (Figure 49.3) 
MiSeq Sample 3 was known to be heterozygous for the (α-3.7/) deletion on 
chromosome 16, for the sickle cell variant on chromosome 11, and heterozygous for a 
duplication on chromosome 11 which was resolved with to-the-base accuracy in HiSeq 
Run 1 (Sample 7). The novel duplication identified on the HiSeq 2000 was once again 
clearly visible in the RPKM data, and in the reads aligning to the break point regions in 
the NextGene viewer (Figure 56). The sickle cell mutation was listed in the mutation 
report with a mutant allele frequency of 31%. 
Appearence of a duplication identified in HiSeq sample 7 when resequenced on 
the MiSeq platform (as MiSeq Sample 7) 
 
Figure 56: Appearence of a duplication identified in HiSeq sample 7 when resequenced on the MiSeq 
platform (as MiSeq Sample 7). (A) RPKM plot identifies novel duplication of approximately 145Kb 
encompassing entire globin gene cluster. (B) Read pile-up at approximate duplication start point 
includes multiple reads showing string of mismatched bases. (C&D) BLAT query of reads 
containing misaligned reads indicate they represent the break point of the duplication. Duplication 
includes insertion of 11 bp (red) creating 13 bp mirror repeat (underlined).  
The 3.7 Kb Deletion 
Detecting the (α-3.7/) deletion in this sample had been challenging using the HiSeq 
2000 data, as the homology between the breakpoint regions prevented any opposite 
direction reads or break point sequences from being generated. We investigated 
whether the longer fragment and read lengths of the MiSeq improved the visibility of 
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this rearrangement during analysis. As this variant is located on chromosome 16, the 
two other samples in the Run (which both had variants on chromosome 11) could be 
used as additional negative controls for this locus.  
Detection of the (α-3.7/) Deletion in Sequencing Data
 
Figure 57: Detection of the (α-3.7/) Deletion in Sequencing Data. Blue line indicates standard 
deviation seen in samples known to be negative for structural variants at this locus. Expected 
position of 3.7 Kb deletion indicated by red bar.  
The deletion is faintly visible in the RPKM data (Figure 57), but many of the bait 
positions in the affected region do not exceed the negative control standard deviation. 
This would make this variant difficult to detect in persons who were not previously 
known to carry the deletion. The variant is also not visible as misaligned reads in the 
sequencing data, or in the opposite direction reads report, despite both break points 
covered by the bait design. Alignment ambiguity affecting this region may also be 
responsible for the faint signal of this deletion in the RPKM data. This is a common 
variant, and detecting its presence can be diagnostically important. Issues with 
detecting this deletion will be discussed in detail in a later section.   
Evaluation of MiSeq Vs HiSeq Sequencing Platforms 
The HiSeq platform allowed sequencing of 12 samples simultaneously (in one lane) at 
an average read depth (across the bait-covered region) of 363x. Samples were 
sequenced on the MiSeq in smaller batches as the sequencing depth required to 
characterise variants had not been established. A run of four samples on the MiSeq 
achieved an average coverage of 387x across the bait tiled region. A run of five 
samples achieved an average coverage of 266x. The coverage provided by the HiSeq 
2000 was sufficient to identify deletions and duplications in the RPKM data, however 
some variants could not be resolved with to-the-base accuracy. There were several 
reasons for this, as discussed earlier. One important factor was the read length (2x97 
bp) which was not sufficient to align reads that contained a large amount of novel 
sequence to the reference. This problem was compounded by the fact that many of the 
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variant break points were within repetitive regions not included in the bait capture 
library. The small read length meant that it was challenging to align reads originating 
from these regions to the correct positions in the reference sequence. The bait capture 
design did not cover enough of chromosome 16 to capture both break points of several 
large rearrangements affecting the alpha globin gene loci. This meant that not only 
could the break point sequences not be resolved for these variants, their approximate 
size and number of genes affected could not be determined.  
Sequencing on the MiSeq platform allowed longer read lengths of 2x250-2x300 bp. 
Larger DNA fragments could be sequenced for longer distances with this technique, 
and several variants affecting the beta globin gene cluster on chromosome 11 could be 
fully characterised, where this was not possible from HiSeq 2000 sequencing data. The 
3.7 Kb deletions could not be reliably identified or resolved with to-the-base accuracy 
using either sequencing platform. The HiSeq 2000 showed the deletion with greater 
clarity in the RPKM plot, due to the greater number of controls for this region included 
in the run. Better alignment algorithms may be required to reliably detect this variant by 
assigning reads to HBA1 and HBA2 with greater accuracy. It was suggested that the 
changes to the bait library could improve the ability of this assay to detect 
rearrangements. As described earlier, this new design would have a higher tiling 
density across the regions most likely to be involved in structural rearrangements, 
cover a larger region of chromosome 16, and use newer bait tiling algorithms 
developed by Agilent to improve performance (See Methods).  
On both platforms, bait performance varied between different samples and between 
different runs (See Figure 58). Some regions showed more inter-sample and inter-
batch variation than others. This variation created noise that interfered with the 
detection of some rearrangements, including the 619 bp and 3.7Kb deletions. Figure 58 
shows the variance between different samples, where any bait that show low variation 
in the RPKM values obtained from the two samples (<+/-0.5) is plotted in green, while 
baits showing significant variation (>+/-0,5) are plotted in red. Figure 58.A shows the 
same sample prepared twice on the HiSeq 2000 (Sample 11 and Sample 12). Only 
2.2% of bait covered positions had significantly different RPKM values  between the 
two identical samples. B Shows the variation between two sequencings of the same 
sample on different platforms: the HiSeq 2000 and the MiSeq. Significant variation is 
recorded between the two sequencing experiments at 20% of bait-covered positions. It 
should be noted that other factors, such as the different fragment and read sizes used, 
facility in which the samples were prepared, and level of experience of the researcher 
changed between these sequencing experiments in addition to the platform, so this is 
189 
 
not a particularly accurate measure of the difference between the platforms. C shows 
the difference in RPKM values for the same negative control sample prepared and 
sequenced separately for MiSeq Run 1 and 2, and the variation between these two 
runs was 9.8%. D Shows two identical iterations of a sample that were prepared 
separately and then included in the same sequencing run on the MiSeq (MiSeq 
Samples 7 and 9). Significantly different RPKM values between these two samples are 
recorded 4.7% of bait positions. This suggests that the sample preparation process 
accounts for approximately half the variability seen between different MiSeq runs. That 
the HiSeq platform showed least variability was unexpected. This may have been 
impacted by preparing these samples under close supervision from the experienced 
staff at Guy’s Campus. MiSeq Run 1 and MiSeq Run 2 were prepared with 
considerably less guidance, and sample preparation during MiSeq Run 2 suffered 
numerous setbacks which were eventually determined to be due to the temperature of 
the laboratory in which preparation was carried out (the lab in which these samples 
were prepared rose to a temperature of 34°C in the summer which was eventually 
determined to cause severe evaporation of the ethanol used during wash stages).   
These comparisons provide a rough idea of the variation between samples prepared in 
different batches and sequenced in different runs and on different platforms. This 
comparison was not planned in advance, so the comparisons made given the data 
available are not ideal. It appears that some variation occurs between different 
instances of sample preparation. The introduction of the automated sample preparation 
platform may reduce this variation, and increase the sensitivity of the assay.   
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Bait Variability on Chromosome 11 between Different Samples, Runs and 
Platforms 
 
Figure 58: Bait Variability on Chromosome 11 between Different Samples, Runs and Platforms. A-
C: Variation between different preparations of the same sample (this was not possible for 
comparison D). (A) Variation between instances of same sample run twice on HiSeq 2000 (HiSeq 
Samples 11 and 12). (B) Variation between the same sample sequenced on HiSeq and MiSeq 
platforms shows significant variation in 20% of baits. (C) Inter-run variation on the MiSeq platform 
between the same sample is 10% (D) intra-run variation on the MiSeq platform is 4.7%  
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The high inter-run variability on the MiSeq platform means than multiple negative 
controls should be included in each run to distinguish genuine rearrangements from 
random noise. The noise itself may be reduced by improving the uniformity of the 
sample preparation process, which can differ substantially between samples. This is 
demonstrated by the variability in success of amplification at the final stage of the 
process within MiSeq Run 1 (Figure 44). We expect this variability is the culmination of 
many minor differences in the treatment of samples at each stage of the library 
preparation process (i.e. concentration, quantity and purity of DNA sample; number of 
PCR cycles employed; exact hybridization conditions; quality of post hybridization 
washes). Inter-sample variability may additionally be improved by the introduction of 
the new bait capture design, with more intelligent bait placement and more baits 
covering regions expected to perform poorly.  
Redesigning the Bait Capture Library 
The process of redesigning the bait capture library is described in Methods. The 
performance of the new design was evaluated on the MiSeq. The key requirements of 
the new library were to: 
 Reduce the amount of off-target sequence captured 
 Extend the regions covered in the bait design to cover all variants 
affecting the globin gene loci up to the largest published rearrangement 
size 
 Reduce the variability in bait performance  
The new library, Bait Capture Library 2, was used for target enrichment in subsequent 
runs. The performance of the new library in comparison to Bait Capture Library 1 used 
for target enrichment in the sequencing runs performed in this chapter is evaluated in a 
later section. To reduce inter-batch and inter-sample variation that occurred due to 
differences in sample preparation conditions, a robotic platform was set up to automate 
the sample preparation procedure.  
Automated Sample Preparation Using the BioMek FXp 
Robotic Platform 
Automating the library preparation procedure adds value to the diagnostic workflow: It 
means more samples can be processed in parallel, with a more uniform approach, 
which should result is less inter-sample variation. We believed that the hybridisation 
reaction during library prep contributed to a large portion of the batch to batch variation 
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due to the sensitivity of this step. Reducing this variability by automation would be 
helpful. 
Issues with the performance of the robotic platform caused the failure of several s 
which would otherwise have been used to evaluate the robotic sample preparation 
method. The failing runs used the last of Bait Capture Library 1.  
Initial issues with the robotic preparation platform included: 
i) Errors with the program, in which tips were re-used at inappropriate times, causing 
cross-contamination of samples 
ii) Errors with the hardware, (a) the robotic arms would fail to eject tips correctly and 
continue its operations with lower than expected clearance of the robot platform, 
leading to physical crashes and damage to the machinery (b) incorrect calculation of 
the height of the labware on the robot platform, causing damage to the gripper arms. 
iii) Pipetting errors, leading to incorrect reagent mix assembly and sample loss.  
iv) Hybridization errors, in which the extremely sensitive hybridization stage of sample 
preparation failed. Factors contributing to this included: (a) the behaviour of the thermal 
cycler (b) the makeup of reagent mixes (c) the manner in which reagent mixtures were 
combined with DNA libraries. 
Errors i-iii were eventually resolved, but errors with hybridization on the robot platform 
persisted (See Results Section: MiSeq Run 3). Failure at this stage was costly, due to 
expenditure of the capture library, and particularly problematic because the failure of 
this stage could not be detected until sample preparation and sequencing had been 
completed and sequence alignment had been performed. For this reason, once the 
problems with robotic sample prep in pre and post-hybridization had been resolved, the 
hybridization step was still performed manually.  
Validation of both the new library and the automated sample preparation platform were 
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Introducing an Automated Sample Preparation Platform 
into the Diagnostic Laboratory 
The aim of this research is to implement Next Generation Sequencing for routine 
diagnostic use in the Molecular Pathology laboratory at King’s College Hospital. The 
manual sample preparation workflow for NGS is extremely time consuming and can 
result in high variation both within and between different runs. To increase the 
throughput of this process and with the intention of also reducing variability, a BioMek 
FXP (Beckman Coulter) laboratory automation workstation was purchased. This is an 
automated liquid handling platform that can be used to mix and distribute reagents at 
each stage of the Agilent sample preparation procedure, as well as the size selection, 
washing and PCR steps. The workstation consists of two CNC (computer numerical 
control) arms which move over a modular deck. The arms move along the X and Y 
axes across the workstation on bridges. The arms can be fitted with tip adapters to 
transfer liquids between different positions on the workstation, or with grabbers to move 
items around the workstation. The workstation is protected by a cover and a light 
curtain, which will freeze all movement on the platform if it is activated. The basic 
layout of the workstation is shown in Figure 59.  
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The BioMek FXP Laboratory Automation Workstation
 
Figure 59: The BioMek FX
P
 Laboratory Automation Workstation - Main Components. Image taken 
from Beckman Coulter BioMek FX
P
 User Manual (PN 987834AF), P31. ‘ALPs’ are Automated 
Labware Positions. 
The layout of the BioMek FXP workstation at the Department of Molecular Pathology is 
shown in Figure 60. This platform has two CNC arms: ‘Pod 1’, with a 96 well head 
(used for transferring reagents between plates and performing washes) and a grabber 
(for moving plates and tip racks around the platform) and ‘Pod 2’ with a span-8 head 
(with 8 individually manoeuvrable probes for mixing and dispensing reagents). The 
deck can take a variety of different plates, such as 96 well PCR plates and 1 ml 
capacity round-bottomed plates for washing reagents. Automated Labware Positioners 
(ALPs) included in the workstation are the T-Robot thermal cycler (for use in PCR and 
incubation stages), tip loading and disposal points, two static heating/cooling peltier 
modules, a shaking peltier module and a non-temperature controlled shaking module.  
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The BioMek FXP Setup in the Dept. Molecular Pathology
 
Figure 60: The BioMek FX
P
 Setup in the Dept. Molecular Pathology. ALPs indicated by dashed 
lines. Various pieces of kit arranged on the deck are highlighted in yellow. Picture taken by 
Frances Smith. 
The instrument was set up by engineers from Beckman Coulter. A Beckman Coulter 
product specialist wrote a series of programs that would perform the Agilent SureSelect 
Automated Sample Preparation protocol. Four programs were used to manage 
different stages of sample preparation. The advantage of this was that each program 
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could then be optimised separately. This also allowed the workstation layout to be 
changed between stages, rather than all reagents for the entire process being thawed 
at the start of sample preparation. The division of the process between programs is 
outlined in (Figure 61). The last stage of sample preparation is an AMPure clean-up 
after the post-hybridization PCR. To reduce the risk of PCR products from this stage 
contaminating unamplified samples in future preparations, this stage was performed on 
a separate BioMek platform already operating in the laboratory – the NXP. The NXP 
program was already in routine use for purifying PCR products in the laboratory and no 
optimization of this step was required. The Pre-Hybridization PCR stage only consists 
of six cycles of amplification, so the contamination risk from this stage was 
considerably lower and continuing the sample preparation procedure on the same 
platform was considered to be acceptable. 
Division of Automated SureSelect Sample Preparation between Programs and 
Equipment 
 




A second program was also created that performed a SPRIselect double size-selection 
on DNA samples that had been fragmented using the Covaris which would be 
performed before the Agilent sample preparation program.  
There was a plethora of problems with implementing automated sample preparation. 
Issues encountered and fixes made are summarised in Table 37. 
The pre and post-hybridization stages of sample preparation were successfully 
implemented on the platform fairly quickly, but automating the hybridization stage of the 
process was challenging. At the end of the experiments outlined in Table 37, the 
remains of the first bait capture library had been exhausted. While a second library was 
designed and we awaited its delivery, the issues with the automated hybridization 
stage were tackled by the Molecular Pathology operations manager Frances Smith, 
using a different capture library panel for another study, in collaboration with Beckman 
Coulter engineers. Frances Smith found that factors affecting the success of 
hybridization included: 
 Wash Buffer 2 was not properly heated by the peltier module during the post-
hybridization clean-up. This buffer needs to be heated to 65°C for optimal 
performance 
 The amount of DNA available for the hybridization stage was often lower than 
expected. Several changes were made to increase pre-hybridization DNA yield: 
 DNA input concentration, which was increased to ensure the optimal amount of 
DNA for hybridization was available.  
 Bead carryover during clean-up stages may have reduced sample yield 
 Pipetting during the elution stage of the post-hybridization clean-up was causing 
bubbles to form, which decreased the amount of liquid aspirated at this stage, and 
therefore reduced the DNA yield.  
 After the 24 hour hybridization stage is complete, the samples are aspirated from 
the T-robot and transferred to a fresh plate. It was noted that in some wells several 
microlitres of DNA remained in the old plate. The aspiration speed at this step was 
reduced in order to ensure all of each sample was transferred to the new plate.  
 The ethanol used at the clean-up stages can sit on the workstation for up to five 
hours before the final time it is used during library prep over the course of a day. 
Changing the ethanol halfway through the day significantly increased pre and post 
hybridization yields. This suggested that the ethanol evaporating over the day had 
decreased its concentration resulting in lower DNA yields.  
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 Additional steps where tip changes should have been included in the program but 
were not, where contamination could occur, were identified. These steps were 
modified.  
By the time these issues had been completely resolved, all the runs performed for this 
study had been completed: MiSeq Runs 3 and 4 as part of the process of developing 
the automated protocol, and MiSeq Runs 5 and 6 with automated sample preparation 




Table 37 Issues Encountered Implementing Automated Sample Preparation on 









MiSeq Run 3 for Validation of New Capture Library and 
the Automated Sample Preparation Platform 
Sample Details 
Four samples were prepared for sequencing on the MiSeq using the BioMek FXP 
automated sample preparation platform. The samples were from four individuals who 
were homozygous controls for the HbC variant. The samples would be used primarily 
to evaluate sample preparation on the BioMek FXP, but information about the haplotype 
background on which the HbC variant occurs was also of interest. The samples were 
sheared to 200 bp on the Covaris and post-shearing clean-up, sample preparation and 
hybridization were all performed on the BioMek FXP. Target enrichment for this Run 
was performed using Bait Capture Library 2 (See appropriate methods and results 
sections for details of the new capture library), with the hope that this Run could be 
used to evaluate the performance of the new library.  
Sample Preparation 
The samples were sheared to 200 bp. As these samples had single nucleotide variants 
rather than large rearrangements, this smaller fragment size was not expected to have 
a negative impact on interpreting the sequencing results. During sample preparation it 
was noticed that the master mixes were not being dispensed into the sample tubes 
correctly. Furthermore, the beads that were added to the BioMek FXP deck during 
setup of the protocol ran out before the last clean-up stage was completed, resulting in 
sample loss in three of the four samples.  
After fixes were made to the protocol to address these problems (Table 37) sample 
preparation produced good results at the pre-hybridization stage. During the 
hybridization stage, excess capture library was added to the samples as the ‘Library 
Size <3Mb Protocol’ option (in which 2µl of capture library are used per sample, as 
opposed to 5µl in the <3Mb protocol) had not been checked. After the 24 hour 
hybridization period had been completed, Pod 1 crashed into a tip box that had been 
left on a deck position listed as blank in the sample preparation program. The crash 
caused damage to the grabbers and moved Pod 1 out of alignment. Subsequently, the 
post-hybridization sample preparation steps were performed manually for this run.  
Sequencing  
The samples were pooled to an equimolar concentration and sequenced on the MiSeq 
platform using the MiSeq V3 2x250 reagent kit. The run data showed that pooling had 
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been successful and the run had produced an acceptable cluster density for the V3 
2x250 kit (Table 38, Figure 62).  
Table 38 Sequencing Statistics for MiSeq Run 3 
 
Proportion of Reads on the Flow Cell from Each Sample Index MiSeq Run 3
 




Reads in the FASTQ files were successfully converted to FASTA format in 97% of 
cases, all passing quality filters. Of those reads that did not pass quality filters, 79% 
failed due to not meeting the “Median Score” requirement (Table 39). The quality of 
base calls along Read 1 and Read 2 remained high along the entire length of both 
reads (Figure 63).  





Figure 63: Quality of Base calls across Length of Read 1 and Read 2 for MiSeq Run 3. 
Sequence Alignment 
Reads were aligned to a reference sequence of the Human Genome in NextGene. The 
alignment statistics revealed that hybridization on the BioMek FXP automated library 
prep workstation had not worked: only 10% of sequence was on target, covering the 
region of interest at an average read depth of 13x (Table 40). This was not sufficient to 
produce reliable variant calls for use in haplotyping these samples, as variant score 
calculation assigns penalties for low coverage (See Methods).  
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Table 40 Alignment Statistics for MiSeq Run 3 
 
There was extremely high inter-sample variation across the region of interest in this 
run. This may be primarily the result of the extremely low level of coverage, but could 
also indicate that the success of hybridization and uniformity of sample preparation 
between the samples were different in the manually and automated sample 
preparation/hybridization procedures. A 0.5 Mb segment of the region of interest on 
chromosome 11 (chr11:5,500,000 - 6,000,000) was selected to compare inter-sample 
variation within this run to inter-sample variation within MiSeq Run 1. This region was 
selected as it was not involved in any of the structural variants included in MiSeq Run 
1. The samples in MiSeq Run 1 had been prepared for sequencing manually, and had 
been enriched using the old bait capture library. The new capture library used for 
enrichment of MiSeq Run 3 increased bait tiling density across this region from 1x to 
2x, with the specific aim of reducing inter-sample variability. In MiSeq Run 1, the 
amount of baits showing high inter-sample coverage variability (i.e. the standard 
deviation from the average of the four samples was >0.5 on a log2 scale) in this region 
was 1.5%. In MiSeq Run 3, 29.5% of baits within the same region showed high inter-
sample coverage variability (Figure 64).  
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Comparing Inter-Sample Variation between MiSeq Run 1 and MiSeq Run 3 Shows 
Substantially More Variability in MiSeq Run 3
 
Figure 64: Comparing Inter-Sample Variation between MiSeq Run 1 and MiSeq Run 3 Shows 
Substantially More Variability in MiSeq Run 3. Graph: Standard deviation within the sample cohort 
from the RPKM average for each bait position in the design. The graph depicts a ‘snapshot’ region 
of chromosome 11. Orange line shows MiSeq Run 3 (using the new bait capture library) and purple 
line shows MiSeq Run 1 (using the old bait capture library). Green box indicates acceptable limits 
of inter-sample variation (+/- 0.5). Table: number of baits in each design showing high inter-sample 
variability in coverage.  
This data shows that hybridization is still ineffective on the robotic platform, and that the 
automated sample preparation may result in high-inter sample variation in coverage of 
the bait tiled region. These issues must be resolved before automated sample 
preparation can be introduced into the diagnostic laboratory for routine use. The low 
coverage and high variability mean that this data could not be used to accurately detect 
structural variants in prepared samples.  
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MiSeq Run 4 
Sample Details 
Eight samples were prepared for sequencing on the BioMek FXP platform following 
fixes to the method implemented after the previous run (Table 37). A larger number of 
samples were included in the run to get a better idea of inter-sample variation within 
the run. We suspected that mixing issues that had been identified over the course of 
optimizing the automated library preparation protocol may result in lower quality sample 
preparation at some positions than others. By including eight samples we would be 
able to identify the positions on the plate where sample preparation was worst. The 
eight samples including a range of positive and negative controls for rearrangements 
affecting the alpha globin gene cluster on chromosome 16, to see whether the new bait 
capture library covered a large enough region of chromosome 16 to cover all these 
rearrangements.  
Sample Preparation 
The samples were fragmented to 400 bp on the Covaris. Sample preparation was then 
carried out on the BioMek FXP automated library preparation workstation. Target 
enrichment was performed using Bait Capture Library 2.  Sample preparation had to be 
halted due to a crash on the BioMek FXP that required realignment of the robot arm, 
but this did not appear to affect sample preparation negatively. Tapestation traces at 
various stages during sample prep showed consistency between the samples, and that 
there was not unacceptable sample loss across the preparation process. After the final 
post-PCR clean-up some primer dimer was visible on the Tapestation 4, 5, 6, 7 and 8. 
Two additional clean-ups were necessary to remove this product.  (NB: These products 
are more obvious after the second clean-up because the first clean-up trace was 
measured using the D1000 kit instead of the D1000 High sensitivity kit) 
Sequencing Results 
The samples were sequenced twice on the MiSeq, as the first run (MiSeq Run 4a) had 
an unworkably low cluster density (96 +/- 38 K/mm2), resulting in under loading of the 
flow cell. A second run (MiSeq Run 4b) was performed loading 10pM of the pooled 
samples onto the flow cell. A MiSeq V3 2x150 reagent kit was used for this run, as no 
more V3 2x250 kits were available in the lab. This run achieved an acceptable cluster 
density (1215 K/mm2), so the run data and FASTQ output were downloaded and 
analysed. Of the eight pooled samples, two samples accounted for 47% of the reads 
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that were produced (Figure 65). This was most likely to be the result of a quantification 
or pipetting error.  
Proportion of Reads Achieved Per Index for MiSeq Run 4
 
Figure 65: Proportion of Reads Identified on the Flow Cell Containing Each Index Tag, MiSeq Run 
4b. MiSeq Samples 14 and 15 together account for 47.5% of total reads. 
The read data was converted from FASTQ to FASTA. In all samples >99% of reads 
passed quality filtering.  
Sequence Alignment 
Alignment of the FASTA data showed that overall the alignment statistics corresponded 
to the amount of DNA sequenced on the flow cell, with the two overloaded samples 
showing higher values than the other 6 for most criteria. The only statistic where this 
isn’t the case is in the amount of on-target sequence for Sample 14, which is 
significantly less than that achieved for Sample 15. Sample 14 had been in position A1 
of the plates used during sample preparation on the BioMek FXP platform. Issues had 
been identified with the accuracy of pipetting at this position, which may have affected 
hybridization efficiency for this sample. The same issue was seen in the data from both 
the first and second MiSeq runs. On-target capture ranged from 18% to 49% (Table 
41). This was substantially lower than expected. The average coverage of the ROI was 
too low to effectively use this data, and an extremely high level of inter-sample variation 
was found across the bait-covered regions. It was concluded that there were still 
problems with the hybridization stage of the sample preparation process at this time. 
These issues were not resolved until after data collection for this project ended. For 




Table 41: Sequence alignment results for MiSeq Run 4. 
 
MiSeq Run 5 
Following the redesign of the Agilent Bait Capture Library, two sequencing runs were 
performed on the MiSeq to test the ability of this technology to characterise a range of 
rearrangements affecting the alpha and beta globin gene loci. Some samples that had 
been previously run with the old library design were re-run with the new design. This 
was in order to determine whether the improved bait placement strategy and coverage 
associated with reduced noise had increased the assay’s ability to detect variants 
(single nucleotide changes and structural variants). 
Sample Details 
Prior to this run, a sequencing experiment was performed as part of another study 
using a cohort of 16 samples. The samples were prepared in tandem, target enriched 
using Bait Capture Library 2, pooled and sequenced on the MiSeq in a single run. This 
experiment was only concerned with genotyping the samples, so high read depth was 
not a priority. Sequence alignment from this run showed that with a batch of 16 
samples, the coverage achieved across the bait-tiled region was approximately 250x. 
We considered this to be a satisfactory read depth for variant detection and as such, 
increased the number of samples included in the following two runs in this study.  
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Fourteen samples were prepared in tandem for sequencing to evaluate Bait Capture 
Library 2 on the MiSeq and to provide NGS data for several known structural variants 
that commonly cause alpha thalassaemia. The sample group included eight positive 
controls for alpha thalassaemia variants commonly encountered in the diagnostic 
laboratory, four test samples predicted to have unknown variants affecting the alpha 
globin gene cluster from screening data, one negative control, and one test sample that 
had been previously sequenced on the MiSeq using the old bait capture library (Table 
42)  
At the time that MiSeq Run 5 was ready for sequencing, a MiSeq platform was brought 
into the Molecular Pathology laboratory. Prior to this, MiSeq sequencing had been 
carried out on an instrument in another department. In order to validate the new 
instrument, we sequenced MiSeq Run 5 twice, once on the machine used for previous 
runs, and once on the new instrument. Subsequently, the first sequencing run – MiSeq 
Run 5a – was not analysed in great detail. General run statistics will be described, 
followed by a more detailed account of the analysis of the second round of sequencing 
for these samples – MiSeq Run 5b. 
Sample Preparation 
Sample preparation was performed using the automated BioMek FXP platform in 
accordance with the manufacturer’s protocol (see Methods). Hybridization was 
performed manually, as this part of the process had not yet been optimized on the 
BioMek FXP. Size selection was also performed on the robot.  
Size Selection Using SPRISelect Beads 
For MiSeq Run 1 and MiSeq Run 2, DNA had been sheared to a mean fragment size 
of 500 bp in order to take advantage of the longer read length of the MiSeq platform 
and to improve fragment mappability. We found that the sample preparation process 
favoured smaller fragments and these were preferentially amplified, leading to a 
smaller than expected average sample size at the sequencing stage.  
To combat this, we introduced a double size selection step to remove small fragments. 
Several samples were sheared on the Covaris E220 using a range of settings specified 
by the manufacturer. Fragmented DNA was electrophoresed on the Tapestation using 
the gDNA kit (Figure 66). We found that the manufacturer’s settings for shearing to 
400bp and 500 bp produced the most DNA in our target size range of 400-600 bp 
(Figure 66 D&E). The 500 bp shearing settings produced a mean fragment size of 736 
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bp, but with the largest proportion of fragments in our target range relative to the 
smaller fragments we intended to exclude from sample preparation.   
Results of DNA Fragmentation on the Covaris E220 According to Manufacturer-
Recommended Settings
 
Figure 66 Results of DNA Fragmentation on the Covaris E220 According to Manufacturer-
Recommended Settings. Settings and resulting mean fragment size are shown in the table, and 
charts below with corresponding numbers show the range of fragments produced. Target fragment 
range is indicated by a red bar. 
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To tighten the fragment size range prior to sample preparation, DNA sheared using the 
500bp fragmentation settings was purified twice with SPRIselect beads. The first 
purification used a concentration of 0.4x SPRIselect beads per sample volume. This 
removed fragments <~250 bp from the sample. A second purification using a 
concentration of 0.6 x SPRIselect beads per sample volume removed fragments >~800 
bp from the sample (for further details see Methods). This produced a mean fragment 
size of 694 bp, but with a substantial reduction in small fragments (Figure 67). The 
volume of input DNA was increased from 3 µg to 5 µg to accommodate the increased 
sample loss resulting from this purification process. 
Bioanalyser Traces Before and After Double Size Selection to Concentrate DNA 
Fragments Of Desired Size
 
Figure 67: Bioanalyser Traces Before and After Double Size Selection to Concentrate DNA 
Fragments Of Desired Size. Electropherogram traces (Tapestation DK 1000 kit) show sample post 
fragmentation above, and post size selection below. Target fragment is size represented by red 
box.  
Following fragmentation, samples were prepared according to the protocol as outlined 
in Methods. 2nM of each sample was added to an equimolar pool for sequencing. 9pM 





Table 42: Sample List, MiSeq Run 5 
Sample Status Variant Locus 
MiSeq 22  Test sample Duplication Alpha 
MiSeq 23 Positive control (---
FIL/) Deletion (HbVar.1094) Alpha 









Compound heterozygous deletions  
(HbVar.1086, HbVar.1076) 
Alpha 
MiSeq 27 Positive control (--SEA/) Deletion (HbVar.1086) Alpha 
MiSeq 28 Positive control (--
MED/) Deletion (HbVar.1078) Alpha 
MiSeq 29 Positive control (ɑ-4.2/) Deletion (HbVar.1079) Alpha 
MiSeq 30 Positive control (--20.5/) Deletion (HbVar.1088) Alpha 
MiSeq 31 Positive control (ɑɑɑ/)  Insertion Alpha 
MiSeq 32 Negative control None None 
MiSeq 33 Test Sample Deletion Alpha 
MiSeq 34 Test Sample Duplication Alpha 
MiSeq 35 Test Sample Duplication Alpha 
 
Sequencing Statistics 
Samples were sequenced using the v3 2x300 MiSeq Reagent Kit (MS-102-3001), 
which was prepared in accordance with the manufacturer’s protocol (see Methods). 
Sequencing showed that MiSeq Samples 32 and 35 had been under loaded when 
creating the equimolar sample pool (Figure 68). The cluster density achieved on the 
flow cell was within acceptable limits (600-1400 k/mm2) for the v3 kit. The large 
fragment size used in this experiment meant that it was difficult to produce cluster 
densities towards the higher end of this range, due to the space required for long 
fragments to bend over during bridge amplification. The quality of base calls at the 
ends of both reads dropped below acceptable levels (Figure 69). This is a known 
feature of the longer read length of the v3 kit.    
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Proportion of Reads On Flow Cell For Each Index Included In MiSeq Run 5
 
Figure 68: Proportion of Reads On Flow Cell For Each Index Included In MiSeq Run 5.  
 
Figure 69: Quality of Base calls Across Read 1 and Read 2 During Sequencing MiSeq Run 5. 
Format Conversion 
An average of 98% of reads in the sample input files were successfully converted from 
FASTQ to FASTA format, passing all quality filters. 98.2% of reads that did not pass 







Table 43: MiSeq Run 5 Format Conversion Statistics. 
 
Sequence Alignment 
Sample data in FASTA format was aligned to the reference sequence in NextGene 
using standard parameters. The average coverage across the entire genome was 6x, 
and across the bait-tiled region was 230x, indicating that hybridization had been 
successful.  
Variant Detection 
Detection of large structural variants 
Large structural variants are identified where the RPKM (a normalised measure of the 
number of reads covering a location) differs from the values for the bait-covered 
positions in a negative control. A comparative increase in coverage implies a 
duplication, and a decrease in coverage implies a deletion. As coverage is highly 
variable throughout the regions of interest, multiple controls are used to generate a 
control average to compare with the RPKM data from samples. If the RPKM data from 
the sample deviates by more than one standard deviation from the negative control 
average (the negative control standard deviation, or for short: ‘NegC StDev’), this 
suggests that that region has been affected by a structural rearrangement.  
216 
 
Accurate detection of large structural variants was not possible using this dataset. The 
low number of negative controls resulted in high levels of noise in the data which 
prevented reliable identification of structural variants some positive controls, as well as 
the test samples. Figure 70 shows the RPKM plot for MiSeq Sample 24 (--Thai/), with the 
position of the known variant (‘Thai 1 Deletion’, HbVar.1095) indicated by an orange 
bar. While 76% of baits covering the deleted region did show a significant departure 
from the ‘Neg C StDev’, this was matched by 56% of baits exceeding the NegC StDev 
in the balanced region (Table 44). This level of variation in the balanced region 
prevents differentiation between genuine dosage changes and noise. More negative 
controls are necessary to reduce the level of noise in the data.  
Detection of the (--THAI/) Variant Using Coverage Data from Two Negative Controls
 
Figure 70: Detection of the (--THAI/) Variant Using Coverage Data from Two Negative Controls. 
Graph shows RPKM plot for MiSeq Sample 24. The position of the known deletion in 
highlighted in yellow. Baits where RPKM was within the limits of the NegC StDev are plotted 
in black and baits where RPKM exceeds the NegC StDev are plotted in red  
Table 44: Difference in RPKM Values between a Positive Control Sample and the 
Average Values for Two Negative Controls.  
Difference in RPKM values between 
a positive control sample and the 
average values for two negative 
controls. 





In deleted region (chr16) 24% 76% 




For this reason, variant detection analysis of MiSeq Run 5a was discontinued. The 
pooled samples were re-sequenced in order to compare the performance of the off-site 
MiSeq with the new instrument in the lab (discussed below). We attempted to integrate 
the data from both runs to increase the read depth across the region, but found that 
this was not possible, as the MiSeq platform recycles its naming system between runs, 
meaning that many reads from the two runs would have identical names, and thus the 
files could not be merged together. Subsequently, structural variant analysis for these 
samples was performed using the data from MiSeq Run 5b, with samples from MiSeq 
Run 6 that were balanced at the alpha globin gene locus used as additional negative 
controls. 
MiSeq Run 5b 
Sample details 
The pooled sample libraries from MiSeq Run 5 were re-run on the MiSeq using a new 
2x300 v3 MiSeq Reagent Kit. The samples were prepared for sequencing in 
accordance with the manufacturer’s protocol as before, and sequenced on the MiSeq. 
This produced a cluster density similar to the previous run (861 +/- 31 K/mm2). Lower 
cluster densities are a consequence of the longer fragment read length (as each 
fragment requires more space during bridge amplification) and this density is 
considered to be acceptable by Illumina using the 300bp read kit. Base call quality 
dropped at the end of Read 1 and 2, as in the previous run.  
Format Conversion 
Format conversion was performed to convert sequence files from FASTQ to FASTA 
format. 98.4% (+/- 0.11) of reads passed format conversion (Table 45).The majority of 
those that failed were rejected based on the ‘Median score threshold’ filtering 
parameter. 50% of reads required trimming based on their quality score, which is a 




Table 45: Format Conversion Statistics MiSeq Run 5b. 
 
Comparison between Sequencing Metrics from MiSeq Run 5a 
and MiSeq Run 5b 
Comparison of the quality metrics from the off-site and new on-site instruments showed 
that they had a comparable performance (Table 46). A comparison between variant 
calling from each run was performed by the on-site bioinformatician, Dr David 
Brawand, using his bespoke alignment and analysis pipeline (in development). Variant 
call information was compared for all fourteen samples sequenced in this run, using 
four independent variant callers to create a consensus list of variants in each sample 
(variant callers were FreeBayes, Samtools, Platypus and Varscan). The consensus 
variant calls from the data produced by the two sequencing instruments showed 97% 
concordance between them (data not shown). We concluded that the new instrument 
produced data that was comparable to that produced at the other site where routine 




Table 46: Comparison between quality metrics from off-site run 5a and new on-
site instrument run 5b. 
Metric MiSeq Run 5a MiSeq Run 5b 
Library type Globin Mapping Globin Mapping 
MiSeq Liver MHL 
Read length 2x300bp 2x300bp 
Loading conc. (pM) 9 9 
Cluster density 850 861 
%PF clusters 90.83 96.45 
Phasing/prephasing (%) 0.121/0.084 0.174/0.071 
Read number PF (million) 18.01 20.58 
Intensity cycle 1 read 3 164 312 
% >Q30 78.6 82.4 
Total yield (G) 10.9 12.4 
PhiX % aligned 2.21 2.16 
PhiX error rate % 2.47 2.29 
Sequence Alignment 
FASTA data was aligned to the reference sequence using standard alignment 
parameters, with a paired gap distance of 0-800 bp to accommodate the mean 
fragment size of the run which was 600 bp. Across the 14 sample run, an average of 
57% of reads aligned to the target region (of a total of approx. 2.6 million matched 
reads), giving the target region 225x coverage (Table 47). Four percent of reads could 
not be aligned to the reference sequence. The coverage obtained for each sample was 








Table 47: Alignment Statistics for MiSeq Run 5b. 
 
Variant Detection 
The alpha globin locus on chromosome 16 contains five globin genes of similar size, 
structure and sequence. The most abundantly expressed genes, HBA1 and HBA2, 
share very high homology and other highly homologous regions are common across 
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the alpha globin gene cluster. Deletions are common causes of alpha thalassaemia 
and this is believed to be due to non-homologous recombination occurring between 
these positions (See Results Chapter 3). Carriers of alpha thalassaemia variants are 
protected from the severe effects of p.falciparum malaria and this has increased its 
prevalence to as high as 1:3 in some populations where p.falciparum malaria is 
endemic. Being able to detect these common alpha thalassaemia variants is important 
if we are to offer a single diagnostic test for all haemoglobinopathies. 
The aim of this sequencing run was to evaluate the capability of the capture library 
(which now covered a larger part of chromosome 16 than the previous library) to 
resolve large structural variants affecting the alpha globin gene locus. The previous 
capture library only covered chr16: 60,000 to 260,000 bp, whereas the new capture 
library extends from chr16: 60,000 to 2,000,000 bp. Baits cannot be designed against 
the telomeric region of chromosome 16 (0 to 60,000 bp). Known alpha zero and alpha 
plus variants commonly encountered in the diagnostic laboratory were used as positive 
controls. All heterozygous variants (test samples and positive controls) could be 
identified from the RPKM plots (Table 48), with the use of the additional negative 
controls afforded by resequencing the samples and including negative controls from a 
subsequent run (MiSeq Run 6). The coverage depth achieved per sample in the 14 
sample pool was adequate for variant detection with the introduction of these additional 
negative controls. Many variants in the run could be identified broadly, based on just 
the two duplicates of the negative control in MiSeq Run 5a and 5b. The (ɑ-3.7/) deletion 
and its counterpart, the triplicated alpha (ɑɑɑ/) variant were exceptions to this (see 
Table 48 and also later section devoted to these variants) until the additional negative 
controls from MiSeq Run 6 were added. It appeared that for these two variants, several 
controls would be necessary to reliably detect their presence.   
With the additional control data, all variants could be identified easily in the RPKM data 
(with the exception of the (α-3.7/) deletion). Despite this, not all of the variants could be 
characterised with to-the-base accuracy (Table 48). In these cases, the breakpoint 
sequences were either within repetitive regions and not captured, or situated in regions 
with such high homology to one another that the mutant sequences could not be 






Table 48: Variant Characterisation in MiSeq Run 5b. NB: Same direction read data was not 





MiSeq Run 5b Coverage Graphs Chromosome 16
 
Figure 71: MiSeq Run 5b Coverage Graphs Chromosome 16. Plots show depth of coverage (Y axis) 
at each bait-covered position on chromosome 16 (X axis) in relation to the average coverage of that 
position in negative controls on a log2 scale. Combined NegC StDev from this run and the negative 
controls in MiSeq Run 6 is shown in blue. The positions of the alpha globin genes are shown in red 
horizontal blocks. Graphs: (1) Test sample22 (2) positive control sample 23 (3) positive control 




Figure 71 continued: (6) positive control sample 27 (7) positive control sample 28 (8) positive 




Figure 71 continued: (11) negative control sample 32: plot shows raw RPKM data rather than 
deviation from average (12) test sample 33 (13) test sample 34 (14) test sample 35: scale zoomed 
out to show entire rearrangement.  
Variant Characterisation: Positive Controls 
Ten positive controls for known rearrangements affecting the alpha thalassaemia locus 
were included in this run, comprising of eight heterozygous deletions, one insertion and 
one compound heterozygote with two known deletions affecting the same globin gene 
locus (Variant list: Table 42. Positions of known rearrangements in the run: Figure 72). 
All variants except the (ɑ-3.7/) deletion could be identified on RPKM plots. Three of the 
10 alpha thalassaemia variants (--SEA/, --MED/, --20.5/) could be identified by pile-up of 
reads at the break point locations in the opposite direction read report. These 
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rearrangements could also be identified with to-the-base accuracy by inspection of the 
read pile-up in the NextGene Viewer at the break point positions estimated by the 
RPKM data. Some break point reads were also included in the opposite direction read 
report. No inversions were included in the run (no inversion rearrangements that affect 
the alpha globin gene cluster have been reported), so same direction read data was 
not analysed for the positive control samples.  
To-the-base characterisation was not permissible where the rearrangement break-
points were situated in repetitive regions not covered by the bait design, or where the 
homology between the start and end points of the rearrangement was too high. The 
alpha globin gene cluster contains many highly homologous sequences, including the 
globin genes themselves and many Alu repeats. Even if the two homologous regions 
are included in the bait design, they may be so alike that breakpoint-crossing reads 
show very little deviation from the reference sequence. If multiple other regions include 
this homologous sequence, this can cause a higher level of noise and misalignment 
between these positions due to inadequate alignment by NextGene, further obscuring 
any misalignment genuinely related to a rearrangement breakpoint.  
Six variants with known breakpoints were included in this run. The three that showed 
the highest degree of sequence homology around their breakpoints could not be 
characterised with to-the-base accuracy. The three variants with a lower degree of 
homology between their break point regions were characterised successfully. Figure 73 
shows Pip plots for the homology of the breakpoint regions of these deletions: 1 Kb 
sections of the reference sequence around each pair of breakpoints are compared. A 
graph is created where the X-axis represents the first breakpoint region from base 1-
1000, and the Y-axis represents breakpoint region 2 from base 1-1000. A dot in the 
graph area represents a position of homology. A line in the graph area shows an 
extended region of homology. The pip plot for the (--Thai/) deletion shows that both this 
deletion’s breakpoints occur in completely homologous sequences. The same is true 
for the (ɑ-3.7/) deletion (and also the (ɑɑɑ/) insertion). The (--FIL/) deletion has 
moderately homologous break point regions. The extreme homology between the 
approximate breakpoint regions of the (ɑ-3.7/) deletion and the triple alpha insertion 
made these variants challenging to identify in the RPKM data. The lack of identifiable 
break point sequences in conjunction with this was concerning. These variants are 
common, and it would be essential for a diagnostic assay to be capable of detecting 
them. The (ɑ-4.2/) deletion is also believed to have homologous breakpoints, but was 
not included here as the breakpoints have not yet been reported in the literature. 
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In MiSeq Run 5b, the (--SEA/) deletion in a normal heterozygous state (Positive control 
Sample 6) could be resolved with to-the-base accuracy, as could the (--MED/) (Positive 
control Sample 7) and (--20.5/) (Positive control Sample 9) deletions. A previously 
identified duplication of the beta globin cluster on chromosome 11 (Positive Control 
Sample 4 - not shown) could also be identified successfully with to-the-base accuracy, 
conferring with previous sequencing data (See Results: MiSeq Run 2, Sample 3).   
Positions of Variants Included as Positive Control Samples in MiSeq Run 5 in 
UCSC Genome Browser
 
Figure 72: Positions of Variants Included as Positive Control Samples in MiSeq Run 5 in UCSC 
Genome Browser. The region removed by each variant is depicted by a black bar, with the variant 
name to the left. NB: The (ɑ-
4.2
/) deletion is not included as its breakpoints are not defined in HbVar. 
The (ɑɑɑ/) variant affects the same region as the (ɑ-
3.7
/) deletion.  
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Homology of Breakpoint Sequences in MiSeq Run 5 Positive Control Variants
 
Figure 73: Homology of Breakpoint Sequences in MiSeq Run 5 Positive Control Variants. Each 
square plot concerns a different variant. The X axis represents 1 Kb of sequence centring on the 5’ 
break point. The Y axis represents 1 Kb of sequence centring on the 3’ break point. A red dotted 
line indicates the breakpoint position on each axis, and thus the position in the graph area at which 
they intersect. The graph area depicts homologous parts of these sequences as dots and lines. 
The (α-
3.7
/) deletion breakpoints have almost absolute homology, a single diagonal line running 






/) deletion breakpoints are 




/) deletion breakpoint regions have no 
homology. The variants where breakpoint sequences could not be identified show a higher level of 
homology to one another than the variants where to-the-base characterisation was achieved.  
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Detecting the (ɑ-3.7/) Deletion and (ɑɑɑ/) Insertion 
The most commonly occurring rearrangement of the alpha globin gene cluster is non-
homologous recombination between the homologous ‘z box’ regions of HBA1 and 
HBA2. The recombination event results in a 3,804 bp deletion on one allele (creating a 
single functional alpha globin gene by joining the remaining exons of HBA1 and HBA2 
together) and a 3,804 bp insertion (creating an additional alpha globin gene) on the 
other allele. These are referred to as the (ɑ-3.7/) deletion (HbVar.1076) and triple alpha 
(ɑɑɑ/) (Figure 74). The (ɑ-3.7/) deletion is the most common variant affecting the alpha 
globin gene locus. Co-inheritance of this variant with an alpha zero thalassaemia can 
result in HbH disease. The (ɑɑɑ/) insertion can have clinical consequences when co-
inherited with beta thalassaemia.  
Formation of the (ɑ-3.7/) Deletion and (ɑɑɑ/) Insertion via Misalignment and 
Reciprocal Crossover during Meiosis
 
Figure 74: Formation of the (ɑ-
3.7
/) Deletion and (ɑɑɑ/) Insertion via Misalignment and Reciprocal 
Crossover during Meiosis. The cross-over results in alleles with a reciprocal deletion and insertion 
of 3804bp, and the triplicated alpha globin gene (ɑɑɑ/ɑ-
3.7
). Recombination between the X-box 
homologous regions results in the (ɑ-
4.2
/) alpha thalassaemia deletion, and its reciprocal (ɑɑɑ
anti-
4.2/). 
Detection of these variants via the analysis techniques developed to this point in this 
study was not possible, due to the high degree of homology between the two alpha 
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globin genes (Figure 75) which cause multiple alignment issues in NextGene. Issues 
with the strategy used for other rearrangements characterised during this study are 
listed below.  
DotPlot Showing Homology between HBA1 and HBA2 Gene Regions
 
Figure 75: Dot Plot Showing Homology between HBA2 and HBA1. The X axis represents the HBA2 
gene and 1 Kb of surrounding sequence. The Y axis represents the HBA1 gene and 1 Kb of 
surrounding sequence. Homologous stretches of sequence are represented by dots or lines in the 
chart area. Between HBA2 and HBA1 only a single base change breaks the homology of the two 
sequences (circled).  
NextGene Viewer 
These variants bring together (or insert) homologous sequences, leaving no unique 
signature. As such, like the (--Thai/) and (--FIL/) deletions, these variants cannot be 
identified in the NextGene Viewer, as none of the reads that capture the rearrangement 
breakpoint produce any detectable misalignment (Figure 76).  
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Breakpoint Sequences Left By the (ɑ-3.7/) Deletion and (ɑɑɑ/) Insertion 
 
Figure 76: Breakpoint Sequences Left by the (ɑ-
3.7
/) Deletion and (ɑɑɑ/) Insertion. The breakpoint 
sequences resulting from these rearrangements are indistinguishable from the expected normal 
sequence, and as such align perfectly to the reference sequence.  
Opposite Direction Read Data: 
The homology between HBA1 and HBA2 confounds the data in the opposite direction 
read report at this location by simultaneously creating multiple false positives in 
balanced alignments, and false negatives in alignments containing these 
rearrangements. False positives (reads which are rejected from normal alignment as 
opposite direction reads when they are in fact from normal sequence) occur when 
NextGene erroneously assigns one half of a read pair to HBA1 and the other half to 
HBA2. Pile-up of opposite direction read pairs between the two alpha globin genes is 
high both in samples and in negative controls (Table 49). False negatives (reads which 
originate from fragments that crossed the rearrangement break point) are created when 
NextGene erroneously aligns both reads to the same alpha globin gene and accepts 




Table 49: Opposite direction reads between HBA1 and HBA2 in samples with and 
without 3.7 variants. Data shown is (i) the number of opposite direction reads for 
each sample where positions are within 1 Kb of the HBA1 and HBA2 genes and 
(ii) the number of those reads that show the expected gap distance for the 3.7 Kb 
rearrangements.  
Samples in MiSeq 
Run 5b 
(αα/αα) (αα/αα) (αα/αα) (αα/αα) (ααα/αα) (α-
3.7
/αα) 
Opposite direction reads 
aligning to HBA1/HBA2 
region 
9 16 6 20 16 16 
Opposite direction reads 
aligning to HBA1/HBA2 
region with a 3000-4500 
bp gap distance 
0 15 5 15 1 11 
 
Thus, the data cannot be used to identify these rearrangements due to the high level of 
noise, compounded by the reduced level of genuine reads recorded between these two 
regions.  
Same Direction Read data is not applicable in this case because the rearrangements 
do not involve sequence inversion.  
Mutation report 
SNP Detection using the mutation report may bolster evidence of a rearrangement 
from the RPKM data, but single nucleotide changes do not occur with a high enough 
frequency (average of one per Kb) to reliably identify these rearrangements. It is 
unlikely that enough SNPs would occur within this region on the balanced allele that it 
would produce a notably large string of homozygous SNPs to indicate a deletion. SNPs 
showing an allele frequency indicative of the insertion (1:2) would also be unlikely to 
occur with a high enough frequency to identify this region.  
RPKM 
RPKM plots are the only means available through NextGene capable of detecting 
these two variants. However, the sequence that these rearrangements remove/insert is 
identical to the sequence that is expected to follow the breakpoint in the normal 
genome (Figure 76). This means that this rearrangement can only be identified by the 
dosage change it creates. The high homology of the two sequences also means that 
the impact of the dosage change is diluted, as it is spread between the sequences of 
HBA1 and HBA2. The fact that misalignment is frequent between these positions is 
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evidenced by the number of opposite direction reads aligning across the two regions - 
even in negative control samples. Reliably identifying this variant requires multiple 
negative controls to compare the amount of sequence captured in the affected region 
to other normal regions within the affected sample. In this run, only the negative control 
and Test Sample 33 have a normal dosage of sequence at this position.  
MiSeq Run 5 includes samples with the following rearrangements: (ɑ-3.7/ɑɑ) deletion 
heterozygote, triplicated alpha (ɑɑɑ/ɑɑ) heterozygote, (ɑ-3.7/--SEA) compound 
heterozygote.  The run only contained a single negative control for the alpha globin 
gene cluster, which was insufficient for detecting these rearrangements in RPKM plots.  
MiSeq Run 6 contained a large number of samples which could be used as negative 
controls for alpha globin rearrangements. Crucially, both runs contained the same 
number of samples, meaning that the coverage per sample was comparable between 
the runs. Inter-run variability was still high, with the normal control from MiSeq Run 5 
outside the standard deviation of the negative control average (‘NegC StDev’) from 
MiSeq Run 6 at 66% of bait positions (Figure 77).  
MiSeq Run 5 Negative Control Deviation from MiSeq Run 6 Negative Control 
Average
 
Figure 77: MiSeq Run 5 Negative Control Deviation from MiSeq Run 6 Negative Control Average. 
RPKM values for MiSeq Run 5 (black) and the negative control average of MiSeq Run 6 (blue).  
Combining these controls with the negative control from MiSeq Run 5 improved the 
visibility of the (ɑ-3.7/) rearrangements. The deletion and insertion could be identified 
visually in heterozygous states. In compound heterozygous states, the region that was 
absent on both chromosomes had an RPKM value of zero. As calculating the 
difference in the sample from the negative control average for these positions resulted 
in a ‘divide by zero’ error, it was necessary to assign an arbitrary value to baits that 
returned this error so that they could be plotted correctly on the graph. The arbitrary 
value assigned was -5. This improved visibility of the (ɑ-3.7/) rearrangement when it 
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occurred in a compound heterozygous state. As compound heterozygotes showed 
complete absence of sequence in the smaller region affected by both rearrangements, 
they could be clearly distinguished from single copies of either rearrangement (Figure 
78). 
The number of RPKM values falling outside the NegC StDev values was compared 
between the region of the rearrangement and the same number of bait positions from a 
balanced region. The effect of the number of negative controls used to calculate NegC 
StDev on these regions was investigated in a negative control, (ɑɑɑ/) duplication (het) 
and (ɑ-3.7/) deletion (het) samples.  As the number of negative controls used to 
calculate NegC StDev was decreased, the number of baits falling outside these values 
from the balanced region increased, while in the affected region they decreased (Table 
50). Three negative controls provided sufficient data to discern deletions from balanced 
regions. The insertion remained harder to detect. This is, in part, because the relative 
dosage change caused by a heterozygous duplication (30%) is smaller than a 
heterozygous deletion (50%), meaning that fewer affected baits can be distinguished 
from the noise across the region. For this reason, it may be prudent to increase the 
number of negative controls either included in the same runs, or from other runs to 




Table 50: Effect of negative control number on number of positions exceeding 
NegC StDev in test and control regions and samples. ‘Del’ indicates the (ɑ-3.7/) 
positive control, ‘dup’ indicates the (ɑɑɑ/) insertion positive control, and ‘Neg’ 
indicates an additional negative control. Data shows how number of positions 
exceeding NegC StDev increases as N(negative controls) increases in the 
balanced region, and decreases in the affected region in positive controls. 
 
The exact breakpoints of the (ɑ-3.7/) deletion are not known, as they do not produce any 
signature sequence which does not match the reference. They may not be the same in 
every case of the deletion, occurring at any pair of matching points between the two 
iterations of the Z box. For this reason, diagnosis must rely on RPKM values alone, 
when they indicate a rearrangement corresponding to the approximate size and 
position of the (ɑ-3.7/) rearrangements, and by the lack of break point sequences in the 
read pile up. For the purposes of diagnosis, lack of break point sequences indicates 
that regardless of where the break has occurred, the new gene created by the 
rearrangement will be functional.  The position of the insertion was less clear than the 
position of the deletion, and a larger number of controls may be necessary for their 
reliable detection than for the deletion (Figure 79).   
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Detection of the (ɑ-3.7/) Deletion in Heterozygous and Compound Heterozygous 
States with Varying Numbers of Negative Controls  (enlarged image overleaf)
 




/) Deletion in Heterozygous and Compound Heterozygous States 
with Varying Numbers of Negative Controls. Both graphs: light blue line indicates standard 
deviation in the negative controls from the negative control average. Orange line indicates RPKM 




/)  deletion. Green line indicates RPKM 
value per bait position in a sample heterozygous for the (--
SEA
/) deletion. Brown line indicates 




)  sample. Positions of the 
globin genes are indicated by red bars. Known region affected by the (ɑ-
3.7
/) rearrangement is 
indicated by the blue bar at the bottom of the graph, and the (
--SEA
/) deletion by a green line. X axis 
shows position on chromosome 16 and Y axis shows deviation from negative control average on a 
Log2 scale. Upper panel shows data when two negative controls are used. Lower panel shows data 




Simplified Version of Figure 78
 
Figure 79: Simplified Version of Figure 78. Graphs focus on region affected by (ɑ-
3.7
/) Deletion and 
(ɑɑɑ/) Insertion, showing distinction between heterozygous deletions and limits of NegC StDev.  
Variant Characterisation: Test Samples 
Run 5b included four test samples with novel rearrangements affecting the alpha globin 
gene locus. All four rearrangements could clearly be identified from the RPKM plots. 
Three samples showed a novel copy number variant at the same position, with a pile-
up of reads with strings of misaligned sequence at this position. In all three cases this 
238 
 
copy number variant removed different numbers of an iteration of the same sequence 
which is repeated multiple times at this location (Figure 80). This region was highly 
homologous to the same chromosomal location on chr18 and also to regions on chrX 
and chrY. This CNV presented as misaligned sequences in the variant report, which 
were evaluated as potential breakpoints for the rearrangements investigated in two of 
these samples, increasing the time required to complete characterisation of those 
variants.  
A Copy Number Variant in Three Test Samples from MiSeq Run 5b 
 
Figure 80: A Copy Number Variant in Three Test Samples from MiSeq Run 5b. Green and red text is 
used to show iterations of the same sequence. The grey highlighted region shows the region 
deleted by the copy number variant in MiSeq Samples 22, 33, 35. 
MiSeq Sample 22 (Test) 
MiSeq Sample 22 showed a duplication that began between positions Chr16: 82,980 
and 83,274. This was consistent with the results of sequencing this sample on the 
HiSeq 2000 (HiSeq Run 1 Sample 3). The duplication appeared to extend beyond the 
bait covered region (>Chr16:2,097,990) making it >2Mb in length (Figure 81).  
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A Novel Duplication in MiSeq Sample 22
 
Figure 81: A Novel Duplication in MiSeq Sample 22. RPKM data indicates a duplication from 
approximately chr16:83,000 extending beyond the bait tiled region. A trend line is included to 
better illustrate the relative increase in coverage, due to the high level of coverage variability in this 
sample.  
The mutation report showed a mix of ‘duplicated’ (1:2) and ‘balanced’ (1:1) allele 
frequencies for heterozygous SNPs occurring within the duplicated region which did not 
help inform variant characterisation. Opposite direction and same direction read reports 
and visual inspection of the alignment in NextGene failed to identify any misaligned 
read pile-up in the covered break-point region that could represent the start position of 
the duplication. Many small mismatches were found which BLAT query showed were 
spurious alignments from other regions of the genome with high homology to this 
region of chr16. The target region did show a small deletion of 43 bp. Without complete 
coverage of the region, or any candidate regions for the 5’ breakpoint identified by the 
usual methodology, this variant could not be resolved.  
MiSeq Sample 33 (Test) 
MiSeq Sample 33 had been referred to the clinic for sequencing with the following red 
cell indices: HbA2 2%, HbF 0.2%, RBC 6.1, Hb 133, MCV 71.4, MCH 21.7. This was 
consistent with an alpha thalassaemia phenotype. CGH array data had indicated that 
MiSeq Sample 33 had a deletion removing the tip of chromosome 16, up until 
approximately chr16:175,000. RPKM data for this sample showed a clear deletion of 
approximately 70 Kb ending at the same approximate position, but with a small intact 
region between the deletion and the telomere (Figure 82C). The RPKM data also 
showed a negative dosage change affecting the tip of the chromosome. 
The telomeric region of the bait-tiled region also appears deleted (Figure 82B). 
However, as discussed previously, this region is highly variable and this degree of 
variation at this position has been seen in multiple samples. It is not possible to confirm 
the presence or absence of this region via Gap PCR, as rather than bringing together 
two sequences against which Gap PCR primers could be designed; in a telomere tip 
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deletion this sequence is simply absent. The start point of the possible telomeric 
deletion was also situated in an unmapped repetitive region. If the position had been 
covered by the bait design, it may have been identifiable by reads in the alignment that 
started at the exact same position, followed by an immediate drop in read depth, which 
would indicate that one copy of chromosome 16 ended abruptly at that position. In the 
absence of this data, the presence or absence of this region could not be determined 
by coverage or alignment data.  
We also speculated that the RPKM data may indicate an inversion event had occurred 
between the small intact region and the balanced region, followed by a single telomeric 
deletion event removing both the deletion within the bait tiled region and the potentially 




Possible Rearrangement Scenarios in MiSeq Sample 33
 
Figure 82 Possible Rearrangement Scenarios in MiSeq Sample 33, Based on RPKM Data Plot. 
(Scenario A) An inversion (green) occurs between the intact regions of the chromosome, followed 
by a single deletion (orange) removing the inverted sequence between chr16:110,000-175,000 and 
the telomeric region. (Scenario B) Two separate deletions have occurred, (Scenario C) a single 
deletion has occurred and the dosage change indicated by baits between positions chr16:60,000-
80,000 is due to the bait variability seen in multiple samples at this region. Three primers were 
designed to determine whether the sequence between chr16:110,000-170,000 had been removed by 
a deletion (Pr1 and Pr3) or an inversion deletion (Pr2 and Pr3).  
 A telomeric deletion would not leave any misaligned sequence at the breakpoint or any 
reads in the opposite or same direction reads reports. The high homology between this 
region of chromosome 16 and other parts of the genome produced a high number of 
same direction reads partially aligning to these regions, but none gave a strong 
consensus towards a genuine rearrangement. Primers were designed across the break 
points of the deletion as estimated by the RPKM plot, and additionally between the 
intact sequence at position 84,174+ and the intact sequence after the deletion, to 
detect a potential inversion between these two points (Figure 82).  
The primer pair that had been designed assuming a straightforward deletion (Pr1-Pr3) 
successfully amplified a PCR product. The primer pair that had been designed 
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assuming an inversion (Pr2-Pr3) did not make a product (Figure 83). Sanger 
sequencing analysis of the deletion product on the 3130 Sequencer revealed the 
deletion break point in several reactions. The deletion breakpoints were chr16: 
(104,934-104,943) - (177,954-177,966). The breakpoints shared 12 bp of homologous 
sequence, meaning the precise start and end points could not be determined beyond 
this accuracy (Figure 83). The deletion was 73 Kb in length.  
Breakpoint Confirmation for a Novel Deletion in MiSeq Sample 33
 
Figure 83: Breakpoint Confirmation for a Novel Deletion in MiSeq Sample 33. Gel Image and 
Chromatogram of Sequenced PCR Product from Pr1 and Pr3. Gel image: (L) 1 Kb+ Ladder (1) 
MiSeeq Sample 33 (2) Negative Control (3) No Template Control. Chromatogram: Base calls that 
match the reference sequence up to position 104,931 highlighted in yellow. Base calls that match 
the reference sequence from position 177,942 onwards highlighted in blue. The 12 bp ambiguous 
sequence is highlighted in green.  
The deletion left the alpha globin gene cluster intact, but removed the main regulatory 
region, HS40, which is located 40 Kb upstream from HBZ. MPG and parts of NPLR3 
and RHBDF1 were also removed (Figure 84A). The deletion breakpoints both occur in 
gene introns within Alu repeats (Figure 84B). The breakpoint itself is located in a highly 
homologous region. Multiple sequences in the surrounding region also show high 
homology to one another (Figure 84C). 
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Schematic of the Novel Deletion in MiSeq Sample 33
 
Figure 84: Schematic of the Novel Deletion in MiSeq Sample 33. (A) The deletion removes 73 Kb of 
sequence between positions 104,934-104,943 and 177,954-177,966. The deletion removes MPG and 
parts of RHBDF1 and NPLR3. The HS40 alpha globin regulatory region is removed by the deletion, 
while the alpha globin gene cluster remains intact, (B) The deletion breakpoints occur in the 
introns of RHBDF1 and NPLR3 within two Alu Repeats. (C) Pip Plot showing homology between the 
1 Kb of sequence surrounding each breakpoint.  
MiSeq Sample 34 (Test) 
MiSeq Sample 34 showed a duplication encompassing the alpha globin gene cluster. 
Both duplication breakpoints were situated within unmapped repetitive regions. The 
duplication was approximately 120 Kb within the region chr16: 148,000-270,000. At the 
centromeric break point of the duplication, two repeats occurred in close proximity. The 
covered region between the two repeats showed highly variable coverage, and it was 
not clear whether this region was part of the duplication or signified the start of the 
balanced region. Primers were designed against the unique sequence outside this 
region. The primers were designed with the assumption that this duplication was top-to-
tail in orientation, as reported in the literature for all duplications of this cluster, have 
been. Several PCR conditions were tested, and one intermittently produced a 10 Kb 




The PCR conditions were as follows: 
Forward Primer sequence: TCTACTGCCCTCTCCCTTCA 
Reverse Primer sequence: CAGGGTACGGCTTCTCTCAA 
The reagent mix (per sample) was: 2.5 µl LongAmp taq buffer (NEB), 2.5 µl MgCl2 
25mM (Qiagen), 0.1 µl LongAmp taq polymerase (NEB), 1 µl forward primer 10 
pmol/µl. 1 µl reverse primer 10 pmol/µl, 9.9 µl molecular biology grade water, 4 µl 
DNTPs (Qiagen). 4 µl DNA template (providing approx 200ng total). The thermal 
cycling program for the reaction is listed in (Table 51).  
Table 51: Thermal Cycling Conditions for Gap PCR Confirmation of Duplication 
in Test Sample 34. 
Step 1 2 (30 cycles) 3 4 













This reaction produced a weak band with intermittent success. Final characterisation of 
the duplication breakpoints was performed by Dr Xunde Wang (Sickle Cell Branch, 
National Heart Lung and Blood Institute, NIH, USA) who cloned the PCR product into a 
pCR2.T/A cloning vector. Clones of with the correct size inserts were confirmed by 
RFLP analysis and sanger sequencing analysis using the primers M13F(-20), 
GTAAAACGACGGCCAGT; M13R-pUC(-40), CAGGAAACAGCTATGAC, followed by 
walking sequence primers, NPRL3-R1-seq, CAGAAATGACCAATCCCAGG; NPRL3-
R2-seq, TCTTCTGGCACCACCTGTTC, NPRL3-R3-seq, 
GGCCCTTCTCTCCGCAGTTAA. This revealed that the breakpoints of the duplication 




Breakpoint Confirmation for a Novel Deletion in MiSeq Sample 34
 
Figure 85: Breakpoint Confirmation for a Novel Deletion in MiSeq Sample 34. Gel Image and 
Chromatogram of Gap PCR for Sample 13. Gel image: (1) Sample 34 (proband); (2) Sibling of 
proband; (3) Parent of affected; (4) Negative Control; (5) No Template Control; (6) Blank. 
Chromatogram: Breakpoint sequence is identified, where bases in blue match the reference 
sequence until position 269,041, followed by three ambiguous bases that could be from either 
position, followed by bases in purple that match the reference sequence position from position 
148,451. This picture is by courtesy of Dr Xunde Wang (NHLBI/NIH) 
The duplication of 120,590 bp encompassed the entire alpha globin gene cluster as 
well as part of NPLR3 upstream of the cluster and LUC7L downstream. The duplication 
was top-to-tail in orientation and brings together two Alu repeats with a high degree of 
homology to one another (Figure 86). The proband had inherited this duplication in 
conjunction with a copy of the beta thalassemia c.135delC variant on chromosome 11 
Table 52, The excess alpha produced by the total number of alpha globin genes, 
combined with the reduced beta globin chain synthesis resulting from this variant led to 
a beta thalassaemia phenotype of intermediate severity, requiring intermittent blood 
transfusions.  













Schematic of the Novel Duplication in MiSeq Sample 34
 
Figure 86: Schematic of the Novel Duplication in MiSeq Sample 34. Upper panel: 120,500 bp of 
sequence beginning within NPLR3 and ending in LUC7L, encompassing the entire alpha globin 
gene cluster, was duplicated. The duplicated sequence was reinserted immediately adjacent to the 
original sequence in top-to-tail orientation. Primers had been designed under the assumption that 
this was the layout of the duplication, and a 10 Kb PCR product was produced across the 
breakpoint sequence.  
Lower panel: a dot plot of the sequence surrounding the breakpoints (500 bp upstream and 
downstream of the precise break point position) showed that two Alu repeats brought into close 
proximity by the duplication had a high level of homology to one another.  
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MiSeq Sample 35 (Test) 
MiSeq Sample 35 shows a duplication of approximately 274,000 bp encompassing the 
alpha globin gene cluster (Figure 87A). Noise in the RPKM data plot at the 3’ region of 
the duplication makes it difficult to estimate the position of the break point (Figure 87B).  
Issues Estimating Rearrangement Size from RPKM Data in Sample 35
 
Figure 87 Issues Estimating Rearrangement Size from RPKM Data in MiSeq Sample 35  (A) 
Rearrangement in MiSeq Sample 35. (B) Expanded view of 3’ breakpoint region - end point of 
duplicated region is unclear due to the presence of a repeat that is not covered in the bait design, 
plus noise in the RPKM data which makes the position at which normal sequence dosage resumes 
unclear.  
Both the approximate start and end positions of the duplication indicated from the 
RPKM data include repeats not covered by the bait library. These repeats share a 
region of high homology (See dotplot, Figure 88) and were considered to be the most 
likely locations of the duplication breakpoints, as no opposite or same direction reads 
or misaligned sequence strings were obtained from the read data. Primers were 
designed against positions that appeared to be balanced. Two separate primers were 
designed against the 3’ region of the duplication because noise in the data made the 
duplication end point unclear. We made two assumptions about the most likely layout 
of the duplication: that the duplication was in the adjacent and top-to-tail layout, and 
that the breakpoints would occur between regions of high homology. A dotplot of the 
Alu repeats situated at the start and end positions of the duplication identified a region 
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of high homology which was considered to be the most likely position for the 
duplication breakpoints. This allowed us to estimate the probable size of the PCR 
products our primers might produce.  
DotPlot Showing Homology at Break Point Regions for MiSeq Sample 35
 
Figure 88 DotPlot Showing Homology at Break Point Regions for MiSeq Sample 35. The two 
breakpoint regions share a homologous region between a simple repeat (5’) and a LINE repeat (3’). 
In the event that either assumption was false, we also used these primers to test for a 
head-to-head duplication (where Pr2 could effectively be used as both the forward and 
reverse primer for the inversion break point, assuming again that the duplicated region 
was adjacent to the original copy of the sequence), and used a range of thermal cycling 
conditions to accommodate products of up to 10 Kb. At the time of writing we were 
unable to isolate a unique PCR product from any of the primers that were designed. 
The presumed layout of the rearrangement is shown in Figure 89, but is not confirmed. 
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Presumed Layout of the Novel Duplication in MiSeq Sample 35
 
Figure 89 Presumed Layout of the Novel Duplication in MiSeq Sample 35. 
 
MiSeq Run 6 
Thirteen samples with a range of novel rearrangements affecting both the alpha and 
beta globin gene loci were prepared for sequencing on the MiSeq (Table 53). The run 
also included three controls that were negative for rearrangements at both loci. The run 
included samples with rearrangements affecting the beta globin gene cluster to 
evaluate the performance of the new bait capture library, along with further samples 
with rearrangements affecting the alpha globin gene loci, which appeared to be more 
challenging. Sequencing a mixture of alpha and beta rearrangements in a single run 
allowed samples with alpha rearrangement to be used as negative controls for 
evaluation of the beta locus and vice versa, increasing the number of negative controls 
available for each locus within the batch. Three of the samples (40, 41, 42) were a 
family trio. Sample 44 was included as part of a duo of siblings who had a discordant 
phenotype, however, the sibling  was not successfully prepared (Figure 90). Sample 36 
was a relative of affected individual (ROA) HiSeq Run 1 Sample 11 and Sample 46 
was a relative of affected individual (ROA) MiSeq Run 6 Sample 48. 
Samples were fragmented to an average of 600 bp using double size selection to 
tighten the fragment size range. The samples were then prepared for sequencing on 
the BioMek FXP platform (asides hybridization which was performed manually). The 
double size selection step ensured that fragments of the target size (500-600bp) were 
highly represented in the finished libraries, as the smaller fragments which had been 
preferentially amplified in earlier runs had been removed. Sample preparation failed for 
one sample during either the hybridization or post-hybridization clean-up stage. The 
reason for this was not known (Figure 90). The remaining 12 samples were prepared 
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successfully and were taken forward for sequencing. The samples were pooled and 
diluted to a concentration of 2nM before being sequenced on the MiSeq using a V3 
2x300 reagent kit. Sequencing was successful, generating 861k/mm2 clusters on the 
flow cell. All sample indexes were equally represented on the flow cell. The quality of 
base calls dropped towards the end of Read 1 and Read 2 due to their long length 
using this sequencing kit (Figure 91).   





Figure 90 Electropherograms showing samples from MiSeq Run 6 at three stages of library 
preparation. Stages shown are fragmentation, pre-hybridization and post-hybridization. NB: the 
negative control Sample 47 was prepared once and then different indexes were added to the 
aliquots of the sample to create three negative control samples to be run on the MiSeq. Lane H1 
shows a sample that was prepared for sequencing but was shown to have failed at the post-






Figure 91: Base Call Qualities for Read 1 and Read 2, MiSeq Run 6. 
Format Conversion 
Sequencing data from each sample was downloaded from BaseSpace in FASTQ 
format, converted to FASTA format and filtered according to  standard parameters (see 
Methods). The majority (93.5%) of reads passed the quality filtering metrics (Table 54). 
Of those that failed to pass, 96.7% failed the ‘Median Score Threshold’ parameter. The 
drop in base call quality score towards the ends of the long reads meant that 83% of 


















Reads that passed quality filtering were aligned to the reference sequence using 
standard parameters, with an expected gap distance of 0-800 bp. The region of interest 
was covered at an average depth of 250x, with 61% of reads on target (Table 54). Of 










Variant Characterisation MiSeq Run 6 
Seven test samples and four samples from potentially affected relatives of patients had 
been sequenced (Relative of Affected: ‘ROA’). RPKM plots were created for all 
samples, showing the coverage across the ROI compared to the average coverage in 
negative controls, and also in test samples with variants at the alternate loci (Figure 92, 
Figure 93). To-the-base characterisation of the test samples and determination of 
presence or absence of the variant in related samples was possible in 8 of 11 cases 
(Table 56). One relative of a test sample was found to also carry the test sample 
variant.  





MiSeq Run 6 Coverage Graphs Chromosome 11
 
Figure 92: MiSeq Run 6 Coverage Graphs Chromosome 11. Plots show depth of coverage (Y axis) 
at each bait-covered position (X axis) in relation to the average coverage of that position in 
negative controls on a Log2 scale. Standard deviation from the average in the negative controls is 
shown in green, the positions of the beta globin gene locus are shown in red. (1) Sample 36 




Figure 92 Continued: (5) Sample 43 (Test) (6) Sample 44 (Test) (7) Sample 46 (Test)  
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MiSeq Run 6 Coverage Graphs Chromosome 16
 
Figure 93: MiSeq Run 6 Coverage Graphs Chromosome 16. (1) Sample 37 (Test) (2) Sample 38 




MiSeq Sample 36, Figure 92.1 (ROA) 
Sample 36 was a relative of an affected sample from a previous run (MiSeq Sample 
34). This individual appeared to be negative for the structural variant affecting that 
sample.  
MiSeq Sample 37, Figure 93.1 (Test) 
This sample was compound heterozygous carrier of the 3.7 Kb deletion and a large 
novel deletion removing the entire tip of chromosome 16, including the alpha globin 
gene cluster. The resulting genotype was (--/ɑ-3.7) with a clinical phenotype of HbH 
disease. The patient had red cell indices of 1.9% HbA2, 0.2% HbF, 6.01 RBC, Hb 9.2, 
MCV 49.1, MCH 15.3. The RPKM data indicated that the large deletion removes 791-
793 Kb of sequence (Figure 94). The deletion breakpoint was in a repetitive region not 
included in the bait design comprising a LINE repeat and two SINE repeats (Figure 95).  
Two Deletions Affecting the Alpha Globin Gene Cluster in MiSeq Sample 37
 
Figure 94: Two Deletions Affecting the Alpha Globin Gene Cluster in MiSeq Sample 37. Upper: A 
large novel heterozygous deletion removing all bait-covered sequence - including the entire alpha 
globin gene cluster - up until position ~chr16:789,357. Lower: The co-inherited (α-
3.7
/) deletion 
reduced the coverage of the region affected by both rearrangements to zero. This returns an error 
when calculating the deviation in coverage from the negative control average, so the error calls 
have been replaced by the value -5 so that they can be correctly plotted on the chart. 
No breakpoint data was captured for this deletion: The rearrangement may have 
brought together part of the unmapped telomere region of the chromosome and the 
unmapped repetitive region, in which case neither part of the breakpoint sequence 
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would be captured by the bait library. This would also be the case if the chromosome 
was bluntly severed at this location. Even if the deletion breakpoint was in a captured 
region, in this situation it may not leave any abnormal sequences behind that could be 
identified in the alignment. It is possible that the breakpoint in this situation could be 
identified by a sudden drop in coverage with reads from multiple DNA fragments 
showed the exact same start position on the chromosome. This deletion could not 
resolved with to-the-base accuracy, as the bait capture library did not cover the 
breakpoint position, and it is not possible to design Gap-PCR primers against this 
region. Theoretically, it may be possible to capture this breakpoint via southern blotting, 
but due to time constraints this was not investigated.   
Approximate Region of Chromosome 16 Removed By Large Deletion in MiSeq 
Sample 37 
 
Figure 95 Approximate Region of Chromosome 16 Removed By Large Deletion in MiSeq Sample 
37. Upper image: Approximate region and genes removed by large shown in UCSC Genome 
Browser (red box shows deleted region). Lower image: enlarged image of region of 5’ breakpoint 
with suspected breakpoint position highlighted in red. The region is repetitive and not included in 
the bait design.  
MiSeq Sample 38, Figure 93.2 (Test) 
MiSeq Sample 38 was from a patient with reported red cell indices of 2.7% HbA2, 0.2% 
HbF, RBC 5.57, Hb12, MCV 68.2, MCH 21.5. The RPKM plot for MiSeq Sample 38 
identified a deletion extending from Chr16:164,041 – 248,193, removing 84,152 bp of 
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sequence. Reads containing break point sequence could be derived from inspection of 
the read pile-up at the start and end points for the deletion indicated by the RPKM plot 
in the NextGene Viewer. BLAT query of these reads showed that these sequences 
matched the break points suggested by the RPKM plot. Additionally, the read 
sequences revealed that an additional 341 bp deletion was present 71 bp upstream of 
the large deletion (Chr16:248,263-248,605) (Figure 96A). The presence of both 
deletions was confirmed via Gap PCR and dye-terminator sequencing analysis (Figure 
96B).  
The 5’ breakpoint of the large deletion is situated in unique sequence. The 3’ 
breakpoint of the large deletion is situated in an Alu repeat, AluY, which has no 
homology with the 5’ breakpoint region. The large deletion removes NPRL3 exon 1-
3/12, the alpha globin gene cluster, and LUC7L exons 7-9/9. The small deletion 
removes part of intron 6/8 of LUC7L. The 5’ breakpoint of the small deletion is situated 
in the same Alu repeat as the 3’ breakpoint of the large deletion. The 3’ end of the 
small deletion is situated in unique sequence, but adjacent to another Alu repeat, 
AluSx. The homology between AluY and AluSx is extremely high. There is a novel 















Novel Deletion in MiSeq Sample 38 
 
Figure 96: Novel Deletion in MiSeq Sample 38. (A) A schematic of the deletions on chromosome 16: 
A deletion of 84 Kb removes the alpha globin gene cluster. 71 bp upstream of this, an additional 
deletion removes 341 bp of sequence. Repetitive elements in the region are represented by 
coloured bars – blue (SINE), orange (LINE), purple (LTR) and DNA (green). The positions of primers 
designed to confirm the presence of these deletions are included on the schematic (not to scale). 
(B) Confirmation of the two deletions by Gap PCR: Left panel shows gel image of products 
amplified by primer pair Pr1 and Pr2 (L-R: 1. 1 Kb+ ladder 2. proband 3. negative control (58°C 
annealing temperature) 4. Proband 5. negative control (60°C annealing temperature) 6. Proband 7. 
negative control (63°C annealing temperature) 8. no template control).  A 400 bp PCR product is 
present in the proband and absent in the negative control. Dye-terminator sequencing of the PCR 
product reveals the breakpoints of the two deletions, matching the co-ordinates predicted by NGS.  
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MiSeq Sample 39 Figure 93.3 (Test)  
The RPKM data showed MiSeq Sample 39 was heterozygous for the (α-3.7/) deletion. 
The number of negative controls included in the Run was sufficient to clearly identify 
this rearrangement in a heterozygous state from the RPKM data (Figure 97). No 
concurrent deletions affecting the globin gene loci were included in the mutation report 
and the beta globin gene locus on chromosome 11 appeared balanced.   
Identification of (α-3.7/) deletion in MiSeq Sample 39
 
Figure 97: Identification of (α-
3.7
/) deletion in MiSeq Sample 39. RPKM data shows a region 
corresponding to the size and position of the (a-
3.7
/) deletion as listed in HbVar (which is indicated 
by a red bar). 
MiSeq Samples 40, 41, 42, Figure 92.2,3,4 (Test) 
Samples 40, 41 and 42 are a family trio (Sample 40 = mother, Sample 41 = father, 
Sample 42 = proband). The mother was a carrier for HbS (HbS 33.3%). The father was 
a carrier for HbS with an abnormally high HbS fraction of 41.3%.The proband had a 
majority fraction of HbS, with some HbF and no HbA. A duplication affecting the beta 
globin gene loci was suspected based on these abnormal HbS fractions. The mutation 
report identified the sickle cell variant in all three samples. The mutant allele frequency 
was 1:1 in the mother indicating that she was heterozygous for the variant. The father 
showed a 2:1 ratio of the normal allele to the variant, and the proband showed a 1:2 
ratio of the normal allele to the variant (Table 57).  RPKM plots showed that both the 
father (Sample 41) and the proband (Sample 42) had a large duplication encompassing 
the beta globin gene cluster. Inspection of the read pile-up at the start and end points 
of the duplicated region as indicated by the RPKM plots showed reads containing 
breakpoint sequences (Figure 98). While BLAT query of these sequences showed 
multiple matches to repetitive regions in the genome, complimentary matches to the 
expected break point regions according to the RPKM data were assigned the highest 
scores. The duplication break points were confirmed by Gap-PCR and dye-terminator 
sequencing analysis. Comparison of the mutant allele frequencies between the father 
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and the proband showed that the duplication included one copy of β-S and one copy of 
β-A. The proband was surmised to have inherited the father’s duplicated HBB allele with 
its copies of HBBS and HBBA, plus a β-S allele from the mother. 
























T 226 18.2 T>AT 61.06 
 
The inheritance of a 2:1 ratio of βS:βA  genes did not fully explain the red cell indices in 
the sample. Alone, this would be expected to give a HbS fraction of up to 66%. It was 
noted that the duplicated region did not include the beta globin gene cluster locus 
control region (LCR), meaning that one of the two copies of the globin gene cluster on 
the duplicated allele was missing an immediately upstream LCR on the chromosome 
(Figure 99). We hypothesise that the HBBA gene that was located further away from the 
common LCR, and hence produced less product that the more closely located HBBS 
gene. The duplication showed two notable regions where the dosage did not indicate 
three copies of the sequence: the first was attributed to copy number variation 
producing additional copies of the sequence between positions chr11:4,967,214 and 
4,976,583. Multiple CNVs affecting this region are recorded in dbVAR, entry 
‘dgv187e199’ most closely matching the loci of the rearrangement seen in the samples. 
A small balanced region with normal dosage also appears to interrupt the duplication 
between positions 5,200,463 and 5,244,326. This is seen in both the proband and 
father, suggesting it is a part of the duplicated allele, rather than a concurrent deletion 
on the other chromosome inherited by the proband. The break points of this deletion 
were both situated in repeats, and were not identified. Gap-PCR to resolve the 
breakpoints of this interruption to the duplication was performed by the referring 
laboratory at the University of Utah.  
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The breakpoints of the duplication were confirmed by Gap-PCR. Primer design 
assumed that the duplication was top-to-tail in orientation, based on the sequence of 
the break point reads. The primer sequences were PrF:GGTTCCCTCTCTCCCTGTTT 
and PrR:ACAAATGGGTACAGCGAGGT. Standard reagents and cycling settings (as 
detailed in Methods) were used to amplify the product, with a 60°C annealing 
temperature. The primers produced a 227 bp product in the proband and the father. No 
product was amplified in either a negative control sample or in the mother, who was 
concluded to be negative for the rearrangement. Dye-terminator sequencing analysis of 
the Gap PCR product in the proband and the father confirmed the breakpoints of the 
duplication as identified by NGS (Figure 100).  
A Novel Duplication in MiSeq Samples 40, 41, 42
 
Figure 98: A Novel Duplication in MiSeq Samples 40, 41, 42. Upper: RPKM Plot Showing Duplicated 
Region in Proband and Breakpoint Reads in NextGene Viewer. Note quadruplicated CNV from 
4,967,214-4,976,583 and balanced region from 5,200,463-5,244,326. Lower: Reads aligning to the 




Schematic of the Alleles Inherited By the Proband (MiSeq Sample 42) 
 
Figure 99: Schematic of the Alleles Inherited By the Proband (Sample 42). Primer locations 
represented by blue arrows Proband inherited an allele with a novel duplication from their father 
(Sample 41) and a balanced allele with the sickle cell variant from their mother (Sample 40). Note 




 on duplicated genes). 
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Breakpoint Confirmation for a Novel Deletion in MiSeq Samples 41 and 42
 
Figure 100: Breakpoint Confirmation for a Novel Deletion in MiSeq Samples 41/42. Left panel shows 
gel image of products amplified by Gap-PCR Primers Pr1 and Pr2 (L-R: 1. 1 Kb+ ladder 2. proband 
(sample 42) 3. Father (sample 41)  4. Mother (sample 40) 5. negative control  6. no template control). 
Right panel shows chromatogram of PCR product. Sequence confirms breakpoints as determined 
by NGS. The reference sequence expects two ‘A’ bases at each break point, thus the origin of the 
two centre bases is ambiguous.  
Sample 43, Figure 92.5 (Test) 
Sample 43 had reported red cell indices of 3.5% HbA2, 23.9% HbF, RBC 4.56%, Hb 
126, MCV 84.6, MCH 27.6. Sample 43 exhibited a deletion removing the HBB gene. 
Inspection of the read pile-up at the positions indicated by the RPKM data revealed the 
breakpoint sequence. The deletion removed 27,412 bp between chr11:5,222,877 and 
5,250,289 (Figure 101). Primers were designed to confirm the variant, 
PrF:TCAAAAGCCTCATGGTAGCAG and PrR:GCATTTTCTTTGACCCAGGA. The 
PCR was performed using the standard reagent mix and cycling parameters detailed in 
Methods (with an annealing temperature of 60°C). Dye-terminator sequencing analysis 
of the 150 bp product confirmed the breakpoints of the deletion as identified by NGS 
(Figure 101).  
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Characterisation of a Novel Deletion in MiSeq Sample 43
 
Figure 101: Characterisation of a Novel Deletion in MiSeq Sample 43. Upper panel: schematic of 
deletion, which removes HBB. Repetitive elements in close proximity to the breakpoints are 
denoted by coloured bars: blue (SINE), orange (LINE), green (DNA), brown (Simple), fuchsia (low 
complexity). Approximate positions of the primers PrF and PrR are indicated on the schematic. 
Lower panel: digital gel image of PCR product taken on Tapestation (Left to right: 25-1,500 bp 
ladder, E1: MiSeq Samples 43, F1: negative control, G1: no template control). The PCR product was 
sequenced, confirming the breakpoints indicated by NGS sequencing.  
MiSeq Sample 44 Figure 93.3 (Test) 
MiSeq Sample 44 was one of a sibling pair with a discordant phenotype that were 
prepared for sequencing. Both samples were known carriers of the codon 39 beta 
thalassaemia variant. The sample for the sibling of this individual failed to complete 
sample preparation, resulting from an unknown error occurring between hybridization 
and the final AMPure bead clean-up. The known deletion was included in the mutation 
report for MiSeq Sample 44. Both the alpha and beta globin gene clusters appeared to 
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be balanced, with no evidence of rearrangements visible in the RPKM data or 
opposite/same direction read reports. It was presumed that the discordant phenotype 
between this individual and their sibling was produced by a variant in the sibling sample 
which was not sequenced due to failure during the sample preparation stage.  











G 320 19.3 G>AG 48.53 
  
MiSeq Sample 45 Figure 93.10 (Test) 
The RPKM plot for MiSeq Sample 45 showed a deletion of approximately 11 Kb 
removing two exons of HBZ. No opposite or same direction reads showed any 
clustering at either position.  
Novel Deletion in MiSeq Sample 45 
 
Figure 102: Novel Deletion in MiSeq Sample 45. RPKM plot shows a deletion of approximately 11 
Kb removing two exons of HBZ 
A small number of reads were identified in the alignment that showed strings of 
mismatched bases that had potentially crossed the break point of the deletion. BLAT 
query of the reads showed that the regions had extremely high homology to one 
another. Gap PCR primers were designed against the co-ordinates indicated by the 
RPKM data and BLAT data to be the potential breakpoints of the rearrangement: PrF 
(5’-CCTGTAAGGCCACAGGAGAG-3’) and PrR (5’-CTCAGCTTCTCCCCTCCTTC-3’). 
Multiple attempts to amplify the breakpoint product were unsuccessful.  
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Positions of BLAT Hits From Partially Aligning Reads Found At The Break Point 
Regions  
 
Figure 103 Positions of BLAT Hits from Partially Aligning Reads Found at the Break Point Regions. 
Secondary Y axis shows BLAT match score for each hit, where two positions attract hits at the 5’ 
end of the deleted region. Approximate positions and orientation or PrF and PrR are indicated by 
blue arrows.  
Unresolved Rearrangements: MiSeq Sample 37, 45. 
Rearrangements affecting the alpha globin gene loci proved exceedingly difficult to 
resolve: homology between the alpha globin genes and their surroundings, large 
numbers of repeats, frequent CNVs in samples and controls, and the low mapability of 
the tip of chromosome 16 were all problematic. These features caused issues with (i) 
successfully aligning reads to accurately identify breakpoints (ii) capturing and aligning 
sequences containing breakpoints (iii) identifying significant reads against high 
background noise in opposite and same direction read data (iv) designing unique 
primers against the estimated breakpoints of rearrangements. Two novel 
rearrangements sequenced in MiSeq Run 5 (MiSeq Samples 22, 35) could not be 
resolved with to-the-base accuracy. Another two rearrangements sequenced in MiSeq 
Run 6 (MiSeq Samples 37, 45) are also unresolved. Attempts were made to resolve all 
the rearrangements that did not remove the telomere via Gap-PCR, but no unique 
products were successfully amplified.  
Understanding the factors commonly associated with these rearrangements may help 





Evaluating the New Capture Library 
A new capture library was successfully used for sequencing samples in MiSeq Runs 5 
and 6 (See Methods for details of new design). The new design intended to improve 
upon the first capture library in the following ways: 
 Reduce Variation between Samples and Provide More Reliable Data 
The new design increased the bait tiling density of the core regions of interest (chr11: 
5,000,000-6,000,000 and chr16:0-1,000,000) from 1x to 2x, with the hope that this 
would increase the coverage depth across this region and also reduce the coverage 
variability seen between different samples in these locations. We also employed the 
‘max performance’ boosting strategy offered in the Agilent SureDesign suite in order to 
ensure that baits with a high GC content performed as well as baits with GC <50%. It 
was not possible to precisely evaluate the difference in performance between these 
two libraries with the data included in this study. MiSeq runs performed using the old 
capture library contained less samples, used different shearing strategies and were 
prepared manually rather than using the BioMekFXP. The different bait densities, 
regions covered and boosting parameters also made a detailed comparison different. 
Dr David Brawand (Bioinformatician, Dept. Molecular Pathology, King’s College 
Hospital) made a preliminary analysis of the differences between the coverage 
variability of four samples from MiSeq Run 5b and four samples from MiSeq Run 2.  
Random samples of one million read pairs from each sample were used in the analysis 
in order to control for the different read depth in the two runs.  
The regions where the bait tiling density in Bait Capture Library 2 was increased to 2x 
tiling (where 1x tiling had been used before) was covered at a higher depth than both 
the 1x region in the old design and the 1x region in the new design. As the coverage 
increased, the inter-sample variability also increased. We had expected that the 
increased bait density at regions with high GC content would decrease the level of 
variation across the covered region, and also the inter-sample variation. This was not 
the case: inter-sample variability increased with depth of coverage, and the difference 
in coverage across the region remained broadly the same (NB: The samples used to 
calculate this data were primarily samples with structural variants affecting the beta 
globin gene locus. Consequently, the region of the beta globin gene loci (outlined in 
red) appears to show more inter-sample variability than the rest of the region.).   
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Inter-Sample Variation between Bait Capture Library 1 and Bait Capture Library 2
 
Figure 104: Inter-Sample Variation between Bait Capture Library 1 and Bait Capture Library 2. 
Upper panel shows part of the region covered by both designs on chromosome 11 (including a 
region that is covered with 1x tiling in both libraries) in new design. Lower panel shows the same 
region covered by the Bait Capture Library 1. Solid line shows average coverage and dotted lines 




Inter-Sample Variation between Bait Capture Library 1 and Bait Capture Library 2
 
Figure 105: Inter-sample variability between Bait Capture Library 1 and Bait Capture Library 2. The 
entire region covered by Bait Capture Library 1 is shown in both panels. Upper panel shows 
variation in this region in Bait Capture Library 2, lower panel shows variation in this region in Bait 
Capture Library 1. Solid line shows average coverage and dotted line shows standard deviation.   
 Cover a Larger Area of the Regions of Interest 
The new capture library extended the region of chromosome 16 covered by baits from 
260,000 bp to 2,000,000 bp. This permitted to-the-base characterisation for MiSeq 
Samples 34 and 35. These samples could not have been characterised using the old 
design, as no breakpoint sequence was captured so it was necessary to know the 
approximate locations of both breakpoints to design Gap-PCR primers. Both of these 
samples had rearrangements that extended beyond the covered region of the first 
design.  
 Increase Functionality 
The new capture library included baits that covered larger regions of chromosome 11 
and 16. This allowed improved detection of large rearrangements, particularly on 
chromosome 16. The library also included regions on chromosomes X and Y, which 
made sex determination possible through this assay. The inclusion of regions on 
chromosomes 2 and 6 (where variants that modify disease phenotype in 
haemoglobinopathies have been reported) is yet to be used. The inclusion of these 
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regions is useful, as determining whether these regions are balanced can differentiate 
between imbalances on chromosome 11 and 16 that are due to extremely large 
variants, versus just the result of lower coverage from a particular sample as a whole. 
This was the case for MiSeq Sample 22, where the entire bait covered region of 
chromosome 16 appeared to be duplicated. To ensure that this was not due to the 
sample being overloaded and thus obtaining comparatively more sequence than all 
negative controls, the RPKM data from the covered regions on chr2, chr6 and chr11 
was inspected. These regions were determined to be balanced, indicating that the 
duplication indices on chromosome 16 were genuine.  
Due to the inclusion of regions of the X and Y chromosomes into Bait Capture Library 
2, sex determination was possible with this assay. Sex could be successfully 
determined for every sample where gender was known: females showed an RPKM 
ratio of 0:1 Y:X, and males showed a ratio of 1:1 Y:X (Table 59).  
Table 59: Sex Determination in the New Design Run. The average RPKM value 
achieved across the covered region of the X and Y chromosomes is shown for 16 
samples from female subjects and 12 samples from male subjects. The Y:X ratio 
in the female samples is 1:1 and in the males is ~1:1.  
 
Comparing the Sensitivity of NGS Analysis to MLPA 
MLPA data was available for a number of samples included in this study, where the 
assay had been performed as part of routine diagnosis when these samples were 
received in the diagnostic laboratory at KCH. Figure 106 shows RPKM plots for four 
samples included in this study where MLPA data was also available. The positions of 
probes in the MLPA assay used are depicted by green squares. The MLPA probes 
effectively identify both duplications and deletions occurring at the alpha globin gene 
cluster (indicated by a value >1.3 on the secondary vertical axis for a duplication or a 
value of < 0.5 for a deletion). However, the number of probes and distance between 
the probes limits the resolution of the assay. A comparison between the resolution of 
NGS data and MLPA data is given in Table 60.  
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Comparison between MLPA assay and NGS data 
 
Figure 106 Comparison between MLPA and NGS data for four samples. RPKM plots are shown for 
four samples analysed in this study, including two positive controls and two novel rearrangements 
characterised successfully as a result of NGS sequencing. Deviation of RPKM values per bait from 
the negative control average are plotted on a Log2 scale on the primary vertical axis and 
represented by black dots on the charts. NegC STDev is plotted in blue on the same scale. The 
positions of probes included in the Mol. Pathology lab diagnostic assay are shown as green 
squares with a yellow outline. The deviation of these values in each sample from a negative control 
average is plotted on the secondary vertical axis. A value > 1.3 indicated a duplication, and a value 
< 0.5 indicates a deletion in the MLPA data. 
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Table 60 Resolution achieved for variants through MLPA probe dosage data 
versus NGS RPKM data (based on distance between first position to show a 
dosage change and last probe to show balanced dosage at either end of each 
variant). 
Variant 
Resolution achieved by 
MLPA  
Resolution achieved by 
NGS 
Positive control (--SEA/) +/- 16 Kb +/- 600 bp 
Positive control (/) +/- 264 bp +/- 120 bp 
MiSeq Sample 33 +/- 48 Kb +/- 1.5 Kb 
MiSeq Sample 34 +/- 50 Kb +/- 7.5 Kb 
 
Resolution is calculated as the distance between probes or baits that indicate balanced 
sequence, versus probes or baits that indicate a dosage change has occurred. The 
size of this region is the length of the sequence where the dosage is not known, based 
on these metrics. While both assays achieve a good resolution of the (ααα/) insertion 
(albeit at the cost of numerous controls for the NGS assay – see previous section), the 
resolution achieved by NGS sequencing and RPKM data analysis is significantly higher 
than the resolution for MLPA for the other three samples. NGS analysis can also be 
furthered by inspecting the sequences of captured DNA fragments, which is not 
possible via MLPA analysis.  
Chapter Discussion 
Over the course of these sequencing experiments, many steps were taken to improve 
the utility of this assay for detecting and resolving variants for the diagnosis of 
haemoglobinopathies. The key steps taken to improve the assay were: 
 Redesigning the Capture Library 
 Increasing DNA fragment size 
 Increasing read length 
 Increasing the number of negative controls 
 Automating sample preparation 
Over the course of this study, 25 structural variants were sequenced and analysed. All 
variants could be detected through RPKM data analysis (Table 61). In 15 of these 
cases, the rearrangement could be resolved with to-the-base accuracy. This was 
achieved either by identification of breakpoint sequences in the reads aligning to the 
reference, or through Gap-PCR and sanger sequencing, where primers were designed 
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based on the RPKM data analysis. All novel variants identified will be submitted to 
HbVar. 
Table 61 Summary of success of variant characterisation in this study 
 
Redesigning the capture library allowed larger variants on the alpha globin gene loci to 
be characterised with to-the-base accuracy. The redesign also allowed the inclusion of 
other genomic regions with potential diagnostic importance, such as positions on 
chromosome 2 and chromosome 6 that may contain variants that modify disease 
severity of beta thalassaemia and sickle cell disease. Additionally, regions of the X and 
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Y chromosomes were included in the study, which allowed sex determination. Contrary 
to our expectations, employing the manufacturer recommended boosting strategy did 
not reduce variation across the region of interest or between samples compared to our 
first design. Furthermore, increasing the bait tiling density of this region increased the 
level of inter-sample variability in the assay, as a result of the increase in coverage. 
While this did not help to reduce the noise associated with the assay, the increased 
bait density in the core locations for the assay increases the amount of sequence 
captured in these regions, allowing a higher read depth per sample.   
Increasing DNA fragment size and read length improved the capability of this assay to 
sequence into repetitive regions and increased the alignment specificity for captured 
sequences. The increased read length also allowed longer strings of mismatched 
sequences to be included in the alignment, which improved break-point 
characterisation. There were still issues with correctly aligning reads containing small 
indels to the reference sequence, with many being discounted as the software tried to 
‘shoe-horn’ reads into alignments that matched the reference sequence. Where indels 
were included in the mutation report, they were indexed incorrectly, resulting in multiple 
entries in the report for each base affected by the indel, rather than a single call for the 
entire variant. Single nucleotide changes that were known to occur in certain samples 
were successfully identified in the variant reports for both capture libraries, where the 
most severe impact to their confidence scores came from low read depth. 
Increasing the number of negative controls used in the assay was crucial to successful 
characterisation of the structural variants. Negative control samples can be used to 
reduce the noise in the assay even when they are not prepared or included in the same 
run. As more sequencing runs are carried out, it would be useful to assemble a ‘bank’ 
of negative controls that can be used to analyse data in new runs. This will increase the 
number of test samples that can be included per run, although some negative controls 
should still be prepared and sequenced with each batch of test samples for quality 
control purposes, to check inter-run variation.  
The utility of these negative controls from other runs is dependent on minimising the 
inter-run variation. Inter-run variation (between runs on the same sequencing platform) 
appears to be produced during sample preparation and hybridization. In order to 
streamline the time consuming sample preparation process, and also to reduce 
variability between runs, a robotic sample preparation platform was introduced. There 
were extensive problems with programming the platform to reliably carry out sample 
preparation. For MiSeq Run 5 and Run 6, sample preparation was carried out on the 
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robotic platform, but the sensitive hybridization stage was still performed manually. It 
was possible to use negative controls from one run to identify structural variants 
occurring in the other run thanks to the uniformity in the sequencing data achieved by 
this method. An automated hybridization step could further reduce the inter-run 
variability of this assay, providing it could be engineered to work reliably.  
Future Directions: Moving Away From the NextGene Software 
Package and on to a Custom Analysis Pipeline 
The NextGene software package was an essential tool to develop this assay. The 
department had no experience with manipulating and analysing NGS data at the 
beginning of this project, and an off-the-shelf toolkit was instrumental in determining 
whether this technology was able to fulfil the requirements for a diagnostic assay, to 
optimise the sample preparation procedure and the bait capture library for our 
purposes, and to evaluate our data while developing a routine SOP for using this 
technology in the diagnostic laboratory. The platform was found to have some 
limitations which meant that not all variants in this study could be reliably characterised, 
particularly where the breakpoints occurred within repetitive or homologous regions. 
Variant characterisation with this software was performed on a time-consuming, case-
by-case basis. The structural variant detection tool offered within the NextGene 
package was found to be extremely poor, calling large numbers of false positive results 
and missing known variants within the samples. Additionally, while excellent at 
reporting SNPS, NextGene was extremely poor at reporting small indels in the mutation 
report, where it called each base affected by an indel as a distinct variant, which 
impeded efficient analysis of the data because these redundant calls needed to be 
separated from the clinically relevant data. 
Developing a Bespoke Sequencing Analysis Pipeline for Diagnostic Use 
A bioinformatician was recruited into the diagnostic laboratory to develop a custom 
analysis pipeline for analysing NGS data from this assay, as well as others that were 
being concurrently developed on site after the acquisition of the MiSeq platform. 
Moving to a custom pipeline will provide multiple advantages in variant analysis. 
NextGene is an expensive tool which was not built specifically for the purposes of this 
study. This is exemplified by the use of RPKM throughout this study as a normalised 
measure of coverage, which is a tool intended for use in RNA sequencing. Identifying 
and characterising both known and novel structural variants in NextGene requires the 
user to manually compile data from up to five separate sources (Expression Report, 
Mutation Report, Opposite Direction Reads Report, Same Direction Reads Report, 
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NextGene Viewer) and even go back into the raw FASTA data. A purpose-built tool can 
avoid work-arounds of this nature, and also has the advantage that the inner workings 
of the tool are precisely understood, and can be manipulated for optimal efficacy.  
The pipeline uses multiple publicly available and widely used SNP callers together to 
create extremely accurate consensus variant calls. This includes haplotype-aware SNP 
calling programs that evaluate variant calls based on known information about the 
allelic backgrounds on which different variants commonly occur.  
The pipeline also identifies structural variants with high sensitivity using multiple tools. 
A CNV calling algorithm called ExomeDepth is the primary tool used to detect dosage 
changes (Plagnol, Curtis et al. 2012). This tool controls for technical variability between 
samples by creating an optimized reference set of controls for comparison with sample 
data. The tool aligns read data to a reference using a beta binomial distribution (i.e. 
determining the best alignment of each read based on maximum likelihood, assuming 
the data has a binomial distribution where the probability of success is random). A 
hidden Markov model is used to calculate the probability of three scenarios (deleted, 
balanced, duplicated) for each covered exon in the design and identifies the scenario 
which best fits the coverage data, corroborated by pre-existing estimates of the 
likelihood of each scenario in each exon, based on previous data. The model also 
applies penalties for sequencing depth, GC content and Phred score to the calls it 
makes. This tool is most sensitive when calling rare CNVs that are unlikely to occur in a 
normal reference dataset, so is well-suited to detecting novel or rare rearrangements 
causing thalassaemia and distinguishing them from the frequent copy number variants 
occurring in these regions. Additional tools are also used to increase the power of the 
analysis, including ‘Delly’ and ‘Lumpy’. Lumpy identifies rearrangements in alignment 
data based on similar attributes to those compared manually from NextGene data in 
this study, including coverage, discordant read mapping (pairs of reads mapping at 
unexpected distances or orientations to one another) and split read mapping (where 
one read from a pair crosses a rearrangement breakpoint and therefore maps partially 
to two normally non-adjacent sequences or with a change in orientation) (Layer, 
Chiang et al. 2014).  Delly operates in a similar manner, focussing on discordant read 
mapping. The combined use of all these programs allows sensitive variant detection by 
the analysis pipeline (Rausch, Zichner et al. 2012). 
The implementation of this pipeline is expected to call both single nucleotide variants 
and structural rearrangements with superior accuracy to NextGene, and to require less 
user input to do so. This tool will allow the sample preparation techniques optimised 
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during this study to be used for routine diagnosis, rather than for case-by-case analysis 
developed in NextGene.  
Rapid Detection of known breakpoints in FASTA data 
One novel feature that could be incorporated into this pipeline which was developed in 
this study is a search for sequences within the FASTA file that are unique to known 
variants. This could provide rapid and reliable detection of certain variants without the 
need to perform alignment and other downstream analysis steps. As proof of principle 
for this concept, we devised a script that could search FASTA files for sequences 
containing the unique breakpoint sequences produced by several variants (the sickle 
cell variant, the Asian-Indian inversion-deletion, the 619 bp deletion, and English V 
inversion-deletion).  The script also searches for the wildtype counterparts to these 
sequences. It then returns the result of “Negative”, “Homozygous” or “Heterozygous” 
calls for each variant. The output of the script for HiSeq Sample 6 (Positive control for 
the Asian-Indian inversion-deletion) is shown in Figure 107. The results of running this 
script for read files from several variants are shown in Table 62. The script itself is 
included in Appendix 5. In future versions of the Bait Capture Library, it could be 
possible to include additional baits which target these sequences. However, as many 
breakpoints occur within repetitive regions, including baits to target them could have 
the consequence of increasing off-target sequence captured at these regions.  
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Variant Finder Script in Python Shell
 
Figure 107: Variant Finder script applied to HiSeq Sample 6. Left window shows script, right 
window shows output in python shell.  
This is an extremely basic example of how this strategy could be incorporated into data 
analysis. The only stringency measure included in this script is that a minimum of three 
reads including either the mutant or wild type sequence are necessary to form a 
diagnosis. If neither sequence is identified in >3 reads, the script returns “neither 
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sequence found”. In two of the cases shown here, a reads that contain the unique 
sequence for the sickle cell variant are picked up in samples which are not carriers of 
this variant. This demonstrates the necessity for employing a minimum read 
requirement to provide accurate variant calling, an appropriate threshold for which 
would need to be investigated. In order to be suitable for diagnostic applications, this 
script would need to be heavily modified to provide more robust results. Requirements 
of a script for diagnostic use would include a score calculation for each call, tolerance 
for SNPs or miscalls within the variant and normal allele-identifying sequences and 
detection of the reverse-compliment of the sequences. A provision could also be 
included for unusual allele frequency, as in the case of HiSeq Sample 7 (in which the 
sample has a duplication of the beta globin gene cluster resulting in an unusual mutant 
allele frequency for the sickle cell variant).  Determination of reliable cut-offs for false 
positive and false negative read numbers would need to be calculated, and provisions 
would also have to be made for the possibility of mosaicism and contamination in the 
sample.  





Results Chapter 3: The Basis and Characteristics 
of Structural Rearrangements Affecting the Alpha 
and Beta Globin Gene Loci 
 
Introduction 
At the alpha and beta globin gene loci, a large number of structural variants of different 
kinds have been reported. Different parts of the genome are subjected to different 
types of structural rearrangement, and the events occur at different rates. 
Understanding what factors contribute to the formation of these rearrangements is of 
scientific interest, and is potentially useful for diagnosis. This chapter will examine how 
recorded variants at the globin gene loci relate to known drivers of structural 
rearrangement to see if they have a common cause.  
Interactions between features of the DNA sequence and the pathways that repair DNA 
breakages – particularly double stranded breaks (DSBs) – lead to the formation of 
structural rearrangements. Some of these interactions have been described in detail to 
explain how certain rearrangements arise. Other interactions are not yet fully 
understood.  
Features of the DNA Sequence that are Associated with 
Structural Rearrangements 
DNA bases are charged molecules, and the sequence of bases within a section of DNA 
can influence its 3D structure: complimentary sequences can contort the entire 
molecule because of their attraction to one another. Certain sequences of bases can 
cause tight loops to form, or for the molecule to take on non-double helix conformations 
such as hairpins and quadruplexes. Various DNA features have been reported to be 
associated with the formation of structural rearrangements and DNA mutation (Lupski 
1998, Bacolla, Jaworski et al. 2004, Gu 2008, Bacolla 2009). 
Repeats 
Non-coding, repetitive DNA sequences make up over half of the human genome 
(Richard, Kerrest et al. 2008). These repeats can be divided into several classes based 
on their sequence, or the pattern which their sequence takes. Different classes may 
have different functional properties in the genome. The classes of repeats found at the 
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globin gene loci on chromosomes 11 and 16 are described in Table 63. Some 
repetitive DNA sequences are highly homologous and the breakpoints of structural 
rearrangements often fall within, or near to, these repeats (Lovett 2004). Repetitive 
elements arrive and propagate through DNA via different mechanisms, so they are not 
evenly dispersed throughout the genome (Katti, Ranjekar et al. 2001). LINE repeats 
are extremely common in the region of the beta globin gene cluster on chromosome 11 
and less frequent around the alpha globin gene cluster on chromosome 16. 
Conversely, Alu-type SINE repeats – the most common class of repeats in the human 
genome – are more abundant on chromosome 16 than chromosome 11 (Richard, 
Kerrest et al. 2008).  
Table 63 Major repeat types found at the globin gene loci (data from (Katti, 
Ranjekar et al. 2001, Antonarakis 2010) 
Repeat type Description 
Long Terminal Repeat (LTR) Long terminal repeats are vestiges of proviral DNA 
formed by reverse transcription of retroviral RNA 
Tandem Repeat Repeated iterations of the same sequence of bases. 
Depending on the number of bases forming the unit 
of sequence which is repeated, these are subdivided 
into dinucleotide repeats, minisatellite repeats, 
microsatellite repeats, and short tandem repeats 
(STRs). 
DNA Transposons Cut-and-paste repeats, or Class II Transposons are 
a common type of repeat left behind by viruses 
which multiply through the genome by replicative 
transposition 
Non-LTR Retrotransposons 
 Short Interspersed 
Nuclear Elements (SINE) 
 
 Long Interspersed 
Nuclear Elements (LINE) 
In the human genome most SINE repeats are of the 
subclass ‘Alu’ 
The complete SINE repeat sequence is 280 bp long 
In the human genome most LINE repeats are of the 
subclass ‘L1’ 
The full LINE element is 6 Kb in length 





Segmental Duplications  
Segmental duplications (also known as low copy repeats) are 1 – 400 Kb highly 
homologous (>95%) and region-specific repeats. Particular segmental duplications are 
often confined to a single chromosome or chromosomal region, so are classed 
differently from the other types of repeats which occur many thousands of times 
throughout the genome (Samonte and Eichler 2002, Gu 2008). Segmental duplications 
make up approximately 5% of the genome (Samonte and Eichler 2002). They have 
been found to coincide with the breakpoints of recurrent deletions and duplications 
where their homology mediates non-allelic homologous recombination (NAHR). 
Segmental duplications are frequent in the region of the alpha globin gene locus.  
Non-B DNA  
Non-B DNA conformations are 3D structures that double stranded DNA can adopt, 
other than the Watson-Crick double helix (Bacolla 2009). Non-B DNA conformations 
include triplex and tetraplex helixes, cruciforms and hairpins (Table 64). The ability of 
DNA to adopt these structures is dictated by sequence motifs, such as mirror repeats, 
G Quadruplexes and Z DNA. Some non-B DNA conformations are associated with 
rearrangements and sequences that take on non-B DNA conformations are more 
vulnerable to double stranded breaks (DSBs) than DNA that retains the double helix 
formation (Stankiewicz and Lupski 2002, Bacolla 2009). When DNA breakages occur, 
the physical shape of the DNA and the sequence occurring at the breakpoint both 
affect the manner in which it is repaired, giving rise to different types of DNA 
rearrangement. Tetraplex DNA is associated specifically with duplications, the 
breakpoints of which occur in G-Quadruplex DNA repeats. Slipped hairpin and 
cruciform structures have been associated with sequence inversions (Bacolla 2009, 










Table 64 Non-B DNA motifs from (Bacolla 2009) 
Non-B DNA Motif Composition 
Resulting non-
B conformation 
G-Quadruplex > Four iterations of the sequences GG, 
GGG or GGG separated by 1-7 other 
nucleotides 
Tetraplex 
Z DNA Dinucleotide repeats of CG CG CG ... and 
occasionally TG CA TG CA TG ... 
Left-handed Z 
DNA 
Mirror Repeat TTGGACTTCAGGTT Triplex 
Inverted Repeat TCGGTTACCGA 
AGCCATTGGCT 
Cruciform  
Direct Repeat TCGGT·TCGGT·TCGGT Slipped hairpin 
Short tandem 
repeats 
Repeated iterations of a 2-13 nucleotide 
sequence 
Slipped DNA 
A phased repeats Repeats of alpha nucleotide sequences 
interspersing normal sequence at regular 
(~10bp) intervals  
Static bending 
 
Origin of Replication 
During DNA replication many small sections of the DNA are concurrently ‘unzipped’ 
creating replication forks, both strands of which are then copied simultaneously (Slack, 
Thornton et al. 2006). The DNA segments replicated from all the forks along the 
chromosome are then eventually joined together to make a complete copy. The fork 
start positions are ‘origin of replication’ (ORI) points (Tiller 2000). Structural 
rearrangements can arise from errors that occur during fork replication. In a study of 
replication in plasmids transformed into E. Coli, deletion breakpoints were found to 
frequently occur within 150bp of a ORI (Bacolla, Jaworski et al. 2004). For this reason, 
the location of ORI in relation to the breakpoints of rearrangements in thalassaemia is 
of interest. In budding yeast, where ORI have been studied most closely, these points 
are marked by the same 11 bp sequence. In humans, multiple sequences are 
associated with ORI. A database of replication origin points mapped in humans to date 
has been created (DeORI) (Gao, Luo et al. 2012), which  lists ORI that have been 
identified by replication initiation point mapping in cell lines as described in (Karnani et 
al 2009). The database currently includes 433 entries from human cell lines. A common 
feature of replication origin sites is their high AT content. The database also includes 
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replication origin sites from cancer cell lines, which are extremely abundant due to 
interruptions to the cell replication process. 
DNA Repair Pathways 
DNA molecules can experience breaks, interstrand crosslinks and other issues during 
replication. Several mechanisms are in place to repair these breaks. A successful 
repair may completely restore the original sequence. Alternatively, homologous 
recombination may occur, in which the two copies of a chromosome exchange allelic 
segments with one another (Figure 108). Structural rearrangements result from 
incomplete repair of a DNA break via one of the numerous non-homologous repair 
mechanisms available. In these instances, repairing the break results in the loss, 
insertion or translocation of sequence.  
Homologous Recombination Hotspots 
Positions where homologous recombination has taken place can be identified by 
changes to the chromosome haplotype – the pattern of SNPs that occur along the 
chromosome. These patterns change when homologous recombination has occurred, 
swapping part of the haplotype from one allele with another. The variety of haplotypes 
that occur across a region can be used to calculate its recombination rate. This value is 
usually given in centimorgans (cM). The HapMap Project has identified large numbers 
of haplotypes in the population due to the frequent homologous recombination events 
at certain positions. These regions are called recombination hotspots. There are two 
recombination hotspots at the site of the beta globin gene cluster on chromosome 11, 
one situated within the cluster and another in close proximity to it (Paigen and Petkov 
2010). The large number of haplotypes reported across the beta globin gene cluster 
indicate that homologous recombination events are frequent at this position (Heyer, 
Ehmsen et al. 2010).  
Homologous recombination involves equal exchange of genomic material and is 
mediated by different repair mechanisms than events which lead to non-homologous 
recombination. In spite of this, there is some correlation between the locations of 
segmental duplications and homologous recombination hotspots. As such, 
recombination rate will be evaluated as a potentially contributing factor in the 
generation of thalassaemia-associated structural rearrangements (Gu 2008).  
Non-homologous recombination 
Several mechanisms repair DNA breaks via means other than reciprocal homologous 
recombination: Non-allelic homologous (NAHR), Single Strand Annealing (SSA), non-
289 
 
homologous end joining (NHEJ), and microhomology-mediated end joining (MMEJ). 
These repair mechanisms leave deletions, duplications, insertions and inversions of 
various sizes in their wake, which sometimes include specific DNA signatures 
identifying the repair mechanism that created them.  
Non-allelic Homologous Recombination (NAHR) 
Non-allelic homologous recombination (NAHR) is a DNA repair mechanism that occurs 
between two homologous sequences that are not allelic counterparts (Figure 108). 
Recombination via NAHR is closely associated with segmental duplications.  
Homologous Recombination and Non-Allelic Homologous Recombination 
 
Figure 108 Homologous Recombination and Non-Allelic Homologous Recombination (NAHR). Two 
alleles are depicted in red and blue, with the homologous sequence along each allele represented 
by numbers. In left panel, reciprocal crossover between the homologous and allelic sequences 
results in an equal exchange of homologous sequence. In the right panel, three low copy repeats 
(green) which are all highly homologous but NOT allelic are situated in this region. Homologous 
recombination between these regions can result in interchromosomal or intrachromosomal NAHR.  
Examples of NAHR include the frequently recurring duplications causing Charcott-
Marie Tooth Syndrome (CMT1A) and the haemoglobin alpha (α-3.7/) and (α-4.2/) 
deletions and their counterparts. Non-recurrent recombination events can also occur 
via NAHR, primarily between repetitive and highly homologous Alu or LINE sequences 
(Gu 2008).  
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Charcott-Marie Tooth Syndrome is caused by a duplication on chromosome 17 in 70% 
of cases, 10% of which are de novo events (Blair, Nash et al. 1996). The duplication 
break points invariably occur in two discreet regions that are segmental duplications 
with a high level of homology. In the alpha globin gene cluster, the (α-3.7/) and (α-4.2/) 
deletions, plus the (ααα) triplication complex that is the counterpart of the  (α-3.7/) 
deletion all occur between low copy repeats with high homology (Emmanuel 2001, 
Samonte and Eichler 2002). A study by Lam et al. investigated the frequency with 
which these rearrangements occurred during meiosis and mitosis (using assays to 
detect the rearrangements in sperm and blood). In two non-carrier men, the deletions 
arose spontaneously at a rate of 6.7/6.8x10-6 per haploid genome in blood and in 
sperm at a rate of 16x10-6/68x10-6 per sperm. Four percent of these rearrangements 
were the leftward 4.2 conformation and 96% were the rightward 3.7 conformation (Lam 
and Jeffreys 2006). The (ααα/) triplication did not occur at the same frequency as its 
counterpart, (α-3.7). This indicates that NAHR can occur intrachromosomally between 
the two points on a single chromosome - creating a single deletion allele - as well as 
interchromosomal NAHR - creating both alleles by removing the segment from one 
chromosome and inserting it into the other (Lam and Jeffreys 2006, Gu 2008). Studies 
of recurrent duplications in other regions noted that minimal efficient processing 
segments (MEPs) were required for recurrent segmental duplication mediated 
recombination events to occur. This is the length in nucleotides and percentage of 
homology required for recombination. MEPs were estimated to be 300-500bp in length 
based on studies of several genomic regions. The segmental duplications in the alpha 
globin gene region, however, were found by this study to have substantially shorter 
MEPs: recombination could occur between homologous stretches of as little as 37 
nucleotides, owing to the close proximity of the alpha segmental duplications to one 
another (Gu 2008, Liu, Lacaria et al. 2011).  
Single Strand Annealing (SSA) 
Single strand annealing digests DNA on either side of a break point until a 
microhomology between the ends is reached. The DNA is trimmed to these regions 
and the two ends are then ligated back together. Single strand annealing principally 
occurs at tandem repeat sequences, with the general result that one of the two 
homologous repeats is deleted, along with the intervening sequence (Lee 2014). This 
mechanism of repair is considered to be distinct from NHEJ and MMEJ because it is 
mediated by Rad51-family proteins which are associated with homologous 
recombination, rather than Ku and PARP which govern NHEJ and MMEJ (Sancar, 
Lindsey-Boltz et al. 2004).  
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Non-Homologous End Joining (NHEJ) and Microhomology-Mediated End 
Joining (MMEJ) 
NHEJ is frequently used to repair unequal DSBs, and evidence of NHEJ activity can be 
identified at DNA break points by the ‘signatures’ it leaves behind. MMEJ appears to be 
a less frequently used mechanism, and is considered by some to be a subtype of SSA 
repair, although it appears to follow a different pathway and have a less destructive 
impact on the sequences it operates on (McVey and Lee 2008).  
When a DSB is detected, molecular bridging from both broken strands is employed to 
make them compatible and ligatable. The two sequences need to have some homology 
to join correctly. This can happen between regions with existing microhomologies (5-25 
bp) via MMEJ, frequently leading to the loss of any sequence between the 
microhomologous regions (Boulton and Jackson 1996, McVey and Lee 2008). 
Alternatively, the DSB can be repaired via NHEJ which either joins regions with small 
microhomologies (1-5 bp), or otherwise creates small sequence insertions, deletions or 
duplications to produce microhomology (Roth and Wilson 1986, Lupski 1998). The 
breakpoints of NHEJ and MMEJ events are frequently within or in close proximity to 
LTR, LINE, Alu, MIR and MIR2 sequences. As these process can used to mediate 
repair of DSBs created by non-B DNA conformations, breakpoints are also often 
associated with these DNA motifs, particularly inverted repeats. Both deletions and 
duplications have been attributed to mistakes by NHEJ repair of DSBs. Non-recurrent 
tandem duplications have been described that show junction microhomology and small 
insertions characteristic of NHEJ repair. These duplications were believed to be the 
result of NHEJ and homologous recombination (HR) being employed in combination to 
repair a DSB, and in doing so invaded and copied the sister chromatid (Gu 2008). 
MMEJ is always associated with deletion events, removing bases until a 
microhomology is found (McVey and Lee 2008).  
Fork Stalling and Template Switching (FoSTeS) 
As described previously, DNA replication is initiated at multiple points across the 
chromosome simultaneously, at ORIs. At these locations, the DNA opens into fork 
structures, and both strands of open chromatin are replicated simultaneously. During 
this process it is possible for replication to stall on one strand of a fork, causing it to lag 
behind the replication of the complimentary strand. The lagging strand can then 
become disengaged from the DNA it is replicating and anneal to another fork that is 
open and has microhomology to the lagging sequence. The replicating strand 
continues to extend along the new fork and may disengage and jump to other forks 
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before returning to its original position (Michel 2000, Jennifer A. Lee 2007). These forks 
could be from other regions of the same chromosome, or other chromosomes currently 
undergoing replication. FoSTeS can create high complexity rearrangements, such as 
inversion-deletions. FoSTeS events are associated with segmental duplications, Alu 
repeats and high GC sequences. Some non-B DNA conformations such as palindromic 
sequences and loop structures may provoke a stalling event (Jennifer A. Lee 2007, Gu 
2008).  
The genomic landscape at the alpha and beta globin gene loci 
The alpha and beta globin gene clusters are situated on different chromosomes. The 
two gene clusters exhibit many similarities, and the genes are believed to have evolved 
from a single common ancestor via a series of duplication and gene conversion events 
(Czelusniak J 1982, Zhang 2003). Conversely, there are also some marked differences 
in the features of the two clusters (Table 65) 
Table 65 The alpha and beta globin gene clusters: similarities and differences 
Alpha globin gene cluster Beta globin gene cluster 
Similarities 
 Arose by duplication 
 Both clusters include 5 active genes, two of which are close homologues (HBA1, 
HBA2, HBG1, HBG2) 
 Each globin gene consists of three exons and two introns 
 Organised in order of expression 
 Structural variants of the genes are common: 800 variants with no clinical 
significance have been recorded to date 
 Situated on the short arms of their respective chromosomes near the telomere 
 Duplications recorded to date are top-to-tail in orientation 
 Both clusters include pseudogenes 
Differences 
 Situated on chromosome 16 
 The first location where the globin 
 Situated on chromosome 11 
 Thalassaemia is mainly caused by 
point mutations and deletions are rare 
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genes evolved (Hardison 2012) 
 Thalassaemia is mostly caused by 
deletions and point mutations are rare 
 No thalassaemia causing variants in 
the promoter have been recorded 
 Cluster is spread over 28Kb 
 Genes cover 800-1.6Kb of sequence 
 Cluster spread out over 45Kb 
 Genes cover 1.5-2 Kb of sequence 
 Two recombination hotspots are 
situated within the cluster 
 The cluster is near to an ‘origin of 
replication’ point. 
 
Variants that are associated with thalassaemia differ between the two globin gene 
clusters: Most reported variants on chromosome 16 are deletions, while those affecting 
chromosome 11 are mainly point mutations (Trent 2006). On a more subtle level, 
duplications of the alpha globin genes that can modify the severity of beta 
thalassaemia disease phenotype have been recorded with a higher frequency than 
duplications of the beta globin cluster, and inversion-deletions have only been recorded 
on the beta globin gene cluster. Duplications that have been identified in the beta 
globin cluster to date have been phenotypically silent, unless inherited with another 
globin variant or thalassaemia. These co-inheritance incidents are the only occasions 
when these duplications have been detected, so the frequency of phenotypically silent 
duplications at this locus will not be known until we start screening DNA on a wider 
scale (Harteveld, 2008).  
This study has shown that features of the DNA sequence can impact the ability of NGS 
to resolve some rearrangements:  
 The (α-3.7/) deletion and insertion are difficult to detect because they affect one of 
two highly homologous regions and has no identifiable breakpoint sequence (See 
Results: ‘Detection of the 3.7 Kb Deletion and Insertion’) 
 The English V inversion-deletion first characterised in this study was difficult to 
resolve because it interrupted a DNA palindrome that impeded sequencing 
 Rearrangement breakpoints frequently fell in repetitive regions that had not been 
sequenced.  
Identifying DNA features that associate with rearrangements at the globin gene clusters 
could improve our ability to locate likely breakpoints positions that are not readily 
apparent from NGS sequencing data. This could improve diagnosis in thalassaemia 
and be scientifically valuable. 
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Previous studies of structural rearrangements at the globin gene loci 
A previous attempt to identify common factors causing rearrangements at the alpha 
globin gene cluster was undertaken by Nicholls et al (1987). The study looked for 
features that united 12 known deletions causing alpha thalassaemia. They found that 
five of these deletions removed a similar region of sequence (20-30 Kb) and at least 
one breakpoint in each deletion mapped within, or close to, an Alu repeat (Nicholls, 
Fischel-Ghodsian et al. 1987). Despite this observation, this study was not able to draw 
conclusions about the significance of the relationship between Alu repeats and 
rearrangements on chromosome 16 due to the small sample size used and the 
extremely high frequency of Alu repeats throughout the genome. Regardless, they 
posited that mechanisms by which Alu repeats could induce deletion events were that 
their homology created misalignments in meiotic chromosomes, or that Alu repeats 
may act as origins of replication. 
One deletion, (ααRA/) was found to seamlessly join two homologous Alu repeats, 
resulting in a breakpoint that was indistinguishable from normal sequence. They 
concluded that this indicated the deletion mechanism was a linear chromosomal 
deletion, representing the first example of a deletion resulting from homologous 
recombination between two members of a family of interspersed repeats to be reported 
in higher eukaryotes. Other features noted in the study were a GC rich inverted repeat 
adjacent to one deletion breakpoint, and short region of mild homology between the 
break points of another deletion including a 6-8bp direct repeat.  
In their analysis of the (–Med/) deletion they found a 134 bp insertion at the deletion 
break points. This was identified as an Alu repeat fragment originating from 37 Kb 
upstream of the affected region, which had be reinserted in an inverted orientation at 
the break point position.  
Nicholls et al. noted that the deletions tended conform to a distinct size range of 20-30 
Kb. They hypothesised that this could be attributed to chance and the small sample 
cohort, or that these regions has characteristics making them particularly prone to 
recombination. Further, they could be a consequence of the way chromatin at this 
position loops during the cell cycle, with the loop between these two points being 
removed. This is supported by the chromatin loop model proposed by Vanin et al 
(1983) of rearrangements on the beta globin gene cluster. The insertion of novel 
inverted sequence in the (–Med/) deletion, originating from a position a similar distance 
away, could also be explained by this model (Vanin, Henthorn et al., 1983).  
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The study by Vanin et al examined four deletions impacting the beta globin gene 
cluster, also aiming to identify a common underlying feature of these rearrangements 
(Vanin, Henthom et al. 1983). The DNA breakpoint sequences of these deletions were 
studied via restriction digest mapping and Maxam-Gilbert sequencing of the resulting 
fragments. Vanin et al did not find any homology occurring at the break points in the 
four variants they examined at the beta globin gene cluster, although one of the eight 
breakpoints examined was in close proximity to an Alu repeat, which had also been 
reported at the break points of other deletions causing beta thalassaemia. The principle 
finding reported by this study was that the deletions analysed were all approximately 
the same length, removing different but equally sized sections of sequence (Figure 
109).  
Deletions at the Beta Globin Gene Cluster from Vanin et al. (1983)
 
Figure 109: Deletions at the Beta Globin Gene Cluster Studied by Vanin et al. “Schematic 
representation of normal DNA and deletions in γδβ-thalassaemia samples 1 and 2 and HPFH 
deletions 1 and 2. Letters A through Z represent normal DNA; the β-globin gene cluster is 
underlined. The brackets surround the regions known or predicted to be deleted in the respective 
haemoglobinopathies” (Image and quoted legend taken from Vanin et al, 1983).  
Vanin et al suggested that this consistency in size, along with the lack of homology at 
the 5’ and 3’ break points in these deletions implied that the they had come about as a 
result of recombination between DNA segments that are physically close within the 
nucleus due to the looping of chromatin during replication. (Vanin, Henthom et al. 
1983). Nicholls et al. suggest that this mechanism is also in play at the alpha globin 
gene cluster, but involving smaller chromatin loop sizes. There is no universal marker 
for loop size, and this size varies between different cell types, in different stages of cell 




Summary and Section Aim 
Structural rearrangements can be caused by many different processes that occur 
during DNA replication. The locations of these events are dictated by the DNA 
sequence itself and the influence it has on the 3D structure of the DNA molecule. Next 
generation sequencing has the capability to characterise rearrangements with to-the-
base accuracy, but in some circumstances this is difficult and time consuming, or not 
possible. In these situations, it could be useful to identify sequence motifs that are likely 
to cause structural rearrangements, and target them specifically when looking for 
rearrangement breakpoints, for example when designing Gap PCR primers. 
Understanding the mechanics of structural rearrangements could also be scientifically 
valuable.  
The locations of known breakpoints of rearrangements affecting the globin gene loci 
(from HbVar) will be examined to determine if they are commonly associated with any 
known DNA features that provoke DNA rearrangement. Several additional variants 
were also identified from a literature search and included, along with novel variants 
from this study where breakpoints were identified. The alpha and beta globin gene 
clusters are situated on different sequence backgrounds, and the different 
characteristics of the clusters may mean that rearrangements affecting these loci have 
different causes. 
This chapter will investigate whether any trends exist between the locations of motifs 
associated with DNA rearrangements and the rearrangements reported at the globin 
gene loci. This may reveal particular motifs that associate strongly with different types 





A list of variants affecting the alpha and beta globin gene loci was obtained from the 
globin gene server at HbVar.org. The list was filtered to all rearrangements affecting 
>50 bp of sequence with known breakpoints. Rearrangements characterised in this 
investigation were added to the list, as were duplications reported in the literature that 
were not recorded in the globin gene server database. The resulting list comprised of 
56 pairs of breakpoint co-ordinates for rearrangements on chromosome 11 and 29 
pairs of breakpoint co-ordinates on chromosome 16. This included several separate 
entries for breakpoint co-ordinates of two complex rearrangements on chromosome 11 
– the Asian-Indian inversion deletion and English V deletion – which are the 
culmination of several different rearrangement events (See Results: HiSeq Sample 6 
and MiSeq Samples 2 and 3 for details). The alpha and beta globin gene clusters were 
investigated separately, as rearrangements at the two loci may be driven by different 
mechanisms.  
Sequence features identified in the literature as associated with structural variation 
were obtained from various online databases. Some databases were extremely large 
and data collected from them were restricted to a region of interest for each locus. 
These regions were defined according to the broad locations of the most 3’ and most 5’ 




The data collected for these regions of interest were: 
 Repeats identified by RepeatMasker along each region downloaded from 
http://www.dfam.org/search/hits.   
 Non-B DNA motifs downloaded from the non-B database (National Cancer Institute 
at Fredrick https://nonb-abcc.ncifcrf.gov/apps/site/default) 
 Recombination Rate data for chromosomes 11 and 16 downloaded from 
HapMap.org 
 The locations of segmental duplications downloaded from the Segmental 




 The locations of origins of replication identified in the HeLa cell line were 
downloaded from OriDB (http://cerevisiae.oridb.org/)  
Where breakpoint sequence data was available (primarily from rearrangements 
characterised in this study via NGS), they were inspected for novel sequences and 
other features associated with different modes of DNA rearrangement.  
The proximity of deletion and duplication breakpoints recorded at each cluster were 
compared to the locations of DNA features associated with DNA rearrangement. 
Breakpoints that fell (a) directly within or (b) within 500bp of these features were 
counted. The proportion of breakpoints meeting condition (a) or (b) were compared to 
an equal sized group of randomly selected genomic co-ordinates from within the region 
defined by the most 5’ and most 3’ breakpoints recorded on each chromosome in the 
HbVar database. The random co-ordinate group was regenerated a total of 20 times, 
and the average count for conditions (a) and (b) was used. These comparisons were 
included in the analysis because of the limited amount of breakpoint data available for 
study. We felt that there may be some mild associations between these datasets and 
the sequence motifs examined that could have some biological importance may be 
overlooked during simple statistical examination due to lack of power.  
Genome Annotation Tester (GAT) is a publically available tool for comparing whether 
sets of genomic intervals overlap significantly (Heger, Webber et al. 2013). In addition 
to the experiments outline above, Dr David Brawand (Bioinformatician, Dept. Molecular 
Pathology, King’s College Hospital) used GAT to calculate whether any relationships 
between breakpoint locations and sequence features were strong enough to reach 
statistical significance. Co-ordinates of the breakpoints and the sequence features in 
BED format were analysed by the tool, and P and Q values for the overlap between the 
datasets (in both conditions a and b as described above) were returned.  
Note: two entries in the chromosome 16 rearrangement cohort are telomere tip 
duplications, effectively beginning at position chr16:1. To avoid generating random 
control co-ordinates within the poorly mapped telomere region of the chromosome, the 
next most telomeric breakpoint in the dataset was used to define the random control 






A total of 29 rearrangements on chromosome 16 with known breakpoints were collated 
from the HbVar database, sequencing experiments in this study and the literature. The 
29 rearrangements provide 58 breakpoints for investigation. Twenty-three 
rearrangements were deletions and six were duplications. A control group of 58 co-
ordinates not associated with rearrangements were randomly generated between the 
most 3’ and most 5’ locations of the breakpoints in the known rearrangement cohort.  
The locations of these variants and of sequence motifs associated with structural 
rearrangement across the region of interest on chromosome 16 are shown below 
(Figure 110), and the described in detail in the following sections.  
300 
 
The Region of Interest on Chromosome 16 in UCSC Genome Browser
 
Figure 110 The Region of Interest on Chromosome 16 in UCSC Genome Browser . The locations of 
known thalassaemia related rearrangements included in this study are shown, along with the 
relative positions of genes and sequence features associated with structural rearrangements.  
Repeats According to RepeatMasker 
Repetitive elements that occurred within the region of interest on chr16 were separated 
according to their class. The region contained five classes of repetitive element: Cut 
and Paste, LINE, LTR, SINE and RNA. In Condition (a) there was no substantial 
difference in the number of breakpoint co-ordinates that occurred within Cut and Paste, 
LINE, LTR or RNA repeats and the random control cohort. Compared to the random 
control cohort, rearrangement breakpoints were 50% more likely to occur within SINE 
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repeats. In Condition (b) the difference between rearrangement points and randomly 
generated points that were adjacent (+/-500bp) to a SINE repeat was less pronounced 
(Table 66).  
Table 66 Co-localisation of rearrangement breakpoints and repetitive elements 
on chromosome 16 compared to randomly generated control co-ordinates 
 
Replication Origin Points 
The DeORI database records 16 replication origin points on chromosome 16 (Table 
67). Only a single ORI on chromosome 16 is situated within the region of interest, and 
none of the breakpoints being investigated fell (a) directly within or (b) within 500 bp of 
this location.  
Table 67 Replication origin points on chromosome 16 as listed in DeORI. The 




Non-B DNA Motifs 
Rearrangement breakpoints were not clearly associated with any non-B DNA motif 
compared to randomly generated controls in either condition A or condition B (Table 
68).  
Table 68 Co-localisation of rearrangement breakpoints and Non-B DNA motifs on 
chromosome 16 compared to randomly generated control co-ordinates 
 
Recombination Rate 
Recombination rate is a continuous variable, and as such it was not analysed using the 
same ‘within’ or ‘adjacent’ conditions as other variables. The recombination rates 
calculated across chromosome 16 were downloaded from HapMap. An average value 
for the recombination rate was calculated per 1 Kb of the region of interest. The 
average recombination rate across the region of interest was 1.0231cM. The number of 
breakpoints occurring per 1 Kb of the region of interest was also calculated. The two 
datasets showed a weak negative correlation with an R2 value of 0.0076 (Figure 111). 
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Relationship between Recombination Rate and Breakpoint Frequency 
 
Figure 111 Relationship between Recombination Rate and Breakpoint Frequency per 1000 bp of 
sequence on chromosome 16 
Segmental Duplications 
Thirty-one percent of rearrangement breakpoints were situated within segmental 
duplications compared to 5% of randomly generated controls. Thirty-six percent of 
rearrangement breakpoints were adjacent (<+/-500bp) to segmental duplications 
compared to 5.7% of randomly generated controls (Table 69).  
Table 69 Co-localisation of rearrangement breakpoints and Segmental 





Similarities in Rearrangement Size Indicative of Recombination between 
Chromatin Loops 
Previous work has suggested that rearrangements on chromosomes 11 and 16 may 
fall into certain size groups dictated by the chromatin loop length across these regions. 
Rearrangements in the cohort on chromosome 16 were plotted according to their size 
and median position on the chromosome. The reported common rearrangement size 
on chromosome 16 was 20-30 Kb. The distribution of rearrangements in this study by 
size and median position is shown in Figure 112. Two scales are used to clearly show 
the range of variant sizes. The majority of variants are <5 Kb and appear to occur at an 
evenly dispersed range of sizes below this length.  
 
Figure 112: Range of Variant Sizes on Chromosome 16. Rearrangements on chromosome 16 
analysed in this study, plotted by median affected position (X-axis) and rearrangement size (Y-
axis). Two scales are provided for clear illustration of the size ranges. 
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Notable Features of Breakpoint Sequences 
Rearrangements that had been mapped using Next Generation Sequencing were 
studied in closer detail, as permitted by our knowledge of the exact breakpoint 
sequences. Details of the breakpoint sequences were examined to identify common 
features of the rearrangements. This included features that caused the initial double 
stranded break and mutational signatures left behind in the rearrangement, indicative 
of the repair mechanism that sutured the chromosome (Table 70). For detailed 
description of the rearrangements described in Table 70 please see sections 









A total of 57 rearrangements on chromosome 11 with known breakpoints were collated 
from the HbVar database and from sequencing experiments in this study. The 57 
rearrangements provide 114 breakpoints for investigation. Forty-eight rearrangements 
were deletions, seven were duplications and two were inversions (Table 71). A control 
group of 114 co-ordinates not associated with rearrangements were randomly 
generated between the most 3’ and most 5’ locations of the breakpoints in the known 
rearrangement cohort.  
Table 71 Breakpoint pairs included in the study on chromosome 11 by type 
 
The locations of these variants and of sequence motifs associated with structural 
rearrangement across the region of interest on chromosome 11 are shown below 




The Region of Interest on Chromosome 11 in UCSC Genome Browser 
 
Figure 113 The Region of Interest on Chromosome 11 in UCSC Genome Browser . The locations of 
known thalassaemia related rearrangements included in this study are shown, along with the 
relative positions of genes and sequence features associated with structural rearrangements.. 
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Repeats According to RepeatMasker 
No duplication or inversion breakpoints are within a recorded repetitive region. In 17% 
of deletions the breakpoint occurred within a repeat of some kind. The majority 
(13.16% of deletion breakpoints) occur within LINE repeats, compared with 3.15% of 
randomly selected co-ordinates. There was no difference in the frequency of adjacent 
(+/-500bp) repeats to break point positions and randomly selected positions for any 
repeat class (Table 72). 
Table 72 Co-localisation of rearrangement breakpoints and repetitive elements 
on chromosome 16 compared to randomly generated control co-ordinates 
 
Replication Origin Points 
The DeORI database lists 18 replication origin points identified on chromosome 11 
(Table 73), of which five are within the region of interest for beta thalassaemia related 
rearrangements. No rearrangement breakpoints fell within, or adjacent to (+/- 500bp) 








Table 73 Origins of replication on chromosome 11 from the DeORI database. 
Origins of replication within the region of interest for thalassaemia 
rearrangements are highlighted in yellow 
 
Non-B DNA Motifs 
Breakpoints occurred within mirror repeats at a greater frequency than randomly 
generated controls. Breakpoints were more likely to be situated adjacent to (<+/- 
500bp) Z DNA motifs than randomly generated controls. Breakpoints were less likely to 
be adjacent to A phase or G-quadruplex repeats than randomly generated controls. All 
four inversion breakpoints were adjacent to mirror repeats, and 75% were adjacent to 









Table 74 Co-localisation of rearrangement breakpoints and Non-B DNA Motifs on 
chromosome 11 compared to randomly generated control co-ordinates 
 
Recombination Rate 
Recombination rate is a continuous variable, and as such it was not analysed using the 
same ‘within’ or ‘adjacent’ conditions as other variables. The recombination rates 
calculated across chromosome 11 were downloaded from HapMap. An average value 
for the recombination rate was calculated per 1 Kb of the region of interest. The 
average recombination rate across the region of interest was 1.69 cM. The number of 
breakpoints occurring per 1 Kb of the region of interest was also calculated. The two 
datasets showed a weak negative correlation with an R2 value of 0.0108 (Figure 114). 
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Relationship between Recombination Rate and Breakpoint Frequencies
 
Figure 114: Relationship between Recombination Rate and Breakpoint Frequencies per 1000bp of 
Sequence on Chromosome 11 
Segmental Duplications 
Rearrangement breakpoints were more likely than randomly generated control co-
ordinates to occur within segmental duplications. No additional breakpoints were 
situated adjacent to segmental duplications (Table 75).  
Table 75 Co-localisation of rearrangement breakpoints and segmental 





Similarities in Rearrangement Size Indicative Of Recombination Between 
Chromatin Loops 
Rearrangements in the cohort on chromosome 11 were plotted according to their size 
and median affected position (Figure 115). Previous research had suggested 
rearrangements affecting 40 Kb of sequence may be the most common at this locus. 
The majority of rearrangements affected less than 50,000 bp of sequence, so the graph 
is shown on two scales to provide clearer illustration of the size distribution of the 
smaller variants. The size range of variants < 50,000 bp shows small clusters of 
rearrangements 6-8 Kb in size and 12- 14 Kb in size. No pronounced grouping of 
rearrangement lengths into blocks is visible on the larger scale. 
 
Figure 115: Range of Variant Sizes on Chromosome 16. Rearrangements on chromosome 11 
analysed in this study, plotted by median affected position (X-axis) and rearrangement size (Y-
axis). Two scales are provided for clear illustration of the size ranges. 
Notable Features of Breakpoint Sequences 
Table 76 describes the findings of an in-depth inspection of the features and 
sequences of breakpoints in rearrangements described with to-the-base accuracy on 
chromosome 11 during this study. For detailed description of the rearrangements 
described please see appropriate results sections in Results Chapters 1 and 2.  
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Table 76 Notable features of breakpoint sequences in DNA samples 




Summary of Significance of Structural Variant Association 
Genome Association Tester (GAT) is a tool to determine whether two sets of genomic 
intervals overlap one another more than just by chance alone (Heger, Webber et al. 
2013). To return quantitative values for the data described above, the co-ordinates of 
the structural variant sets from chromosomes 11 and 16 were compared to co-
ordinates lists of genome features potentially associated with them. A second dataset 
tested the association between genome features and broader regions (+/- 500bp) 
containing a structural variant breakpoint. For each genome feature, the significance 
with which they are associated with structural variants is returned as a P value and a Q 
value, based on the Expected versus Observed overlap between the two datasets. The 
data generated by GAT is summarized in Table 77. 
Chromosome 11 variants were associated with CutandPaste type repeats and mirror 
repeats with a P value of P=<0.05. Chromosome 16 variants were associated with 
LINE repeats with a P value of P=<0.05 and SINE type repeats and segmental 
duplications at a P value of P=0.01. Widening the structural rearrangement co-
ordinates from the breakpoint locations to the breakpoint regions (breakpoint +/- 500 
bp) did not increase the association between any genomic features and the list of 
variants. From this we conclude that there is a significant association between the 
breakpoints of recorded structural variants on chromosome 16 and the locations of 
SINE repeats and segmental duplication regions. On chromosome 11, only a mild 
association between sequence motifs and rearrangement breakpoints is found. This 
suggests either that a different mechanism is responsible for the rearrangements that 
occur on the two chromosomes, or that there are issues with the validity of this data. 
SINE repeats are far more frequent on chromosome 16 than chromosome 11. The 
apparent involvement of these repeats with rearrangements at this locus may explain 






Table 77: Identification of significant overlaps between DNA sequence features 
and thalassaemia breakpoint co-ordinates. Findings calculated by GAT. 
Relationships that are significant at P<0.05 are highlighted in red. Relationships 






The positions of known structural variants on chromosome 11 and 16 were compared 
to data from multiple databases of genome sequence features. Genome sequence 
features that had significant, mild or no association with break point positions were 
identified. There were clear differences between the factors involved with 
rearrangements affecting the alpha and beta globin gene loci. 
Previous studies have implicated segmental duplications in the creation of structural 
rearrangements. This is attributed to their high homology to one another, which allows 
non-allelic homologous recombination (NAHR) to occur between these points. There 
was some localization of structural rearrangement breakpoints to segmental duplication 
regions at both loci, although this was only statistically significant for the cohort of 
rearrangements on chromosome 16. The fact that segmental duplications are 
associated with variants on one locus, but not the other, suggests that a different 
process may cause rearrangements at these two loci. Alu-type SINE repeats and LINE 
repeats have also been associated with structural rearrangements. These are also 
believed to facilitate NAHR due to their high level of homology to one another. SINE 
repeats were found to be significantly associated with the structural rearrangement co-
ordinates on chromosome 16, but not on chromosome 11. LINE repeats were also 
significantly associated with rearrangements on chromosome 16 at P<0.05.   
An investigation by Nicholls et al identified Alu repeats and homologous sequences as 
sequence features associated with alpha thalassaemia breakpoints (Nicholls, Fischel-
Ghodsian et al. 1987). The study noted that all four of the variants they surveyed fell 
into a broadly similar size range. This led to the suggestion that rearrangements at the 
alpha globin gene locus happened between DNA sequences brought into close 
physical proximity by chromatin looping during replication. The rearrangements 
investigated in this study did not appear to show any grouping into distinct size 
brackets, or into the particular size bracket (20-30 Kb) suggested by Nicholls et al. 
Therefore, our findings do not support their suggestion.  
Nicholls et al described an inverted insertion at the breakpoints of the (--MED/) deletion. 
Although this variant was sequenced as a positive control sample in this study, the 
breakpoint sequences of this variant could not be identified in the read data. This was 
concluded to be a result of high homology at the breakpoint sequences, along with their 
location within unmapped repetitive regions (low complexity and SINE). This inversion 
is not included in the description of this variant HbVar or mentioned elsewhere in the 
literature, and so the case found by Nicholls et al may be a rare sub-variant of (--MED). 
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Without further information about this inversion deletion, we will not comment on what 
process that may have caused it. 
The breakpoint locations of rearrangements that had been characterised by NGS were 
examined closely. On chromosome 16, four rearrangements that had been 
characterised with to-the-base accuracy were examined. Three of these showed 
homology at the breakpoint and association with Alu repeats, which implicated NAHR 
in the generation of these variants. One of the four rearrangements had an insertion of 
novel sequence at the breakpoint, which is associated with DNA repair by non-
homologous end joining (NHEJ). An additional variant which had not been 
characterised with to-the-base accuracy at the time of writing (MiSeq Sample 35) also 
appeared to occur between two Alu repeats with high homology to one another. NAHR-
mediated structural rearrangements have been previously implicated in numerous 
diseases caused by a variety of structural variants (Amos-Landgraf, Ji et al. , 
Nagamani, Erez et al. 2011). Our findings support the notion that this is also the case 
in alpha thalassaemia.  
Two rearrangements of the alpha globin gene cluster that were included in this study 
included the telomere. We are unable to design baits against the telomere sequence, 
so this represents a limitation of the study where breakpoints within the telomere may 
have significant and unknown properties.  
Rearrangements on the beta globin gene cluster were not significantly associated with 
any sequence features at a significance of P<0.01. Mirror repeats were associated with 
rearrangements at a significance of P<0.05, as were proximal (+/- 500 bp) Cut-and-
Paste repeats. Unlike the alpha globin gene cluster, there was no significant 
association between LINE or SINE repeats or segmental duplications and breakpoint 
locations. This confers with previously reported findings by Henthorn et al (Henthorn, 
Smithies et al. 1990). In their study, of twenty beta thalassaemia rearrangements 
investigated, 15 showed microhomology at the breakpoint, six had novel insertions, 
and four were associated with inverted repeats. Only two rearrangement breakpoints of 
the cohort in our study were directly within inverted repeats, although thirty breakpoints 
were within close proximity to one. However, inverted repeats are extremely frequent 
across this region of the genome, and this association was not statistically significant: a 
set of randomly generated co-ordinates showed proximity to inverted repeats with a 
similar frequency to the genuine rearrangement breakpoints. Henthorn et al. conducted 
their study before detailed databases of such DNA features were available, so the 
association they reported may have been a false positive result.  
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In the six NGS characterised rearrangements on chromosome 11 studied in close 
detail, five showed microhomology or a small novel insertion at the breakpoint. 
Microhomology at the breakpoint is indicative that the microhomology-mediated end 
joining (MMEJ) repair mechanism was employed to repair a DSB at this position, while 
small insertions indicate the NHEJ mechanism was used. This is in clear contrast to the 
rearrangements associated with alpha thalassaemia which occur between homologous 
regions, implicating the NAHR mechanism in repairing DSBs at that location.  
The lack of significant association between rearrangement breakpoints on 
chromosome 11 and any of the sequence features analysed suggests more than one 
mechanism may contribute to rearrangements occurring at this location. Alternatively, 
they may coincide with another sequence feature that is yet to be linked to the 
generation of structural variants. Inversion-deletions – which have been reported in 
beta thalassaemia but not in alpha thalassaemia – may occur via a different 
mechanism to simple deletions and duplications. A larger cohort of inversion 
breakpoints would be necessary to draw any conclusions regarding this. The factors 
that determine which repair pathway is used to repair double stranded breaks are not 
yet fully understood, but may be influenced by chromatin structure. Differences in 
chromatin folding at the alpha and beta globin gene loci may be the reason that 
different varieties and rates of structural rearrangement are recorded at the two loci 
(Henthorn, Smithies et al. 1990, Yu and McVey 2010). The sizes of rearrangements in 
this study did not conform to discreet size intervals, but showed an even distribution 
between 1 and 50Kb, with some variants much larger. This does not support the 
suggestion by a previous study that rearrangements at this locus are confined to 
certain size range dictated by the size of chromatin loops at this location (Vanin, 
Henthom et al. 1983).  
Replication origin points showed no association with rearrangements at either locus. 
However, the FoSTeS mechanism of recombination is likely to occur inside replication 
forks rather than at their start or end points, so a lack of association of the replication 
fork origin point with structural variants does not suggest that recombination events are 
not mediated by FoSTes. There may be more replication origin points in both clusters 
that have not yet been identified and included in the DeORI database.  
There was no association between homologous recombination rate and frequency of 
structural rearrangement breakpoints. This result is in line with previous findings in the 
literature that homologous and non-homologous recombination events are governed by 
different mechanisms, so an association between the two was not likely.  
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This study has multiple limitations: The breakpoint cohorts on both loci are small, due 
to the lack of breakpoint data for many recorded variants affecting the globin gene loci. 
Furthermore, the data that are available could be affected by a sampling bias, in that 
their breakpoints were in DNA regions that allowed them to be characterised in the first 
place, rather than in large repeats or highly homologous sequences. Small numbers of 
inversions and duplications were included in the study, and the numbers may not have 
been sufficient to identify any trends specific to these rearrangements. Imperfect 
repeats that have an impact on DNA structure or mutability may not have been 
detected by the algorithms used to populate the non-B DNA database. The segmental 
duplications database appeared to contain some inconsistencies, where multiple 
entries were identified that referred to the same single location. Different mechanisms 
may contribute to the formation of small and large rearrangements. By analysing all 
rearrangements >50 bp as one sample cohort, we may have overlooked significant 
relationships affecting different sized variants formed by different mechanisms.  
The sequence motif databases used in this study may not be complete – the DeORI 
database only represents a fraction of the expected ORI sites in the genome. The 
relationship between ORI and structural rearrangement is difficult to comment on. The 
requirements for a region to become an ORI are unclear and there may be additional 
unreported ORI occurring within the studied in this investigation. The manner in which 
ORI may influence structural rearrangement is also not fully understood: it is possible 
that breakpoints are more likely to occur somewhere within replication forks, e.g. at the 
midpoint of the fork furthest from ORI positions. If this were the case, our analysis, 
which only examined whether rearrangement breakpoints were associated with ORI’s 
themselves, would not identify that relationship.  
Previous attempts to determine a common cause of rearrangements at either of the 
globin gene clusters have been limited by the small number of rearrangements for 
which the breakpoint sequences had been determined. With the advent of NGS, the 
number of fully characterised rearrangements available for study may shed new light 
on the underlying mechanisms of rearrangements. However, as demonstrated in this 
study, NGS also has limitations that may prevent to-the-base characterisation of 
rearrangements under some circumstances. This is a limiting factor of the conclusions 
that can be drawn from studies that rely on this technology, as the rearrangements that 
cannot be characterised may display some significant common element that we are 
unable to detect. Furthermore, many other rearrangements affecting these loci may be 
unreported, as they are frequently silent when inherited in a heterozygous form, so 
variants identified from phenotypic screening may only represent a small subset of the 
321 
 
genetic variants present in the general population. This may change as variant 
screening becomes faster, cheaper and more commonplace with the increased 
availability of NGS platforms. To make the best use of this data, an improved standard 
for describing structural variants is needed with a single reference sequence for both 
loci, large enough to cover all the structural variants in thalassaemia. Reporting these 
variants should be encouraged, and a high standard of accuracy for doing so 
maintained. An example of an issue with the current practise is that the HbVar 
database entry for the 619bp deletion omits the insertion of 7 nucleotides at the 
deletion breakpoint, despite this being published in the literature. The presence of such 
insertions may have scientific value. This highlights the need for manual curation of 
variant databases. However, as variant calling becomes an increasingly automated 







Haemoglobinopathies are a common group of highly heterogeneous disorders in both 
their genetic cause and phenotypic consequences. Increasingly, the diagnostic 
laboratory at King’s College Hospital (KCH) is required to provide diagnostic testing for 
a large range of variants causing haemoglobinopathies, as global migration increases. 
The two key requirements of the diagnostic service are to provide results with accuracy 
and with speed. The current standard laboratory protocol can require up to five tests 
and may or may not arrive at a diagnosis. This process is time consuming, particularly 
when rare or novel rearrangements are encountered. The current standard practise 
could be streamlined by adopting a NGS approach. Targeted NGS has advantages 
over other methods such as SNP arrays and CGH array for detecting structural 
variants, as the dataset provides variant calls, coverage and phase across the length of 
the sequence fragment. Its main drawback is that it only works for a targeted area and 
if the structural variant is bigger than the ROI it may not detect the breakpoints. 
This study set out to evaluate NGS as a tool for the diagnosis of haemoglobinopathies. 
In order to improve upon the current standard of diagnosis, we intended to create an 
assay that was fast, medium to high throughput, comprehensive and highly accurate. 
This technology has already been proved to be a highly accurate means of detecting 
single nucleotide changes, which are a frequent cause of haemoglobinopathies. 
Structural variants also cause haemoglobinopathies and therefore we needed to 
evaluate the capability of NGS to detect these variants before it could be claimed that a 
single technology could detect all pathogenic genetic variation.   
The development of this assay for diagnostic use can be divided into three stages: 
sample preparation, target enrichment and analysing sequencing data.  
The Sample Preparation Process  
There are multiple methodologies available for preparing DNA samples for sequencing 
and enriching for target regions, as well as a variety of sequencing platforms. At the 
start of this investigation, we opted to use Agilent SureSelect library preparation in 
combination with in-solution bait capture target enrichment with Illumina sequencing 
technology. Illumina sequencing platforms are widely available, with an increasingly 
diverse technological portfolio, catering for different sequencing requirements, and 
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associated with a low error rate, making them ideal for our investigation (Harismendy, 
Ng et al. 2009).  
The first sequencing run we performed in this study was on the Illumina HiSeq 2000 
platform. A cohort of 12 samples were prepared for sequencing manually according to 
the Agilent SureSelect protocol. The run achieved high read depth per sample as 
expected given the sequencing capacity of this platform. This allowed dosage changing 
rearrangements to be identified based on coverage (RPKM) data, and known SNPs in 
the cohort were accurately reported. Shortcomings of this method were the length of 
time required for sequencing (the HiSeq 2000 takes two weeks to generate FASTQ 
data), the small DNA fragment (starting size ~150 bp), and the small read size 
available on the HiSeq 2000 (2x97 bp). The small fragment and read sizes used in this 
assay prevented complete characterisation of several of the sequenced variants 
(HiSeq Samples 3, 5, 7, 9, 10, 11). A false negative result for the presence of an indel 
was also identified in one sample, which may have been detected correctly if a longer 
read length had been used (HiSeq Sample 6). This sequencing run showed that high 
sample throughput was possible on the HiSeq 2000, but the assay was not fast or 
accurate enough for diagnosis and did not provide comprehensive variant detection.  
Subsequent runs were performed on the MiSeq platform. In MiSeq Run 1 and MiSeq 
Run 2, the starting DNA fragment size was increased to ~500 bp. Smaller batches of 
samples were prepared for sequencing on the MiSeq platform, which has a lower 
capacity than the HiSeq 2000 but affords faster sequencing and longer read lengths. It 
was found that the sample preparation process preferentially amplified smaller DNA 
fragments, and that over the course of sample preparation the average fragment size 
was reduced from 500 bp to 300 bp. The increased read length and fragment length in 
these assays improved sequence alignment and allowed a rearrangement that could 
not be characterised on the HiSeq 2000 (HiSeq Sample 10) to be resolved with to-the-
base accuracy (MiSeq Sample 3). The rearrangement involved a deletion which had 
been visible in the HiSeq 2000 data, and also a previously unidentified inversion which 
could be detected with to-the-base accuracy in the MiSeq data. With the identification 
of this breakpoint, Gap-PCR primers against the inversion-deletion breakpoints were 
designed and completely resolved the sequence at both positions. Without the 
knowledge that an inversion had occurred, previous attempts to create a Gap PCR 
assay for this rearrangement had failed, as primers had only been designed to target 
the deleted region. Of the four novel rearrangements sequenced in these two runs, 
three were found to have this rearrangement (MiSeq Samples 2, 3 and 6). Two positive 
controls for known deletions were also sequenced and the breakpoints as reported in 
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the literature were successfully identified (MiSeq Samples 1 and 5). With the inclusion 
of only a single negative control in each of these runs, the sensitivity of the assay in 
differentiating genuine structural variants from background noise was reduced 
compared to the HiSeq 2000 platform.  
An automated sample preparation workstation, the BioMek FXP was brought into the 
laboratory. The intention of this was to reduce the man-hours associated with sample 
preparation and make the process more uniform, reducing the noise in this assay 
associated with inter-sample variation. Implementing the complex sample preparation 
workflow on this platform was extremely challenging. Several attempts to prepare 
samples for sequencing using this workstation resulted in failures, including MiSeq 
Runs 3 and 4, in which the sample preparation process was found to have completed 
successfully, but after sequence alignment, it was found that the hybridization stage of 
the process had failed.  
MiSeq Runs 5 and 6 were prepared on the BioMek FXP platform, apart from the 
hybridization stage which was performed manually. The average fragment length of the 
input DNA in these samples was 600 bp. An additional bead-based size selection step 
was introduced prior to the SureSelect library preparation step. This tightened the 
fragment size range, removing the short fragments that had been preferentially 
amplified in previous experiments. The input DNA volume was increased from 3 µg to 5 
µg to offset the increased DNA loss from the double size selection process. Based on 
the read depth achieved in previous runs, we increased the number of samples 
prepared and sequenced per batch to 14. Automated sample preparation increased the 
number of samples that could be prepared for sequencing simultaneously and reduced 
the number of man-hours required for sample preparation. MiSeq Run 5 did not include 
sufficient negative controls for reliable variant detection. It was necessary to use 
additional negative control data from MiSeq Run 6 to reliably identify structural variants 
in this run. In both runs, dosage changing rearrangements could be identified from 
coverage (RPKM) data. Some rearrangements could be resolved with to-the-base 
accuracy and were confirmed by Gap-PCR. Other rearrangements could be broadly 
identified, and then resolved with to-the-base accuracy by Gap-PCR with primers 
designed based on the approximate breakpoint locations. Some samples could be 
broadly identified, but Gap-PCR primers designed against the approximate break 
points did not amplify a break-point product. 
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The Bait Capture Library 
Two bait capture libraries were designed to enrich prepared DNA samples for 
fragments originating from regions of interest. Bait Capture Library 1 was designed 
using eArray (Agilent). This library covered the regions of the globin gene clusters on 
chromosome 11 and 16 using 1x tiling, plus boosting for orphan baits, or baits with a 
high GC content. This library did not cover a large enough portion of chromosome 16 to 
fully capture some structural rearrangements sequenced in this study (HiSeq Samples 
1, 3 and 8). Sequencing experiments performed using this bait capture library also 
showed multiple regions where coverage was highly variable between samples and 
variation between samples across the bait covered region.  
Bait Capture Library 2 was designed to succeed Bait Capture Library 1, extending the 
region of bait coverage on chromosome 16. This extension meant that all but one of 
the rearrangements sequenced at the chromosome 16 locus were completely covered 
by the bait design. The exception was a sample that showed a duplication >2Mb in 
length (MiSeq Sample 22) exceeding the region of coverage. This library increased the 
number of baits covering core regions of chromosomes 11 and 16 where the majority 
of variants were expected to occur. The increased number of baits allowed improved 
resolution of rearrangements (as each 120 bp bait overlaps another by 60 bp, the 
resolution of RPKM data plots increases from +/- 120 bp to +/- 60 bp). Sparse tiling 
was also extended across an even wider region of each locus, increasing its potential 
to characterise large rearrangements. The increased tiling density across the core 
region of interest increased the amount of DNA fragments originating from this region 
which were captured per sample, improving the level of coverage achieved and 
proportion of reads that were on target. Increasing the tiling density and employing the 
boosting parameters recommended by Agilent to maximise bait performance did not 
reduce the variation in coverage across the target region within samples, or the 
variation seen between samples.  
Agilent’s library design tools (eArray and SureDesign) were not able to design baits 
against the first 60 Kb of chromosome 16. This is the telomeric region of the 
chromosome, and the sequence of this region is poorly understood. Several variants 
removed some or all of this region, and because it was not included in the library 
design, the size of these variants and their breakpoint sequences could not be 
determined. Bait Capture Library 2 also included regions of chromosome X and 
chromosome Y so that the assay could also be used for sex determination during 
prenatal diagnosis. Two regions on chromosome 6 and chromosome 2 were also 
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included as they are known to contain genetic variants controlling foetal haemoglobin, 
which influence the clinical severity of beta thalassaemia and sickle cell disease. Such 
genetic variants may also be diagnostically relevant in the future to increase disease 
severity prediction once the role of these loci in modifying disease state is better 
understood. A limitation of Bait Capture Library 2 is that it does not include the ATRX 
region on chromosome X. This is believed to be a regulatory region for multiple genes, 
including the alpha globin loci on chromosome 16. Inherited variants at this locus can 
result in alpha thalassaemia/mental retardation syndrome (Gibbons, Wada et al. 2008, 
Lugtenberg, de Brouwer et al. 2009). Some cases of acquired thalassaemia in patients 
with MDS have also been attributed to somatic mutations at this locus (Steensma, 
Gibbons et al. 2005). Although these conditions are extremely rare, including the region 
would have increased the diagnostic scope of this assay.  
Data Analysis 
Data analysis was performed using an off-the shelf package developed by 
SoftGenetics called NextGene. This package included tools for quality filtering data 
from the sequencing platform, converting it into FASTA format and aligning it to a 
reference sequence of the human genome with user-defined stringency. The program 
included multiple tools for data analysis which were used with varying degrees of 
success. The mutation report successfully identified all sequence variants previously 
reported in all the sequenced samples. It also provided quality score and mutant allele 
frequency information which were both useful metrics for assessment and clinical 
interpretation. Opposite and same direction read reports were able to isolate break-
point spanning reads in several of the rearrangements that were sequenced, but they 
were not always informative (See results: detection of 3.7 Kb deletion in opposite 
direction read data). In some cases, breakpoint reads were included in the alignment 
and not displayed in the opposite direction read report. In the same direction read 
report, a genuine inversion (English V) was only present in one entry in the report 
(MiSeq Sample 2), although this can be attributed in part to the presence of a non-
functional bait covering one of the break point positions which reduced the number of 
reads captured at the breakpoint location. Both these reports were hampered by a 
large amount of ‘noise’ stemming from misalignment between repetitive, off-target or 
highly homologous sequences. This was an issue that affected the most homologous 
of the globin genes (HBA1 and HBA2; HBGA and HBGG) and regions that were 
repetitive. The expression report was extremely useful for calculating coverage across 
a user-defined set of regions. RPKM plots based on this information provided the basis 
of structural variant detection in this study. This method of analysis proved to be 
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extremely accurate in identifying dosage changing variants. Where the breakpoints of 
rearrangements were identified in the read reports or in the NextGene Viewer, the 
breakpoint sequences conformed absolutely to the breakpoint sequences determined 
through Gap-PCR and Sanger sequencing.  
The software had several shortcomings, using the multiple results above to 
characterise structural variants was awkward and time consuming. The ‘structural 
variant’ tool (included in an updated version of the software introduced part way 
through this study) failed to detect any of the rearrangements that were known to occur 
in the samples, and generated multiple false positive calls across the genome based 
on off-target and misaligned sequences. Calling of indels yielded at least one false 
negative result and they were listed in a cumbersome manner in the mutation report, 
with multiple entries giving different scores for the same variant. The software 
frequently produced misalignments of reads from regions with high homology, such as 
the HBGA and HBGG genes and the HBA1 and HBA2 genes. This impaired variant 
detection in several cases, including the Asian-Indian inversion-deletion and the 
English V rearrangement variants in the HBB complex, and the (α-3.7/) deletion in the 
HBA complex. A bioinformatician was recruited into the diagnostic department in order 
to design a bespoke pipeline for NGS data analysis. This pipeline is expected to 
address these issues by employing a range of tools specifically designed for each of 
the required tasks to provide more accurate, consensus based calls (Nielsen, Paul et 
al. 2011) presented in a more streamlined fashion. Preliminary tests of this program 
showed that it was able to confidently detect the (α-3.7/) deletion due to the superior 
precision in sequence alignment capabilities. This pipeline is still under development.  
Conclusions Regarding Assay Potential 
This technique was capable of characterising multiple structural variants. All dosage 
changing variants could be identified with an accuracy comparable to CGH array and 
greater than MLPA, both techniques that are part of the current standards in 
diagnostics. In many cases, the variants could be identified with to-the-base accuracy. 
Thirteen novel variants were sequenced in this study, which had eluded 
characterisation by other techniques. Eight of these variants were resolved with to-the-
base accuracy. For the remaining five variants, it was possible to identify dosage 
changes that affected the globin genes and estimate the size of the rearrangement 
(except in the instance of the large duplication in MiSeq Sample 27 which exceeded 
the size of the target region). Twelve positive controls for known structural variants 
were also sequenced. All of these could be detected with accuracy comparable to CGH 
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array, and seven could be resolved with to-the-base accuracy. In addition identifying 
structural variants, the technique is capable of determining the location and orientation 
of duplicated sequences and identifying novel inversion events. The presence of 
concurrent sequence variants affecting the globin genes could be also be detected 
without the need to perform additional tests. None of the techniques currently used in 
the standard diagnostic protocol have this capability. In theory, the technique is also 
capable of detecting translocations, although none were identified in this study.  
The two principle limiting factors of characterising variants in haemoglobinopathies 
using this technique are the inability of the assay to sequence repetitive regions, and 
shortcomings of the alignment software. It is necessary to employ repeat-masking 
when designing the bait capture library in order to avoid capturing huge amounts of off-
target sequence. In bait capture library 1, baits were allowed to extend up to 20 bp into 
repetitive regions. A DNA fragment must share 40bp of homology with a bait in order to 
be selected for during hybridization. In spite of the specificity for the target region that 
this should confer on the captured fragments, a large amount of off-target sequence 
(An average of 39% of total reads in MiSeq Run 6) was still captured. The amount of 
off-target sequence fell over the course of the runs performed in this study, so it is 
possible further improvements will be seen as the persons performing library 
preparation become more experienced. The inclusion of these fragments which limited 
read depth of the target regions and contributed to noise in both RPKM data and 
opposite/same direction read reports. In spite of this, break-point sequences for 
multiple variants were not captured when they fell within repeat sequences that were 
too large to be covered by fragments ligating to baits surrounding these regions. The 
alignment software was unable to detect any of the structural rearrangements 
sequenced automatically, and this required work-arounds including using the 
expression report to detect coverage changes, opposite and same direction read 
reports which contained a large number of false positive results, and having to delve 
into the FASTA data files to retrieve the sequences of read pairs that appeared to 
contain rearrangement break point sequences. Although we did not have a large 
amount of data concerning indels and SNPs in the sequenced samples, a clear indel 
was noticed in one sample that had not been called (HiSeq Sample 6). This indel was 
present in a large proportion of reads in a region with a high level of coverage, and was 
also included in dbSNP. NextGene appeared to have issues with aligning indels that it 
did detect, which provided cause for concern in using this tool for accurate diagnosis. 
Several samples had known single nucleotide changes. All of these were identified with 
satisfactory accuracy. For this reason, although the sample preparation and target 
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enrichment strategies were clearly capable of indicating the presence of variants (if not 
capturing the breakpoints), it was necessary to develop a bespoke in-house pipeline for 
data analysis rather than relying on the NextGene package. Balanced rearrangements 
between repetitive regions not included in the bait capture library could be undetectable 
using this technique. There is a possibility that some of the variants that could not be 
resolved in this study included balanced rearrangements that were not identified, 
meaning that Gap-PCR primers were not designed against the correct breakpoint 
positions for these variants. This represents a theoretical blind spot in this assay, 
although cases where thalassaemia is caused by a rearrangement that doesn’t 
increase or decrease the globin gene dosage (by deletion or duplication) are likely to 
be extremely rare. This is one instance where third generation sequencing technology, 
such as single molecule sequencing could prove to be a significant improvement on 
this assay.  
The current diagnostic strategy involves a series of tests, each followed by a review of 
the results and then if necessary, progression to another test. The turnaround time for 
an individual sample following this algorithm may take up to a month for 
comprehensive testing in the case of a rare variant. The cost for characterisation of 
novel rearrangements by MLPA/CGH array resolution may reach £700 per patient. 
Complete characterisation of novel variants with to-the-base accuracy is not 
considered to be viable in terms of time and cost in a diagnostic laboratory and hence 
in the past characterisation has been carried out by research groups. By contrast, this 
technique represents a single assay that can achieve MLPA/CGH array level resolution 
with a turnaround time of less than two weeks. The cost of the assay per patient is 
approximately £500 and sequencing costs will continue to fall. The technique has the 
potential to detect novel balanced rearrangements and provide to-the-base 
characterisation of novel variants. Accurate diagnosis is essential if individuals will use 
these results for prenatal diagnosis and in these tests gap PCR is preferred rather than 
NGS, due to the speed and accuracy. Gap PCR is only possible when the breakpoints 
have been characterised, or are at least approximately known. 
To surmise, CGH array and MLPA add to the current diagnostic repertoire, patching 
diagnostic holes where specific types of variants need to be identified. NGS promises 
to be a single technique replacing all that has gone before with increased diagnostic 
yield.  
It would have been advantageous to re-sequence some samples to assess how 
changes we made to the assay improved its ability to characterise rearrangements. 
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The false negative indel identified in the Asian Indian inversion deletion (HiSeq Sample 
6) may have been detectable with the longer fragment and read lengths used in MiSeq 
sequencing runs. This could also have benefitted analysis of the British deletion 
sample (HiSeq Sample 9). Time constraints due to extensive issues first with off-site 
sample preparation and then with the setup of the BioMek FXP platform prevented re-
runs of these samples. Two variants were not resolved due to insufficient DNA being 
available to complete the investigation (HiSeq Sample 11; and HiSeq Sample 3, later 
MiSeq Sample 22).  
Novel Rearrangements of the Globin Gene Cluster 
Many of the novel ‘test’ variants sequenced in this study were selected for NGS 
because they had eluded diagnosis by other means. Eight of the variants were 
resolved with to-the-base accuracy in this study, where other techniques had failed to 
determine their breakpoints. Some of these rearrangements had interesting molecular 
features and phenotypic consequences.  
The English V Deletion (MiSeq Samples 2, 3 and 6) 
The proband for this deletion was an English Anglo-Saxon female who had 
hypochromic microcytic anaemia that was unresponsive to oral iron supplements. Her 
haematological profile showed an imbalanced α/β globin chain synthesis (reduced β 
globin)  with normal HbA2 and HbF fractions. This phenotype is consistent with 
heterozygous εγδβ thalassaemia (Shooter, Rooks et al. 2015). Southern blotting had 
identified a deletion removing the β globin gene cluster LCR, but the breakpoints of the 
deletion could not be resolved.   
Next Generation Sequencing revealed that the rearrangement consisted of two events: 
the deletion identified in southern blotting which removed the LCR, HBE and the third 
exon of HBG2, and additionally an inversion of 59 Kb encompassing the rest of the 
beta globin gene cluster. The inversion had occurred first, bringing together two 
sequences that were highly homologous to one another. This was followed by a 
deletion that removed 122 Kb of upstream sequence and also 82 bp of the adjoining 
inverted sequence. The inversion breakpoint was at the centre of a 156 bp palindrome 
which may have played a role in forming this rearrangement.  
Despite rearranging HBB, HBD, HBG1 and both deleting and inverting HBG2, the 
inversion portion of this variant is phenotypically silent, as the LCR removed with the 
deletion prevented any of these genes from being transcribed. Only one other 
inversion-deletion causing thalassaemia has been reported in HbVar. No 
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rearrangements causing εγδβ  thalassaemia that have been reported to date include 
inversions. All but one εγδβ thalassaemia rearrangements reported to date have been 
confined to a single family. This rearrangement was found in 3 different families, all of 
Caucasian Anglo-Saxon origin. Given the complexity of the rearrangement, it seems 
likely that the rearrangement is of a single origin. This is supported by the similarities 
between variant calls in the region around the rearrangement in all three cases 
sequenced.  In one family, the proband was adopted. Undetected inversion events may 
underlie other εγδβ rearrangements that have been reported in the past where break 
point products were resistant to PCR amplification. A previously reported εγδβ deletion, 
English I, is reported to delete approximately 100 Kb of sequence including the LCR, 
extending from the third exon of HBG2 (Curtin, Pirastu et al. 1985). This bears a close 
resemblance to the deletion portion of English V, and may be another example of this 
variant. In that case, the breakpoint was never fully characterised.  
The African I Duplication (MiSeq Sample 7) 
The African I duplication is the first reported duplication of the entire beta globin gene 
cluster. Although this rearrangement displaces 80Kb of sequence, the additional globin 
genes are expressed and would be phenotypically silent during screening. It was only 
identified due to the dilution affect it had on the expression level of the HbS (13% total 
not 40%) variant on the other chromosome, seen by the screening laboratory.  
The duplication is top-to-tail in orientation, as all other reported duplications in the 
alpha and beta globin gene cluster have been to date. This may suggest a common 
mechanism is responsible for duplications affecting the globin gene clusters. 
Throughout the duplicated region, only two genotypes were recorded (with mutant 
allele ratios of 70% or 30%). This suggested that the rearrangement that caused the 
duplication had been intrachromosomal, creating an identical copy of the original 
sequence immediately adjacent to it.  
Novel Beta Globin Duplication 2 (Not yet named) in MiSeq 
Samples 41 and 42 
A second duplication affecting the beta globin gene cluster was also characterised in a 
family trio, where it was also identified by an abnormal HbS fraction in the proband, 
who had inherited the duplication from the father. In this case, the duplication 
incorporated sequences from two different alleles into the same chromosome, one of 
which carried the normal HBB gene and the other the HbS variant. The proband had 
inherited this duplication from the father and also inherited another copy of the HbS 
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allele from the mother (MiSeq Sample 40). Thus, the proband genotype was 
HbS/HbS/HbA, the father’s genotype was HbS/HbA/HbA and the mother’s genotype 
was HbS/HbA. 
Like the African 1 duplication, the rearrangement inserted the duplicated sequence 
immediately after its first iteration on chromosome 11 and in top-to-tail orientation. 
Unlike African 1, the duplication resulted from inter-chromosomal recombination 
resulting in two different genotypes in the duplicated region.  
 One breakpoint of the rearrangement was in a LINE repeat and the other within unique 
sequence. The breakpoints had a 2 bp microhomology. The duplication did not include 
the beta globin LCR, meaning that the two copies of the globin gene cluster present on 
the duplicated allele shared a single LCR. We were unable to determine the order of 
the two duplicated regions on the chromosome based on the NGS data, however, the 
HbS fractions reported in the father (HbS 41.3%) and the proband (no detectable HbA) 
implied that the HbS gene was transcribed at a higher level than the HbA gene. We 
suspect from this that the HbS gene is in the copy of the duplicated region closest to 
the LCR, and is thus preferentially expressed.  
Novel Deletion of the HS40 Regulatory Region of the Alpha 
Globin Gene Cluster (MiSeq Sample 33) 
A novel 73 Kb deletion on chromosome 16 was identified which removed the HS40 
locus that controls alpha globin gene expression. This variant conferred an alpha 
thalassaemia phenotype similar to an alpha zero thalassaemia variant (both HBA 
genes deleted) despite leaving the entire alpha globin gene cluster intact. Several 
similar deletions removing this region and resulting in alpha thalassaemia have been 
reported previously (Hatton, Wilkie et al. 1990, Viprakasit, Kidd et al. 2003, Viprakasit, 
Harteveld et al. 2006). Like these deletions, the breakpoints of this rearrangement were 
both situated in highly homologous Alu repeat sequences. This demonstrates the 
importance of including regions other than the globin genes themselves in assays for 
diagnosing haemoglobinopathies. This sample had previously been analysed on a 
targeted CGH array but the results from the array did not show a clear breakpoint at 
both ends making it difficult to accurately design GAP PCR primers. This may be due 
to the GC content and repetitive nature of the genome at the tip of chromosome 16.   
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The Molecular Basis of Structural Rearrangements 
Causing Haemoglobinopathies 
A wide range of variants causing haemoglobinopathies have been identified (Gibbons, 
Wada et al. 2008, Lugtenberg, de Brouwer et al. 2009). These can range from a single 
base change to the rearrangement of kilobases or even megabases of DNA. This is in 
contrast to the majority of inherited diseases, which are caused by a single variant in 
the majority of cases. The range of variants that can cause thalassaemia presents a 
challenge to diagnosis.  
Understanding the molecular basis of these rearrangements could be beneficial to 
diagnosis by informing break point characterisation. Many rearrangements occur within 
repetitive regions that cannot be effectively selected for by target enrichment for NGS. 
Identifying features of these sequences that contribute to rearrangements could help in 
cases where one or more breakpoints are within repetitive regions and no breakpoint 
spanning sequences are captured by the NGS design. By understanding what types of 
sequences are involved may allow a simplified approach to the design of Gap-PCR 
assays allowing confirmation and to-the-base characterisation of the rearrangement.  
In the case of the novel duplication identified in MiSeq Sample 34, both breakpoints of 
the rearrangement were situated in unmapped repeat regions. Based on findings from 
two other duplications characterised in this study (African 1: MiSeq Sample 7 and 
HiSeq Samples 1/8), we hypothesised that the duplicated sequence would be adjacent 
to the original sequence, and in head-to-tail orientation. We designed primers 
according to this hypothesis, and were successfully able to produce a Gap-PCR 
product and achieve to-the-base characterisation of this rearrangement. The English V 
inversion-deletion initially evaded characterisation in part because the inversion 
breakpoint was within a palindromic sequence. The palindrome rendered the bait that 
covered this position non-functional, which made coverage at this position appear 
balanced in relation to the negative control (when in reality coverage in both samples 
was zero), confounding diagnosis. Identifying such features within the target region 
during bait design could allow improved positioning of baits that cover this region to 
improve their performance and reduce the risk of false-negative results in the read 
coverage data. In the second design no baits were tiled in this region. 
We found that many rearrangements affecting the alpha globin gene locus began 
and/or ended in SINE repeat or segmental duplication regions. These can result in a 
breakpoint that is indistinguishable from the normal sequence expected at either 
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location. Therefore, we recommend that when designing PCR primers for 
rearrangements based on suspected but unknown breakpoint locations, nearby 
segmental duplication or SINE repeat regions should be treated as likely breakpoint 
positions and included in the target region for the rearrangement breakpoint.   
Better understanding of how these rearrangements occur is scientifically interesting: It 
could help illuminate what mechanisms cause mutation and what elements in the DNA 
sequence contribute to its propensity to mutate. In particular, it could identify features 
of the regions in the alpha and beta globin gene loci that make them more susceptible 
to mutation, or whether the variety of variants we see at these locations are 
predominantly due to other factors, such as selection pressures (Lam and Jeffreys 
2006).  
Previous studies had investigated small numbers of variants causing thalassaemia at 
both the alpha and beta globin gene loci (Vanin, Henthom et al. 1983, Nicholls, Fischel-
Ghodsian et al. 1987). These studies had shown a relationship between 
rearrangements of the alpha globin gene cluster and both segmental duplications and 
SINE repeats (an association also reported in numerous other diseases caused by 
duplications (Potocki, Chen et al. 2000)). Rearrangements at the beta globin gene 
cluster had been noted to show some association with inverted repeats. In both 
studies, only a small number of fully characterised rearrangements were available for 
analysis. Since then, many rearrangements causing thalassaemia have been identified 
with to-the-base accuracy and recorded online in the HbVar database. We compared 
the locations of known breakpoints at the globin gene clusters to databases of DNA 
features that have been implicated in causing structural rearrangements. The dataset 
available for this study was still small and was limited by sampling bias. Principally, 
rearrangements in which breakpoints have been successfully identified may represent 
an inherently different subgroup of rearrangements at from those that have not been 
characterised. A common underlying cause of the uncharacterised rearrangements 
may also make them difficult to sequence. Furthermore, several of the datasets of DNA 
features may not be comprehensive at this point. As the catalogue of fully 
characterised variants causing thalassaemia grows with the expansion of DNA 
screening, we hope that further studies will examine their relationship with more 
comprehensive lists of DNA features. Nonetheless, we used GAT, a tool for comparing 
the overlap of genomic co-ordinates to identify associations between our small variant 
dataset and DNA features and identified some significant trends. Variants on 
chromosome 16 were significantly associated with SINE repeats (P<0.001) and 
segmental duplications (P<0.001). A mild association with proximity to LINE repeats 
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was also uncovered at this locus. Variants on chromosome 11 showed a mild 
association with mirror repeats and proximity to cut-and-paste repeats. Although many 
rearrangement breakpoints on chromosome 11 coincided with inverted repeats as 
previously suggested, this relationship was not statistically significant and may result 
from the high frequency of these features on chromosome 11.  
Examination of the break points of rearrangements sequenced in this study revealed 
that on chromosome 11 most variants showed either novel insertions (4/6) or 
microhomology (2/6) at the breakpoint. These features are associated with two related 
DNA DSB repair mechanisms – NHEJ (non-homologous end joining) with insertions 
and MMEJ (microhomology-mediated end joining) with microhomology. This is in line 
with the findings of the previous study of rearrangements on chromosome 11 (Vanin, 
Henthom et al. 1983). Rearrangements on chromosome 16 primarily brought together 
highly homologous SINE or segmental duplication regions. This is associated with the 
NAHR (non-allelic homologous recombination) DSB repair mechanism, and also 
echoes previous study of rearrangements at this locus (Nicholls, Fischel-Ghodsian et 
al. 1987, Emmanuel 2001, Liu, Lacaria et al. 2011). There is no clear rule governing all 
rearrangements seen at either of the globin gene clusters. Multiple mechanisms clearly 
contribute to rearrangements at both locations, but both loci also appear to be 
governed by different factors. This may be due to either the features of the DNA 
sequence at these locations, or perhaps with the 3D conformation of the 
chromosomes.  
Interestingly, the two duplications on chromosome 11 appear to have been formed by 
different processes, one by intra-chromosomal and the other inter-chromosomal 
recombination. Inter-chromosomal recombination is believed to be responsible for one 
duplication because only two haplotypes are detectable in the sample, and it is unlikely 
that two different chromosomes would have identical sequence over the entire 80 Kb 
duplicated region.  
The polymorphic feature of the globin genes has been noted for some time. 
Homologous recombination occurs at a high rate on chromosome 11, and de novo 
non-allelic homologous recombination events, such as those causing the (α-3.7/) 
deletion, occur frequently on chromosome 16. It has been suggested that the globin 
loci are exposed to multiple gene conversion events that may be exchanging small 
(<100 bp) sections of genetic material during meiosis and that the genes and their 
protein products tolerate this well. Hence, there are over 800 globin gene variants and 
some of the more common variants are on multiple backgrounds (Law, Luo et al. 2006, 
336 
 
Borg, Georgitsi et al. 2009). The sickle variant is believed to have arisen on 5 separate 
occasions, according to founder theory, due to the haplotypes with which it is 
associated.   
Applications of This Work and Future Directions 
This work has shown that next generation sequencing can capture the entire range of 
variants associated with haemoglobinopathies to at least the accuracy of the 
techniques that are currently in use. For rare pathogenic variants, this can be delivered 
with higher speed, lower cost per patient and fewer man-hours of work. The technique 
also has the added advantage that it can detect balanced rearrangements. While the 
technology is capable of capturing these rearrangements, it can be let down by the 
analysis software. For NGS-led diagnosis to be delivered with the accuracy necessary 
for diagnostic assays, it is imperative that the correct analysis software is used. As a 
result of the findings of this study, a red cell diagnosis panel has been developed in the 
Department of Molecular Pathology at King’s College Hospital to be used for the rapid 
diagnosis of multiple haematological disorders affecting erythrocytes. This panel will be 
used to quickly and efficiently identify the majority of variants in a number of diseases 
that the laboratory is tasked with diagnosing. The bait library developed during the 
study reported here will be used to characterise novel structural variants that are 
identified by this panel, which can then be resolved more rapidly than via the previous 
diagnostic workflow, and with the potential to definitively determine the break points. 
The techniques used in this study could be applied to the diagnosis of other diseases 
with the same accuracy and constraints.  
Efforts are currently being made to introduce NGS to multiple domains within the NHS, 
most notably through the 100k Genomics England project. The 100k project intends to 
sequence 100,000 genomes from around 70,000 NHS patients with cancer or rare 
diseases and their family members. This project intends to pave the way towards 
personalised medicine by identifying new or improved treatment strategies for these 
diseases which could become available for the wider population in the future as 
screening becomes more commonplace. Developing new treatments based on data 
generated by the 100k genome project is likely to be a slow process: a new drug takes 
many years to progress from target identification to approval for clinical use. This raises 
the issue that many of the individuals who initially provide the data for the 100k 
genome project are unlikely to themselves benefit from its findings. In some cases, 
however, the project has already permitted better treatment of current subjects, by 
achieving a more accurate diagnosis of rare or poorly characterised conditions. 
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Introducing genomics as an aspect of routine care will require a huge amount of work 
on the part of the NHS in terms of training, cost and logistics. New ethical guidelines 
and data protection policies may need to be implemented to ensure public support of 
the initiative. Many individual laboratories are also introducing disease targeted gene 
panels or exome sequencing, replacing the low-throughput high-cost sanger 
sequencing that was previously the gold standard in many of them. In the UK many 
laboratories are participating in the NHS Laboratory England Redesign scheme to help 
prepare laboratories to provide genomic services. New tests are being commissioned 
by the NHS for many diseases. In the USA the ACMG (American College of Medical 
Geneticists) has issued a list of recommendations that should be considered before 
patients are submitted for genetic testing. A major aim of these guidelines is to limit 
testing when it is unnecessary, rather than the practise being given an inaccurate ‘cure-
all’ reputation. They also recommend limitations to discourage ‘hypothesis free testing’ 
which is likely to confound results without proper controls being in place. Concerns also 
include the use of markers that have not been fully validated to inform patient care, 
highlighting the particular examples of APOE and MTHFR (in Alzheimer’s Disease and 
hereditary thrombophilia, respectively), the clinical significance of both of which are not 
yet fully understood.  
Future work should be performed to evaluate bioinformatic strategies that allow 
accurate diagnosis and reporting of indels, SNPs and structural variants automatically. 
A bespoke pipeline for this is currently being developed in the Molecular Pathology 
laboratory at King’s College Hospital. Variants affecting the regions on chromosome 2 
and 6 included in this assay should be recorded and compared with clinical data from 
patients wherever possible in order to discern the roles of these regions in modifying 
haemoglobinopathy disease phenotype. Attempts should be made to characterise any 
novel variants identified by this assay in the future with to-the-base accuracy. 
Successfully characterised variants should be submitted to HbVar, where this data 
could lead to a better understanding of how rearrangements at the alpha and beta 
globin gene loci are formed. Furthermore, creating a comprehensive library of 
breakpoint sequences for known thalassaemia variants could speed diagnosis of such 
variants in the future. As demonstrated here, it is possible to deliver a diagnosis by 
querying FASTA data for a list of known unique breakpoint sequences. This could be 
incorporated as a preliminary step in future analysis pipelines that could speedily 
identify previously recognised rearrangements.  
Applications of this assay that were not investigated in this study include the detection 
of translocations, genetic mosaicism, and non-invasive prenatal diagnosis. 
338 
 
Translocations are balanced rearrangements that excise DNA from one chromosome 
and move it to another location. Translocations affecting the alpha globin genes have 
been reported, but are extremely rare. These incidents have been phenotypically silent, 
as the enhancer regions for the genes were also translocated, meaning there was no 
effect on the expression of the alpha globin genes (Ledbetter 1992). Such events still 
have potentially serious consequences as the balanced nature of these 
rearrangements could mask the potential of carriers to pass on alpha-zero 
chromosomes and with them the risk of Bart’s Hydrops Fetalis, if the partner has alpha-
zero  thalassaemia. The current diagnostic standard is unable to detect translocations, 
but in theory the assay developed in this study would have this capability: the 
chromosome from which the sequence had been removed would show opposite 
direction reads spanning the excised region, and the transplanted sequence would also 
be captured on the recipient chromosome, with opposite direction reads occurring at 
the points where chromosome 16 sequence (still captured by the bait library) gave way 
to the sequence of the original chromosome.   
Genetic mosaicism and acquired alpha thalassaemia are known but relatively rare 
phenomena (Harteveld, Refaldi et al. 2013). Acquired alpha thalassaemia is 
occasionally reported in MDS sufferers (Steensma, Gibbons et al. 2005)1.  NGS has 
been widely reported to amplify all the input DNA from a sample at an equal rate, 
meaning that the final allele frequencies in analysis are representative of the sample 
makeup (as seen in this study where the frequencies of heterozygous SNPs in 
duplicated regions have allele frequencies of 30% or 70%). Therefore, subpopulations 
of the sequenced DNA with a different genotype to the sample consensus that are 
indicative of mosaicism can be identified by this method.  
NGS has great potential in non-invasive prenatal diagnosis of haemoglobinopathies as 
it is capable of identifying the small fraction of foetal DNA that circulates in the maternal 
blood stream during pregnancy (Lo, Hjelm et al. 1998, Lo, Tein et al. 1998). This 
technique is still in early development, but could one day be applied to 
haemoglobinopathies. An additional boon to prenatal diagnosis offered by NGS is that 
it can be used to identify mosaic abnormalities that can occur in the foetus during 
pregnancy without the need for re-sampling via CVS or amniocentesis, which is 
                                               
1
 The majority of cases of acquired alpha thalassaemia in MDS are X-linked and associated with 
acquired clonal mutations inactivating the ATRX gene that regulates alpha globin gene 
expression. The current bait capture library Bait Capture Library 2 does not include this region. 




necessary using the currently used diagnostic techniques (Mendilcioglu, Yakut et al. 
2011). We are still exploring the diagnostic potential of NGS but it is clear it will 
transform how healthcare is delivered. For haemoglobinopathies and many other 
conditions it may be logical to sequence first and then follow up with phenotypic 
assessments, reversing the current diagnostic paradigm. How this technology is 
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SureSelect - How it Works 
 
http://www.genomics.agilent.com/article.jsp?pageId=3083  
eArray https://earray.chem.agilent.com/  
SureDesign https://earray.chem.agilent.com/suredesign/  
SureSelect Sample 





dbSNP http://www.ncbi.nlm.nih.gov/SNP/index.html  
dbVar http://www.ncbi.nlm.nih.gov/dbvar 
deORI http://cerevisiae.oridb.org/ 
Segmental Duplication Database 
http://humanparalogy.gs.washington.edu/SDD/) 




Non-B DNA Motif Database https://nonb-abcc.ncifcrf.gov/apps/site/default 
Primer3Plus http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/ 
UCSC Bioinformatics Site https://genome.ucsc.edu/ 
Clustal Omega http://www.ebi.ac.uk/Tools/msa/clustalo/ 
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Appendix 2: List of Solutions 
1. Lysis Buffer (for 1L)  
o In a 1L autoclaved Duran, combine: 
 10 ml 10 mM Tris HCL 
 3.3 ml 10 mM NaCl 
 20 ml 10 mM EDTA 
 967 ml pure water 
o Mix until dissolved 
2. Proteinase K  
o In a 1.5 ml microcentrifuge tube, combine: 
 10 ml molecular grade water 
 500 mg stock of proteinase K  
o Shake to mix and incubate at room temperature for 10 minutes (Unused 
Proteinase K was frozen in aliquots) 
3. 5x ANE Buffer  
o In a falcon tube, combine: 
 0.05 M NaOAc.3H2O pH6 
 0.5 M NaCL 
 0.005 M EDTA 
 2.5 % SDS 
o Mix until dissolved 
4. 20x SSC Buffer (for 500 ml) 
o In a 500 ml autoclaved Duran, combine: 
 87.65g NaCL 
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 44.1g Na Nitrate 
 400 ml pure water 
o Place on stirrer until all powder is dissolved  
o Measure pH and adjust to pH7 using 15% HCL as necessary 
o Autoclave 
5. 0.5% NP40 (for 500 ml) 
o In a 500 ml autoclaved Duran, combine: 
 497.5 ml pure water 
 2.5 ml Nonidet P40 
o Stir until dissolved 
o Autoclave 
6. Lysis buffer mix  
o In a 1.5 ml microcentrifuge tube, combine: 
 1.5 ml Lysis Buffer 
 50 µL Proteinase K 
 80 µL 10% SDS 
o Invert tube several times to mix 
7. 3M NaCl (for 1L) 
o In a 1L autoclaved Duran, combine: 
 175.2g NaCl 
 800ml water 
o Stir until dissolved 
o Autoclave 
8. 1x TE (for 1L) 
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o In a 1L autoclaved Duran, combine: 
 10 ml Tris-Cl pH 7.6 
 2 ml EDTA pH 8 
 988 ml pure water 
o Stir until dissolved 
o Autoclave 
9. 1M Tris-HCL pH 7.6 (for 1L) 
o In a 1L autoclaved Duran, combine: 
 121.1 g Tris base 
 800 ml pure water 
o Stir until dissolved 
o Autoclave 
10. 0.5M EDTA pH 8 (for 1L) 
o In a 1L autoclaved Duran, combine: 
 186.1 g disodium EDTA 2H2O 
 20 g NaOH pellets to bring pH to 8 (and 15% HCL to reduce pH to 8 if it 
became too high) 
 800ml pure water 
o Stir until dissolved 
o Autoclave 
11. 70% Ethanol (for 1L) 
o In a 1L autoclaved Duran, combine: 
 300 ml pure water 
 700 ml absolute ethanol 
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o Shake vigorously 
o Aliquot into 50 ml falcon tubes 
o Store at -20 ◦C 
12. 1x TE (for 1L) 
o In a 1L autoclaved Duran, combine: 
  
13. 0.5M EDTA pH 8 (for 1L) 
o In a 1L autoclaved Duran, combine: 
 186.1 g disodium EDTA 2H2O 
 20 g NaOH pellets to bring pH to 8 (and 15% HCL to reduce pH to 8 if it 
became too high) 
 800ml pure water 
o Stir until dissolved 
o Autoclave 
14. End Repair Mix for one reaction:  
o Keep reagents and mix on ice until use 
o In a 1.5 ml microcentrifuge tube, combine: 
 1.6 µL dNTP mix 
 1 µL T4 DNA polymerase 
 2 µL Klenow Polymerase 
 .2 µL T4 Polynucleotide Kinase 
 35.2 µL Nuclease-free water 
o Vortex briefly to mix 
15. Adenylation Mix for one reaction:  
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o In a 1.5 ml microcentrifuge tube, combine: 
 5 µL 10 x Klenow Polymerase Buffer 
 1 µL dATP 
 3 µL Exo(-) Klenow 
 11 µL Nuclease-free water 
16. Adapter Ligation Mix for one reaction: 
o In a 1.5 ml microcentrifuge tube, combine: 
 10 µL 5x T4 Ligase Buffer 
 10 µL SureSelect Adaptor Oligo Mix 
 1.5 µL T4 DNA Ligase 
 15.5 µL Nuclease-Free water 
o Vortex briefly to mix 
17. Pre-Hybridization PCR mix for one sample:  
o Keep reagents and mix on ice until use 
o In a 1.5 ml microcentrifuge tube, combine: 
 1.25 µL SureSelect Primer 
 1.25 µL SureSelect ILM Indexing Pre Capture PCR Reverse Primer 
 10 µL 5x Herculase II Rxn Buffer 
 0.5 µL 100 mM dNTP Mix 
 1 µL Herculase II Fusion DNA Polymerase 
o Up to >21 µL Nuclease-free water to make a final volume of 50 µL after addition 
of 250ng DNA sample) 
o Vortex briefly to mix 
NB: Herculase reagents and 100mM dNTPs are from a separate kit. No other 
dNTPs must be used with the Herculase reagents 
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18. Hybridization Buffer Mix for one reaction:  
o Keep reagents and mix on ice until use 
o In a 1.5 ml microcentrifuge tube, combine: 
 25 µL SureSelect Hyb #1 
 1 µL SureSelect Hyb #2 
 10 µL SureSelect Hyb #3 
 13 µL SureSelect Hyb #4 
o Vortex briefly to mix 
19. SureSelect Capture Library Mix:  
o Keep reagents and mix on ice until use 
o Different mixes are made for libraries greater than or equal to, or less than, 3Mb 
in size. Library design 1 was > than 3Mb and library design 2 was <3Mb. The 
appropriate mixes were made for both.  
o For a <3Mb Library, in a 1.5 ml microcentrifuge tube, combine: 
 2 µL of capture library 
 5 µL of RNase block dilution (10% block, 90% nuclease-free water) 
o For a ≥ 3Mb Library, in a 1.5 ml microcentrifuge tube, combine: 
 5 µL capture library 
  2 µL RNase block dilution (25% RNase block 75% Nuclease-free 
water).   
o Vortex briefly to mix 
20. SureSelect Block Mix:  
o Keep reagents and mix on ice until use 
o In a 1.5 ml microcentrifuge tube, combine: 
 2.5 µL SureSelect Indexing Block #1 
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 2.5 µL SureSelect Indexing Block #2 
 0.6 µL SureSelect Indexing Block #3  
o Vortex briefly to mix 
21. Indexing PCR mix:  
o Keep reagents and mix on ice until use 
o In a 1.5 ml microcentrifuge tube, combine: 
 10 µL 5x Herculase II Rxn Buffer 
 0.5 µL 100 mM dNTP mix 
 1 µL Herculase II Fusion DNA Polymerase 
 1 µL SureSelect ILM Indexing Post Capture Forward PCR Primer 
 22.5 µL Nuclease-free water 
o Vortex briefly to mix 
22. Wash Solution for HiSeq Instrument 
o In a 5L carboy, combine: 
 750 ml laboratory grade water 
 250 ml 10% tween 
 1.5 ml ProClin 300 
23. Dye-terminator sequencing PCR mix (for one reaction): 
o In a 1.5 ml microcentrifuge tube, combine: 
 0.5 µL Dye-terminator ready mix 
 0.5 µL Dye-terminator buffer 
 3 µL nuclease free water 
 4 µL template DNA for sequencing (approx 100ng/µL) 
 1 µL 5pM PCR primer  
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o Pulse vortex to mix 
o Centrifuge for one minute at 280 x g 
24. Generic Gap PCR reaction mix (for one reaction): 
o In a 1.5 ml microcentrifuge tube, combine: 
 10 µL Q Multiplex Mix (Qiagen) 
 1 µL 10M forward primer 
 1 µL 10M reverse primer 
 1-8 µL Template DNA (50-500 ng DNA) 
 Nuclease free water to bring total reaction volume to 20 µL 
o Pulse vortex to mix 
o Centrifuge for one minute at 280 x g 
25. Generic long amplicon Gap PCR reaction mix (for one reaction) 
o In a 1.5 ml microcentrifuge tube, combine: 
 LongAmp Taq Reaction Buffer (NEB, USA) 
 1 µL 10mM forward/ reverse primer 
 0.75 µL dNTPs 
 1-2 µL 30-200ng/ µL template DNA 
 nuclease-free water to make a total volume of 25 µL 
o Pulse vortex to mix 




Appendix 3: Cluster Generation and Sequencing 
on the HiSeq 2000 
Cluster generation and sequencing on the HiSeq 2000 was performed off site at the 
Department of Haematological Medicine, Rayne Institute, KCL by Dr Alex Smith. One 
12 Sample Run was performed. Cluster generation was performed using reagents from 
the Illumina HiSeq PE Cluster Kit (v2) (Illumina part # PE-401-4001). Sequencing was 
performed using the HiSeq PE Sequencing Kit (v2) (Illumina # FC401-4001).Tris-Cl 
and NaOH were obtained from generic laboratory suppliers. The steps below are in 
accordance with the current version of the protocols supplied by Illumina.   
Cluster Generation 
Preparing the DNA:  
Index-tagged DNA samples were pooled at 2nM. Reagent HT1 from the HiSeq 
Sequencing Kit was thawed and stored on ice until use.  
The pooled library concentration was normalised to 2 nM using Tris-HCL 10 mM (pH 
8.5) with 0.1% Tween. 10 µL of the pooled library was combined with 10 µL freshly 
made 0.1 N NaOH. The mix was briefly vortexed and centrifuged at 280 x g for one 
minute. The mix was incubated at room temperature for 5 minutes. 980 µL of chilled 
HT1 reagent was added to the mix which was then placed on ice. The library was 
diluted to 12 pM by adding 600 µL of the library to 400 µL HT1.  
Preparing the PhiX control:  
A PhiX control was prepared. Two µL 10 nM PhiX library was combined with 8 µL 10 
mM Tris-Cl (pH 8.5) with 0.1% Tween 20. The mix was briefly centrifuged and 10 µL of 
0.1 N NaOH was added to the tube. The tube was vortexed briefly, spun for one minute 
at 280 x g and incubated for 5 minutes at room temperature.  980 µL of HT1 were 
added to the Phi-X control. The Phi-X was diluted to 12 pM by combining 600 µL of the 
diluted Phi-X with 400 µL HT1 and kept on ice. 
Spiking the DNA pool with Phi-X:  
Ten µL of the Phi-X Control was added to 990 µL of the DNA library and mixed by 
pipetting.  
Preparing clustering reagents:  
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The cBot reagent plate was thawed in a room temperature water bath containing 
deionised water. Once thawed, the plate was inverted 5 times to mix, vortexed for 10 
seconds and then tapped firmly on a hard surface to collect all reagent droplets at the 
bottoms of the wells. The tubes were inspected for a secure seal and absence of air 
bubbles.  
Clustering on the cBot:  
The cBot wash reservoir was filled with 12 ml deionized water, closed and set to 
“wash” on the cBot software interface. Once the wash was complete, the reservoir was 
dried with lint free tissue.  
The reagent plate was placed in the cBot and foil was removed from the wells in row 10 
of the plate. The flow cell clamp was lifted and the adapter plate was washed with 
deionized water, and then wiped dry with lint free tissue. The flow cell was removed 
from storage using plastic forceps, rinsed using deionized water and dried with lint free 
tissue. The flow cell was then positioned on the thermal stage with the flow cell port 
holes facing upwards. The manifold was inspected to ensure no parts had been 
damaged and positioned over the flow cell, with the guide pins aligned on the thermal 
stage. The flow cell clamp was closed. The outlet manifold was connected to the wash 
reservoir and snapped shut. The run was initiated on the cBot screen and a pre-run 
check was performed by the machine.  
Upon completion of the run, “Unload” was selected on the cBot screen. The manifold 
and wash reservoir were disconnected from one another and the flow cell and reagent 
plate were retrieved. The wash reservoir was then filled with 12ml deionized water and 
“Wash” was selected on the cBot.   
 
Sequencing on the HiSeq 2000 
Preparing Reagents for Sequencing Read 1: 
Reagents from the SBS reagent kit were removed from cold storage and thawed. The 
SRE and CMR reagents were thawed in a room temperature waterbath for one hour. 
Each reagent was inverted five times to mix and then placed on ice until use. Reagent 
LFN36 was thawed in a beaker containing room temperature deionized water for 20 
minutes and placed on ice until use.  
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Preparing ICB: ICB mix was prepared using reagents from the SBS reagent kit: One 
tube of LFN36 was added to one bottle of ICB-50. One tube of EDP-50 was then added 
to this mix. The bottle was then gently mixed several times by inversion, and placed on 
ice.  
Reagents HP3, HT2 and HP8 were removed from cold storage and thawed in a beaker 
filled with room temperature deionized water for 20 minutes until thawed completely. 
Reagent HT2 was then inverted five times to mix and centrifuged at 280 x g for one 
minute. HP3 was inverted five times to mix and then pulse centrifuged. 325 µL PW1 
was transferred into a 15 ml Sarstedt conical tube. 175 µL of HP3 was added to the 
tube, which was then inverted five times to mix, centrifuged at 280 x g for one minute 
and then set aside at room temperature. Reagent HP8 was inverted five times to mix, 
centrifuged at 280 x g for one minute and then set aside at room temperature.  
Run parameters were then entered onto the Instrument. The appropriate storage route 
was selected, the type and ID of the flow cell were input and the experiment was 
named. On the Advanced screen, “Confirm First Base” and “Align to PhiX” were 
selected. One the Recipe screen, “Single Index”, “96 cycles” and the “Paired end 
cluster kit” settings were selected.  
The ID numbers of the reagents were scanned and “prime reagents” was selected. 
The reagent compartment of the HiSeq was then opened, sippers were removed from 
the reagent rack and the  rack was retrieved.  The SBS reagent mix was fitted with a 
funnel cap. Reagents directly from the kit, and reagent mixes described above were 
placed in the correct positions on the reagent rack. 25 ml of PW1 was added to the 
bottle in reagent position 2. The reagent rack replaced and the sippers were 
repositioned. Indexing reagents were loaded into the indexing reagents rack in the 
same manner. Any unused rack positions were filled with 15 ml conical tubes 
containing 10 ml laboratory grade water and the rack was replaced.  
The flow cell holder was cleaned with a lint free tissue and a priming (used) flow cell 
was washed and placed inside. The vacuum was engaged  and the flow cell lever was 
moved to position one. After five seconds, the flow cell lever was slowly moved to 
position two. A green light indicates that the flow cell is ready for use. The “Vacuum 
engaged” checkbox was checked.  
Proper flow was then confirmed: “Solution 2” was selected from the drop down list on 
the HiSeq 2000 prompt screen. “Pump” was selected and the flow cell was inspected 
for bubbles or leaks. If no problems were found, position tubing and start prime was 
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initiated: waste tubing was placed in empty 15 ml tubes and placed in the waste 
container. “Start prime” was then selected from the on screen prompt. Once the step 
was complete, the volume of waste collected in each tube was checked to be > 1.75 
mls.  
The flow cell lever was returned to position 0 and disengaged from the vacuum. The 
used priming flow cell was removed from the flow cell holder, which was then cleaned 
with a lint free tissue. The run flow cell was inserted into the flow cell holder. The flow 
cell lever was slowly moved to position 1, and then to position 2. A green light indicates 
that the manifold are in position. Flow was confirmed as before, and “vacuum 
engaged” and “door closed” were selected on the instrument screen. The sequencing 
run was initiated by selecting “start”.  
Preparing Reagents for Sequencing Read 2 
Thaw reagents LMX2, BMX, AMX2, APM2, AT2, HP3, HT2, HP7 and RMR from the 
SBS kit in a beaker filled with room temperature deionized water for 20 minutes. 
Reagents RMR, LMX2, BMX and AMX2 were placed on ice. Reagents LMX2, BMC 
and AMX2 were inverted five times and centrifuged at 280 x g for one minute, and then 
set aside on ice. AMP2, AT2, HP3, HT2 and HP7 reagents were inverted five times to 
mix, centrifuged at 280 x g for one minute and set aside at room temperature.  
Reagent HP3 was inverted five times to mix and pulse centrifuged. 2.85 ml of PW1 was 
added to a 15 ml Sarstedt conical tube followed by 150 µL HP3. The tube was inverted 
five times to mix, centrifuged at 280 x g for one minute and set aside at room 
temperature.   
Reagent RMR was inverted five times to mix, centrifuge at 280 x g for one minute and 
set aside on ice.  
Fresh ICB was prepared as described for Read 1.  
Once Read 1 and index reading had completed, The sippers were removed from the 
reagent rack. The reagent tubes were placed at their labelled positions with the lids 
removed. The reagent compartment was replaced and the sippers lowered into the 
sippers into the reagent tubes.  
Select “Next” on the instrument to continue the run.  
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Washing the Instrument 
Five litres of Maintenance Wash Solution was prepared: 250 ml 10% tween was made 
(See Appendix: List of Reagents). In a 5 L carboy, combine (adding water first): 750 mL 
laboratory grade water, 250 ml 10% tween, 1.5 ml ProClin 300. Place on a stir plate 
until mixed.  
 “Wash | Maintenance” was selected on the instrument. Select “Yes” to wash PE 
reagent positions. Fill 8 SBS bottles with 250 ml maintenance wash solution and 10 PE 
tubes with 12 mls PE wash solution. Load bottles and tubes into the reagent racks in 
their assigned positions. Check the “Wash solution loaded” and “template loading 
station closed” checkboxes on the screen and select “Next”.  
Remove the flow cell, replace the front and rear gaskets and then reload the same flow 
cell. Check “Vacuum engaged” and select “Next”.  
Perform a fluids check as described above for Read 1. 
Remove the eight waste tubes from the waste container and bundle the tubes with 
parafilm to direct them into a single 250 ml bottle. Select “Next” to start the wash. When 
the wash is complete, select “Return to start” and unwrap the waste container tubes 




Appendix 4: Phenol-Chloroform DNA Purification 
The following procedure was performed by Mrs Helen Rooks, Department of Molecular 
Haematology, King’s College London.  
DNA samples obtained from the Molecular Haematology group at King’s College 
London were extracted using the phenol chloroform method.   
The following  solutions (compositions of which are listed in Appendix 1: List of 
Solutions) were prepared in advance:  Lysis Buffer, Proteinase K, 5x ANE Buffer, 20x 
SSC Buffer, 0.5% NP40, 3M NaCl, 1x TE, 1M Tris-HCL, 0.5M EDTA pH8, 70% 
Ethanol. 
3-10 ml of whole blood was equilibrated to room temperature in a 15 ml Falcon tube by 
leaving them to stand for 30 minutes on the bench. The Falcon tubes were centrifuged 
briefly to remove liquid from the lid of tubes before making the volume up to 10 ml with 
1x SSC and centrifugation (make model) at 3000 rpm for 10 minutes at 4°C. The top 
layer of blood was aspirated and discarded, leaving a pellet remaining in the bottom of 
the Falcon tube. 2 ml 0.5% NP40 was added to the tube. The pellet was broken up with 
a pastette and vortex briefly. The Falcon tube was centrifuged at 2000 rpm (930 x g)for 
5 minutes at 4°C. The supernatant was poured away carefully, so as not to dislodge 
the pellet. Lysis buffer mix was added to the Falcon tube, vortexed briefly, and placed 
in a 37°C water bath to incubate overnight (16 hours). Lysis was complete when the 
pellet had disappeared and the liquid was an amber transparent colour.  
Following the incubation, the Falcon tube was centrifuged briefly prior to opening.  5x 
ANE Buffer was equilibrated to 37°C in the water bath and 0.2x lysis volume of 5x ANE 
was added to the sample, followed by a 1:1 volume of phenol. The Falcon tube was 
inverted to mix and then centrifuged at  2110 x g for 10 minutes at room temperature. 
The aqueous, DNA containing, phase lay on top and was carefully transferred to a new 
Falcon tube with a pastette. The total volume of the aqueous phase was measured and 
0.5x that volume of phenol and of chloroform was added to the sample. The Falcon 
tube was inverted to mix and centrifuged at 3000 rpm for 10 minutes at room 
temperature. The aqueous DNA was transferred into a new 15 ml Falcon tube. 10 % of 
the total volume of the tube of 3 M NaCl was added. The mixture was made up to 11 ml 
with ice cold absolute ethanol (100 %) and inverted to mix. The mix was incubated at -
20°C for a minimum of 30 minutes to aid DNA precipitation.  
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The Falcon tube was centrifuged at 2110 x g for 10 minutes at 4°C. The ethanol was 
carefully poured off the pellet and washed with 5 ml 70% ethanol and again centrifuged 
at 3000 rpm for 10 minutes at 4°C. The pellet was washed a further 2 times before 
removing all ethanol and placing the Falcon tube in the fume hood to completely dry 
the pellet. The pellet was re-suspended in 500 µL TE buffer and left overnight on a 
turning roller. After 12-24 hours the DNA was inspected for full re-suspension and even 
viscosity. 5 µL of sample was diluted in 45 µL molecular grade water. The diluted 
sample was vortexed and left at room temperature for one hour. The concentration of 




Appendix 5: Python Script for Identifying Known 
Rearrangements in FASTA Data 
#open user specified file 
file = input("enter file path (e.g. F:\Sequencing\File.FASTA)") 
 
# check for sickle 
Wildtype_sc_count = 0 
Sickle_count = 0 
lines = 0 
with open(file) as handler: 
    for string in handler: 
        if "AACGGCAGACTTCTCCACAGGAGTCAG" in string: 
            Sickle_count += 1 
        elif "AACGGCAGACTTCTCCTCAGGAGTCAG" in string: 
            Wildtype_sc_count += 1 
        else: 
            lines += 1 
             
if Wildtype_sc_count == 0: 
    print('no wildtype found, check alignment') 
else:            
    if Sickle_count >= 3 and Wildtype_sc_count >= 3: 
        print('Heterozygous for Sickle') 
    elif Sickle_count <=3 and Wildtype_sc_count >= 3: 
        print('Negative for Sickle') 
    elif Sickle_count >=3 and Wildtype_sc_count <= 3: 
        print('Homozygous for Sickle') 
    else: 
        print('neither sequence found') 
 
print('wt(sickle)', Wildtype_sc_count) 
print('Sickle', Sickle_count)  
print('lines searched', lines) 
 
#check for Asian Indian inversion deletion 
Wildtype_AI_count = 0 
AI_Indel_count = 0 
lines = 0 
with open(file) as handler: 
    for string in handler: 
        if 
"CAGAGGACTAACTGGGCTGAGACCAGTTGTCCAAAGTTGCGGGCCAGCACAC" in 
string: 
            AI_Indel_count += 1 
        elif 
"GGTGAATTCCTTGCCAAAGTTGCGGGCCAGCACACACACCAGCACATTGC" in 
string: 
            Wildtype_AI_count += 1 
        else: 
            lines += 1 
             
if Wildtype_AI_count == 0: 
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    print('no wildtype found, check alignment') 
else:            
    if AI_Indel_count >= 3 and Wildtype_AI_count >= 3: 
        print('Heterozygous for Asian Indian Inversion deletion') 
    elif AI_Indel_count <=3 and Wildtype_AI_count >= 3: 
        print('Negative for Asian Indian Inversion deletion') 
    elif AI_Indel_count >=3 and Wildtype_AI_count <= 3: 
        print('Homozygous for Asian Indian Inversion deletion') 
    else: 
        print('neither sequence found') 
 
print('wt (AI)', Wildtype_AI_count) 
print('Asian Indian Inversion deletion', AI_Indel_count)  
print('lines searched', lines) 
 
#check for english V inversion deletion 
Wildtype_EV_count = 0 
English_V_count = 0 
lines = 0 
with open(file) as handler: 
    for string in handler: 
        if "TAAAGATGAACCCATAGTGAGCTGAGATCCCCACTATATTCTTTGTTCCT" 
in string: 
            English_V_count += 1 
        elif 
"CAGAATCAAGCCTATGTTAACTTCCCTCAAAGCCTGAGATTTTGCTTTCCCATTAA
ATGCAGGTAGTTGTTCTTCTTGCAGC" in string: 
            Wildtype_EV_count += 1 
        else: 
            lines += 1 
             
if Wildtype_EV_count == 0: 
    print('no wildtype found, check alignment') 
else:            
    if English_V_count >= 3 and Wildtype_EV_count >= 3: 
        print('Heterozygous for English V') 
    elif English_V_count <=3 and Wildtype_EV_count >= 3: 
        print('Negative for English V') 
    elif English_V_count >=3 and Wildtype_EV_count <= 3: 
        print('Homozygous for English V') 
    else: 
        print('neither sequence found') 
 
print('wt(English V)', Wildtype_EV_count) 
print('englishV', English_V_count)  
print('lines searched', lines) 
 
#check for 619bp deletion 
Wildtype_619_count = 0 
count_619 = 0 
lines = 0 
with open(file) as handler: 
    for string in handler: 
        if "TCTACTTGAATCTCTACTTGTTA" in string: 
            count_619 += 1 
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        elif "CTTACATCAGTTACAATTTATAT" in string: 
            Wildtype_619_count += 1 
        else: 
            lines += 1 
             
if Wildtype_619_count == 0: 
    print('no wildtype found, check alignment') 
else:            
    if count_619 >= 3 and Wildtype_619_count >= 3: 
        print('Heterozygous for 619bp deletion') 
    elif count_619 <=3 and Wildtype_619_count >= 3: 
        print('Negative for 619bp deletion') 
    elif count_619 >=3 and Wildtype_619_count <= 3: 
        print('Homozygous for 619bp deletion') 
    else: 
        print('neither sequence found') 
print('wt(619)', Wildtype_619_count) 
print('619', count_619)  
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ABSTRACT: Genetic testing for hemoglobinopathies is re-
quired for prenatal diagnosis, understanding complex cases
where multiple pathogenic variants may be present or in-
vestigating cases of unexplained anemia. Characterization
of disease causing variants that range from single base
changes to large rearrangements may require several dif-
ferent labor-intensive methodologies. Multiplex ligation
probe amplification analysis is the current method used
to detect indels, but the technique does not characterize
the breakpoints or detect balanced translocations. Here,
we describe a next-generation sequencing (NGS) method
that is able to identify and characterize a novel rearrange-
ment of theHBB cluster responsible for εγ δβ thalassemia
in an English family. The structural variant involved a
59.0 kb inversion encompassing HBG2 exon 3, HBG1,
HBD, HBB, and OR51V1, juxtaposed by a deletion of
122.6 kb including 82 bp of the inverted sequence,HBG2
exon 1 and 2, HBE, and the β-locus control region. Iden-
tification of reads spanning the breakpoints provided to-
the-base resolution of the rearrangement, subsequently
confirmed by gap-PCR and Sanger sequence analysis. The
same rearrangement, termed Inv-Del English V εγ δβ tha-
lassemia (HbVar 2935), was identified in two other un-
related English individuals with a similar hematological
phenotype. Our NGS approach should be applicable as a
diagnostic tool for other disorders.
Hum Mutat 36:142–150, 2015. C© 2014 Wiley Periodicals, Inc.
KEY WORDS: hemoglobinopathy; hemoglobin; inversion–
deletion; εγ δβ thalassemia; NGS, palindrome
Introduction
Hemoglobinopathies are a diverse group of disorders caused by
genetic variants affecting the structure and abundance of the α-
like and β-like globin chains that form the subunits of hemoglobin
(Hb) [Forget and Bunn, 2013]. Non-synonymous changes result in
Additional Supporting Information may be found in the online version of this article.
∗Correspondence to: Swee Lay Thein, King’s College London, James Black
Centre, 125 Coldharbour Lane, London SE5 9NU, UK. E-mail: sl.thein@kcl.ac.uk,
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globin chains with altered amino-acid sequences and give rise to
Hb variants. Variants that lead to reduced synthesis of the globin
chains cause thalassemia, with α and β thalassemia being the most
common forms, characterized by a quantitative deficiency of the
α and β globin chains, respectively. The variants underlying both
α and β thalassemia are extremely heterogeneous ranging from
single base changes to large deletions, and rearrangements of their
respective gene clusters [Giardine et al., 2011; Higgs, 2013; Thein,
2013]. Some rare forms of both α and β thalassemia result from
deletions of their respective upstream regulatory elements, but leave
all of the downstream globin genes unaltered.
A phenotypic primary screen based on a complete blood count,
Hb electrophoresis for Hb fractionation and quantification of HbA2
and HbF, identifies a carrier for a thalassemia variant. DNA testing
is required for definitive analysis and is a prerequisite for identifying
genetic disease risk and prenatal diagnosis. Hb DNA diagnostics
follow a sequential process that can be time consuming when the
genetic variant is uncommon [Game et al., 2003; Rooks et al., 2005;
Rooks et al., 2012]. A case in point is the large deletions and rear-
rangements of the HBB and HBA cluster. In current routine prac-
tice, these are identified by multiplex ligation probe amplification
(MLPA) analysis of the suspected loci on chromosome 11 or 16 re-
spectively, after negative gene sequencing analysis [Harteveld et al.,
2005; Traeger-Synodinos and Harteveld, 2014]. Further character-
ization of the break-points involves refining the region of interest,
followed by gap-PCR of the specific break-points [Craig et al., 1994]
and sequence analysis of the break-point fragment. This intensive
workup can be hampered by the difficulty in designing gap-PCR
primers andobtaininga specificbreak-point fragment, leavingmany
cases still not completely characterized [Rooks et al., 2012; Shalev
et al., 2013].
Here, we present to-the-base resolution of a complex inver-
sion/deletion rearrangement of the HBB cluster, and use it as an
example of how analysis of a single next-generation sequencing
(NGS) dataset can detect all genetic variation in a targeted region of
the genome.
We designed a SureSelect bait capture panel (Agilent, Santa
Clara, CA) to cover both the α and β globin loci on chromosomes
16p and 11p, respectively, in two contiguous regions, and analyzed
the sequence data in NextGene (Softgenetics, State College, PA)
software. The software enabled us to identify small genetic variants
(1–3 bases) and by comparing coverage between controls and
patients, we were able to identify large deletions to within a single
bait-covered position of 120 bp. Using this technique, a εγ δβ
thalassemia rearrangement previously identified by CGH array,
qPCR, Southern blotting and MLPA, could be fully characterized.
C© 2014 WILEY PERIODICALS, INC.
The deletion of 122.6 kb was consistent with previous findings,
it also included 82 bp of an inversion at one side of the deletion
adjacent toHBG2 (MIM#142250) exon 2 extending to the upstream
β-locus control region (β-LCR). The inversion of 59.0 kb was
previously not detectable by CGH array or MLPA, a confounding
factor in previous attempts to fully characterize this rearrangement.
We identified the same rearrangement using gap-PCR and DNA
sequence analysis in the proband’s daughter and two other unre-
lated English individuals with the same hematological phenotype.
The structural variant is named the English V εγ δβ thalassemia
(g.5215690 5274684invdel5215690 5215772del5274684 5397195,
HbVar 2935 in Hb Var Database of Human Hemoglobin Variants
and Thalassemias, http://globin.cse.psu.edu/hbvar). To our knowl-
edge, this is the first inversion–deletion rearrangement causing
εγ δβ thalassemia and this diagnosis highlights the strengths of an
NGS approach, being applicable to any inherited disease.
Materials and Methods
Patient Samples and DNA Extraction
Patient samples were submitted for clinical testing to The Red
Cell Centre at King’s College Hospital, London, a reference center
for hemoglobinopathy diagnosis. Samples were collected in EDTA-
containing tubes and DNA extracted from whole blood either by
the QIASymphony (Qiagen, Venlo, The Netherlands) Midi kit or by
phenol-chloroform extraction. DNA from the proband in Family 1,
two negative controls (determined by MLPA), and two positive
controls with known variants (619 bp HBB deletion, HbVar 979,
NG 000007.3:g.71609 72227delinsAAGTAGA [Orkin et al., 1979;
Pritchard et al., 2010] and 106 kb HBB deletion [Feingold and
Forget, 1989] causing hereditary persistence of fetal hemoglobin1,
HPFH1, HbVar 1021, NG 000007.3:g.59478 144395del84918) were
selected for sequence analysis.
Target Enrichment Library Design
A SureSelect Custom Target Enrichment Library was designed
usingAgilent’s in-browser tool eArray (Agilent). 120 bp biotinylated
RNA baits were designed against a 4.26 Mb region of chromosomes
11 and 16 (genome build 37.3) covering both globin gene clusters
(Chr11: 3250000–7250000, Chr16: 0–260000). One times tiling was
used and the region was repeat masked allowing baits to extend up
to 20 bp into repetitive regions (see bait library design parameters in
Supporting Information, Supp. Table S1). Baits which were likely to
perform poorly (those with a high GC content or ‘orphans’ which
were >20 bp away from their neighbors) were “boosted” according
to parameters listed in Supp. Table S2.
Sample Preparation and Sequencing
DNA samples (3 μg) were sonicated to a mean size of 500 bp
using a Bioruptor (Diagenode, Ougre´e, Belgium) and prepared for
sequencing using the SureSelect Library Preparation Kit (Agilent)
in accordance with the manufacturer’s protocol (v1.4.1). DNA frag-
ments underwent end repair, followed by the addition of an adeno-
sine overhang allowing subsequent adapter ligation. Target enrich-
ment was performed using the custom bait library and separated
from non-hybridized fragments using streptavidin magnetic beads.
The fragments were purified, amplified, and ligated to indexing tags.
Each step was followed by clean-up using AMPure XP beads (Beck-
man Coulter). Samples were pooled at an equimolar concentration
of 12 pMols and sequenced on an Illumina MiSeq using the v2
2 × 250 bp sequencing kit (Illumina, San Diego, CA). Sequencing
parameters and quality statistics from the MiSeq run are listed in
Supp. Table S3.
Data Analysis
All NGS data analysis was carried out using NextGene soft-
ware (SoftGenetics). Quality filtering was performed by NextGene’s
Format Conversion tool using its standard parameters to generate
FASTA files (see Supp. Table S4 for the format conversion settings).
FASTA files were aligned with high stringency to a reference se-
quence of the human genome (hg 19 build 37.3) as paired reads
using NextGene (SoftGenetics: State College, PA). The alignment
settings are listed in Supp. Table S5. The alignment produced a
variant report, a coverage report, and opposite and same direc-
tion read reports. The uses of these reports in detecting muta-
tions are outlined in Supp. Table S6. The in-browser tool BLAT
(http://genome.ucsc.edu/cgi-bin/hgBlat)—part of the University of
California, Santa Cruz (UCSC) Genome Bioinformatics Site—was
used to query sequences in the alignment that could represent ei-
ther novel sequence or the misalignment of off-target sequence.
The UCSC tool used the same human genome build (37.3) as the
reference sequence in NextGene.
Characterization of the Deletion Breakpoints by gap-PCR
and DNA Sequence Analysis
Genomic DNA encompassing the inversion points and deletion
breakpoints was amplified by PCR using specific primers. For prod-
ucts <2 kb, PCR was carried out using the Qiagen Multiplex Mix
reagent kit (Qiagen) in a 20 μl volume containing 10 pmol each
of the forward and reverse primers, and 10 μl of the reagent mix.
Cycling parameters were 95°C for 10 min, followed by 35 cycles of
95°C for 40 sec, 63°C for 40 sec, 72°C for 1min, and a final extension
at 72°C for 10 min. For PCR products >2 kb, PCR was carried out
in a 25 μl volume using LongAmp Taq Polymerase (NEB, Ipswich,
MA) with 200 ng DNA, 10 pmol each of the forward and reverse
primers, and 5 μl of the reaction mix. The cycling parameters were
94°C for 30 sec, followed by 35 cycles of 94°C for 30 sec, 64°C for
30 sec, 65°C for 10 min, and a final extension at 65°C for 10 min.
The PCR products were resolved by electrophoresis in a 1%
agarose gel and the specific fragments purified using AMPure beads
(Beckman Coulter, Pasadena, CA) and then sequenced in tripli-
cate using BigDye Terminator sequencing chemistry v3.1 (Thermo
Fisher Scientific,Waltham,MA). Dye terminator products were pu-
rified using Cleanseq beads (Beckman Coulter) before being run
on a 3130xl Genetic Analyzer (Thermo Fisher Scientific). Sequence
data were analyzed with Sequencher Software version 4.1 (Gene
Codes, Ann Arbor, MI).
Results
Identification of εγ δβ Thalassemia in an English Family –
Case 1
The proband was a 39-year-old woman of English Anglo-Saxon
origin who had been noted to have hypochromic microcytic ane-
mia since infancy, unresponsive to oral iron supplements. She
was referred for further investigation at 14 years of age with a
hematology profile of Hb 99 g/l, RBC 5.37 × 1012/l, MCV 58.0 fl,
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Table 1. Hematological Indices of Individuals Heterozygous














Proband 14 y 9.9 5.37 58.0 18.4 2.7 0.9 0.26
25 y 7.8 4.02 61.9 19.4 3.0 <1.0 0.59
Daughter 3½ y 9.3 5.05 56.6 18.4 3.2 1.0
Mother 56 y 8.0 4.96 53.5 16.2 2.6 2.0 0.54
Case 2 52 y 6.8 4.53 50.0 15.0 2.5 2.1
Case 3 24 y 9.7 5.01 62.7 19.4 2.6 1.0
MCH 18.4 pg, reticulocytes 0.6%, HbA2 2.7%, HbF 0.9%, and
serum ferritin 160 μg/l. Globin chain synthesis ratio was β:α = 0.26
(Table 1). Her mother had a similar hematological profile with
hypochromic microcytic red blood cell indices, HbA2 2.6%, HbF
2.0% and globin chain synthesis ratio β:α = 0.54 (Table 1), a phe-
notype typical of heterozygous εγ δβ thalassemia. DNA sequence
analysis excluded any causative variants in theHBB (MIM #141900)
gene but Southern blotting indicated a deletion extending from
HBG2 upstream to the β-LCR leaving theHBB gene intact, that is, a
diagnosis of Type II εγ δβ thalassemia. Breakpoints of the deletion
proved extremely difficult to characterize because of the difficulty
in designing specific gap-PCR primers. The proband was referred
for antenatal genetic counseling, nine years later, to King’s College
Hospital, when she was 25 years of age. Her hematological pro-
file remained hypochromic microcytic with normal HbA2 3.0%,
HbF < 1.0% and globin chain synthesis ratio β:α = 0.59 (Table 1).
A fetal blood sample revealed a globin chain synthesis ratio of
β:α = 0.07 indicating that her baby was heterozygous for εγ δβ
thalassemia. The newborn had received two intra-uterine blood
transfusions followed by another blood transfusion at birth when
she developed neonatal jaundice and anemia. Hematological profile
of her daughter at 3½ years of age confirmed the thalassemic indices
characteristic of εγ δβ thalassemia (Table 1).
Cases 2 and 3
Case 2 was a 52-year-old English woman referred for further
analysis of her hypochromic microcytic anemia as was Case 3 (also
English) who was also pregnant. Both patients 2 and 3 had HbA2
levels within the normal limits (Table 1) and were negative for the
common alpha thalassemia deletions. Sequence analysis of their α
and β globin genes did not detect any causative variants. In both
cases 2 and 3, however, MLPA detected a deletion of >42 kb on chro-
mosome 11p15.5, removing the β-LCR, causing εγ δβ thalassemia
consistent with the hematological phenotype.
NextGene Sequence Analysis
Sequence data from the five DNA samples generated on the Il-
lumina MiSeq instrument were converted from FASTQ to FASTA
format prior to alignment at high stringency to the reference se-
quence using NextGene. The proportion of fragments on the flow
cell attributed to each sample were within acceptable margins of
equality (with no sample being over or under represented by >10%).
Significantly fewer reads were produced for the unknown patient
sample compared with controls (Supp. Table S3) despite >99% of
reads passing quality filtering steps during the conversion of the
data from FASTQ to FASTA format. The lower number of reads for
this sample resulted in a lower mean coverage compared to con-
trols but this did not adversely affect the ability to characterize the
rearrangement breakpoints.
Genotype and SNP Calling
As part of clinical diagnostics, a small number of variants had
been previously identified in the alpha and beta globin genes by
dye-terminator sequencing. Despite the high degree of homology
between the different globin genes, all previously identified variants
were correctly aligned by NextGene and were in the variant report,
confirming its correct alignment and variant calling capability (data
not shown).
RPKM Analysis
After sequence alignment NextGene produces an expression re-
port for each sample, including a coverage statistic called the ‘reads
per kilobase exon model per million mapped reads’ (RPKM). The
RPKM value is an average coverage value for every 1 kb of the
alignment, divided by the total number of mapped reads within
the length of the reference region. This internal sample normaliza-
tion allows coverage comparisons to be made between controls and
patient samples, similar to MLPA analysis. By uploading the bait
BED file, the average RPKM value for each 120 bp bait within each
1 kb region could be calculated. This permitted increased resolution
and review of individual bait performance. Baits that covered the
start and end points of large rearrangements could then be iden-
tified. Differences in coverage between controls and test samples
that represent the presence or absence of insertions or deletions
(indels) were represented as a ratio, by dividing the RPKM values
of the patient by the mean RPKM values of the normal controls.
These RPKM ratios were plotted on a log2 scale in Excel (Microsoft,
Redmond, WA) allowing direct comparison to CGH array data (al-
though this was not necessary for the fold differences observed).
The known breakpoints of the positive controls and MLPA analysis
of undetermined samples allowed quick adjustment of the x-axis
(chromosomal location) to best display the indel position.
Normal and positive control samples were prepared, hybridized,
and sequenced together with each batch of unknown samples. In-
cluding normal controls and test samples in the same batch during
library preparation reduced variation seen between the RPKM val-
ues in balanced regions, giving clearer discrimination of the break-
points in unbalanced regions. The variation is most likely due to the
manual library preparation method, particularly the hybridization
of the baits to the genomic fragments, which is temperature depen-
dent. The RPKM data plots could be used to identify the location
of the deletion start points and end points to within a single bait-
covered position, giving this methodology an accuracy of ±240 bp,
assuming that the region is tiled continuously. Where break points
are situated >500 bp into repetitive regions that are not included in
the bait design, this accuracy is reduced to the size of the repeat.
Most normal variation in the RPKM values of the patient was
less than 0.5 from the values for the same bait in the control, when
plotted on a log2 scale. Most bait positions involved in a heterozy-
gous deletion, however, had RPKM values that deviated by >0.5
from the control. Two issues with this analysis method are identi-
fying small changes that may only affect a few bait positions, and
differentiating genuine changes from copy number variation and
bait-performance variability, which can also produce variation of
>0.5. However, both copy number variations and bait performance
variability tended to be localized to the same regions in both samples
and controls. Superimposing a plot of the standard deviation from
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the average RPKM values for several controls over the RPKM data
for specific samples provided an effective means of separatingmuch
of the spurious data from genuine variants (see Supp. Fig. S1). These
same regions appeared to be consistently variable between batches
and were not investigated during the analysis. The genome browser
confirmed the presence of true copy number variants identified in
the analysis.
The HBB-like globin genes cover a 50 kb region accounting for
less than 1.25% of the entire bait-tiled region on chromosome 11.
Although large deletions (>100 kb) may still be easy to identify at
low resolution, it is also necessary to look more closely at the globin
cluster region at higher resolution for smaller deletions. Using the
619 bp deletion as a positive control, we generated the comparative
RPKM plot on three different scales focusing on 6 sequential baits
with variation >0.5. Viewing the alignment in this region charac-
terized the 619 bp deletion to-the-base, including the additional
7 bp insertion characteristic of this deletion [Pritchard et al., 2010],
data not shown. Breakpoints for the other positive control (HPFH1
deletion) were also accurately resolved in this way.
Opposite and Same Direction Reads Data Analysis
Paired reads that did not map during the first alignment (either
because of their orientationor their distance fromone another)were
separated into opposite and same direction read reports. Opposite
direction reads are the expected norm from Illumina paired end
data as eachDNA strand is read in opposite directions. The opposite
direction reads in the report are rejected from the alignment as the
two paired ends map back at a gap distance of >600 bp (as specified
in the sequence alignment settings) andmay indicate an indel in the
test sample. Same direction reads were recorded when both halves
of the read aligned to the reference in the same orientation, which
may indicate the break points of an inverted sequence. Both these
reports are useful when trying to detect structural variation greater
than the fragment size (mean 500 bp) as described in Supp. Table
S6.
Using Excel (Microsoft), reads in the opposite and same direc-
tion reports were filtered, removing sequences where neither of the
two reads aligned within the bait-tiled region of interest (chr11:
3500000–7500000, chr16: 0–260000). Because of the large number
of opposite direction reads produced for all samples, this report was
filtered again to remove pairs where neither end aligned near the ap-
proximate break points of a region indicated as deleted by theRPKM
plots. This was not necessary for the less-frequent same direction
reads. The reads were plotted, being overlaid on the RPKMdata plot
with both halves of each pair being given the same arbitrary y-axis
value. Regions where opposite or same-direction reads “piled up”
indicated the potential break points for rearrangements. Spurious
pile-up was frequently recorded between highly similar or repetitive
regions such as between the two gamma globin genes. These were
excluded as evidence of genuine variation as similar results were
obtained using normal control sample data. Visual inspection of
the reads aligning to these regions in NextGene and BLAT query of
the sequences of the rejected opposite or same direction reads also
removed false positives.
Mismatched Base String Analysis
NextGene visually indicates deviations in the sample sequence
from the reference in three ways: (1) deviations that do not meet
the criteria of a variant are indicated by gray bars in the NextGene
viewer; (2) deviations that are recorded as variants as listed in dbSNP
are indicated by purple bars and, (3) deviations which are recorded
as variants that are novel are indicated by blue bars. A string of novel
mismatched bases that are blue in a large number of records can
suggest the break-points of a large rearrangement. The mismatched
string of bases in the read indicates a break in the continuation of
the normal reference. NextGene does not currently have a method
for identifying these regions. Identifying the regions in Excel is also
difficult because, as NextGene attempts to make the sequence fit its
expected alignment, it breaks themismatched sequence into smaller
chunks aroundanybaseswhichare similar enough to the reference to
be aligned successfully. Furthermore,many of themismatched bases
may not meet the criteria to be recorded as a genuine variation and
will be excluded from the report. As such, it is necessary to visually
inspect the sequence aligning around the suspected deletion break
points identified by the RPKM and opposite/same direction read
plots and look for mismatching bases in the sequence alignment
viewer.
Once these regions are identified the names of reads containing
these break-point sequences can be recorded, and their two halves
can be identified in the original FASTA files. The entire read se-
quence can then be queried in BLAT (UCSC). Themismatched base
sequence string can represent misaligned data but if the sequence
produces partial high fidelity alignment to two distinct regions it is
likely to represent a genuine break point, particularly if they align
to the same regions identified by RPKM analysis. The break point
can be confirmed by Gap-PCR and sequencing of the breakpoint
spanning amplicon.
Characterization of the (εγ δβ)0 Rearrangement
An RPKM plot showed that the unknown variant deviated from
a normal control indicating a large deleted region which included
the β-LCR, HBE (MIM #142100) and part of HBG2 (Fig. 1A).
This was consistent with previous data fromMLPA and CGH array
analyses. Mismatched base strings were identified in the region of
the breakpoint identified by RPKM analysis. After BLAT query the
mismatched region was found to align 59.0 kb upstream (telomeric
to the deletion) indicating the presence of an unsuspected inversion
(Fig. 1B). A same direction read also mapped to these locations
(Fig. 1B).
PCR primers in the same direction were designed to confirm the
inversiondeletion breakpoints (Fig. 2A–C).Aunique gap-PCR frag-
ment of 1,031 bp was successfully amplified using same direction
primers, P1: 5′-AGCTGGTTGGTCCGTTTTGG-3′ (from UCSC
5215416 to 5215435), and P3: 5′-CTCTGCATCATGGGCAGTGAG-
3′ (fromUCSC 5274485 to 5274505) (Supp. Fig. S2). Sequence anal-
ysis of this unique PCR product confirmed the inversion, consistent
with the NGS data.
Confirmation of the deletion breakpoint at the centromeric
end, however, required a longer amplicon to accommodate the 6
kb LINE repeat (Fig. 2C and Supp. Fig. S2). A unique gap-PCR
product of 4,499 bp was successfully amplified using primers
P2: 5′-AGTGCAAAGGATGCCAGGAC-3′ (from UCSC 5216446
to 5216465), and P4: 5′-GAGCAAGTGCATGCAAGGAGA-3′
(from UCSC 5401092 to 5401112) (Supp. Fig. S2). Sequence
analysis of the unique fragment confirmed the breakpoint within
the LINE repeat as suspected and revealed that the deletion
had also removed 82 bp of the now adjacent inverted sequence
(Supp. Fig. S3). A thymidine base at the exact break point of
the inversion–deletion may belong to either the pre-deletion
or post-deletion sequence as a thymidine is expected at either
position. The coordinates used assume the thymidine base is
post-deletion, position 5397195. The new rearrangement in this
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Figure 1. A: RPKMplot across chromosome 11 in patient and a normal control.RPKMplot showing variation of sample RPKMvalues fromcontrol
on a Log2 scale. A continuous region (highlighted in yellow) of 120 kb yields significantly lower coverage—producing values of >−0.5 equating
to 50% less sequences aligning to each bait position—in the test sample compared with control. This indicates the presence of a heterozygous
deletion of this region in the test sample. The deletion removes part of the HBB globin cluster including the β-locus control region (LCR).
B: Positions of same direction reads across chromosome 11. Upper panel: The positions of same direction reads are overlaid on the RPKM data
plot and are useful in detecting inverted sequences. The positions at which the two same-direction reads from each fragment align (marked green
cross) have the same y-axis value. Two same-direction reads of a single fragment are boxed in red, indicating the break points of an inversion of
the sequence (shaded green region) between them. Lower panel: Inspection of these positions (green cross) at one potential inversion point in
the NextGene viewer reveals reads with strings of misaligned bases—the bases highlighted in gray, blue, and purple do not match the reference
sequence—indicating mutated allele, whereas some reads are perfect match to the reference sequence (indicating normal allele). Reading the
sequence from left to right, all the aligned sequences match the reference sequence up until the black vertical arrow. From the black arrow
onwards, five of the reads do not match the reference at this location and correspond to the point at which the inversion occurs. The reads that
do not contain any mismatched bases, compared with the reference, are from the normal allele and confirm that the individual is heterozygous for
the inversion.
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Figure 2. Line representation of the rearrangement events on chromosome 11p. A: Representation of the normal region encompassing the HBB
cluster on chromosome 11p. Downstream of the OR51V1 gene is a 159 bp palindrome between two LTRs (details shown in Supp. Fig. S4). B and C:
A 59.0 kb inversion (gray box) occurs between positions chr11: 5215690–5274684 encompassing HBB, HBD, HBP1, HBG1, and two exons of HBG2.
The start point for the inversion is in the 159 bp palindrome sequence, one base-pair from its central point. The inversion event is followed by a
122.6 kb deletion, which removes 82 bp of the newly inverted sequence, and the adjoining uninverted third exon ofHBG2,HBE, and the β-LCR; chr11
5274684–5397195. It should be noted that the inversion deletion fuses two previously distant LINE repeats. The first LINE repeat, which is flipped
during the inversion, is 98% homologous to the 5′ end of the second line repeat, of which 3.5 kb is intact after the deletion. Solid black arrows (P1,
P2, P3, and P4) in A and C indicate the location of the primers used in gap-PCR to confirm the rearrangement.
individual is therefore described as Chr11 Hg19 (build 37.3)
g.5215690 5274684invdel5215690 5215772del5274684 5397195
and has been submitted to the HbVar database
(http://globin.cse.psu.edu/hbvar), HbVar ID 2935. The rear-
rangement involves a single 122.6 kb deletion, but because this
affects two normally distant areas, it is listed here as two separate
deletions (122.5 kb and 82 bp) to describe both the affected
regions, respectively, interrupted by an inversion of 59.0 kb. The
inversion–deletion mutation is likely to have been created in
two events, the first being the 59.0 kb inversion followed by a
single deletion event. The start point of the inversion is one base
from the center of a 159 bp palindrome sequence which abuts
an LTR/LINE repeat region which is inverted (Fig. 2A and Supp.
Fig. S4). Following the inversion, a LINE repeat that shares a
high level of homology with a 6 kb LINE repeat upstream of the
β-LCR, is now adjacent to HBG2 exon 1. The inverted region of
the palindrome and the abutting LTR, and part of the upstream
6 kb LINE repeats were removed, leaving one inverted LINE
repeat and 3.5 kb of the 6 kb LINE repeat intact after the deletion
(Fig. 2C). Identical Gap-PCR products using primer pairs P1/P3
and P2/P4 were amplified in the daughter of the proband and the
other two patients, all of which had a similar hematological pheno-
type, confirming that they all had identical DNA rearrangements
(Supp. Fig. S2).
Discussion
An antenatal patient was referred to the molecular pathology
laboratory at King’s College Hospital for thalassemia variant iden-
tification. The hypochromic microcytic anemia with normal HbA2
level suggested that she could be heterozygous for α thalassemia,
but common alpha thalassemia deletion variants were excluded by
gap-PCR, and sequence analyses of the alpha globin genes did not
identify a causative variant. These negative results together with re-
sults of the globin chain synthesis ratios, prompted MLPA analysis
of the HBB loci. The test identified a deletion which removed the
β-LCR, causative of the phenotype of an εγ δβ thalassemia carrier.
Various other techniques including Southern blotting, quantitative
PCR and CGH array were employed in an attempt to character-
ize this mutation, but generating a gap-PCR product spanning the
breakpoint was not possible. One end of the deletion in HBG2
exon 2 appears similar to that previously reported in 1985 and
1988, that was named English I [Curtin et al., 1985; Curtin and
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Kan, 1988]. However, as we do not have DNA to confirm if En-
glish I εγ δβ thalassaemia is identical to the present case, we have
termed the newly characterized rearrangement as English V εγ δβ
thalassemia.
We sequenced the patient sample on the MiSeq platform (Illu-
mina) using an in-solution target enrichment chemistry (Agilent)
covering two contiguous regions which included theHBA andHBB
globin gene loci, respectively. Two negative controls with no struc-
tural rearrangements and two positive controls with known tha-
lassemia deletions were prepared and sequenced in parallel. After
sequence alignment the coverage per bait was normalized using to-
tal reads for the sample, allowing coverage between normal samples
and the test case to be compared. The coverage comparison plot
allowed identification of the deleted region and highlighted specific
areas where the breakpoint spanning sequences could be located.
Inspection of the aligned sequence surrounding the deleted region
showed a mismatched string of bases that, when analyzed in BLAT,
indicated an inversion of 59.0 kb adjacent to one end of the deletion.
Once the inversion was confirmed by gap-PCR, the deletion could
also be confirmed by long range PCR. As the 122.6 kb deletion in-
cludes a part (82 bp) of the abutting inverted sequence, we suggest
that the inversion event occurred first, followed by the deletion.
Sequence analysis of the Gap-PCR amplicons allowed to-the-base
resolution of the inversion–deletion mutation and further screen-
ing of previously uncharacterized historical samples with a similar
phenotype.
This sequencing and analysis methodology allows identifi-
cation of all known categories of variants causing not only
hemoglobinopathies but also other diseases. More importantly, the
approach detects deletions to a greater resolution than MLPA and
Southern blotting. A one times tiling density across the region al-
lows a resolution of ±240 bp (2 × 120 bp) where both breakpoints
were in bait-covered regions. It is likely that even greater resolu-
tion could be achieved with increased tiling density, or by taking
averages of smaller regions of each bait position. Our experience
suggests that the technique is able to detect single base changes and
indels up to the length of the fragment size being analyzed as well as
larger structural variants of over a megabase. As long as one end of
the breakpoint is less than 500 bp into a repetitive sequence it can
also identify breakpoint sequences without resorting to gap-PCR
analysis.
Key to the success of the methodology was being able to shear
the DNA into large fragments, (mean 500 bp) allowing a long read
length (2× 250 bp), in combination with flexibility of alignment in
NextGene. The small basematch percentage necessary for successful
bait hybridization further allowed reads with large amounts of novel
sequence to be aligned to a reference sequence with a high degree
of accuracy, permitting sensitive detection of small mutations and,
uniquely, the detection of inversions. Although not demonstrated
here, the methodology should also be applicable to characteriza-
tion of other forms of rearrangement mutations, such as balanced
translocations and insertions. Using an in-solution bait capture
chemistry with minimal PCR amplification permitted relative com-
parison of coverage and the capture of breakpoint sequences. It is
unlikely that a PCR based capture approach such as Ampliseq or
Raindance [Cheng et al., 2014; Tewhey et al., 2009; Zhang et al.,
2014], would reduce noise in the assay, being affected by variants in
the primer regions and differences in amplification efficiency. The
PCR approach would not identify novel breakpoint sequences as
this would require prior knowledge of the breakpoint trying to be
detected. Hence, the bait capture approach is probably unique in its
ability to identify and characterize unknown breakpoints in a single
assay.
Characterization of this novel rearrangement also highlighted
some major considerations for a routine diagnostic laboratory.
Problems were posed by the repetitive nature of both ends of the
deletion which prevented baits being tiled into these regions, such
that sequences which were picked up at these points were mostly
misalignments of off-target sequence. Another problem was that
the inversion was hard to identify against background noise in the
same-direction paired reads report. This was partly because of the
low number of baits covering the region, and partly a consequence
of NextGene’s increased tolerance for mismatching bases resulting
from the large read length of the MiSeq. Finally, as many break-
point reads were included in the alignment rather than being re-
jected as same direction reads, their mismatched base strings were
dismissed as errors by the software and were excluded from the vari-
ant report. The consequence of these problems was that breakpoint
sequence detectionwas largelymanual which slowed down the diag-
nosis. Gap-PCR and dye-terminator sequencing was still necessary
to establish the deletion breakpoints when it fell >500 bp within a
non-tiled repeat.
Large rearrangements are a common feature of alpha thalassemia
and to a lesser extent in beta thalassemia so a technique that can
handle these in addition to sensitive SNP detection is highly useful
[Giardine et al., 2011; Higgs et al., 2012]. Currently, five separate
tests—multiplex gap-PCR, sequence analysis of specifically ampli-
fied alpha and beta globin gene products, and MPLA of the alpha
and beta globin loci are routinely used in a diagnostic laboratory for
complete characterization of all variants [Traeger-Synodinos and
Harteveld, 2014]. NGS represents a comprehensive single method-
ology that can fully characterize all the types of variant by analysis
of a single data set [Berglund et al., 2011; Nielsen et al., 2011]. If this
process can be honed and applied to routine diagnostics it will have
a dramatic effect on molecular diagnostic laboratories [Kassahn
et al., 2014]. NextGene can identify SNPs automatically but there is
currently no reliable way of detecting large rearrangements. Dosage
changing deletions and duplications can be detected by compar-
ing the coverage of a test subject to a normal control but this is
still associated with high background noise and inter-sample vari-
ability which could impact detection accuracy. Increasing the bait
tiling density, automating the sample preparation process to pro-
duce less variable results and the use of multiple negative controls
for comparison to test subjects are steps that are likely to improve the
methodology. A comprehensive bioinformatic setup that includes
indel detection (currently requires a Linux environment), would
automate data analysis and reduce the need for Excel. Non-dosage
changing rearrangements will require more work for robust routine
identification. Reducing the noise associated with same direction
reads is challenging when dealing with such large fragment sizes,
so the best method for identifying these is likely to be by identify-
ing the strings of mismatched bases with which they are associated.
These strings are also frequently associated with the misalignment
of off-target or otherwise repetitive sequences, so it is likely to be a
challenge for software developers.
eγ δβ thalassemias describe a rare sub-groupof thalassemias char-
acterized by downregulation of the genes on the HBB cluster, that
is, HBE, HBG2, HBG1 (MIM #142200), HBD (MIM #142000) and
HBB itself. They are rare and caused by large deletions, classified
molecularly into two categories: group I deletes all or most of the
HBB cluster, including the HBB gene, and group II, which removes
the upstream β-LCR, leading to inactivation of the downstream
globin genes.We summarize the total number of εγ δβ thalassemias
reported to date (Fig. 3) that includes 17 type I (the longest being
1.78 Mb in a Bedouin family [Shalev et al., 2013]), and 13 type II
deletions. The inversion–deletion mutation described here is first
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Figure 3. Summary of 31 εγ δβ thalassemias reported to date. The newly reported inversion–deletion English V mutation (highlighted in bold,
bottom of panel) is first of its type. The hashed box indicates the inverted sequence and the gray filled box the deleted sequence. For details of all
the other mutations, refer to Rooks et al. (2012).
of its type to cause εγ δβ thalassemia; the deletion removes the up-
stream β-LCR but leaves HBG1, HBD, and HBB intact, although
the sequences are inverted. We suggest that the inversion event is
initiated by the inverted palindromic sequence at the breakpoint,
as was also noted in a previously reported structural variation in
the HBB region [Rooks et al., 2012]. It is also worth noting that
palindromic sequences are associated with genomic regions that
have undergone genome duplication [Butler et al., 2002] and this
is consistent with the globin gene loci. In many cases where the
breakpoint of the deletions have been characterized, they occurred
within regions of repeat sequences (LI, LINE, or Alu) containing
short regions of direct homology between the flanking sequences
[Rooks et al., 2005], a feature that is likely to have contributed to
the illegitimate recombination in this case.
εγ δβ thalassemias have only been found in the heterozygous
form; presumably homozygotes for such deletions are not compat-
ible with fetal survival because of the inactivation of all the β-like
globin genes. Heterozygotes may have severe anemia at birth, and
in some cases (as in the daughter of the proband in Case 1), intra-
uterine and perinatal blood transfusions are required to tide them
over the neonatal period. All except for one εγ δβ deletion (Scottish-
Irish 205 kb [Pirastu et al., 1983; Trent et al., 1990]) characterized
to date, have been unique to the families described, and several mu-
tations appear de novo. It is remarkable that all three cases of εγ δβ
thalassemia reported here had the same inversion–deletion rear-
rangement, raising questions about the frequency of this variant.
This case illustrates the power of NGS that has allowed us to fully
characterize the mutation, and design gap-PCR primers to confirm
the samemutation in two other non-related individuals with a sim-
ilar hematological phenotype. We have detailed our NGS approach
that should be applicable as a diagnostic tool for other diseases.
Automation of sample preparation and data analyses should allow
the methodology to eventually be applied in routine diagnostics.
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lymphocytosis to those without del(17p), suggesting that the
effect of T12 on lymphocytosis pattern is dominant; this is
consistent with the prior observation that up-regulation of in-
tegrin signalling in T12 is not modulated by additional del
(11q) or del(17p) (Riches et al, 2014). We did not have confir-
matory integrin expression data. In contrast to the effect on
lymphocytosis pattern, the presence of T12 in addition to del
(17p) did not attenuate the adverse impact of del(17p) on out-
comes. Further studies are required to ascertain the mecha-
nisms underlying the abbreviated lymphocytosis in T12 CLL
and its relationship, if any, to therapeutic efficacy.
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First reported duplication of the entire beta globin gene
cluster causing an unusual sickle cell trait phenotype
Heterozygotes for the HBB p.Glu7Val mutation (bS gene)
typically have ~40% haemoglobin S (HbS, a2b2
S), and ~55%
HbA (a2b2) with normochromic normocytic red blood cells
(RBCs). Co-inheritance of a thalassaemia with HBB p.Glu7-
Val reduces the amount of HbS in peripheral blood, as the
normal bA chains compete more effectively than bS chains
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for the limiting number of a globin chains. The relative
amount of HbS reduces with the severity of co-existing a
thalassaemia, paralleled by the reduction in mean cell volume
(MCV) and mean cell haemoglobin (MCH) of the RBCs.
Thus, AS individuals with (aa/a) genotype have 30–35%
HbS, and those with (a/a) genotype, have 25–30% HbS
(Steinberg, 2001).
A 26-year-old West African woman underwent routine
antenatal screening for haemoglobinopathies. Her blood
counts showed Hb 119 g/l, RBC 445 9 109/l, MCV 772 fl,
MCH 268 pg. High performance liquid chromatography
(BioRad variant II, Hercules, CA, USA) screen identified a
haemoglobin variant in the HbS position comprising 135%,
HbF 02% plus normal adult haemoglobins. When separated
at acid pH the unknown variant migrated to the HbS posi-
tion but this could not be confirmed by a solubility assay
due to the low HbS percentage.
DNA was extracted from EDTA whole blood using a Qia-
gen Symphony midi kit (Qiagen, Hilden, Germany) and
from a saliva sample (Oragene kit, Genotek, Ontario, Can-
ada) using a Qiagen Virus kit (v2) on an EZ1 Biorobot (Qia-
gen). Genomic DNA was analysed for variants in the HBA
and HBB genes, as described (Clark & Thein, 2004). Genetic
testing showed that the individual had the aa/a37 genotype
and no alpha thalassaemia variants. Sequence analysis of the
HBB genes did not identify any b thalassaemia mutations
that could have been in cis with the HBB p.Glu7Val muta-
tion, which would have explained the unusually low HbS
percentage. We confirmed the HBB p.Glu7Val mutation by
TaqMan analysis but the relative proportions of the sickle
and normal alleles in the gene sequencing and TaqMan assay
suggested the presence of an additional functioning normal
HBB allele.
A next generation sequencing (NGS) assay and bioinfor-
matic strategy was used to identify any potential rearrange-
ment in the HBA and HBB globin gene loci that could
explain the unusually low HbS (Shooter et al, 2014). Leu-
cocyte-extracted DNA (3 lg) was sheared to 500 bp using
a Bioruptor (Diagenode, Denville, NJ, USA) and used to
construct a sequencing library with minimal polymerase
chain reaction (PCR) amplification. In-solution bait cap-
ture (Agilent, Santa Clara, CA, USA) target enrichment
isolated DNA fragments from two genomic regions, 4 Mb
on chromosome 11 encompassing the HBB cluster, and
260 kb on chromosome 16, covering the HBA globin loci.
Sequencing was carried out on a MiSeq using a 500 cycle
sequencing kit (V2) (Illumina, San Diego, CA, USA). Nor-
mal and positive controls with known genetic rearrange-
ments were analysed in parallel with the test samples. All
data analyses were carried out using NextGene (SoftGenet-
ics, State College, PA, USA) as described (Shooter et al,
2014). A normalized measure of the coverage across the
sequenced region, known as repeats per kilobase exon
model per million mapped reads (RPKM), was calculated
for each 120 bp region covered in the in-solution bait
capture. By comparing the RPKM values between the
patient sample and a normal control, duplicated regions
are suggested by a 33% increase in aligned sequence, and
heterozygous deletions, a 50% decrease.
Comparing the RPKM values of the patient sample to a
normal control across the sequenced region on chromosome
16 confirmed the 37 kb deletion affecting one copy of the
HBA cluster. A comparison on chromosome 11 showed a
1457 kb duplication encompassing the entire HBB cluster
(Fig 1A). Heterozygous single nucleotide polymorphisms
(SNPs) in this region showed allele frequencies of ~33% or
~66% (reflecting dosage in one or two of three alleles respec-
tively), as opposed to ~50% of each, which would be
expected with two alleles present. The HBB p.Glu7Val muta-
tion (rs334) was identified in a third of the reads, indicating
that it is one of three functional HBB genes, consistent with
the HbS level of 135%.
The RPKM coverage data indicated the approximate start
and end points of the duplication (Fig 1A). Reads aligning
to the reference sequence at these positions showed that the
duplication was head to tail; the sequence repeating itself
immediately after it finished, interrupted by 11 bp of novel
sequence. The duplication break-points were confirmed by
Gap-PCR and dye-terminator Sanger sequencing of the gap-
PCR amplicon (Fig 1B). This sequence matched the NGS
data exactly, confirming a novel duplication of the beta glo-
bin region, Hg19.Chr11 g.5372677_5372678insCACCTCC-
ACTTdup5226885_5372677 (HbVar ID 2961). Gap PCR on
the saliva DNA sample showed amplification of the duplica-
tion-specific PCR product (Fig 1B,C), confirming that this
was a germline mutation, and excludes any haemopoietic
mosaicism or other non-Mendelian inheritance, such as uni-
parental disomy (Joly et al, 2013).
Haemoglobinopathies are caused mainly by single base
substitutions or deletions. Triplicated or quadruplicated HBA
genes are the best described duplications and most clinically
relevant (Origa et al, 2014). Recently, duplication of the
whole HBA cluster has also been described (Harteveld et al,
2008). Although these duplicated genes are expressed, this is
only clinically significant when co-inherited with beta thalas-
saemia when the extra a globin chains exacerbate the chain
imbalance, increasing the ineffective erythropoiesis (Thein,
2008). Duplications in the HBB cluster are rare; the gene
encoding anti-Lepore haemoglobin (e.g. Hb Miyada) which
creates fusion products of the 50 end of HBB gene and 30
sequences of HBD (i.e. HBD-HBB/HBD-HBB) could be con-
sidered as a partial HBB duplication (Weatherall & Clegg,
2001).
This is the first description of the entire HBB gene cluster
being duplicated and would have gone undetected during
screening, if it had not been for the unusually low sickle
percentage. Definitive analysis was helpful as it informed
genetic counselling. This report demonstrates the impor-
tance of accurate interpretation of haemoglobin electropho-
resis results in combination with genetic testing. A dataset
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of haplotypes for the duplicated region (HapMap, www.hap-
map.ncbi.nim.nih.gov) were compared to the haplotype of
the proband at 49 SNP loci. Four individuals (one of Nige-
rian and three of Kenyan origin) shared the proband haplo-
type across the 122 kb region, but none carried the
duplication. We suggest that such HBB duplications are
rare, but more examples could be identified as multiplex
ligation probe amplification and comparative genome
hybridization are applied in screening methods (Traeger-
Synodinos & Harteveld, 2014). However, this specific dupli-
cation is likely to be very rare, and perhaps unique to the
proband.
Our NGS approach, which permitted to-the-base resolu-
tion of the breakpoint and orientation of the HBB duplica-
tion, should be applicable as a diagnostic tool for other




Fig 1. (A) Coverage across chromosome 11 in patient relative to normal control. Each black dot represents a 120 bp segment of chromosome 11
that is covered in our bait capture library. Gaps in the coverage arise due to repetitive regions which cannot be included in the bait library design.
The difference in coverage between the proband and a normal control is represented on a Log2 scale on the Y-axis. A distinct region of ~140 kb
is overrepresented in the sequence of the patient compared to the control (indicated by the horizontal red bar), which implies this area – which
contains the entire beta globin gene cluster – has been duplicated in the patient. The duplicated region includes the whole HBB gene cluster
[HBB, HBD, HBBP1, HBG1, HBG2, HBE1 genes and beta LCR (locus control region)] as indicated below the red bar. The read pile-up in the
NextGene Alignment Viewer shows the reference sequence at the top and aligned sequences below with strings of mismatching bases in some of
the reads at this position (within the blue box). The mismatch begins at the same point and contains the same sequence in all affected reads.
BLAT [Basic Local Alignment Search Tool (BLAST)-like Alignment Tool] query of the sequence from the point where this mismatch begins
reveals these sequences align to the region at the end of the duplication indicated by the repeats per kilobase exon model per million mapped
reads (RPKM). At this location, similar mismatch is seen in reads in the NextGene Viewer, where the misaligning sequences match to the dupli-
cation start point. This suggests that these reads have captured the duplication break point and that the duplication is ‘head to tail’ in orientation.
Eleven bp of mismatching bases showed up in reads at both the start and end of the duplication (purple box). BLAT query could not match these
11 bp to anywhere in the genome, which appears to be a novel insertion at the start of the duplication, creating a 13 bp mirror repeat. (B) Line
representation of the rearrangement on chromosome 11p in proband. Allele 1 represents the chromosome that contains the HBB cluster with the
HBB p.Glu7Val mutation (HBB gene in red), and allele 2, the other chromosome, with a 1457 kb duplication encompassing the entire normal
HBB cluster. Solid blue arrows (Pr1 and Pr2) indicate the position and direction of the primers used to confirm the head-to-tail duplication.
Amplification using Pr1 (50-GCTGTATCCCCAACGTAGTATCCA-30) at the end of the duplicated region, and Pr2 (50-
CTGCTTGGTTTTCTTCTTTCATTCAG-30), at the start of the duplicated region produces a unique 350 bp PCR amplicon.(C) Upper panel - Gel
picture showing the unique Pr1-Pr2 PCR product of 350 bp. The lanes are represented by (1) 1 kb ladder; (2) Blank; (3) Normal control; (4)
Proband genomic DNA from peripheral blood; (5) Proband genomic DNA from saliva. The presence of the product in DNA extracted from both
blood and saliva indicates that this is a germline mutation. Lower panel - Part of the chromatogram of the Pr1/Pr2 PCR amplicon. Dye-termina-
tor sequencing of the unique PCR product confirmed the breakpoints indicated by NGS analysis and also the insertion of 11 bp of novel
sequence situated between the duplicated regions. Red bars above the DNA sequence show the mirror repeat created by the novel insertion, cen-
tering around a ‘T’ base.
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Ibrutinib-associated lymphocytosis corresponds to bone
marrow involvement in mantle cell lymphoma
Bruton tyrosine kinase (BTK) is involved in the signalling
pathway of the B-cell receptor (BCR). Signal regulation
within this pathway is critical for the maturation and func-
tioning of normal B cells (Gauld et al, 2002). Functional
BCR signalling has been shown to be necessary for maintain-
ing the viability of malignant B cells in varied non-Hodgkin
lymphoma subtypes (Davis et al, 2010; Cinar et al, 2013).
Ibrutinib is a selective inhibitor of the BTK protein that irre-
versibly binds to cysteine-481 within the active site (Honig-
berg et al, 2010). In vitro, ibrutinib blocks B-cell activation,
arrests cell growth and induces apoptosis in human B-lym-
phocyte cell lines (Davis et al, 2010; Honigberg et al, 2010;
Cinar et al, 2013). In clinical trials, ibrutinib has exhibited
significant activity in certain B-cell malignancies, including
chronic lymphocytic leukaemia (CLL) and mantle cell lym-
phoma (MCL) (Advani et al, 2013; Byrd et al, 2013; Wang
et al, 2013).
Peripheral blood lymphocytosis was a significant feature
observed with ibrutinib therapy during phase 1 and 2
studies in CLL (Byrd et al, 2013) and MCL (Wang et al,
2013). In a phase 2 study of single-agent ibrutinib (PCYC-
1104-CA; NCT01236391), 34% of the enrolled patients
with MCL (n = 111) experienced a transient increase (to
≥50% of baseline and >5 9 109/l) in peripheral absolute
lymphocyte count (ALC). This lymphocytosis peaked at a
median of 4 weeks of treatment and gradually decreased
over 15–18 weeks of therapy (Wang et al, 2013). The
circulating lymphocytes were characterized as
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